{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Webscraping Walkthrough for Singapore's Ministry of Health (MOH)'s List of Drugs for Drug Subsidies "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Table of Contents\n",
    "- [Section 1: Introduction](#Introduction)\n",
    "- [Section 2: Setup](#Setup)\n",
    "- [Section 3: Exploring the target website](#website)\n",
    "- [Section 4: Exploring the html](#html)\n",
    "- [Section 5: Setting up Script](#Script)\n",
    "- [Section 6: References](#References)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 1: Introduction<a id='Introduction'></a>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Ministry of Health (MOH) provides subsidies for drugs at our public hospitals, specialist outpatient clinics and polyclinics to ensure that patients have access to effective medications for common medical conditions in Singapore.\n",
    "\n",
    "Patients receive drug subsidies and assistance based on their subsidy and means-test status, and the scheme under which the drug is covered (e.g. Standard Drug List (SDL), Medication Assistance Fund (MAF)). The subsidy may go up to 75% subsidy for Singaporeans at polyclinics and subsidised specialist outpatient clinics in public hospitals for drugs on the Ministry of Health's (MOH) list of subsidised drugs.\n",
    "\n",
    "This list of drugs is available on MOH's website [here](https://www.moh.gov.sg/cost-financing/healthcare-schemes-subsidies/drug-subsidies-schemes) on HTML format. However, the CSV format is unavailable on the website and thus webscraping of the data will be useful for data analysis."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 2: Setup <a id='Setup'></a>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- Beautiful Soup is a Python library for pulling data out of HTML and XML files\n",
    "- Requests is an elegant and simple HTTP library for Python\n",
    "- Csv module implements classes to read and write tabular data in CSV format"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup\n",
    "import requests\n",
    "import csv\n",
    "from IPython import display\n",
    "from IPython.core.display import display, HTML\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 3: Exploring the target website<a id='website'></a>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The target website can be accessed [here](https://www.moh.gov.sg/cost-financing/healthcare-schemes-subsidies/drug-subsidies-schemes)  where the MOH's website contains the List of Drugs for Drug Subsidies in Singapore. Below picture also shows a screenshot of the List of Drugs for Drug Subsidies in Singapore"
   ]
  },
  {
   "attachments": {
    "ss_list%20of%20drug.JPG": {
     "image/jpeg": "/9j/4AAQSkZJRgABAQEAYABgAAD/4RD4RXhpZgAATU0AKgAAAAgABAE7AAIAAAAPAAAISodpAAQAAAABAAAIWpydAAEAAAAeAAAQ0uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAFRlbyBDaG9uZyBKdW5uAAAABZADAAIAAAAUAAAQqJAEAAIAAAAUAAAQvJKRAAIAAAADNTIAAJKSAAIAAAADNTIAAOocAAcAAAgMAAAInAAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADIwMjE6MDY6MjEgMjI6MDc6MTcAMjAyMTowNjoyMSAyMjowNzoxNwAAAFQAZQBvACAAQwBoAG8AbgBnACAASgB1AG4AbgAAAP/hCyFodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIxLTA2LTIxVDIyOjA3OjE3LjUxOTwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5UZW8gQ2hvbmcgSnVubjwvcmRmOmxpPjwvcmRmOlNlcT4NCgkJCTwvZGM6Y3JlYXRvcj48L3JkZjpEZXNjcmlwdGlvbj48L3JkZjpSREY+PC94OnhtcG1ldGE+DQogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgIDw/eHBhY2tldCBlbmQ9J3cnPz7/2wBDAAcFBQYFBAcGBQYIBwcIChELCgkJChUPEAwRGBUaGRgVGBcbHichGx0lHRcYIi4iJSgpKywrGiAvMy8qMicqKyr/2wBDAQcICAoJChQLCxQqHBgcKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKir/wAARCAMLBJQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6RopHdY0Z5GCqoyzMcAD1qppesaZrlobrRdRtNRtwxQzWk6ypuHUblJGeRxQBcoqvf6jZaVYyXuqXkFlaxYMk9xKscaZOBlmIA5IFEF/Z3WnpfW11BNZyJ5iXEcgaNk67gw4I96ALFFZFh4s8Oaremz0vX9LvblesFtexyOP+AqSan1bX9H0CGOXXdVsdMjlbbG95cpCHPXALEZNGwGhRXN/8LG8Ef9Dl4f8A/BpB/wDFVu2V9aanZRXmnXUN3azDdHPBIJEceoYcGgCeiorm6t7K3e4vJ47eGMZeSVwqqPcngVR0vxNoWuSPHoutadqLx/fW0u0lK/UKTigDToqlqut6VoVqtzrep2emwM+xZby4WJS2M4BYgZwDx7Vkf8LG8Ef9Dl4f/wDBpB/8VQB0lFIrK6B0YMrDIIOQRWNqPjTwvpF89lq3iTSLG6jwXgub+KORcjIyrMCMgg0BubVFZ2leIdF11WOh6vYakE+8bO5Sbb9dpOKbq3ibQdAeJNd1vTtMaYExreXccJcDqRuIz1oA06Kw7Hxt4V1S6W10zxNo95cOcLFb38Ujt9AGJq9qet6VokcUms6nZ6ekz+XG13cLEHb+6CxGT7UAXqKiuLmCztZbm7mjgt4ULySyuFVFAySSeAAO9Radqdhq9il7pN7b31rJkJPbSrIjYODhlJBwRigC1RWVqfinw/ok6w6zrumafK33Y7u8jiY/gxFX7W7tr62S4sriK4gcZWWFw6t9CODQBNRWbqviTQ9BKDXNZ0/TTJ9z7ZdJDu+m4jNXLS8tr+1S5sbiK5gcZSWFw6t9CODQBNRVeO/s5b+axiu4Hu4EV5bdZAZI1bO0svUA4OCeuKsUAFFVn1Kxi1KLTpb23S+mQyRWrSqJXUdWC5yQPUVFqut6VoVstxrmp2emwO+xZby4SFWbGcAsQM4B49qAL1FQWV7a6lZxXmnXMN3bTLujngkDo49Qw4IqPUtX03RrX7Tq+oWthBnHm3UyxL+bECjYNy3RVLTNZ0vW7cz6NqVpqEIODJaTrKoP1UkVdoAKKqalq2naNbfadX1C1sIOnm3UyxL+bECm6ZrOl63bmfRtStNQhBwZLSdZVH4qSKALtFZmreJtB0B4k13W9O0xpgTGt5dxwlwOpG4jPWqVt4+8H3l1FbWnivQ555nCRRRalCzOxOAoAbJJPYULXYDoKKKqalqun6NZNeaxf21haqQGnupliQE8AFmIHNAFuikVldA6MGVhkEHIIpScDJ4FABRWVpXijw/rtxJb6Jrmm6jNEu6SO0u45WQZxkhSSBmrGq6zpeh2gutb1K0063Zwgmu51iQsckDLEDPB49qA8i7RWBb+PfB95cLBaeK9Dnmc4WOLUYWZj7ANWpqWradotkbzWL+1sLUEKZ7qZYkBPQbmIFGwFuiudj+IfguWRUi8X6C7scBV1OEkn6bq27i/tLSwe+urqCC0jTzHuJJAsar13FjwB70dLh5E9FZkniXQodFTWJta06PTJDhL5rtBCxzjiTO08gjrWhFLHcQpNBIssUihkdGyrAjIII6igB9FFUtU1rStDtxca1qVnp0LHaJLudYlJ9MsQKALtFQ2l5a6hapc2FzDc28gyksMgdGHsRwapt4j0NNYGktrOnrqR6WZuk84/wDAM7v0o62Dpc0qKbJKkMTSzOscaAszscBR6k1n6X4i0TXHkXRdY0/UWi/1gtLpJSn12k4oA0qKjuLiG0tpLi6ljhhiUvJLIwVUUDJJJ4AA71Wi1nS59HOrQ6laSaaEMhvEnUw7R1bfnbgYPOe1AF2iora5gvLWK5s5o54JlDxyxOGV1PIII4IPrUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFTVv+QLe/wDXvJ/6Ca8m/Zf/AOSSy/8AYSl/9BSvWdW/5At7/wBe8n/oJr5f+Dfxw8N/DzwO+ja1ZarPcNdvOGtIo2TawUAZaRTng9qINKU/RfmKabUfV/kez/Hr/kiHiH/ch/8AR0deceN9N13Uv2YPB66JBc3VpFBbyajb2ud7wiP0GcqDgng44Patnxx8SdH+JX7P3iy90K2vreK0aCFxeRorEmWM8bWbiifUPHGifA7wNrXgMyXEdnaQtqNhHbpI1xFtU8ZUsMYIO3nDZ7VNrXv3j/Xoap3jG3979Dz2KH4JeKdPtrbQru+8Da2sqNHe3hlmUMOuT5hUezZTBx9K+itY8BaH4y8O6ZY+M4hrhs0VhcLJJAJJNoBkwj9+uMnrXhXj34leFviZoNxpGh+ANQuvFE4VI5Xso/Mt2yMkOhLn6EAHvXvnw+0e/wBA+Hmh6Vq77720s0jm+bO0gfdz3x0/CtN4u66r+l6GO0lbseDeCPhf4P1f45eMvD+o6R52l6agNpb/AGmZfLO5R94OGPU9Sa+jtE0XT/Dui22k6Nb/AGaxtV2Qxb2faM5xliSeT3NeO/Db/k5j4hf9cx/6Ele4VFNv2MPNL9Q/5ez8n+iPnnxJaSfF39om48I6tdzR+H9Ag857aF9vnMAm4/UtIBnqADjGc1a+KPwX8OeFPBdx4o8Cx3Giaro+LlZIrqV94BAP32JBwcgjHp3pfGmna98MvjVL8Q9I0e41jRtSg8rUIrYFnh4UN0zgZRWBPHUHFUPGPxduvix4cm8JfDnw1q8s+oMIrq4uYlVYUyCRlWYDOMEsRgVOrpJQ+L9b/kau3O3Lb9Cp8XfE0vi/9mzwtrd3t8+5vYxOVGAZFSVGI+pUmrGmWf7NuoXFpZQp5l5cukSJnURukYgAZ6Dk/SnfGzwyvg/9nvwzoO9ZGs76JJHA4ZzHIWI9txNey6d4A8HQRWtxD4T0OOeNUkSVNNhDKwwQwO3IOec1s7c0mtub9EZu/JBdbfqdJFGkMKRRjaiKFUZ6AdK+dtQ8J6J4z/a01zS/Etl9tsxpySiLzXj+cRQgHKEHue9fRdfNHiPx1pnw8/ap1zWtagu57Y2EcG20RWfc0URBwzKMfKe9Z399X8/yNI/BK3l+aJPi74B0v4RLovjT4erNpc9verBLD57yLICrN/GScHaQRnBBqb4+XOjXvjf4fXXiZdujTxtJeL8/ERaMt9z5uh7c1X8Z+Lrr9oGTSPDPgrRNSg05LsT3t/eRBVjABXqpYYAZj1yTgAVt/GDTLST4u/DLTLm3jubPzDC0M6B1dA8YwwPBGPWnFPmin/Np935XM5uPLJr+XX79PwPPviInwXl8L+X8M0uH8QvcRrbrALw5+bkETcdOmOc4rtfjampRfCjwAmuljqS3duLouct5nk/Nn3z1qz8VfBkvw21az+I/w5s4bIWbCPUrG3jCwtGTjdsHAU9Dj2PUE1o/FmOf4q/BTS9f8GRSXb29yl8LaIbpBhWV0wOrKT0HocU4ySjftJX8rfp1HKLcrd07Ho/xE/5Jd4k/7BVx/wCi2ryDwv4suvBn7IMWrac2293SwW7/ANx3uGXd9QCT+FR+If2gbTxP4KvvDWm+GNaPiG/tGtXtvJVkjZl2sRglzjPA2j8K6rTfhZfXn7NMPgy/22+qPAZ1DHiOYyGVVY/iFP41Mk+Wb9P1v+BUZL3I9bv8l+pleFvgn4Gg8C2/iD4iyfbr28hS7vL++1CSFIjJggbg6j+IDLEkn64rc+FnhbwX4V8TakPBnjiHU4r5SyaPDqEMyxgY+bCksxHTdxwcHPWuHT4p2Oj+Ak8C/GPwdrW6CJLRvIXCXSRkbDu3of4RypIOM55xS/BvwvLP8XJ/E/h/wlfeHPDAsnhgF5IzMzEL8w3kls4J4yB61pdc7cdtduxlqoLm+Lr/AF95yt8vhzQvih4i/wCF46Bq2oSXt2z2N5HK6x+VuOCArqWXbtAwTjGMCvUfgzoHhq31HXrz4feMnu9Fvkx/ZHkss1i5+6+52ySPmAJTnjk45xf+Fr6z4E1DVtB+NOj3ut2pnJsr6GxhMc0fQDb8iMCOepIJINM+EemPrvxov/GPhrw3N4b8L/ZDCkUkXlLcMQPuqPl6jcQuQMDnmoppWSW1v06+fTvcupo2/P8AXp5dfQ0vDfhbx5D8Qo9S1G61yPS72cWzuZLb7WI7YkxNcMEwUclx8pyRjJORXuVFB5BobfLYOtzxz4TXTeMfil418Y3XzLBMulWIJz5cSkk4+uFP1JrJ+KFqvxL+OWheAy7f2dptu93flGxgsucfXGwf8Dqb9nmWLw9oPjaz1GQRvpOqSPcluNqqmCf/ACG1cd4A8CeI/ipqeveO7HxffeF5Ly+kiRrWNy8qcNt3LInygbRjn7vtUpX5V0ST/DT8XcqWnM0921/XyVjvf2d9WuLPS9b8D6qx+3eHr11QHjMTMentuDH6MK474wwW+nfGpdX+JWjajq/hF7VY7MWkjKsTbRkZBXncGJG4E5B5xim22i6p8FPjtoV3rXiCbW7XxAjW9zf3CMrMSQuGy7E7T5ZyT0rsvF/j/wAV/Dj4jXs3iqyu9a8EXkWbY2trGfsxwMqWwMnIYYduQQQeDVN83LJvv6XWhK05opf8M3cxvhppPw9vfiXaa18L/FEmk7ICt14fuIpGa5XBzhpHyex434K54r6AJCqSeABk18xWkll8T/i/4Z1b4beErnQ7LTrgT6hqTWywLIAwJBCErnAI6kndyMCvp4jIwap35F8/69Bacz+R82+AfDVt8dPGviDxR43kmvNOsrj7NY2CzMiKpyQPlIIAXHQjJJJpfil4Ns/grfaL41+HrTacouhbXVkZ3dJVILYJYk4IUggk9iMYp2j3+q/s9eL9ct9X0S+1HwnqU3n295Zpu8rGcZzgZwcEEj7oIqPxVr2q/tDalpGh+FtC1Cx8O29yLi81G9QL2wehK8AtgAkknsBUQ2h7Py/4N/xKlbmlz7a/8C34Fj4/3GiXfjvwBceI/wDkCTI8l3nf/qSyE/c+bp6c1q+DtP8AgBqfjDToPCMXm6yswmtF3X4w8Y35/eHbxtzg9cU34x6daT/GH4aafc20VxZtKYmgmQOjpvjG0g8EY9a9d0/wV4W0m+jvdK8NaPZXcWfLntrCKORMjBwyqCOCR+NXTso8y7y9dyJXcrPey9Dbr5i/aD0fxlLoc2t+KdUgTTI9U+z6bpVqvyiMhyJZD3chR69T06V9O14v+1J/ySm0/wCwrF/6LkrGe1/T80b09W15P8mevaZ/yCLP/rgn/oIrkfjF4p/4RL4WavfRPsuZo/stsQcHzJPlyPoMt+Fddpn/ACCLP/rgn/oIrwr44rceP/if4a+HGm3JgGGurqYJvERIOCRkZ2orHGR98VpWXNLkXV/8P+BlRajFSfRXOW8PaDN8GfGHgDXpzIltr1p9n1Pf0jeQg4PpgNGf+2Zr0D9qT/klNp/2FYv/AEXJXJ/EH4F+KbfwTfajf/ETU/ES6ZEbpLG7ikKnaOSC0zYIXPb2qH4meK/+Ey/Zc8PapI++5XUIoLr181I5FJP1wG/GlUfNF+TX3N/oyqScZrzT+9L/ACHeNvCXwTsvhre3ei32mprS2ga3Fnq7TyNNgYXy/MYYJ4PHAz0pPEl1qV5+xrpcusNI832iNUaQks0QlYIef9kDHtivT9F+Bnw4gt7S8XwxFJMYkc+dczSqSQDyrOVP5Vm/tIRRwfBSaKFFjjS6t1REGAoB4AHYUq+kWu7X5k09bPyf5HmZP7PI8GDeJTrH2EbhD9u3+fs5xu/d53evy/hXQ+CYNYg/ZF8QjWRKsbW9y1isoIIgKjGM9i28j2NbPir4Q6drXwt0nVvB2nW2meJLCzgu4JrKJYmuGCBirbcZY9QTzn6mo7T4jf8ACwf2cfE7X+2PWtP0+WC/iA2knacSY7BsfgQRVVdFVXX8Ld1+RNLX2b6fj6M5jxF/yZfo3/XaP/0c9fQfhT/kTNF/7B8H/ota+fPEX/Jl+jf9do//AEc9b2iftO+DNN8P6fYz6ZrrS2trFC5S3hKkqgBxmXpxVXXPVX979CIp2pv+6/zPe68l1z4Op4r+J+oeI/H91Bf6CltssrJbiSIwAAcsRjA+8Thup5r0nw9rdt4k8OWGtWKSx21/As8SzABwrDIBAJGfoTXzx8Z/ixZ6l43fwbeXF/beGrKTZqjaaqtPduOTGNzKAoPB5654OBWb0kl1/rU2WsW+g/4a6i3hjTfinqPhGaV/DenxyNpjOxZPNAbBUnrxt57jbms2x+Fui3v7N9x41uEnfxI0ct+L77Q+RtlPG3O08LknGcnrXf8AhDxV4O+I/gXXPAfgLSb3SY49MkVFuoo0TLDaDlXYltxBJPX1rzy38eajp3wgm+E8/hnV/wDhKGD2kcYgG0xtITng7jwSOAQeuack+VqO9lbu9/1t8hRd2m9ru/lseiXmgeIfjD8F/CMcOqx2sUyxyaq0rsGuVT5TjAOSSC3PGcVyfiPwfoHg745eCdM+GaSW2qefu1GGO4eXbDlSS+4nGU8zI4GMcdK6Pxl4uuvgn8FPD+hWmw6/PaiCNj8ywMADK/vgtgdsn0GK5b4VfE/4eeG76CGOx1/UPEmrzJFd6tdwRFpJHYDGfNJVMntknvmtE17ZuOyf3+XoRqqKUt7fd5nafHDRvGWs6JrciarBp3hSwsDO0MS5nvZQM7WPZAfcfQ9R0HwWtorz4EaHa3KB4ZrWWORT0ZTI4I/I1rfFn/kkPij/ALBsv/oNZ3wM/wCSKeHf+uL/APo16zilyyj6f+3FSb5ov1/QwfgDqs0Fj4i8GXcjSP4a1J4IWY5PkszBR+BVvzFevV4l8EYGufih8S9WiGbWXVDCj9mYSSE/kCPzr22qu3GLe9l+Q2kpyS2TYUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOJ0vwRd6H8W9U8S6ZLbrpWtWii+tmLCQXCH5XUYwQRnPI5JPNdtRRRskuwdWwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKraiLxtLuhpnlfbDEwg85iqb8fLuIBIGcdAas0Umrqw07O5yXwz8EjwH4Lg0uaVLi/kdri+uEyRLM33iCQCQOAM9hXW0UVTd2SlYKKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiq9pfW98JjauX8iVoZMqVw69RyOfqOKALFFZmoeJdC0i5FvqutadYzlQ4iubpI2KnocMQccGkt/E2iXjWy2OqWt59qmMETWsglUyBC5UlcgHapPOP1o3A1KKKKACiiq9rf217JcpbSb2tZjDMNpG1wAcc9eGHT1oAsUUUUAFFFFABRRRQAUUx5Y43RZJFVpDtQM2CxxnA9eAT+FQ2GoW2p2puLGXzYhI8RbaR8yOUYcjsykfhQBZoqtfahbabCkt7L5SSTRwqdpOXdgqjgd2IGasMwRSzkKqjJJOABR5gLRVQapZG9W1Fwpla3+0gDO0xZxu3dMZPrVlHWSNXjZXRgCrKcgg9waAHUUUUAFFFFABRRRQAUUVWtdQtr2a6itpd72c3kzjaRsfarY5HPyspyPWgCzRSO4jRnc4VRkn2qGxvbfUtPt76yk822uYllifaRuVhkHB5HB70AT0UUUAFFVxf2x1I6eJP9KEImMe0/cJK5z06g8UXV/bWc9rDcybJLuXyYRtJ3vtLY46cKTz6UAWKKKKACiiigAoopgljMxiEimRVDFN3zAHODj04P5UAPooooAKKZLLHBGZJpFjQdWdsAfjT6ACiikd1jRnkYKqjLMxwAPWgBaKRWV0DowZWGQQcgiloAKKKKACiiigAopiyxtK8ayKZEwXUNyuemR2p9ABRRRQAUVWu9QtrGS2jupNjXc3kQjaTvfaWxx04U8njirNABRRRQAUUUUAFFV5b+2gvrezlk2z3IcxJtJ3BQC3PQYyOtSxSxzxiSGRZEJIDI2QcHB5+tAD6KKKACiiigAooooAKKr2F/banZJd2MnmwOSFfaRnBIPB56g1YoAKKKgvr2303T5729k8u3t42llfaTtUDJOByePSgNyeio0uIpH2JIpfYH2Z+YKehx1wcH8qkoAKKZHLHMpaGRZAGKkq2cEHBH1B4p9ABRVe8v7awEJu5PLE8ywR/KTudug4/n0qxQAUUUUAFFFV7++ttMsJr2+k8q3gXfI+0naPoOaALFFMWaNpWiWRTIqhmQHkA5wSPfB/KhpY0kSNpFV3zsUty2OuB3oAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVeC/tri8ubWGTdNalRMu0jaWG4c9Dx6VYoAKKKKACiiigAooooAKKKKACiq89/bW13a208m2a7ZkhXaTvKqWIyOnAJ5pLnULazurS3uJdkt5IYoF2k72CM5HA4+VWPPpQBZooooAKKKr2F9banYxXllJ5sEoyj7SMjOOh5oAsUUUjusaM8jBVUZZmOAB60ALRSKyugdGDKwyCDkEUtABRRTFljaV41kUyJguoblc9MjtQA+iiigAopnmx+cIfMXzSu4Ju+bHTOPSn0AFFFFABRRRQAUUjuI0Z3OFUZJ9qhsb231LT7e+spPNtrmJZYn2kblYZBweRwe9AE9FV7y/trAQm7k8sTzLBH8pO526Dj+fSrFABRRRQAUVXgv7a4vLm1hk3TWpUTLtI2lhuHPQ8elWKACiiigAooooAKKKKACiiigAooooAKKKKAIL60iv7GW2uEEkcgwVLFc9xyORzXNeFPB8+g3klxfXZvXkQSK7zyuYpWz5iqGJGzpjPzdc9q6yihaO4bqxzvj1VPgfUiQCdi84/wBtaq+MIZ5Na8LR2Ey20ralIPN2Bto+zTZIB4zjOM5GcZB6V0Gr6ZDrOlT6fdNIkU4AZoyAwwQeMg+lJfaVBf32n3UzSLJp8zTRBCMMxjaM7uOmHPTHOKFuHc5i78Qaj4ds/Ecdxcvqj6ZbxTW008Sh2Mm4BXEagEBlzwAcHHvUmg6xqD+IoLNp9V1G1ngd5pr3SJLQW8i7cBSYkBVgW4O4jA5rdm8P2Nzc6lLcq8y6lAkFxEzfLtUMBjHIPznnPpjFJpmjTadOXk1nUb6MLtSG6aMqg+qoGY8dWJNC3DoUtVub+98UW+iWF9Jp0f2Rrua4hjR5Gw4VUXerKBySTgnpjFc3a3msaZbailvdQtezeJVtmmaL5WVkQZK+uME4I5HGK7HVdCj1K6gvIry6sLy3VkS5tSm7Y2CykOrKQSAeRxjjFVLfwfYW0PlpPdtnUV1JmkkDM0wA6kjocZI9+MDApR3V/wCveT/LQUr20/rRr8xGmv8ATvEGi6dJqM14lwty0zzRxhn2hSv3VAAGT0/HNZmpeINRtpPEIS5EcNnf2sAmMan7JC8cRkk6c43M2WyB1PAxXQ6vokerPbTLd3NldWrM0Nzald67hhhh1ZSCOxB6Cud1rw6NL0y4WzbULhdSvYptQuVUzzRbFGJERV5O5EG0KQMn5cDFHXX+tUUi14Uubu81fUpF8QT63pcaxra3BW38tmIJcBoo13EYHIOPmxjIp3ifUxDM8Vrrl/aXEEW9oNP0/wC1kE52mQCJyqnH+znnml8N3GqTarMHu9SvtM8gET6nZLayCXd91VEcZK45JK9cYJ5xbu/C0F1qV1dxX99aC9VVu4LaRVS42jaCSVLKccZRlPAole2go2vqZeleKbhjp1/q0ix2Op6Mt6qhQFhlRQ0gz1IKuCMn+A0g1S6bw9px1TWr6w1C6RrpodPsluJwjHKrsET/ACqCFJ28kda0bvwZpt74c07RZXuBbacI1iZXAdlVNhVjjBDKSDwMgnpVnUPD0d7qkeo29/eafdLD5DyWpT97HncFYOrDg5wRgjJ5qpWbdtv+H/4C+QLRf1/Xn6nN6br11qsHhO4uNjyTandW8jyWwVmEcdwobawzGx2AkDBGSOmRTtEvYrXwb5b6nNp8s2qXwja1gE0z4uZSQiFXycc/dOBW5ZeEdP0+HTYreS52abdTXUO+TcWeUSBgxIyR+9bHfgZJ5zGfB1okFsLO+vbS4tZ554bqJozIvnOXkXDIVKknoV7DnPNOTXQP6/M5S91e91fwncw/aZJZrLxDZ20FzeWhhkcebA6tJFtTBBfHRcgZ4zW7fXeo6Pfz6bdag+pQ3emXNzG9zDGGiePaCuEUKyEP0IJ46nNXG8EabJpt5ZTT3sqXl6l9NI0/7wypswQwGQMxg8dO2BgCxD4XhWS5mvb+91C4nt2thPcsm6KJuqoERVGTg5IJOBknFRLWDiv691L8xxspXf8AWt/yOchnc3VvcYj3/wDCJl8CNQucqfu4xj2xil0+3vL3xR4fkXV7u1RtCEpht44BH96LKgGM4B74wRgYIrpF8MWSbMSz/Jpv9mj5h/q+Oen3uOvT2pD4ZgWTTZbW8u7WbToBbJJEUJli+XKOGUgg7ByAD6EVWilf1/Of+aMlF2t/W0f8mY413U/7MXSvtP8AxOv7U+wGby1zsz5nmbcY/wBRz0xmuh1y8is9NJl1BrBpGEccscYkkLH+FEIO5iAcDB+lYul2Sar45ufEKWt1b28VqttF9pheEyyZO5/LcAjC7VDEc89q2dZ0WHWY7ffPPaz2swnt7i3K74nwVyNwKnIYjBBHNLov6/rv8zXq/wCv67fI4bUtVvdS8IeK7IapqLLYxo0dzcWQtp3R15R0aNRjIPIUZB/GvQLKCSx08Jc3txfMgLGadYw7DrjCKq/pWZH4QsRb6pFdXF5dnVo1ju5J5RubaCARtACnB7AAYGAK1bC0ksrNIJr24vmXP764Cb29jsVR+lD20JXmcHpHi3VL9dL1KKTVLk388Yl08aNKtvDC5xuWbyhyoIJYuVODgDIxd8ReI3sLp7vTdavZ/KuY4mtItO8y0++qOjzLGdrcn/loMHjHat2y8Mrp1yhsdV1GGyjfeunh4zCvOcAlC4XP8O7A6YxxVSTwNZSQzWp1DUVsJJzcCySRBHHIZPMJBCbiN2TtLFeelPTT+uw31C1l1PXda1JodVm0+0067FskEEMbGYhFZi5dWOCWwAu3gZyc8ZNnbapJqnjC4sdXksEg1DeiRQRv5ji1hJ371OV6cLtPXnpjo5vDaNq0t/Y6jfae9wyvcxWzJsnKgAFg6Ng4ABKlSQB6VYt9EtrY6oY3lP8Aakxmm3EfKTGsfy8cDCDrnnNTryu29vx0/wAh6X17/hqNsL59T8J29/Kqo91ZLMyr0BZMkD8647w5Jq+keCvCd+2qtNFOlnbPY+TGIhHIFUEHG/cAQcliCQeBnjubPTorHR4NNiZzDBAsCsxG4qF2gnjGce1U08NWaaDpmkiSfyNNMBhYsNzeTjbuOMHO0ZwB+FXdcza2uvuu7kK/Ik97P77I5G88XanLJql3p8uqGWxupILbTrfRpZobgRttIeURH5mIbBV1C8ZBwa1vFWtG3Wd7HW7+2ubW33m1s9O+1Kr4LDzsRuVBGOMpxzmtSXwyv26a4sNV1HTluJPMngtnj8uR8YLfOjFScc7SuevXmo7zwjbXd5fSrqF/bQ6iP9MtYJFVJzsCbiSpdTtAHysM4rN35bLf9f6/4Y005r9P6/r9THNzNqerS3cc0lnNceG45hJDtLRkuzcbgR+YrNisr9PDvgZYtWmlmnuYmSW5jjPkKbSTKqFVc4Gcbt3PXPSu0tPD1naTxyo0r+XYJYbXYYMa9CcDrz9Paq9n4Ut7SHToTf3txFpk/m2izMh8sCNowmQgJUBj1JbpzWmibt3/AFb/AFIV7a9v/bUvzRj3Wval4fXxDbTXTam+n2kFxbTXMaKxaVnQK/lqoKgoDkAHBP1raWG50bTbq51jxHLKGjA82eGFEgY8ZUKoJ5IwGLHoOamuPDthd3mpT3avMNStY7W4iZvkKJvxjHIP7w857DGKqP4TS402axv9Y1O9icoYjM8e63ZGDKyFUBJBAOW3ZxznmpY+pjWPiC8j1DVbKPUdQvUi0x7uKbUdO+zSRyKSMLmJA68g9DjHU5p0+s6xpfgu21m7v3uLvUhbRpFHah47YyEAsqIu9yAc4yckDAGcVsw+FIFup7u71C/vbq4tGs5Jp3TJjY54VVCqR7Adec1cl0Kzn8PxaPN5jW8UcaI4fbIpTG1gwxhgVByO4pLz8vzd/wALC1v/AF2X63Mjw1qt7ca1c2Msup31ksCzR3moaa9oyvuIaPmONW4wRgZ65zVXxBql3p+peKJrNo45bTQo54ZPJQsr5n5JIyR8o4OR145NdHpmlzae0jXGr32olwAPtflYQewjRfzOTUGoeGrPUpNTeeSdTqVkLKbYwG1Bv5XI4b94euR04plxsnr5fmjLW51fTNa0P7ZqjXqatI0M1u0MaRwsIXk3RlVDYymMMzcGotMv799c+y65q19YXsryrHZNbRC3lXnaYpNhLELhsFyeDlQK6G60e3u7rTJ5HkDabKZYQpGGJjaP5uORhz0xziqkXhsDUIbm71bUb1LeUywW9w8eyJ8EZyqBmwGIG5jTdrkK9jkrBLyy+G11dy6ncXxe8ZRHdwwOiH7YQSAIxknrznB6YrY061u/+E/8QTnWL0xwpARbFYfLYFHIU/u92ATkYIPqTWgPCNqLC7sPtt79iuZvOW3LJtgbzPMOw7N2C3ZicdsVcOhxjX31WC7uYXmRUuIEKGK4CghSwZSQRuP3SM981Lu1oMwF17Uj8PPD+pm5/wBMvJrBZ5Ni/OJJUV+MYGQx6DjtiqcUF5DceN7ttXu5kt3fbbTRwNE3+iowyPLzxnGM4IHIPJOuvgWzEFtbPqWpSWVncR3FpaNKmyAxuGUAhAzLxjDFuOmDg1dn8MwTXuoTJeXcMepRFLq2jKeXIxTZv5UsGCgDggcDINOWqlbrf8bf5MqLSav5fmZkN3qGqahZ6RZX76ZHFpcN3NNbwRl3LkqqrvVkVRsYn5e4xiqj67rcw0+wivIoroa1Jp1zciEESxrC7hgp4DY2njjcOmOK37rw3DN9lktL28sLq1g+zpc2zJvaPj5WDqykZAPK8c4xk0Q+F7CCPT1jafNjdNdq7PuaaVldWZyRzneTxjt2GKrRyv8A1v8A5aELRfL9LfnqV9Dur6HxHqejX19JqCWsEFxFcTRokmJDICp2KqnHl5BwOtQX/iG40S/11L5jMkNqt7YptALDGwxDA5PmAdef3grbh0qCDXLvVEaQz3UMULqSNoWMuRgYzn94c8+lVtX8OWWtX2n3V2ZVewl8xBGwAk5Vtr8cruRGxxyoqXqPYxdSvrm0sLW1u/EV/FqkFqrXK6bpwuWdyPvOqxPtUkHGAufWoLXXNZ1x/DKW14tgNU0qS5umjiVijDysFAwOD85HORzyDgVu3fhmG51ae+h1C+szdIsd1FbOgW4CggZJUspwSMoVNO0/wzZaY+ltbSTn+y7NrOAOwOUbZktxyf3Y9O9Nb3f9b/8AAA57UtdudAk8SzoVnmtY7KKKRrcM7PJ8m5xGoL8nO0fQYzTrHWdba8urTTX1HVN9hLNDPqelPZrFcLgLHkxxgq27pyRtOTzXRT+HbC6m1N7kSSLqaRpOhfAAQEKVIwQec5z1Axim2uhTW8c6Ta7ql2JIzGnnPEDED3UoikkerZqe9wWiRS8MX7XF1PBd6tqE94sYaWx1C1jheHnquxF3LnjILD3rU17Uzo3h3UNTWPzTZ20kwT+8VUnH6VmXHhi6WzvZLfWLy51Sa0e1t7u7dFNurdSoiRRnIBzgnIHNbb2UM2mmxuQZ4Hi8mQSksZFIwck9cinLVBGyeuxxmo2erQah4Um1HWGvxNqStLG8CIsbmCUjy9oBC9Rhix6c+tVfF+p3KyajaSapLIt60UemRaNK8DwrLsOZvK+/tBbIcKDxjiujh8HW6XNhLcapqV2NNlEtpHPKhWL5SuOFBYYbqxJ9+uZ08Mrb3ry2Gq6hZW8kxmks4Xj8pnJyx+ZCy5PJCsByfWmrX+f+X+Qne3y/z/zMyJtd1jWtfgt9caxisLlI7VYreJ8kwIxD7lOVy2eMNyfm6YzT4zutTh0SPzb3The6d9tuJdO097uQNkKEUCNwq53EllPYDrV618Nz3viHxJM17qempc3ca5t2CrcRiCMcb1OOdw3Jg9s8cbNz4Xs3hsl0+a40uSxi8i3ms2UMkfGUw4ZWHyjqD0zS6L5fl/nYp7nPJruvXdroMCyyWU93qc9pLNPZGNpoUjlZZBG4BViEU9MZ7EcVJd67quhQ63ZveHUJ7X7KLW5uYlDA3D+WN4jCqQp54AyOPeuh/sCN30yS6vbu6m02d545ZWTdIzI6HdhQMYc8ADoKS78N2F9NqT3XmSDUoY4Zk34ChN20qRyDls5z1AxTYuphtZajY+PNAS91WTUo2gujvnijR1bamcbFUbfYjI9TVPTdR1WfT/DVpY3cdmL+a7W4eO3j4VC5BVcbQ3HXGOckGuitPC0UGrWupXep6hqF3aJJHE9y6YCOBkYRFHYc4z6k0+z8MWVj/ZnlSzn+zWmaHcw+YyZ3buOfvHGMVLQtbmJPrOr6Zp+u2zXjXkmnTwKt7LCgdIpAhd2VQFJQFjkADA5HBzP4Xurq88Q37Q+I59c0iOCLyZ9tuYzKxbeu+KNdxAVeh43c1J4m0gx2Goy2qXMg1SaJb0xJ5jwxqNpeNAMseBx83XoRwU8O3OqS60QL3U7/AEv7Oxkm1SwW1dJdy7VQeXGSCN2cqRwMHtTjq/67f18xvb+v6/4BYvrjUNT8VS6PY6jLpkNraR3Ms0ESPJIzs6qoMisoUBDnjJyORjnIbXtbuW0mwivIobl9Xn0+6uFhBEiRxSMHVTkBiFU+gbPBHFdJqegpf3qXtve3enXiR+Ubi0KbnjznawdWUjPI4yMnBGTUcPhewtxpvkmZTp1xJcoS+4yyOrq7OSMknzGPbnHbihef9a/5A/L+tP8APUh0K5vo9c1TSL+9e/W0WGWK4mjRJCJA2VbYqqcFOCAOtUIbS7l+KV+41e9SGOwtpPs6rCY2BeUbDmMtjjOQQeTz0A6KDTIbfV7vUUaQzXccccikjaAm7GOM/wARzzUE+iRya9Hq0F3c204jWKZIihS4RSSquGU9CzcqVPPWn1TD7LX9bnFaPJq+leBLfWItVYRw3TAWIhj8p42uSpDErv3YJOQwA44Pe7q3iW+l13VrW0vNRs/7NKxwR2ejyXSTyGMOfMZY2wvzAbVKngnPIrox4Zsx4aGiebP9mD79+4b8+Z5nXGOvt0pL3w4txqMl9Y6nf6ZPOFE5tGj2zbRgFlkRgDjjIwcY54FQk7WGhZNblt/BLa5d2ckM0dgbuS1dSrIwj3FCDyCDxWDrVpqi/D3Wb3VNZlvGn0mVmthDGkMbGPPyYXfgcj5mauxNtG9mbWfM0bR+W/mc7xjBz65rDXwhGNLutMk1fU5rC4tWtUt5ZIyIEYY+Vtm4kDgFi1U9W/67/wDACDty36f8D/gmfcahcWuqa41uY0e20CGaJxEu4P8AvurYyR8o4OR145NEN5rVjJ4dvL3VWuxqsqQXFqYI1ijLQu+6Mhd4IKD7zMDk8Ctubw7aTz30ryTBr2xWxkwwwEXfgjj737w+o6cVJNodtPFpaO8oGlyrLDgj5iqMg3ccjDHpjmn9q/p+bv8AgT0t5fjZW/E5ey1a/ks7TT7KaO0n1DWb2FrlLdP3UcckrEhcbS5CgZYHqScmtvUHbStHitr3xDei4lkIjuEtY5LmQdSqRpGQSB6IeKe3hOxOnC1Sa5ieO8kvYblHAlhldmYlTjGPnYYIIIODmkn8L/aI7R5NZ1L7dZs5ivwYfNAcYZSPL2FSAONvYd6XQp/Ff1/U5ePWJ9VsbeO5mnuPsPiS3t0nubY28si7VcF4yq4Pz4+6M4BxzXWeJ9SutP0+3TT2WO5vLuK0jldNwi3tgtjvgZwOmcVDb+DrC3VgLi8kZ9QTUXeWUMzTKqr1I+6doOPywMAaeq6Xbaxp7Wl4HCFldXjba8bqQysp7EEA0dLea/KN/wAmT9q/l+r/AM0YmovqmkQ2Gnx6xPdXOqXogW8uYIt0CeWztgIiqThCBkHk85xiqOq6tq+g2uu2Tai95LbaS9/aXcsUYkRhuBVgqhDghSPlHcHOK228NLcacbbUNUv72RZlmhupWjWWB16FNiKo79Qc5IOQcVH/AMIlay2GpQXt7eXk+pW/2ae8mZPN8vBAVQqhFA3E8L1OTmj+vw/zKVrr+uuv4FJbnV9M1rQ/tmqNepq0jQzW7QxpHCwheTdGVUNjKYwzNwawtbm1jWvh1qmtnVDHDMsgTT/ITyliWQrycb9+BnO7GT92u5utHt7u60yeR5A2mymWEKRhiY2j+bjkYc9Mc4rIu/A1leWt3ZNqGoxaddM0jWMUqCNXZtxZTt3D5udu7bntTdr6Eq9jG8VzXEn/AAmUMNwbbyNDglWSGOMSHP2jILFSSDtAx2ycYJzWpEtxp+ueHrae9lv/ADIbh2muYYfMGETABRFwPpye+a1rjw7Y3V1qU1z5kg1O0SzuIy2F8td+MYGQT5jc59OlNtPDyW89hPcaheXs1gJFie4MeSrgDB2oucBRg9fUmk+thvp/XRf5HOJrGsnwnH4vOpsYnCznTDBGIhCXxtDY379p67sbv4ccVbWXW9U1bxCkOtSWMGnXCrbLDbxMT+4RyHLqcrlu2G5PzdMXx4OsxII/tt8dOWbz10zzF8gPu3/3d+N3O3dt9scVo22kW9rcalNG8hbUZRLKGIwpEap8vHAwo655pO9nbt/kUrX1OXm13Vb7RdE1SSa807T7vT0uLm4022Sd45WCnDKyuQmCeQp9yK6hdQjh8O/2glwL6KO184Tpj98Audwxxz7VRTwwbfTLCx07WtTsYbK2S2XyWiJkRRgFt8bDPHVQDWnY6dbafpcOn2yf6NDGIlVyWyuMck9ac9ebl+X4kx0auc3Bfarp/hKbxRqWpy3Z/s5rs2CQxrCh2bwFIXfx0yWOetP8/WdGn0m4vtWbUI9QuEt7iB4I0WJnUkNFtAbAYAYYtwevFaFh4Xh0+NrUX97cab5TQpp1wyNDGhGNoOzeQBwAzHim2XhWC0urWWbUL++jsjmzgupFZLc7SuRhQzEKSAXLHmnpfTYWvLbrr/wDmbjU/Eg8L6nr0Wt7JLK/nigtTaxmJ40nKAScbiccZVl6Dqck7kU2q6V4iWxu9Vk1GK50+a5BmhjQwyRsgwuxR8p8zo2SMdavN4Xsn0C70gyz/Z7qaSZ23LvDPIZDg4xjJ9OlXLjSoLnVIr+RpBLFby2yhSNpWQoSenX5Bj8al3tp2/T/ADL05m3tf9TiLS98TyeHfDOqN4g3T6w0Ec8TWkXlRrJGW3IAA28Y7sVz/DjitK51rU/D1t4giuLxtUewt4Z7aa4iRWzKWUK/lhQQGXOQAcH8a24fDdnDpOkaesk5i0homgYsNzeWhUbuOeDzjFS3Gg2V3cahJdI0y6hbpbzxMflKLuxjHIPznnPp0qpWfNbu7emn/BIV9DK83VdC1zSoL7VpNTh1OV4HWWGNDFII2kDJsA+X5GBDbjyOeDnIt9U18eEYfEc+sFnS42GzW3jEUkfn+X8x2792OchgM44PfpbHw3Ha38N3dajfajJbqy232t0IgBGDjaq5OONzbjjPPJyo8M2Y8NDRPNn+zB9+/cN+fM8zrjHX26UnumBz97e3emat4l1GzfC2dzaTXKbQfMgEQ8wcjjCktx3Wt7TtQuNR8UaisMwOnWUccIUKMPMw3sc4zwrRjrjk0l/DZ6N/aN/Jb3l42pFUkt4IGm3EJtAAVTgEDktx7ik8HaLJoPhWzsrjJudvmXBL7j5jckZ746Z9AKURvoZ8761qfifWrO11qTT7WxiheEQ28TsXdWJ3F1bK8DjGfcVT0jUtdk0vw7rd7qvnDVJIknslt0WFFkUkFDjeGBA6sQeeBxjqodKgg1K+vkaQy3yxrICRtGwEDHHv71Xt/DtpbaRpenJJMYdMaNoWLDc2wYG7jB684AoWn3r7r6h0+/8A4BzviLxG9hdPd6brV7P5VzHE1pFp3mWn31R0eZYztbk/8tBg8Y7Ve3azqviXWrODWZNPtbIw+T5EETPuaMMQxdWBXPPTPPUVJJ4GspIZrU6hqK2Ek5uBZJIgjjkMnmEghNxG7J2livPStq20yG11G+vY2kMl8yGQMRgbV2jHHp9aNbD6nNReIjqXhPR7q61W5069vLYTumm2guJZOBuKxlJCFyeu09QM1Ti8U3s/hjTbi81I6fDLfz2l3qjwLE0SRmQIzLIu2NmKKDuXAJIwCRjah8F2tpDp407Ub+ylsbb7Is8LRl5Ysg7X3IV6jOQAfesvV9FGi2+m2Nk+pw6fFczXj3trC13cRTMSVG3a+QfMk5ZWxgdDg1X9fj/l+IadP60/zKq6/qmm+G7q7bVbnUxc6olnY3jWqSDyWI/eokMYL/xY6hioI4NSf8JTqWm2Gsun9oahDa2qS2t3qWmvanzWYqY2HlxhgPlbKjoTk960tKsrvXLG+tNZlvrmw8yN7K6u4Ra3O4fMW2qqFdrAYJVT1yCOunH4eV9Pu7PVdSvdWgu4/LdbsxjavPA8tEx169enNLpr/Wi/XUX9fj/loYd1Y6nZeL/DAvtXk1FHmnLedDGhR/Ib7uwD5evByenNWfGMdxNrfhaOznFtK2pSAS7AxUfZpskA8ZxnGcjOOD0q7beFIotSsb+71TUb+ewL/ZzcyJhFZCpUhUXPB6nLcDnrm3rOg22ttZvcTXEMljMZ4JLeTayvtKg9DnAY8Hg98jimJdTm77VtZ0ebU7T7dJff2XFb6h50kKCSWBncSxsFULkKjEFQD0H13LDUp9S8U3yW84Om2cEceFAIkmf5yc4zwhTocfPUf2G08OWl3eXR1DVrm72pNKYDPNKACFTbEgCqMnsAMknrml8F6I+geFbW0nUrcMDLMGfeVZv4d3faMLn0Wkv6/r0/HUb/AK/r1/rQz4bS7l+KOoONXvUhjsLaT7OqwmNgXlGw5jLY4zkEHk89AMXRptX0jwFpmrpqjGNJ4ovsAhj8lo3uBHyxXfvw2chgM9q7WfRI5Nej1aG7ubacRrFMkRQpcIpJVXDKehZuVKnnrUP/AAjFl/wjUOh+bP8AZoXjdX3LvJSQSDJxjqB26ULp/XUbs5P5fkc7q3iW+l13VrW0vNRs/wCzSscEdno8l0k8hjDnzGWNsL8wG1Sp4JzyK37u/nufAM+oTWxtriTTWme3mjyY3MWSrKw7Hggj60+98OLcajJfWOp3+mTzhRObRo9s20YBZZEYA44yMHGOeBV+5sI7vSZdPmkkMc0Bgd93zkFdpOfWpkm4NdRppTT6HMwT6tqGs2em2upHT7Q6PFcu0EEZkDlsfLuUqBjqMEcDGKiXVteufDitFJPI1tqU9peXVnAjT+VGzqJEjYFSxITICnvhew6S10S2s9QjvInlMkdmlmAxGNinIPTrz/8AWquPDaw2ckFhqd/YtJdy3ZlgaMtukYsy4ZCpXLcAg9uatvX7/wA9PwIW33flr+JzWotJqq+F20/xPfyo+pPE1wsUKSbhDKfnRosBlxjBUdTkZwRF4oa6fTvGNul5JE1vaW37+OKJZJAUbcHbZzn9O2K6V/CVq2nxwLeXqXMd0bxb4Ohm84gqX5UpypIxtxjtU0vhmyuY9TW7knnGqQJDcFmAJCKVBG0DB5z9emKT2/rsPdp/1uyt5t9puvaJpz6lPeR3CXDTSXCRB5NoUr9xFAxk9APfNc/4pvNQvrPxDbLqM9tHZ6pYxQ+SseQj+QWUllOeXJ+uB04rpp/DX2m2sxLrGo/bLJmaG/BiEwDDBUjy9hGOOV7A9eaiTwbp4sdStpJ7uY6lKk880koLiRQu11OMAgopxjAI4GOKXX+vIcdCpJdTaR4nZLid74W2iyztNNFEJpCJAcbkReMcYAA74zzVZNQ1qw0nSddvNUN0l9LbLcWPkRrFGs7Ko8sgB8qXH3mbIB4GeOgttCjhv0vbm7uL24W1NqzziP8AeIW3ZIVVGe3AAx2qpa+ELW1ltgb6+ns7Nw9rYyyKYYCPu4woZtvYMzAcegpx0tf+tW/xViX1t/Wi/W5iXF/r76L4h1dNZaAaTcXX2a3S3jKSpFkhZCVJPTHylTjuTXYi9jXSxe3MiW8Xk+a7uwCxjGSST2FUj4dtG0fVNNMk3k6m0zTNuG5fNBDbeMDrxkH8as3mk2uoaHLpN2rSWs0BgcZwSuMdR3pK/LbyX321K0v8393Q5jStcuB4ts7BdV1DUre8gldje6abdUZdpBifykDAgnjLdjn1qW2q6/H4RsPEdzq7Su08Ub2Yt4xFIjziPJO3eHw2chgM9q6Oz8Lx2+p2uoXWp6hqFzaI8cT3LphVYAEbURQeg5xn1Jp//CMWX/CNQ6H5s/2aF43V9y7yUkEgycY6gdulPqv66iXmZUk2sa3ca5Jaao1jDp0rW0FusCMszCNWLSlhuwS2AEK8DOTmrng6NpfhroccczwM2lwASxhSyHyhyNwIz9QRU134Vt7m+up4r6+tI77/AI/Le3kVY7g7QuTlSynaAMoVPArR0rTodI0e0022LtBaQJBGZCCxVVAGcY5wKPsNd7fhe/5je/3/AKHnVlbah/wrrwxKuqz3E9zfWbRm6jjKwEsc4CKpbrn5ienWuil1e+8OXurw319NqsFppZ1GNp440kBUsCmY1UEHaMcZHPJq/beEbW2tLe0W9vHtLW6jubWB2TbBsJIRSE3Fef4iTwMEVoSaPazarLfzbnea1+yPG2ChTcT0x15PelrZ26t/+kpL8Q05r+n56/gcroev6pLqulh59U1BL4EXiTaNLbQ2p2Fg0btEvy5G3DMxO4HNbWvXl6+t6XounXbWLXqzTS3SRq7okYX5UDArklxyQeAeKn0zw+2lzx+VrGpTWsK7YrOd42jQYwBu2b2x/tMam1fRYtWNvJ9ouLO6tXLQXVsyiSPIwR8wKkEdQQR09BVO3QSv1OOku9U0OHxncrdrcXlvJbGGdo1UuPLXG4AYzzgkADuAK3buXVdJvtEhn1R7pr/USk4MMaqE8iRtiALkLuUHklvepR4NsfsWp28t1eStqjI11NJIpdmQAAj5cDoOAMegFaOsaPDrMEKyTT201vKJoLi3YB4nAIyNwIPBIwQRg0lo/uDv8zC1bXdUtNU8SR2X74WOm289vD5Yba7tMGbjluEU4z/Dx1qlp99qt3qd83h7xK/iG2i05nhLC2MP2okhUZ4419jjcCO/UVa1fw0dP0vVrm0e+1K71SGG1vHlYO5iDFWdUQL8wSRjtXAOBgZzlmkHU7rUEtbbU9autNeCRLibULBbNoGwAhiPlRsW69mHHUdzd/12/r5jf9fh/TL/AIYv2uLqeC71bUJ7xYw0tjqFrHC8PPVdiLuXPGQWHvXSVk6doIsb8311qN7qV15RhSW7MY8tCQSoEaKOSByQTwOa1qZKCiiikMKKKKACiiigAooooAKKzfEWoy6R4Z1LUbZUaa0tZJkWQEqWVSRnBBxx61BqGsXFpqGgQRpGV1K4aKYsDlQIJJPl54OUHXPGaA2V/wCtDZorl9A16/1bVHjubzToGjLebpRt3W6hAJAJZn+YHjkIAc8E0g8TXh8AjW/Kg+0mXZs2nZjz/L6Zz09+tAdbHU1DJe2sMjpNcwxvHH5zq0gBVP7xHZeDz0rnPF3iOfw+jzx6xodoscJkW0vyRLckZO1W8xducYB2tz2rP1i4F3qOq3CqVE3hgyAHtkualysrrz/Jv9Cktbf1ul+p3COskavGwdGAKspyCPUGlrl9L142Cta6n5cdtb6VFewSgEFowmJAeeSpAPbhhWha6jf/APCGjU7+GKO9+xm4aJQdqHaWCnnPHAPPr0qp2jd9F/wf8iI3lbz/AOB/mbFFchbeINchs9G1TVU0/wCw6m8MbwQo4kt2lA2neWIcbiARtXGepxzYsNc1S7m1G7uBaW2maZc3EUv7tmknWPOCp3AJjjJIOeeBwaHpe/S/4W/zQ1ra3X9b/wCR09FcHo/xBF9f6UJdS0S5XVXCCxspw1xZkoWXed539Npwq4J71qaBr9/qupul1eadbtGX87SmgdbqAAkAlmf5gcDkIAc8E0AdRRXOaHqms61bRawHsIdKuFZ4rbyXaYpzsYybwoJ4JXZxnGaxpda1jUvhw+t6nDYiC4s43W0RZAxYsuWLhxhTk4UcjjLHkUA9DuFuYHuZLdJo2njVXeIMCyq2cEjqAdpx64PpUlcaw1Z/iVrCaPJZwE6bZl5rqJpQMPPhQisvXnndxjoc8RXPj4JYadHLcabpV7dzXEEs1/L+4gMDbHI+ZS+WxtXKnBznigOv9drnb1H9oh+0m382Pzwm8xbhu25xux1xnjNcda+OZb7S/LsH0+81FtSGmxXEEha2kYp5nmjBJ2hMkrnORjPerGlf2kvxGuY9Xa2lkXSo9s9sjRrIDK38DMxUj/eOf0o6pf1tf/IHor/1vY6n7RD9pNv5sfnhN5i3DdtzjdjrjPGakrkb8am/xIaPSHtYXbSVLz3MbSKmJmwNispOf94Yx3qS18U3pksxeQ26KuoyabfNHkhZcfu3Uk8Kx2jByQXAzxki1S/rrb/IHo3/AF0udVTJ54rW3knuZUhhjUs8kjBVRR1JJ4ArN0fU59UvdUO2MWdtc/ZrdlB3OVUeYSc4wHJXp/Ca46/l1ufwz45OoajbXFrALmJIltXVlxAhG1jIQFwem3k5OecUr/lf8v8AMpK7S87HooIZQVIIIyCO9LXL2uq61Yaho0GrCxe31QmFIreNw9s4iaTlyxEgwhGQq844rGHxKiaRbxdT0U2zXgthpgmBvCnm+X5n3+v8WzZ0/iqmvesQnpc9BqM3MC3S2zTRid0LrEWG5lBALAdSASOfcVneItWk0fS1ltokmup547a3SRtqmSRgoJPoM5OOcCuca41Kw+IVrLr0lpMlvol3KJ7WJogwEkJYFGZsYwOdxznoMUk1fXbX8Fcq39fOx3FFclD4g1uCy07V9SSx/s7UJIUNvCjiW2ExAQmQsQ/LKCNq4yTk45t2Op6zrWoXE2nSWFvptrdvbFZoXklm2NtdgwdQnIIAw2cZ707O9v66f5oV9L/1/Wh0VFcNpGuaxpvh7W9X1q8tr+K0u7mOOCO3aJy6ylFG8yMAp4AG3jPU99eLU9Z03V9PtdeNjNFqTtFG9pE8ZgkCF9p3M28EK3zfLyBxzwlrYHo2u36HRUVyFh4h8QXnhmfXBaWrxxxyiKziidpZWVyu/IY4HB+UKxPqCcVq+G9Rn1O3lml1XTdSjDBVaxgaIxnurq0jkEceh9qFqBtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdU0+LVtIu9OuSwhuoXhcocEBgQce/NYcXhnU5tS0i71XWo7n+ypWeKOCz8pZA0TR/Pl2+b5s5GB1+XnI6aijYOljn08P6hcaxZXmr6nb3SafI0luIbLypCWUp8772yMN0VVyQPTFUJfBd7JpT6Outqmlifz4o1tP3q/vfM2NJvwy59FB6ZJ5z19FAbnLXnhG7muNZFnq621rrOTcqbXfMp8sR/JIWwFwo4KnHOCM1Zl8LeZ53+mY83SRpv+q6dfn6+/T9a6CilZWt/WzX5Md3e/9dH+hw3iGws9UvtD8P2l2s19assd6sRBZLTYC4kHO0PtQDPXIxXVa5/yLuo/9esv/oBq/RRNc8Wn1CNotNdDjfD/AIfvrvQ9A/tHVhcafaQwXENuLfbIzqgK+ZJuIYKTkAKvQZJ77+naKlla39vNILiO9uZp2BXbgSHlevP1rToqpWk2+/6/8MiYrlSXb9P+HMPSdH1bSjb2v9sRT6ZbKEjiezxOVAwoaXfg445CAnFRr4f1C51iyvNY1O3uk0+RpLcQ2XlSEspT533tkYboqrkgemK6Cii+tx9LGBpWgahpBWzttUibSI9witntMyopzhPND42gnj5M4AGaQ+Fs+A4vDf2z/V20cH2nyuu3HO3PfHTNdBRS6WB6nP3fh/UP+EiutZ0nVo7We5tordop7Xzo9qFzuwHU7vnOOcDnIPaNfCX2Wzsf7Mv2g1CyeWRbuWISCVpTul3pkZDNzgEYwMGukooAwrvQr/UdLiS/1OM6hb3C3NvdQWuxI3AwB5ZZsggsCN2SGPIpdM0K8tvEEusanqa3dxLarbGOK38qNQrlgVBZiOvOSf6VuUUdb/1tYP6/UwtR0G9m8QjWdL1NbS4FqLURzW3nRMu8sSwDKSemMEY565rJ120sdC8G3en3V75+p6g0k8HRZbq7yGUxp7NswBnAAye9dnRStpb+u4+tzO0DTTpGg2lk7b5Y48zSf35D8zt+LEn8ay7zwrc3EWu2sOpRx2WspIXje2LPFK0YQsH3gFcKDtK5z/FXS0U3q7iWljLvdF+2XujXHn7P7LnaXbsz5uYXjx14+/nv0xVSy0HU9LmEGmatDHpfnNL9mms98iBmLMiyBwAuScZUkZ61v0U763FbSxn63pK6zpptjM9vIsiTQzIMmORGDK2D15HI7jIrNt/DV5Lryaprepx3riylsmghtfJiKuyMSAXYg/Jg8nPGMY56Kil/X6fkM5m38KXYjsbK+1YXOlafJHJb2/2bbKxj5jEkm4hgpAPCqSVGT1zZt9C1DT9Tmk0rVIobC5uTczWs1p5jBmOX2OHXaGOTyrck4rdop3d7/wBf1oBzqeFCbbVtOnvFk0vUXllEIhKzRSSNuYiTdggNkgbcj1NSWug38mqWl5rmqR332HcbVIrXyQGZdpd/mbc20kcbR8x46Y3qKS0B6mRpujT6V4aXTLO+CzpvKXJhyAWctymeRzjr+VUo/DmqB9RvW1mGHVryCOBbq1sAiRhCSD5bO25vmIyW6YwBXSUUB0sA6DPNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVk+I9UudL0sHTYo57+4kWG2ik+6zHk5wQcBQx/CrunX0ep6ZbXsGfLuIlkUHqMjOD71XK+XmFzK9izRWVe3txF4n0u0jkxBcQ3DSJtHzFdm3nqMbjU2u30umeH9QvrdUaW2t5JUDglSVUkZx24qVq7IZforml1PW7C/0tNTl0+7h1CXytttbvDJGdhbdy77gNvPTGc10Ny7R2srocMqEg++KqpHkV2TB85JRWd4dupr7wxpl3dP5k89pFJI+ANzMgJOBwOTVS51PUrzWp9N0NbaP7Iqm5urpWdVZhkIqKVJOOSdwxkdc0+R8zXYOZctzcoqvYi9W0Uam8D3AJ3NboyoRnjgkkce5qhbX1xJ4x1GxeTNtDZW0sabR8rO8wY568hF/KptqUtVc16KyPEmo3em6bC+nGATzXcNurToXVd7hScBlJxn1FVxqWraVqNnBrn2O5t72TyY7m0jaLy5MEqrIzNkHBGQ3XAxzmrjTcldEOaTsb9FR3LtHayuhwyoSD74ql4dupr7wxpl3dP5k89pFJI+ANzMgJOBwOTWe9/wCu/wDkX2NGiuekvdcvPEmoWGmXOn20FnHC2bi0eVnLhj1EqgY2+lb0IlECC4ZHlCjeyKVUnuQCTge2TVyjy9SVK+w+isnRb24u73WY7iTettfeTENoG1PKjbHHXlj19aj12/1GDUtLsdKktYnvZJFaS5haUKFQtwFdfT1pRjzNel/wuDkkvw/GxtUVVsEv47cjVLi3nm3cNbQNEuPTDOxz15zVRL24PjCaxMn+jrYRzBNo4cyOCc9egFS9Hb+u41tf+uxq0VQ1rVF0fTHujE08hZY4YVODLIzBVXPbJI57VXtU8R/aYpL2fS/IY/vYIoJNyD2kL4b/AL4FWo3VxOVnY16KbKSsLkdQpIrN8MXk+o+E9Jvbx/MuLizillfAG5mQEnA4HJ7VHf8Ar+tijUorMtdSmn8S6jp7qghtYYJEYA7iX35zz/sj9aXT9Rlu9Y1W1kVBHZyxpGVByQ0asc8+pq+R/hf8v8yVJM0qKyNYvri11bQ4YJNkd3etFMNoO9RBK4HPT5lU8elaV1KYbSaVcFkRmGemQKgu2qRLRVHRL2TUvD+n306qstzbRyuEBCgsoJxntzUGn3k8/iHV7aWTdDbmHyl2gbdyZPPU8+tOScXysiMlKKkupq0VmaxqUmnTaasYjK3V4IJC4Pyrsdsjnr8opuk6ncavcTXMMappeNtvIwO+4OeZBzwnYcZPXpjNcj5eboNySdjVorK1y8nszpv2aTZ59/HDJ8oO5CDkc/StU9Kzvo3/AF0f6j62Cis3w9qMureHrK/uVRZbiIOwjBCg+2SaZ4ovbjTvCWrXtnJ5dxb2cskT7QdrBSQcHg8+tXKLjJxY4+81Y1aKRDmNSepFc5pHiO5vPF2qaTeRwpDA5Fo6Ahn2hC4bJwSPMQjGODTjByvboZuaSTfU6SiudtPENzd+OrjSUji+wxW7kSYO9pUMe7nONo8zHTqDzV3xLeT6f4euLm0k8uZCm1toOMuoPB46E0pRcUm+uo1JNtLoatFFc3oPiWfUNav9O1GGKFknlFm8ecTRxvsYHJ++CAT7MD60Ri5JtdBtpbnSUVl+HtTm1bS3ublY1dbq4hAjBA2xzOg6k84UZ96bLe3C+MbSxWTFtJYzTMm0cuskYBz16MfzocWpcrBSTjzf12NaiqWsammj6TPfSo0oiUbY06uxOFUe5JA/Gsi71HxDpFg2qammnzWsK77i2tkcSRJ/EVcsQ5A5xtXOKcYOQnKx0lFIrB1DKcqwyCO9ZegXtxe29611JvMV/PCh2gYRXIUcegqOtv6/rUrpc1aKw9XvtUXXbDTdJls4DcQzSvJcwNLjYUAACuv9/wDSptC1S5v/ALdb38cS3VhcfZ5GgJ8uT5FcMAeRww4OcHuavkfLzf1vb8yeZXt/Xc1qKyLi+uE8ZWFismLaaxuJXTaOWV4Qpz14Dt+dW9X1KPR9JuL+dWdIE3bE+856BR7kkD8alJu1uv8AnYp6FyiubutQ8R6Xp76pqEeny20K+ZPZ26OJY0HLFZC2HIHONq5x1FdFHIssayRncjgMpHcGqlBxVyVK46isnRb24u73WY7iTettfeTENoG1PKjbHHXlj19ai1m+1OPWdO0/SZbSE3UczvJcwNLjZtwAFdf73rSjHmaXdX/C427XNuisnQ9Surx7611FIRdWM4hd4M+XICiuGAOSvDcjJxjrRqt7cW2s6JBDJtjurmSOZdoO5RC7Ac9OVB49KHFp2BO6ua1FVdTvf7O0m7vfKab7PC8vlr1baCcfpVHR5dauRDdXtzpstpPEHC2sTgrkZGHLkOPfC0KN1cG7NI2KKyvEt5Pp/h64ubSTy5kKbW2g4y6g8HjoTWqc7Tt4PbNSMKK5U3XikeIk0r+0NI+a0a583+zpeMOF248/3znNdSM7RuwTjnAq5Q5ba3uRGXM2rbC0VleGryfUPDtrdXcnmTSBtzbQM4YjoOOgp6ajK3imbTSqeTHZpOGwd25nZSOuMYUdqmK5ti3ojSorMstSmuPEWp2DqgitEgaMgHcd4YnPP+yKbrd7cWlxpK28mwXF+sMo2g7kKOcc9OQOlEk4tJ9bfiJNNNrz/A1aKq6nJdxaXdSacsb3aRM0KyglWYDgHBBrMvPELN4csL/S0V59SeFLZJASAZCM5AIPyruJ5/hqowcthOSW/wDVjdopspKwuR1Ckis3wxeT6j4T0m9vH8y4uLOKWV8AbmZAScDgcntUd/6/rYo1KK5+TxFLaReITeJHu0s74lQH95G0YZM89S25ePSoIfEl8/hezuZIIV1Sa8SylhAJRZPN2OQM5wAGYc9MVqqUn+H4kOpFfj+B09FNlJWFyOoUkVm+GLyfUfCek3t4/mXFxZxSyvgDczICTgcDk9qy7/1/WxZqUVhyeIf7Pu9Vh1cIi2kYuYGjB/ewkY6EnLBgQceq+taWlyXkul28mpxxxXboGljjB2oTzt5J6dM9yKpxaV2TzK9i1RWRo19cXep65FcSb0tb5YoRtA2r5ETY46/MzHn1qzqSamyodLu7O2C5MhurZpc+mNsiY7+tJLa5T0L1FYfhXUdS1XTZbvUjbPE8zC0kt4Wi82IcByrM2MnJHPTB71Pe3txF4n0u0jkxBcQ3DSJtHzFdm3nqMbjTnHklysmL5lc1aKKKkoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDnNR0281nxSjR3V3p0Gmw5inijQ+ZLJkNjzFYHaoxkD+M89ak8MWlzpLX+k3DTTRQTedb3MiAeYkmWIyoC5D7+B0BXit+itfaPl5ehHIubmMPUf+R00T/rhdf+06n8UQy3HhHVobeN5ZZLOVURFLMxKHAAHU1bm0+KfVLW/dnEtqkiIARtIfbnPH+yKtVlHR3LOEtbSx+2aX/wAIrolxp10k8Zup/wCzpLRPJA+dXLKofPQDnnB4612t3/x4z/8AXNv5VNTZEEsTxtnDKVOPerrTdRWIpQVNoyvCX/Il6L/14Qf+ixVEyz+H/Euo3E9ldXFhqPlyrNawtM0UiqEKsigtghVIIBHXNbmnWMemaXa2MDM0VrCkKFyCxCgAZx34qzVc652+jEovlS7EFndre2iXEcc0SvnCzxNG/XHKsAR+NZFn/wAlB1f/ALB1n/6MuK3qqRabDFrFxqSs5muIY4XUkbQqFyMcZz+8OefSs9Lmi+Fp/wBaozPF4k/sq1kjgnnEOoW0rrBE0jBVlUsdqgk4A7Cq9zcTeJdR0+G0sbuGytblbqe5u4GgyUBKoquAxJbBJxjAPNdNRWkanLG1tTOUOZ37q35/5kN3/wAeM/8A1zb+VZ3hL/kS9F/68IP/AEWK1ZEEsTxtnDKVOPeoNOsY9M0u1sYGZorWFIULkFiFAAzjvxWS6/L9f8y3uvn+hyOoWekf8Jnqk3iDQpb9JIbcW8v9lSXS8BtwDKjAdRXZWxja0iMCGOIoNiNGUKjHA2kAj6EcVLRWk6nMkuxEYcrbMLw7/wAhLxD/ANhP/wBoRVF4j0ttT13QkZboQRyzGWS2leIp+6OMuhBXJ4689K17LTorGa8lhZ2a8n8+TcRgNsVcDjphB+tW6UJONmu1vwsOUeZNPv8Arcr2NjHp9sIIXuJFBJzcXDzN/wB9OSf1rLj/AOSgXH/YMi/9GyVuVVXT4l1h9SDP5zwLAVyNu0MWB6Zzlj3qHdyTfn+TLslFpf1qij4nsLm+0lDYIsl1a3EV1FEzbRIY3DbM9sgEZ96xdTvm1a906TT7bXrW9S6gEsbR3EUSxiQF9+P3TcZ5yc12VFawqcvy/r7jOcOa/mrDJv8AUSf7p/lWP4L/AORD0L/sHwf+ixW0y70KnoRiq2l6fFpOk2mn2zO0NpCkKNIQWKqABnAHPFZrZ/L9TXoYLeHbHVPGmqXGsaTBdxfZrZYZLm3DrnMm4KSPpnHtVjw5pUWk6vrkVnYrZ2j3ETQrHF5aN+6XJXAwec9O9dBRWjqyaa6Wt+X+RkqcU79TB8Qf8h3wz/2EX/8ASWate9Uvp9wqgsxiYAAck4qO802G9u7G4lZw9jMZowpGCxjZOeOmHPpzirdZdDa+qf8AW7MvwzFJb+E9JhnjaKWOyhV0dSGUhACCD0NQaV/yNmvfW3/9F1t1Vt9PittQu7xGcyXezzASMDauBjinN80uYzhHkio9jJ8V6YNVGk28tvJPB/aCtOqA4CeW+dxHRckA9ucd6foMV1pFzJok6TS2sK77G5Kkr5WceUzdmXoM9Vx6Gt2ir9o+Xk6A4py5upieJfvaP/2E4f5NW2ehqrfafFqH2bzmdfs06zpsIGWXOAeOnNWqyS0a8/0X+RT3v5fqzlfCGqx2+h6bpdxZ6lDdJGI2EmnTqin3cptx75xV7xt/yIeu/wDXhN/6Aa3Kq6pp0Wr6Rd6dcs6w3ULQu0ZAYBhg4yDzzWtSSnLmS3CneLVyxH/q1+gribqzv7P+1dXtLGea6stXNzDCqHdcRGGNHC+uQTj3X2rtwNqgDsMUtEJ8jbM3Dmik+n+TX6nK6RpNzp/iLTPNjdiumT/aJwp2mZ5Y3bn1J3ED0FX/ABj/AMind/WP/wBGLW3VXUtPi1XT5LO4Z1jk25KEA8MD3B9KmpJz/r5jjHlv/XRL9C1XIw6JdXWj3jwo1tqNtqlxdWTyKR83mNj6oykg+oNddRTjNx2KaTVmc/4JWdfDKtd2k9nLLdXMpgnXDpundgD+fXvT5/8AkoNj/wBgy4/9Gw1u1UfTon1iLUiz+dFA8CqCNpVmViemc5Qd/WiUuapzev5MlRtDl9PzuVvEmnz6noM0Fnt+0qyTQhzgM6OHAJ9CVx+NZWq6tca3otxpVhpWoQ3t5EYH+02rJHbhhhmaQ/I2AScKTntXU0U4zSVmvMbTvdMZDEILeOJeRGoUZ9hisbwr/wAeuo/9hO6/9GGtyqun6fFp0cyQM7CaeSdt5BwztuIGB0yaz15rvt+qKslFJd/0Zja1pP8AafizSzKLtbeO1uN8ttNJDtYtHgF0IPODxnnHtW1Yafa6Za/Z7KLy49xY8lizHqzMclifUkmrNFW5txUei/zuTyq7Zg3f/JQtL/7Bt3/6Mt6t+I9Om1Tw/dWtoVFwQrw7/ul0YMoPtlRViTTYZNZt9TZn86CCSBVBG0q7ISTxnOYx39at0oycbNbr/Nsp2ZyOr+JDf6c2jW1heW+rajE8EcN1AY0QlcM3mH5WCg5+Ukn0rqbW3W1s4bdDlYY1QE9wBiodQ0y01SOJL2LzBDKs0ZDsjI69CGUgirdVKUXFKKt/X9f5kKLvq/6/r/hjC8O/8hLxD/2E/wD2hFUWvaSdU8T6P5gu1gjhuN8ttNJCVJ8vALoQRnB4zzitey06KxmvJYWdmvJ/Pk3EYDbFXA46YQfrVulCTg010VvwsNq90+7/ADMHwrby6bb3WmXMEgktZyRdMp/0pW5WQufvPjhuc5X3FLrn/IxeG/8Ar8l/9J5a3aqXenRXl7ZXMrOHspWljCkYJKMhzx0wx9OaUpc0rsFGysie5mFvbSTGOSUIpYpGu5m9gO5rlNMgh/4SW2m8N2F7YWh8w36TW8lvC+V+XbG4A37sHKjpnJrr6KcZ8qYSjzWMTxj/AMind/WP/wBGLW3VXUtPi1XT5LO4Z1jk25KEA8MD3B9KtVn1KMVoJv8AhPYrjyn8kaY6GXadobzVOM9M4GcVtUUVbldJdiVGzb7/AOSX6GJ4N/5FGx+j/wDobVFfvJpXir+1JLW5uLSezW3ZrWFpWiZXZhlFyxBDHkA4xz1rW0zT4tK06Kyt2do4s7S5BJySewHrVqlB8o2rqxhaFHNcaxqurSW81tDd+VHAk6bHZY1OWKnlcljgHB496XxJ/wAfWhf9hNP/AEXJW5VW90+K/ktHmZ1NpOJ02kcsFK4PHTDGib5pJ+n4WFFWi16/jctVxujaTeReLXtLi3ddN0l5Z7ORlO2Rp+QAf9gGVcdtwrsqKqE3G/mEoqVhk3+ok/3T/KsfwX/yIehf9g+D/wBFitpl3oVPQjFVtL0+LSdJtNPtmdobSFIUaQgsVUADOAOeKlbP5fqX0Ob8Q6Xd3HjDTxbQSPZ34Rb2RVJVBA/mruPYNkr+NC6Xdj4iBfIk/s1S2pCXHyeeYxDsz64y2PxrrqK1VZpW8mvv/pfcZOmm7+n4DJv9RJ/un+VY/gv/AJEPQv8AsHwf+ixW0y70KnoRiq2l6fFpOk2mn2zO0NpCkKNIQWKqABnAHPFZLZ/L9TXoZPiTTFv9W0CU2zTeTfZkZVJCpsZvmx/DvVDzxkCugoopuTaS7E21uYPh3/kNeJf+wkv/AKTQVB4xu5PKtdM8i+NresRdz2lrLMUiXqn7tSQXztz6bj2rastNhsbq+niZy19OJ5AxGAwRUwOOmEHrzmrdOMlFpvol+QT1TsUdKv7a9tyLOC5gjhwgS4tJLfAxxgOoyPpVHUf+R00T/rhdf+063KqzafFPqlrfuziW1SREAI2kPtznj/ZFTKzegRulZlqiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimS/6s/UfzqHaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qNo9B+VAFmiq20eg/KjaPQflQBZoqttHoPyo2j0H5UAWaKrbR6D8qmi/1Y+p/nQA+iiigAooooAZL/qz9R/OqOo38Gl6XdX94+yC1iaaRj2VRk/yq9L/qz9R/OuT+IPh7UvFfhGXRNKuIbYXksaXUsrlSINwMgXAOWIGMHA5PNTK9tNxxtfUx/h3481PxCl/F4rtbXT7qG3h1CFYAwU2kqblY7ifmBBB6D2qQfFOzufD+paxp2g63LZWlo91Ddy2myG6VePkYtnHfkDgE9qzYvhNNpXiq1vtJ1q+u7Oaxn07UV1W8aaQQMvyCI7cDa3ODgVa0Twf4qt/BV34P1i80htLXTZLG0urZZfPbI2ozqflGBnIBOfUU5ap8vb/P/gfewjuubv8A5f8AB/AJfHtzeeGfDeqSwaloT6jqtratG9pFL9oEi5wMv8sbZ+/94Y+7WofiVo40F9T+z325NU/sk2exPPNzv2bcbsf7XXp+VY7+C/FGo+FfDOm6rLpCz6Hq1pcbraSXbJbwLjuud59OB71M3w7u2+K39u/abf8AsIyjUDZ5bzPtoj8oPjG3bt5znOe1aPlvptf8Pd/4PzJ15V3t+Ov/AAPkaNx8S9Ft9WltWt9Qe1gvFsZtTS3zaxXBIAjZs5zkgEhSATyam8e+KL3wta6JJp8VvIdQ1i3sJfPVjtjkJyVwR83HGcj2rlYPhRJYeKry6i0rw3qljeagb03OoxP9rt97BnRcAhsHO0kjGe9dV498L3vim10SPT5beM6frFvfy+ezDdHGTkLgH5ueM4HvUx+zfur/AIX/AFK6y9Hb8bfoUdY+K+jaNqOq2c2naxcNo8iLfy21pvjgRlVhIzbvu/N/vcHjAzVjXviVpWhvMsdjqOqfZ7FdQuDYRoRDbtna5Luuc4PAyeOlZuo+AdUvLf4gRxT2YPiZUFnudv3e2EIfM+Xjkds8Vw3i5I7PxZDZagmkZ07Rreykg1S5uLVb5gNx8oxAm4T+Ha4wD0HJqey9Pyd/udhK7f3/AJq33q56Mfijpg1C00/+ydZe/u7WC7jtYbVZnEUrFQx2MwAXbliTgAjkniprj4l6Lb6tLatb6g9rBeLYzamlvm1iuCQBGzZznJAJCkAnk1U8J6RqV54qh8Y3tlFpkN7oMFr/AGeSfNt5A5cgjaAFwQPX2FYsHwoksPFV5dRaV4b1SxvNQN6bnUYn+12+9gzouAQ2DnaSRjPerslJJ+f5/wCX9dCE24t+n5b/AHjviN8U/wCzdB8QW3hhb9NQ0sxxvqSWYktoZS65jLHI3bSRyuASOc1uQ+MoNO1/xI2s6pMLLSrG1uZIntUVIA6sSVdSWcsR0KjBwBnNc/rnw18Tz2XizSNE1DSk0vxBctehrlZPOjlbaWTgFdpKj5uSPT00dX+Gdxrtz4sS9u4YrXXLC0t4GjJZ45IcncykAY3Y6HkZ6VCvy+f/AAP8/wCupt7t7dL/AIXX6fqakfxM0r7Fqc17p+qWE2m2J1B7S7t1SWW35+dBuKnpjBIIPXFLo/xL0nWtXTT4bHVbeSe0N5ZvdWhjW9iHUxc5PXoQK52z+Gl+nhfXbA6N4V0y9vtMksobrTEkUyMwxmQlflUkA4Ab61uReDNQTxd4S1QzW3kaLpclncKGbc7siqCg24Iyp6kfSr0/r5/8D7zFtrp/Wn/B+4zLD4sTX3gTU9eOgXdtJbyNDaecF8q5kMxijQMGJznbu4GOcZrcvvHkWkazBoNxp9/qurrapcXa6VbBkiUnG7DPnGQeBuNcnN4G8UaX8PdS0YGwvIbK8Go6Z9mL+fOy3Hn7HUjaCeQME5JFaHjfwbq3ji6sr3S7bS7AiKN4NTn8+DULI5yQFUDPX7rEYJNSuny/L/O/3Fvd/O33/wCX5nUaT4gubjxlrOgahFEklpHFdWskYI8yCQEfNkn5ldWBxwQRxXQ1x+i6fd3HxO1rWriCaK2t7KDTYJJUKG4ZS0kjgHquWUA9CQa7Cjov69PwDq/66a/jcKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOY+IniO+8KeB7zV9Jjt5LuF4kjW5Vmj+eRU5CkHo3rWZpfi3xDpfi6x8PeObfSxLqcMstle6W0gjYxjLo6Pkg7ec5xWn8RPDl94r8D3mkaTJbx3czxPG1yzLH8kivyVBPRfSsmw8Ha/rHii117x3d6cZLC2lgs7LSlk8tDKNryM78ltvGMAChdfn+Wn4jdrf13LOk/FLQtX1a1tILbUobe+laGx1Ge12W1265ysb5zng4yBnHFXPD3j2y8T6hLBpWmao1rG8ka6g8Ci3dkOGAbduBz03KM1yujfDXxDbN4e0nUtQ019B8N3hu7R4Ef7TcEbtiyA/KuNxyQTnHanWfw514eLb3V45dK0D7Ta3EMjaM83+lSOpCSPG2FVlJ3ZGST3ofl5/8AA/USv18v+D+h02nfECxvNdGk3umarpFxJBJPAdRthGs6JjeVwxPAIOCAapaZ8UdO1bWNLsbXRtXEeqxvNZ3kkcKQyRJ96TmXcAOuCucdq5jQfhzqvhbUtN8Q6lb6VI+kWFzHdJpscklxfkx8SMzgeY5I+6cAZ4JzxhfDadYNY0uyisNI1WS8jlgnnsby4e40+JwWYvE6+XAM4UqhAzwKOtlr/Tt+n9bLo29Nf8r/AKnpmk/ErRtY1O0tYLbUIYNQd47C/nt9tveMmSQjZz0UkbgM44zVP4keMtU8LXehW2k3Oi2f9pzyxy3WslhDEFTcCWVlxnpz6isrwV8Lp/Cmq2SS6V4aubaxdjHqiwut84wduRjaGGQC245A6V0vizwi/iXxL4avJY7Oax0ueaS6guV3eYHjKqAu0g4ODzihraw11v2KbfEKPSNL0qLU0/t7WL+Fp1h8NQmeN4lPMi7m+5yBktyemamuvij4et9K0jUIhe3cOr+YtqttbF5GkQcxlPvb8jbjHX0HNV9e8G6pb+KbDxF4I/su3uraxfT3s71HSAxFt4K+WMqQ3bGDntVLSPhre6O3g8Je29x/Y13dXd67AoZHnVs+WuDwGbuRwPwo3/rz/wAvxDb+vL/PT0LuofFXS9Nme3m0bXXuo9Pi1GW2jsgZIYXByXG7ClMfMCe/GecT6L8T9E13XLDTbW31KIanC01hd3FqY4bsKMsEJOcgeoA9CaL7whf3Pi7xFqkc1sINU0ZLCFWZtyyDfyw24C/OOhJ68VnaX4A1Sym+HzS3FmR4Ztporza7fvC8IQeX8vIyO+OKcbN6/wBb/wCS+8Lf18l+buj0OiiikAUUUUAFFFFABRRRQAUUUUAYHjnxHN4T8F6hrVtafa5bVAViJIXlgu5iATtGcn2FczL4613RPh1qXifWBousJEqtZvoTyNE+ePnLE4AOMkE/TtXaa6mryaPKvh1rJdQyPL+3qzQsM/MG288jPIrzu2+FeqTeGfFtvez6Xp954iSMLa6ZG4tLdk/iw3OWP3iAPxpdGUrXVzobv4mWGl2elSato+s2tzqizfZ7P7KJJmaMA7QqM2S24bcZ98VJqXxK0vTJDG+m6tPJDaJe3yQWoZrCJhkGYFhg4Byq7jweKqDwv4k1HxF4P1fW30qOXRGuvtSWkkhVhJEETZuXk5GTnGO2azvFHwxm1Dxvd+ILDTtA1YahDHHPb62j/uWQbQ8bKD1GMqQOnWqlpt/X9f13Ercqv2/X/I2dV+KGj6bqJsbex1XVZ/sEeoounWvm74GJ+cHIxjbznHUYyeKlm+JGkfYtKn0y1v8AVpNWtnura3s4l8wxIBvY72VRjOMZznoDUFp4Lu7TxhdanD9ihspNAi0uKCHcvlurMeFxgJggDkn2rzfXNHl8L6f4O8PatNpcM+lWU5mury6ntbafe2PLjuIwJCwHJQgAg854pStsv6+L/JExvfX+vh/zZ2h+MCXM/h46X4Y1i5g1pJpUURxeaUQdVAk29eoJBA7VDdfEu48P+P8Axba6vb6lqGmabFaSwxWNmr/ZUaItK7txxkg8knrgcGq+maTr+v6Z4U8Q+HdN0vR7jRTc26WFyZVt5IW+QSIQoYAhdwyBnNbN34F1S51Hx5ciezA8SWENtaje3yOkLIS/y8DLDGM8U3onbz/4H4fqXTs9JPt+av8Ar8jRHjWO78TR22nvC2lQaT/at5dMrFvLf/VBADxkK7HIPAAxzUeneOJ/E/h2+vfDWkX1vIlqbiyn1O3AguuuMFHJ5x0OCM5xWP4c8N6t4V8QW9q0CXAvPDlvZNcKjSW8dzbKRhzgEIwfjOM7SOtReHfCWr+CZdf1x7OzghmsyI9E0IzSxyzAk+YEYDax4XCjGO9Kel7edvvf/A/p6THdX8vyV/1O78Oa3D4j8M6frNspSO+t0mCN1TI5U/Q5H4Vp1z/gPRJ/DngLR9JvMfaLa2UTAHIDn5mA+hJFdBVSspOxMb8quFFFFSUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnejeNfEXiDx1qGm2I0G1s9Nvmtp7K6llF+8a4/fKB8u05yOMe9eiV5vqvgnxP4j8Y6dfaw+gW9rpl+Lm3vrKKUXzxqSRExPygEEBuSD6UR+NX2B/CzXf4m6NH4XuteNtffZbXUjproI03mUSCPIG/G3J65zjtWFc/Eqfw/8QPF1pq8Go3+mabHaSQx2Nmr/ZEaMtLI7cfLnB5JPXA4NZ1/8LvFcmkaloNlqOkDSbjWP7UieUSCdsyhzG2AVUDHBGc4AwM5Glr/AIE8WXGv+LbvQb7SI7XxJBBayJdrIXijWLYzgqMbvmbC8g8HI6UJvlv1/wCAv1v/AFqOPxSUtv8A7b/5Gxv3vxH0uDWLfTdPsdS1iea0S8P9nQCQRwuflc5YEg+igmqsvjqz0XX/ABe+s6jcGy0WO1cwG0RRD5iHCo6sWkLHHDAYPAyOaxfEvwx1PUbXSNP0ddIhXS7WC3ttZkeaO/tvLABK7BhgQOFLADJqfXfhjqOt3njKRr63iGtLYNZSfMzJJbDOZFxjBYDoTx+VU7a/P81+go7a9l9+hVj+KN0njTVZ7qy1aDR7DQEvn0yaySO4V/Nwz8kZGwg/fI4PcV29v4x0288RWGj2aTzz3un/ANorKijy44cgKWOcgknjAPQ1zEWi6npviK/8X/EC80lLFtF+w3UdoJCkY8zJPzDLKQTzx1xjjJp/BPQZrTSb3WLt5ZUnYWWmyTxlGNjCSIjtPI3ZJ/KktdO3+b/4FvJMnXf+tl/wfnY2td8U+IrrxnL4Y8E2mnG6s7ZLm9vNUZzFEHJCIFT5ixwTnIAFL/bmvwfEPw3pGpy28Yu9MuZr2C1XdG0qFMFWYbsDcfT3put+FvEdp40m8T+CrrTftF7apbXlpqgkEb7CSjqyZIYA4xjFPvfCuu6n4l0jWLu8s4Li20m5tLiS23jbNKFw8YP8IKk8tnpUK6Sfr+Tt+hT1bXp+l/1Ldj4+srrxCmj3ml6tpVxNHJJbPf2wRLhY+X2EMTwOcECq+k/E7SdW0u71aPT9Vg0m1t5Ln+0ZrYCGVEOG2lWJz7EA9fSua8KfC7WdF8Q6Fq19/Yiz6ZFPFcTWwkaa9LpgSySMMs2f4egycE9KsaD8Pde0zXtU1UQeH9PW7sZIG06yaZ7S7mYjEksbABR1GFB4J5qv8v8AP/gf1sdfn/X9f0+x8L+K4/FVq1xBpOp2EOxJIpL6FUWdGzhkKswPT6jIyOa3q4T4d+CtR8KX2rXF39hsrW+KGLS9Nllkt4GGdzqZAMFsjgADgV3dN26CV+oUUUUhnE6/4q8QTeMv+EW8F2mntewWgu7y71Mv5MKs2FQKnzFjgnqABTRrniGD4geHNH1Wa2i+16ZdTXsFou6JpUZApVmG/ABPHHXml17wt4ht/GjeKfBd1pwu7i0W0u7TUw4ikVWyrhkyQwzjoQRVhfDet3XjTQNf1SWw8yx0+4t7tbcuA0khUgxgg/L8p6nNJXsvn+tv0+YS6/L9L/qZOh/E2zt/CGg3epSapq9zq8txFbvFp6JLK8bsNpjjYgdMAg44ycc1Ld/ES01Tw/ZahpVzqGluNch026glskeZJC2GhdWbCg5GWUkjtmqXhv4b6vo9n4KhubmxdtAurya6McjkOs2/bsyoyRvGc479aYfhprHlagv2mxzc+LU1tP3j8QBgSp+X7/HTp71enP5XX5r9LlSS1t5/+3f8D7zp5PHtifFUmhWGmatqMtvMkN1c2drugtXbkB3JHYgnAOO9LcePLSy8SQaRqGlatZrdXP2W3vp7YC3mlwcKrbs84OCVwfWs3T/C/ibw/wCM9UutDudJl0bWL1by6W7EguITgBwm35WyBwSRj3rnLT4T64uuWN7fTaPPLY6yL/8AtFhI15dRbydjOw+TaDwoyDgciojq43+f4f8ABJlopW+X4/8AAOw8Ea3qGr6l4pi1G485NP1mS1thsVfLjCIQvAGeSeTk1mQfExLC18U3/iOELY6LrC6fG1nEWco2wBmBbkgvzjsOATW34R8OXegX/iKe8khddU1V72ERMSVRkUANkDByp6ZHvXLaj8NdYvNF8U2kdzYiTWNci1G3LSPhY0eMkN8vDfIeBkdOaI3vFPsr+vu3/UJaKTXd/rb9DodN+JGjXz6sl5b6hpMmk24uriPUrfymMBBIkUZOV49jnjFYFh8RbvxB8SPDtnp0Go6dpd9ZXM8kF/ZrGZwoBjkVueOp4Ye46Vf1z4fXWu+K/EV5NdQw2OsaGNMQqSZY5NxO4rjGOR3qvovg3xWPFHhvVPEN3pDR6LZT2fl2Qk3OGVVV8sOSdvI4AxwTnhrv5P8A9uX+X3kyvay7r/21/wCf3C6J8S7ODwTot5ey6nrl/qks8dtDBYIlzceW7Bj5auUUKB13dMH2rd1PxsNM0i11B/DevzpPC08kcNope2VevmAuNp9gSevHFcdpfwy8R6FonhafS7zS21vQHuwY52kNtPHO7EjcF3AgEfw9c1b8R+APEfiXW7a+1OTQ7yOTTTaT21ykrw2sxYkzQxnhmwQPmKngc0T68v8AW9jR25n2/wCD/X9aGjq3xPhtdS8ORaPo9/rFvrlu9zG9rGN5jC5G0MygnkZBPAqVvHFnpPiHxcdZ1OcWWix2rtC9oirB5iEgI6sWkLHHBAweBmstfAXiPTdO8EzaPc6W+peHLV7aaO6aQQyh0CkqyruyMZGQM+1O1v4ZXuvX/jKS5vbe3j11LFrR49zNFJbjOXUgDaWA6E8elVpr8/z/AMhR217L7zWt/ifpEun6tPd6fqunXGlWZvprG9thHO8GD86Ddgg4x1GD1xU2g/EfSdf16HSoLPU7SS6tjdWct7amKO7iGMtGSc8Z7gcc1zt38PvEuvHX9T8Q3WlJq1/oj6PaRWRk8hFYli7sw3ZLY4A4HrWzF4M1CPxd4S1QzWvkaLpclncKGbc7siqCg24Iyp6kfShW6/1v/kvvIk2tv62/zf3GpqviG5g8aaVoGnxRu88Et7ds6klIEwoC8j5mdgMngAHisuD4raDcR6A6wXy/27K8UStEubdlkEZ835vl+dgvGeTVjUrG7s/itpOsxQTTWd3YS6dO0UZfyWDCSNmwOFOGGemSM1y//CqdVSbxSYryy2XTebogLN/ozmf7Q3mfLwPMC/dzwKhPa/nf5Pb5qxcutvL8Vv8AJlrxD8TCl1o1xoy3q2X9vy6ZdotskjXnlxtkRgZJBcAA/KcjsK27f4n6HN4fvNTmh1C1ezuxYy2E9vi5E7EbYwgJBLZGMHHvWbY/Dy/stH8FWqz2rS6JfNeX77mxK7o+8p8vPzv3xxVDWPhReazD4kFxcWO6+1mLVLFZFaSM7EC7JlwOD8wOCeD+FGqdn/Xw/wDBYt3f+vtf8A6CX4n6Ja6Lf6hqNtqFi2m3ENve2lxComtzKyhGIDEFfmzlSeAe/FSSfEbT0sLKb+ydZN1qE0kVnpzWey5nCctIEYgBMc5YjgiucuPhpf3Xgm/0y30rw1o17dXVrLjTfMEbpFKHO9imSeGwNvfr3rY+IXgF/Fl/pGp2kOm3dzphkX7HqqFredJAMglQSpBUEHBqn/X3L9RK9/68zpvD3iCx8TaQuo6aZBGXeJ45kKSRSIdrIynoQRismLx5ZnxRb6He6Tq+ny3ckkVpc3dsFhuHQEkKwYnoCRkDI6Vc8LaG2ieGhYmy03TZmZ2aLSkYQoSeCN2CTjGTgZPpXAeHfhTrem65oOoalLo8s+lXkss99GJGur5HRxukdh1BYfJyOpzxgn2vL+vyD7L7nRQ/FvQpruGM2WrRW8l+2nNeyWv7iKcOUCM4buRkEZ6jOOlO1X4r6LpF/qdtcWGrSLpNwsN9cQWm+K3DKpEjNu+782PXg8Y5riPCnhjxB4p0SWxW90+HQF8S3F1OTG/2kGK5LbF/hIJGcnBHoamfQPEXibxB8Q9H0W8063sL/UI4LxrqNzJEpgTLR7eGJHGDj1zURbaXe1//AEn/ADY3v87f+lf5I39W8Y6jb6t46VdUkgsdK0q2urSSC1jmaEujlnVWxvzgcM2PpWzd/EOy0+6tNMisNW1rUHtI7mdNOsw5hjYcO/zALk54BJrJ1T4dalc/8JglncWoj1rSbews/NdgUaNGUmTC8DkdM/SpW8H+KNG8UHWvC1zpDteafb2d7DqIlwjRDAeMoPm4J+U4+tUvit0//a/4APv/AF9n/gm14k8d2vhaY/2npGrtZIqNPqENsGt4AxwNzbs8HrgHFYGrfEO40D4karZXMGoalpsGkwXcVrp9osrR5Z98hbjjAXq30FZfjH4Va54m1TxDJ52j3MWpIhs7i/EjzWJVR+7jGCqKSOWHPJ4Na2teDvFo8U6lrHhq80hBe6VDpxivRIcFS258qOMbhgc5yc4xytbJ9dfyf6/11H5f1uv0uW7fxm2ofETS47G/VtAvPD8mo4KKASJFAckjcMKTxnHtVzRviNpWu6haWltbahaDUUdtNuru22Q3oUZJQ5z05wwUkdKydK+Gc2m6lpUbXcU2n2fh2TR5WyVld3YEsFxgDGe+elVvA/w2uPCWoWhu9J8NSxWCMI9UtoJBey/KQCVxgNg8kE559arTZ7a/nL9LE62v10/Jfrc63wb4gn8Q6LM+oRRw6hZXctleJECE82NsErkk7SMMMk9a6CuR+Hen3dtpWp6jqFtJaTaxqk9+LeVSrxoxCoGU8htqKSD0zXXUdFfey++2v4j6v1f56BRRRSAKKKKACiiigAooooAKli/1Y+p/nUVSxf6sfU/zoAfRRRQAUUUUAMl/1Z+o/nUVTScpz6j+dJ5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAioqXy0/ur+VHlp/dX8qAIqKl8tP7q/lR5af3V/KgCKipfLT+6v5UeWn91fyoAiqWL/Vj6n+dHlp/dX8qWPhOPU/zoAdRRRQAUUUUANk+7+I/nS0kn3fxH86UkAEk4A6k0AFFYA8XWlx4TvddsInljtVkPlSHYzbeR64DDDA+jA1qWWq6fqTTLp99bXTQNtmWCZXMbejYPB+tAFuiqdjrGmanJNHpuo2l28BxKtvOshjPowB4/GmQa9pF0ty1tqtjMtp/wAfBjuUYQ/7+D8vQ9aAL9FUrTWdLv4opbHUrS5jmcxxPDOriRgMlQQeSACcD0pZdTgjvobRHjkkklMTqJkDRHYXGVJycgdACcHPTJoAuUVVt9UsLy4aC0vraeZUEjRxTKzBD0bAOcHsaz7rxNb2mqmza0unRJo4JbpAnlRSSY2KcsGOdy8qpAzyRR5AbVFNkcRRPI2cKpY49qr2OoQX+kW+opmOCeBZx5uAVVl3c84HB9aALVFUbXXNJvrWW6stTs7m3hO2SaG4R0Q+hIOBUB8U+H1gkmbXdNEUUnlSSG8j2o/90nPB9qANWiqU2q20F5HDNJEkckXmCZ5kA5ZVUYJyclhg4xnA6kVNPf2ltII7m6hhcgELJIFJBYKOD6sQPqQKAJ6KjNxCJmhM0YlVPMZNw3Bem4j04PPtWMPFmnz3pi02e2v4FtJrlp4LpCqmMoChOdoPz9SRjFAG7RWdca/pVjEjajqVnZFwp2z3KLgsOByec4OPXBxUt7q+m6YkT6lqFraLM22Jp5ljDn0GTyfpQG5cooByMiigAooooAKKKKACiiigAooooAKKKKACiiigAoqnqd9Np9uJbfTbrUSWw0dq0QZRjqfMdBj6En2rP0vxTBf6P/at7Z3Gkae0STR3OoSwIjqwyDlZGx2+9jrQBuUVkXniOyt7SwvLee3ubO8nEQuUnXy1XazF9wyCBt9aW58RWY0y3v8ATZYNQt57qK3WS3nDJ88gQkMMg4z09qFrp8gehrUVUOracupjTWv7UXxXcLUzL5pX12Zzj8Kr6V4i0rWri5g029hnltZGjkRJVZuMZOAc4ycZo3A06KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk80dtbyTzsEjiUu7HoABkmuXs/El/e+FdXubmFbLULSB5o0UZ2o0fmRMQc84OD23K1a/iHS5Na0ltOVwkFw6pdHcVJhzl1UjuwG3twSc8Vj3Pg02810+jTy4vbCWzuRfXs05OQfKYFyxG0lhgY4cnqKmV3F2Kja6/r+v+GNDSPEQvWtILqyvLV7mESQTXCIFucKCxUKxKnnOGCn24NSw+IYzqDWl/Y3enN5LzxvdGPbLGhG5gUdsY3Lw2Dz061nf2JrV6bWPUJrS2XT4HS3uLV2Z5JWj8sSFSoCYBY7QW5I5GOaNj4Lna+Sa8s9LsF+wT2U7WLM8lwZNn7xnKKSflPBzjPU5q5bu39b2/T7yIbLmOgsNck1C2kuI9I1COARiSF5REPtAPTau/cD7OF61DF4pgLiO7sbyynFxHbyRT+WTEZAdjEo7LtYjHBJyeRVS403xDeaA2m3Caeph8rZJHcyAXYRgWV12fu1ZQQcF+vcda1l4QmS11pHt9O07+0YovIhsFOy3kjDYbO1dxDbWzgdMY4yR2vpt/X9foGuhq3XiCMaxBYwGRSL5bWVvKDK7GF5doO4EYAUk4PUDHJIm0jXo9aZ2tLO6W3Usv2mVVVC6ttKgbtxOQecbffPFZ1t4dvVttIe5ktzdwag9/eshO1meORSE4ycF1AzjhfwrU0DTpdK0aO0uGRpFklYlCSMNIzDqB2YUbDe6t/WrMtvEj3PiNrCDUtLsI4bgQCK7+ea8IALiNfMXbjO3OG5B445bea/qUQvtSgFp/ZWnzmGWJo2MsgUgSOHDYXaS3y7Tnb1GeGXvhvUJBqdhZpY/YNVn8+a5d2WaEkLnChSHPy5BLLjI4OOX3mgalKt9plubT+y9QuDNNK8jCWJWIMiBAuG3EN8xYY3dDjlR6X7fjp/wQfW39LX/gBea/qUS32pwC0/srT5zDLE0bGWUKQJHDhsLty3y7Tnb1GeNnWNYg0WzjuLiOaUSTJAiQJuZnc7VGMjuaxrzQNSlW+0y3Np/ZeoXBmmleRhLErEGRFQLht2G+YsMbuhxzra1p0uow2awMimC8hnbeSMqjAkDA60LaN/K/4X/UT6/P/gGXJ41jhW6M+iarEbEB71WSI/ZkI3ByRIQwxk4QseORVjVfFcGmC5aPT72+js0V7mS28oLEGGRne6k8c8ZwKZqOgXV3b+JUjkhB1W18mDcx+U+UU+bjgZPbNcxrRQa/eyS6np9nLbRxRLpt2JWa+KJuDKiSoHDFtgykn3P+A0iraaf1/Wp6Mjl4ldkaMlQSjYyvscEj8jVfTb+LVdKtb+3V1iuoVmRXADAMMjOM881HcWFprelxRazp1vcI6rI1vcxLKqNj0YYyMnmq3hzw3p3hnSobPTrW2idYkSaaGBY2nZRjc2Op6nnPWq73EtiXStRlvrvVYplQLZ3nkR7QclfLRsnnrlz+lMfXRDrEVjdadeW6XEhigupPLMUrhS20YcuOFY5ZQOPpVK1tNe07WtRa2stOuLK9vBOJZL6SORF8tEI2CFgSNhP3ufasyy8IXyavp11dW+liSxu2mkv1ZnubxSjr8xKDb98cbmHHGMUl09F+gd/n+ti+PG9syRSppWptbzTtbRTiJNskwZl2Ab9wyVI3EBf9qpj4lWe3UrDcWNxHqEVnPbzxI7oz7SAdr7cFWB3BjjPQnimW/h67i0fTLRpITJaagbpyGOCvmO2Bx1wwps/h27l1C8nWSHbPqtteqCxyEjSNWB465Q47dOaI769/8v8Ag/cJ7O3b8df+AX4vEVpNZWFwkc2b6c28cJC70cbtwYZwNuxs4J6cZpbfxFaXOmaVfJHMItUZFhBUblLKWG7njhT0zVOy8PXFt4quL2SWI6eN8trCudySy7fMJGMfwkgg/wDLRqo2Ph7W4YNE0+VrFLLR51ZZUldpLlFRkGVKAIfmB6tnHUULp8v+CV3JdS8VyOtv/ZttdxwSajDbLfNGhil/fBJFHJYcBhuKgeh5FWf+EoitlVZY7m7muL+ezt44IVViyBjt5fHRD8xIHriqY8P6ytnbaUpsfsFpfR3MdwZX810WbzNhTbhSBxu3HOOgzxat/D13DfWczSQlYNTubxgGOSkiyBQOOvzjP480R218/wD23/gky8v63/4BZj8TW76fLO9pdxXENwLV7JlQzeaQCEG1ipyGBzuxg5JGDVvS9WTVFnX7PPaXFu4Se2uAu+MkBhypZSCCDkEisLU/CEmox6n56WVx5+px30EFym+KQLCkZSQEd9rcjOMg84xWr4d0pdLs5FGi6XpDSPlodMOUbjgk+WmT+FC/r7l+txvR6GvRRRQAUUVj2/iD7ZfmGz0u+ntlmaBr5REIQ6kqwwXDkAgjIUjigOlzYornF8Yx+XPcyaPqcen280kUl+RC0a+W5Rm2rIZNoKnnZ056Vrx6nBLqrWEe5pBbrcbxgoVZiBg56/KaAehcooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApI/u/if50tJH938T/OgB1FFFABRRRQA2T7v4j+dY/ilL240KSw0zctxfMLYShCwhVvvyHGOi7u4ycDPNbEn3fxH86Wi19xp22PPNY0bW7LTtcspI4dSi1XTHWNNPsnhRJY02hSC78uhAzkf6sCtWSa5utWS90PTLiOTTtNuIttzbtAryHYY4huA3DKH5lyo7Hmuuood3/X9dxKyf9f10POZLTVdYvZWspNVkaXQ7u3WW8sxapFMxi2oo8tG7HBORxwTg1uz6w3/CO7NG06+tWtjDFNG2myBoI9wDeWpXEhUZxs3D69D1NFO+lv63b/UP6/L/ACOBgsb6VNY1CNNSuJIbi3vbOS8tliluNiYYBAi4JXcmCoPPPartlYXRuNDv5rWZZrrUJ7y5DRnMIeCRUD/3cLsXnuK7Giltt/X9WQnr/X9eZh+DbL+z/CNhA1ubeTy90iMm1txJJJB5zXM6lFeJ4judSjsb641uC4/0W2+yMbS4gAwg80LsRsM3zs25SSMbeD6FRS63H0MjSJry88KpJqCyi9kifzY5ItjI/OUAwMgdAe4AOTnNYOl65NH4FtbLT7DURqVrYRK0dxpVwigqqq+C6BWIGSFB5xxmu1op9/P/AIP+Yu3l/wAD/I83u7G81GHxG6Jqt/Bd6XBDE97ZiF5WEkm5RGI0PAYdVzz6Yrqv7NT/AITj7SLMeWul+Qsvl/KP3n3M/TtW9RQ9bf10a/Uff5fhb/I4HSNCubzS9Lsb23ngVvDptnd4ypik3Jgc9GGM468UrW2p6toN7q17p9xHema0UWxQ7/Lt5UeQqvU5bzSMfeG3Fd7RTvrf+t7/AKh1v/Wy/wAjhdVW78QXWsyafp155EulRxRm4geA3DCVy8YVwCMrxyBnd6c0up/8TjUbu707TL1E/sK6tt8tlJCWclCsYVlDHvjjBycZ5ruaKjl0t6/jf/Md9b+n4W/yOX0vTWXxBqNxPaMN+lWkCyPGcNjzdyAn6jI9xmudtdOv7S30mfUbjWrGB9DtrVvsNgty6yLnekiNDIy5yvIAHykHoK9Koq27tvv/AMH/ADFH3Y2/rp/kUtGs49P0Oys4HneKCBI0a4GJCoUAbuBzjrwKu0UUN3dxLRBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAyUEwuBydprkIJNR0vwH4bhEV3bgQQx3rwWhmntwITyI9rHO8KD8rYyeO47Kijv8vwHc88isrwWMct1YX92ieIvtRE9uPMaLy8iUoqgdecAA54xu4q3cQXGo3V1qFnZXUdrcajp5RJbZ43cxyDzJSjAMoxgZYDhM9MGu4ooWlvK34W/wAiWr387/jf/M8/ttHk/taWy1e+12N21VryOK3sUe2k/e742MwhJUY2ghpAeCOmK6Lw8zQX+rWU8FxHKb2S4VmgcRujYwVkxtJ9gcj0reooWn9en+SG9fvv+f8AmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBHcXENrbvPdSxwwxjLySMFVR6knpVez1fTdQsmvLDULW6tUzunhmV0XHXLA4GKmuoxLbsh8oMfuGZNyh/4SRkZwcHqPrXBagJ4bzVodUlguZzLp0l5cW8Zji8nzyNhjJYrgAk5Zsq3YcULV2Dpc7i01XTr+xa8sb+1ubVc7p4ZldBjrlgccU6w1Gx1S2+0aZeW95Bkr5tvKsi5HUZBIrjfEe3+3tS8vH2XZpv27+7j7S2c/8AAOuf4cdq3bPb/wAJ7qnkfc+w23nY6eZulx+O3GfbbQtdQen9dzeorgNbW6ePxlqC6nqEUulkPZJFdOiQsLWN/uA7WBJ5VgR145Obd7Hd6RdX9tpmoXW6bR5bkPdXDzbJlIAdd2dv3jwoxwOKP6/C42rf16L9TtKK4nwVd2Wq6xd32mX9xJbi2jT7LPrP2xkfLFn2rLIqgjaOecg8Dv21NqxN7hRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcdIwi19T4bi1aC5kvFN5by2sq2kiFv3j7nXYDjJBjYFjjOcmuxoo63DpY4jTtSltdB1DSYtK1KbUZLq9EcTWMqRNvnkKsZmUR7cMDnceOmTxU1uy+F9btor2G/nij0eC2We2sJ7gM6M2c+WjYOMHn1rsaKOt/wCtmv1G9b/11T/QZDKs8KSoGCuoYB0KMAfVSAQfY80+iigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSR/d/E/zpaSP7v4n+dADqKKKACiiigBsn3fxH86WmynbHk9iP51H9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agBLyytdQtXtr+2hureT78U0YdG+oPBqO00rT9PsjZ2FhbW1q2cwQwqiHPX5QMVL9pT0aj7Sno1AEVnpWnafZtaWFha2ts2d0MMKohz1yoGOadYabY6Vb/Z9Msrezh3FvLt4ljXJ74AAzT/tKejUfaU9GoAR7G0kS4SS1hdbr/j4VowRN8oX5v73AA57DFVtW0eDVbKWIhYpnQIs4jDMoDBtvPVcqMr3q19pT0aj7Sno1AGdZaTeDVk1LVr2C5uIYHgiFtbGFFVipbILuScovcAeneteoftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmoqH7Sno1H2lPRqAJqKh+0p6NR9pT0agCaioftKejUfaU9GoAmpI/u/if51F9pT0apIjujyO5P86AH0UUUAFFFFAEc/wDqW/z3qnVyf/Ut/nvVOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqu2oWi2M14LiN7eAOZJIzvC7M7hxnkYII65FVfEOoyaXoNzcW0ZlutojtohjLysdqLz/tEVx9oZdK0vWtIn067sIZ9Me4g+1vEzSSLHslI8t3HPyNycksxqZOyb7FJXaPQI5FliWSM5RwGU46g06uNtriLRf7Hure/uruK6s3lule4aUPGkW7zFQnCc4GFAHz/SqsN/qFjrQa3VgLvS7i8S3fUpbtnZfLMZKOMR/eIwhIOT6CrlaLa7f8H/IiHvJef9fqd5RXLRG103wzHfi7vr+XUEhj3tfuRI8hChly22Mbm6oBgdB0FZcFxf2X9rp57qNHmt7loV1CW7whB81C7gMfkyQpyAcEew1Z2YXutDuJrmG3eJZpVRpn8uMMcb2wTge+AT+FS1x631zdalYX8d3L9mvdYMUKLIdhhSCUdM4IZ1Le/wAvoK0PCUEkunf2hd3d1c3EkkyfvJ2KKglYABM7cgD72M++OKLaDe/9d2at1qun2NxBb3t/bW81wwWGOaZUaUk4AUE5Jz6UsmqWEWoR2Et9bJeSDcls0yiRx6hc5Ncmt5f6Zc6/qyPZHyb3bNBJGzTSoFQIqvuATg/KNrZJ7Z4L7Z/wjfiLft+3f2gdnTd5uU8j8ceXiktbel/y/wAwen9ev+R1kmqWEWoR2Et9bJeSDcls0yiRx6hc5NWq4m+2f8I34i37Pt39oHZ/e83KeR+OPLxW34pM/wBgs47e5mtjNf28bvC21trOAwz7jihapedvxt/mD0v5X/A26K4PULGS0t/ErQanqgGl24ns1N/K3lv5RY5JbMgyB8rlh6CofEupo2rz2F5qUtpdXEEL2Ui6oLOOHdkEsvmIX+YHoG4wOKNweiv/AF/Wp6FRVO8N5b2CjSoIbmVcKFurloxtx13hXJP1HPrWb4NudUuvC9hJq8MKs1rEUkW6aZ5cqMs+5F2t+Ld+ae9w6XLkviPRINQNhPrGnx3gYKbZ7pBICRkDaTnPNaVc5p5sx/wkx1Mwi0+3t53n42bfIiznPGKy9FSa/h0bTdSubyC3OnvPGkdxJBJLiQBdzqQ/yoVyM/xc5xS7edvyuHf+utjsZLyCK8htZHxNOrNGuD8wXG7np3FTVxNheXF3d6TLLK0zImoxxTnrKiOFR+OpKgHPfrUsGovNp3gqJ72UyXwHnbZmDTD7JIWJIOT82Dn1wetC1v8A13/yD/g/gdfHKkyB4nV1JIDKcjg4NOrzy3W40/wbo8WlvI32+98mcz6jLGAP3mFEnzmPLKoyoySccE5qxfy6loWixNr1yI7IagFMdvqjGRYTEcIbmTyz/rPmyzDjjJ6EWqv/AF0/zD+vz/yO7orgrBHns9EjtdXunt7/AFG4LvHqLXDGLy5CsZl3tyAFBKngjg5+aneLLyS20/UpdLaeNtDtwpnm1WaLD7Ay/INwmOCP9Z1PHrTtrYFq7I7uo4LmG5DmCRZBG5jbac7WHBH1FcpeXl3HqFzoS3Uon1C5iltpN7bkgYEyhWzkbfLkxjpvWofNu726srU391FHNrV3FKY5WDNGqSkIDnIHA6cjtg4NJav+vL/MV9L/ANdf8jtaKZBCtvbxwxlysahQZHZ2IHqzEkn3JzT6BhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFXIP9Sv+e9U6uQf6lf8APegCSiiigAooooAjn/1Lf571jazqcOi6Jd6lckCO2iaQ5OM4HAz7nArZn/1Lf571k32nxaisC3BbZDOk+wYw7KcqDx0Bwe3IFJ6jRwSa0t34F8SaeNXt9YubW0M3nQ3CyBhIhJXcCcYcOAOy7a6uHUtQsdVjtNaks2iuLeSeOWGNoxD5e3crbmO7hs7vl6Hip9Y8O2et7vtbTJvtpLWTymA3xvjIPHqoI9PxqNfDNs7Tm/urrUPNt3tVFwy/uonxuRdqr1wOTluBzTb/AK/r5f1uktdf6/rX+tsdPGE9pc3X20pdwR2E19G0VhNbcRlflDSEiTO8fMuBx05rXF1qljpc11rN9p8bMq+SIraTETnjafnJkOSAMBSfTmmw+FbYT+bf3t5qTfZZLPF0ybfKcrlcIqj+Ec9fUnjCnw15li1rPq+ozKrxvbu5i3WzIcqVIj+boPv7s96elv67/wCX9dz+v6/EzbLxRfl2W6EUiW97FBcTfYpbYlJVwpEchLKQ5UEkkEZPFT/2vPea3ZZjj+zHUpreBgXDEJA+5jhsH51YcgjAz1waux+GbYWuoQz3V1cvqKBbiaV13khdoYYUBTjHQAcdKmg0G1gh0yNHmI00loizAlyUZCX45J3E8Y5pf1/X9dRPbT+v6/Qg8NX+p6tpsWoah9ljinjBSCGNtwOfvFi2MH+7jj1NM8UIZ10u2864hjuL9I5DbzvCzLsc43IQwGQO9Wk0UW+j2mm2d3PDFbPGS4bDuqtu2kjGM4wfbI71Jq+kjVoYF+13FnJbzCaOa32FlYAjo6spGGPal29UV3MK6vT4S1KWNZrq7sDp0955VxO0zxtCV6O5LYYP3JwQMd6tm/1W2nittYazlW+hkMRtomQwuqbthyzb+M/N8vTpzxbtvD1tGLlr6a41Ka6i8iaa7ZSWj5+QBQqqOT0Az3pLXw7HBcCa4v7y9aOJooPtDIfIRsAhdqjJwB8zbj78nJJXjb+uv/A/rcVk0/66f8EoeE7+VrTTNOKp5KaNbThsHduIKkfTCiqtjqmsanr2jSJd28EFxZXEksHkMwYpLGv98c4PB5xz1zxrDwzFElmLK/vbNrW2W13wmMmaJeituQj8VweTzSW/ha1s000WN1d2x05WjjZWVi8bMGZG3KcglV5GG461bd5X9fxvb9CYqyt5fojKsPF17fapB5VrLJZz3DQ+Uul3IMSgkCU3BHlsOBkADGfvHHLtO8R6lqOsWcMN3prJJJILqySBmntFXP328zAOQBkqOSMA1r22gmwuWew1K8htyzyCx/dmEMxJPJQuBk5wGx7ViaPo+oW9zZbbTUrS4STfezzajvtps5MmyESEDcxyPkTGe3SoQ5dbF7Tda1G48OjV9RnsbSOaIeSghdyrk4BJ3ZbccYQDPOMmq1l4ovy7LdCKRLe9iguJvsUtsSkq4UiOQllIcqCSSCMnitdvDtsdBg0qOe4jS2KNDOrL5iMjblbkFSc+oI9qZH4Ztha6hDPdXVy+ooFuJpXXeSF2hhhQFOMdABx0oApf2vPea3ZZjj+zHUpreBgXDEJA+5jhsH51YcgjAz1waueGr/U9W02LUNQ+yxxTxgpBDG24HP3ixbGD/dxx6mp4NBtYIdMjR5iNNJaIswJclGQl+OSdxPGOas6bYRaXpsFlbs7RQJsUuQWI98YpiOS1W+mfxgqx3V1HCtzBEl2s7pbQMDmSF0HyuzjABIOC2MggA9Yt7De6ZLc2chePEiq4BHKkqcZ9wefyrNvPClvevdo99epZXrFrmxRk8qUkAHkqXXOOdrCr+naVDpmjx6ZBJK9vEhjj8wgsidlyByAOBnJ45JPNS17luv8AX9IpP3rlTR74x+CLC9vLlVb7BE7zzsSNxQcsep5/E1i/8JbqMFnrIdYrm4sbWO5hZrGazV9zMu0pIS38H3gcHPTitK38JeVpY06bXNSubNYVijhlEA8vbjYwZIlbK7RjJI9QakPhS3ljvftl/e3c17AkE08rIGKqxIwFUKPvHoP15rRtOTfQhXULdSsbvxN/bD6YLjSg/wBn+0rObWQhRu2+WU8zk/7e4f7tVR4hvLuG11GytIzcSaK16ISztk7kJQAEA5GQDjOcdsg9N9gi/tU6hufzTB5G3I27d27P1zVXTfD9rpZszbyTN9ks/saeYwOUyDk4A5+Uf4VK218/1/4BT6/L9L/qZ2oeJZ0eaTTFhltYYbdzI6k7mmkAABBHRMn/AIEv4z6zr82lXl1GkKSrDY+eikkFpDJsAJ7Dkdqfa+FNPtNEudLjacw3EnmF2cb0Ixs2nHAUKoX2UZzSDwpayPcyajeXmoS3Vt9llknZFJTORgIqgEEnkAUuv9dn+odP68jG1KTU7TWZpNUktLiSPRLt0a3jeFT80eVI3k9h8wYZz0GK0F1HV7nVRpultZW6R6fBcma4ieU7mZ1K7Q6kjCDnPHPXPFkeF4pGle91K+vZZbSS0MkzRgrG+MgBUAyMdcZ9c8YvW2kwWuoNeRvIZGto7YhiMbULEHp1+c5/Cmtv67v/ADQd/wCv5f8AJnNy+Mrqa305bWPyJ7izF1My6dcXqrk7doWLBGSG+YnsODnjptIvZdR0e1u7m2ktJpowzwSKVZD3GGAP5gVnjwvBDb2iWF/eWU1pCYEuYTGXaMnO1g6Mp5Gfu5HbGTWzDGYoEjaV5SqgGSTG5vc4AGfoKFtqD30H0UUUAUtU06HUbTZPJdRhMuDbXUsDZx3MbKSPY8VzehsNM8D6ffrqFx9uv7WEl72W4vd8hTcdsW/JPU4THT0Fdgy7lKnoRisd/DcH9kabY213dWzaYFFtcxFDIuEKc7lKnKkg5Xv2oXX5fqPoYM2r32rWOmsqxfbLfWhb73gkhRsRsd/lsdy8NnaTzjrzmp9TvryRf7O1MwSXNpqNg/nW8bRpIjzDB2lmKkFWGNx6A98Vp/8ACJ2f2XyvtV5u+2/bvO80b/O24znGMd8Yx2xjipE8NW4hYXF3dXU73MVzJcysm92jYFAQqhQoxjAA6nuc0R0a9U/yv+TJldp+j/X/ADRjr4wvZtWItbWWa1W9NoYE0u5ZiBJ5bS/aAPLABBO3HQdQeK0/DUmpzTam2oXkNxEl7LHGqQMrLgjHJcjGO2PxqzFoQttQa4stRvLaCSUzSWcflmJ3Jyx+ZCwyeSFYDOfU1NZaUthf3VxDdXBjunMjWzbDGjnGWU7d2TjoWI9qF+n+X/BHLXbv/n/wC/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMkhimKGWNHMbb03KDtb1HoeTzTZ7S3utv2m3im2ghfMQNgEYPX1BIPtVHxFqT6RoFzexPDG8YUK9wCY0JYLlsEcDOeo+tZ0WvTpoEl7Hqml6zJJPHb28lhGUiDuwQBv3j5wWycEcUeQGzbaVp9ncTT2dha281x/rpIoVVpP94gZP40llo+maaSdO060tCSSTBAqZJxk8DvgflVXTL69/tS50zVWgluIYknSe3iaNJEYsMbWZiCCnqeo6VWvvF1tY3GoI1hfTRaaR9sniRCkKlA+7lgWGG6KCRg8dMgWL66Bo6fadmk2K/bBi5xbIPP8A9/j5vxqe102xsoDDZ2VvbxFAhjiiVVKjOBgDpyePc1nJ4otlF0b+0u7AW9ubr/SFX95EOrKEZvyOG5HFSafrzXurSafLpV9ZSxwrMWuDDtKsSBjZIxzkHtxj3FHkHmX0sbSOG3ijtYUjtSDAixgCLAIG0fw8Ejjsakhhit4hHbxpEgJIVFCgEnJ4HuSaimvY4Ly2tnDF7ksEIHA2jJzVfXL+XTNJe6gVGdZIkAcEjDSKp6exNFwJZtK0+4v4r64sLWW7hGI7h4VaRPoxGRSyaXYTahHfzWNtJeRDEdw0KmRB6BsZFPvLh7W1aWK1mu3HSGEqGb6bmUfmRWTJ4rto7OCVrK88+a7Nl9lCoZEm2ltpw23ovUMRyDnGSADTk0uwm1CO/msbaS8iGI7hoVMiD0DYyKnlhinCiaNJAjB1DqDtYcgj3HrWAPGMOJjLpWpRLayCK8Z0jxascEbsOdwwwOU3YB5xVmPXo01qeynMjD7YtrGREAsbGAS4LbiTnnnA5OMdyAab2dtIs4kt4nFwu2YMgPmjGMN6jHHNZE+g3hmv1stQggtdQbM6SWnmSL8gQhG3gAYUYyrY56jirMfiC1l1MWSRzbmuHtlk2jYWSPe2DnOB06dQfrTJ/EdtCZ0SC4nnju/siQRhd80nliTC5YDG05yxHQ0t/wCugXNOCFLa2igjzsiQIuT2AwKkrlbbxFcyS6i05mt1j1O2tY4ZYFZog6xbkOGAOSzfMC2M5GelXW8V24klIsL5raC5NtPdBEEcThgvOW3EZI5VSBnnGDit9f66f5htp/X9aFyTw9os2onUJdHsHvSwY3LWqGTI4B3YznirF9ptjqkAh1Oyt7yINuEdxEsig+uCDzVC68SW9rdyI1pdPbQyCKe8RV8qFzjAOWDH7wyVUgZ5IwcWdZuZrPTmnhvLKxVDmS5vgTHGvqRuXPOB94danoHUtC2gVomEEYaFSsRCDKA4yB6DgdPSq1vomlWlw1xa6ZZwTM/mNJHbqrF8EbiQM5wxGfc+tYtt4iv7rTrdYDaS3N3eNbW14kbeRKgQuZgm7JXCsMBuSOuDmnf29qIY6YRbf2r9tFoJvLbySPK83zNm7ONuRt3de9VqBtDR9MCXSDTrQLeHdcqIFxOfV+Pm/GqM3h2K3+yN4fWz0xrVnKRi0DQneAGOxSvPHBB9euan0a/uLpry1vxH9qsZhFI8KlUkBRXDBSSRw2MZPIPNZ7+M7WPzJP7N1FraK6aze5WNCgmD7AoG7cctgAhSORkjnCDpc0NN0ZLNpZ7to7q8mnNw8ohCKr7BH8i5JUbVA6k8nnmprnRtLvLsXV3ptpPcBDGJpYFZwp6ruIzjk8e9Ul8TQC2uWubK7tri3kjja0kCGRmkOI8FWKncTjO7jnOMVPpOtHVLm8gbTruyks3VJBcmI5JUMMbHbsR+f1pgXmtbdrqO5aCIzxKUjlKDcinGQD1AOBx7CkWytVdWW2hDJI0qkRjKu2QzD3OTk98mpqKQBRRRQAVycA+ya+W8QSanHcSXbC1uEuZPskilv3cexW2KcYX51BJ6E5FdZWQ/h/z7xZL3VL66t0mEyWkvlCNWU7l5VA5wQCAWPQULcHtYw7DTpLrQ7/VE1PUYb+O6vDHK19K8a7JpAoMTMU24UDG3p6da0dH1KfUdchmkLok+kQXBg3HajMzE8evbPtSr4Ri2T28urajJp88sksliWiWM73Lsu5UD7SWPG7pxVq+0A3OpLe2eq3umyiAQEWqwlWUEkcSRtjqemKOt/wCtn/wBy1bt/WqNeimRI0cKI8jSsqgGRwNzH1OABk+wAp9AgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACrkH+pX/PeqdXIP8AUr/nvQBJRRRQAUUUUARz/wCpb/PeqdXJ/wDUt/nvVOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCG8N0tq5sI4ZZxjakzlFb2LAEj8jXPSeHtQ1CS8vr02tpezC3MUUDtLGrQSGRSzFVLZJwflGB6109FAGRpdjff2pc6pqy28VxNEkCQ28rSIiKWOdzKpJJc9h0HWql94furmw8TwRyQhtXBEBZjhf3CR/Nxxyp6Z4roqKY02nc5rxJZSxi51Bkjlg/s17R0IyQXdcsRgjaBkn6dKp+EXEOqvb2+o2WtRyW+ZL61MrmIqQFjZ3llzkMxABGME45rsaKS0/r1/zJt/X3f5GFqPg7Q9U1aK/vNK0+aVSxlMtojmbK7RuJHOPfNWdf0+e/0GS009YRNujaNZWKJ8jq2CQDgfLjoa1KKOlhnNalY67q9tCLzT9LAgnDtZm+kkhuk2sNrkwjGCVYDawJHbrUOneFbqy+y4FlCkWrNfGK2UqiI0LJsUY6gt7Z68dK6uimnZ3/AK/rQN/69f8AM5278P3U+n+IYEkhDanOJISWOFHlRp83HHKHpntS3Xh+6mXWnikhE11dRXVmzE4R444wu7jgbo+cZ4P4V0NFL+v6+4OtzmxoOoWdhpMll9lnv7KSSadJZGjjneRW8whgrEfM5I+U+lQx+H9Xjke/8yze+XUmvY4t7LGytCIjGW2kjAz8205wDjnA6qijrcVjmB4f1Kf7XNdNapNdalbXhSN2ZUWMRgrkqCT+7ODgZz2qeTQbp9A1GxEkPm3V486HcdoVpQ4B464roKKP6/L/ACQ9/wCvX/M5KTwhGuvXN0dC0PUo7q4883F4gE8GQMgfu238jI+ZcZx710eoPqEcKtpVvbXEu75kuZ2iXH+8qNz+FWqKOlg63OYTw9fx7tQU2q6j9v8Atq26swhBMXlFN+3PIyS23r2pRoOoljqbG2/tX7b9rEPmMYQBF5Xl79ucbed23r2rpqKP6/r7gMzRrC5tWvbrUPKF3fTCWRIXLJGAioqhiATwuc4HJPFZ58PXZ0VrPzIfMOrfbs7jjZ9q87HT723j0z3710dFNOzHd2OQ8T2LwrqVxPNDBb6g1tELlydtrsLMZHIxgZxghgckcr1qx4PlO+9t47i01CBSkn9oWnmFZnOQyFnkkLMoVed5wCBgYrp6KS0uIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACrkH+pX/PeqdXIP9Sv+e9AElFFFABRRRQA2T7v4j+dLSSfd/EfzqDUL6LTdNub25OIreJpXx6AZoegbliiuGuNZ1aPwN4gj1WVk1aytmnDQfIwR03ptxj7p3Jnqdme9bQ128ine01WwS0kltZbi2aG583cqY3BsoNr/MOBuHXk4ol7q1BauyN+iuZ0/wAQ3l1cWWn2Vh9odtOtryS4ubnaFWQsCCQhy/y5GAAefu45dJ4s8nxRFpEi6cxuJWhiEOob51YIzgyRbBsUhTyGOMjim007CTur/wBdzpKK4208X3lj4Xk1PxBHYxFryS2gY3mxC3nOoDsyKEVQv3vmJAzjPBfaePI721BtLa2vbn7almy2N6s0JZoy6ssmBkcYOQCOeDjlDOvorBk1rVTd/YbTS7We+hgSe7Q3rLHGGLBVR/Ly7HY3VVHqRUQ8UXF7NZQ6Jpq3El5Zm7U3Nx5KxgMFKuQrkHLdgeQfrR5AdHRXJXnj21tbGxd/sNrdXfm/JqN+ttEhifY48zacndwMLz14rc0HWrfxBosGpWhXy5Sy/K4cblYq2GHBGQcEdRQBo0VzGha9d3uuzC7dfsN+ryaaAoGFibY3PfdlXHsT6VLF4mnOnXOs3FjDDokMUkq3BuSZnVM8+Xs2gHGR8+cYyBSvpcdtbHRUVw6+P/t1lqUWntpUt/BYSXkAs9TW5QKuAd5VPlYbgcYIP96tS58QX+naDZ3V9HpEM8wG77VqhgjPAPDGLlj6bQB60/6/P/IX9f1950lFcpb+JdR1PW9DbTLa3Onajpz3bLNOVcfNF6I3KhzgZwcnkYGYrD4h2F/rdvZxy6e0V1O0EIi1FHuQw3cvCB8qnb13E8jIHOHbW39dg6XOworJu76dvFNhptu/lx+RJdXBwCWVSqKnPTJfORz8vvWbZa9dy+LHWV0/sm5kks7TgZ8+IZY56nd+9GP+mXvSWof1/Xy1OoorjNK8QalZ2d7c3lp5+nQapcxSXMl0fNRftDKCqFSCiggcsCApwDgZuSeI5bO4u0jtZryRtWFlHGZlAUmBXBHyjC56g5PJOego/r8v8weja7fpf/I6eiuc1zxLc6DYQz3sWkxyGNnmim1TyunJWImP94fqFpZPEl9cahNa6NpUdz5NrDdmS4ujCpWTfhRhGO75OnTnqO4B0VFczqPjBLXQ7DVbcaeILyAXAW/vxbMVKhsINjbmwenA96W11vU9Q8TJDawwf2ZNp8V0rtMVkUOT823YQTxjG7Hf2o62/rr/AJB0v/XT/M6Wisvw7fT3+k5vDuubeaW2mcDG9o3K7sDpuwDjtmtSgAooooAKKKKACiiigAoqjqtpcXdpi11K6050JYyWyxMW4PB8xHGPoAfesDQ73ULXwTba3qGr/b5rq0hmYalLDbQRMygn544gQOe+7oKO47HW0Vxc/iifU9O0y605EeddXFrLHaXe+KU7G6SADcnIJO3t0yMVY1HW7yW3W1uYvsF/b6jZLMlvcGRHjklXBD7VJBAYEFR0I5FC1+9L77f5kt2Xy/z/AMjrKK46T4iaemufY/N08xC8FkV/tBftXmb9mRBjOzd33ZxzjFanhzUdV1CfUv7Sgtkigu5IominLMNuBjGxeO+ck+1C1/r0/wAxvTf+t/8AI3aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqG7immtXjtrj7NI3AlCBivqQDxnHTOR7HpXKy3+rW+m65Da393qH2Roo4b1bZHmDsf3ihETa5QEHhO5BBIpXsB2FFcgutNBok4sdZvr69e5gt1/tO0WCW381wgbyxFGcckjI5I61qaVPeWuu3ekXt5JfrHbx3MNxMiLIQzOrKdiqvBUEHA698U/wCv1D+v0NuiuW1Lxbe2U2svBo6T2mikG5la72M6mJZD5a7CCwDdCVHTnnAmfxTcWAvf7Z01bc29k19GLe484vGvBDZVdrcjjkc9aB2sdHRWHpmsanc69NpuoadaW4itkuBLBetNkOzADBiXH3T39MZ5xuUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorlLLULmXxHJBqutXFhci5dYNNaCNYbiIE7Sjsm5yVwTtfg5GBijrYOlzq6K42yOu3ek3urwa7O00NzdCOzmgh+zlYpnVVJWMSfdUDO/rzz0rU0rWpdU1qMxsVtJ9Kgu0iIGVZ2bv16AD8KOtv62b/QHpf+uqX6m9RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSR/d/E/zpaSP7v4n+dADqKKKACiiigBsn3fxH86z9a0iPW7OOzuWU2pmR7iJk3CdFOdh56EgZ65AIxzWhJwnPqP50nmJ/eX86AOXv/AOmSR3Meix2+jR3lnJaXK2dqqCQNja3y4+ZSDg8/eNXU0G8mvHuNV1GO5dLaS2thFbeWI1fG5m+Y7m+UcjaOvAzW35if3l/OjzE/vL+dJq6sC0d0ZOk6B/Zd6lx9p83bp1vY7fL258oud/U9d/TtjqaoWfhO6tptOSXVI3s9NuWnt4UtdjtlXX94+87j855AX3BrpfMT+8v50eYn95fzqm23ditZW/ra35HPJ4XuUspLUakipFeG8sXW2+eBy7OQ5LYkU7yMALwTznmrR0nULtbJtV1C3mmtLsXAa2tGiVgFZduDIxH3s5z+Fa/mJ/eX86PMT+8v50v6/r7hmTfaPetqj6ho9/FZzzxLDOJ7YzKyqWKlQHXaw3tycj24pNN8OxaXeWctvO7R2tkbQK4yz5ZWLlvXI9O9a/mJ/eX86PMT+8v50LTUHqc7H4XuLNLebTNRSG+t3uNss1uZI3SaXzCrIHUnB24IYdPfFas9ne3OhS2cl6iXcsLRm6ihKhSRjcqFjjGePmNXfMT+8v50eYn95fzo6WBaO5zy+B9Es5LKfRNPstMu7OVHW4gtVDuoGGRiMEhlJHJ64POKdF4ZuF0+40ea/jk0WWKSJYPs5WeNWzx5u/BAzx8meBkmt/zE/vL+dHmJ/eX86A2MiLStTnsLux1nU7e6t54GgUwWhhkAIwWZi7AnHoFHtVOPw7q8dxb3K6xaC5jtvskkn9nnBiByCgMvyv6k7gePl4ro/MT+8v50eYn95fzotrf+v61Dpb+v60OetPC82nLon2DUED6XbG0dp7feJomKFuAy7W/djB5A54NWdK0fUdJlS2g1KB9KjLGO3e0JmUEkhfND42jPHyZwOvetjzE/vL+dHmJ/eX86dwMfUdPuz4itNQsNuWtpbSZiAfLDYZJMEjIDLjA5+b2qivgDRbewtxp9naW2pW7RyJqYtVMzSKQSzMMFt2Du55DGum8xP7y/nR5if3l/OktNv66huc0vhO7EU9k2rK2m3N5Jdzwm1/eHdL5nlq+7AXscqSecEZ4t/8I3/pzXH2r72pjUNvl+kIj2Zz7Zz+GK2vMT+8v50eYn95fzo/r8v8kD13/rf/ADMHVPDl3eajez2epR2seoWq21yGtvMkCjdgxvuAX756qw+lWtO0L7BdTzfaPM82zgtduzGPKDjd177+nbHetTzE/vL+dHmJ/eX86VtGu4dbnK2/g67sreGGx1aONTpsWn3DvabnZYwwDRnfhCdx4IcdKvWugXGnXlhcWd4hFvZJZzxvb7jMqcqVO8bGyT13Dn8a3PMT+8v50eYn95fzqm23f+uv+bDff+tv8kZnh2xnsdIxertubiaW5mQEHY0jltuRwdoIGe+K1ab5if3l/OjzE/vL+dIB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgAdd8bL03AjNc+fDE8WhaJZ2V/Gl1owTypprYyRyFYjGS0YcHoxIw3Bx1roPMT+8v50eYn95fzoA5v/hE7j7P/AMhZvtP9pf2j53kDG/Zt2bc/d/HOOM5+apP+EYnnV5tQ1BJr2W6t55JYrfy02wuGWNULEgdeSx5Yn0FdB5if3l/OjzE/vL+dC0/rtb/JCav/AF3v/mY1no2oabfONP1GBdNluHuHtprQvIrOxZwkgcAAsSeVOMnnpixpml3GnahfOLuOSzupTOsJgIkjdsbvn3YK8cDaCM9TWj5if3l/OjzE/vL+dGw3qOopvmJ/eX86PMT+8v50AOopvmJ/eX86PMT+8v50AOopvmJ/eX86PMT+8v50AOopvmJ/eX86PMT+8v50AOopvmJ/eX86PMT+8v50AOopvmJ/eX86PMT+8v50AOopvmJ/eX86PMT+8v50AOopvmJ/eX86PMT+8v50AU9ZtL2+0ma20y+WwuJAAtw0Rk2jPPAZTkjIzkYzmqOn6XrVhpr2i6hpabFAtvI010WM5ydwM7Fs+xU981teYn95fzo8xP7y/nQBz7eF5rxbufVdQWa/uFhVZreDykh8ly8e1CzH7xJOWOenFXdK0m5tb651DU7uK7vbhEiLwwGGNI0LFVClmPV2JJY5z2rT8xP7y/nR5if3l/OgDEvPDX2uy8Q2/wBr2f20CN3l58n9ysXr833c9uuPeo/EGmXG2fULMtLKLFrTyUTLFWdSzjBGSFBwO5rf8xP7y/nR5if3l/Oh6/15W/Id77/1t/kch4Qsf7M1A2+km8fSjCWmN5piWZWUFQgULFEWyu7JIPQcjpXY03zE/vL+dHmJ/eX86bdyR1FN8xP7y/nR5if3l/OkMdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdRTfMT+8v50eYn95fzoAdWFc6LqWo3Ua6lqdtJYQ3KXEcMNkUlyjBkBkMhBGQM4UE+1bfmJ/eX86PMT+8v50dbgczF4X1VLS60463CmmXM00jLBZFLgLLIzsvmmQr/ERkIDjpg81ZutC1CLVkvNBv7KyRbRLUw3Nk04CqxIxtlTHXHfpW75if3l/OjzE/vL+dA3rv8A11EhEiwoJ3V5Qo3silVY9yAScD2yfrT6b5if3l/OjzE/vL+dAh1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1FN8xP7y/nR5if3l/OgB1JH938T/Ok8xP7y/nSx8px6n+dADqKKKACiiigCOf/AFLf571Tq5P/AKlv896xtZ1OHRdEu9SuSBHbRNIcnGcDgZ9zgUm7K40ruxdorzhNaW78C+JNPGr2+sXNraGbzobhZAwkQkruBOMOHAHZdtdP/aesWN99lvY7W8kuLWWe2S2RosNHt/dsWZs53fe+Xp0pvQS1Z0FFcpb+JLwaXLLJdWd3dmWGBLZLSS2e3eRwo81XdmwM5zhc4OKh1+9v00TV9M1ZreaZbMTxz20TRKyl9pBRmYgggc7jnPbFPrb+u4m7K52NFYUut3KQ+I3CRZ0rPk5B+b9wsnzc88semOKpW2o6n/wk1/PPeQ/YINNt7lrcQMSM+aTtO/AOV5ODkYHbJm63fqVZ/wBfL/M6qiuU8P8AifUNT1G2juLaRoLqIyZXTLmAWxwCFaSQbZM8jI28joc03xxraWRtNOj1i30q4mD3ImnnEQIjGVTJI+85QEd1DU3puJa7HW0VyEuuW11qWia5DlrZtIu7nA64/csR9e1XW1TWLHRf7Q1A2Ur3JhS3toYnXynldVAaQud4BYZIVeh4p26f1u1+gdE+50VFcZ4kvtRi8P63puqNbXE/9mSXEMttE0SsB8pUqzNgglec856DFXbnXtQ0Oecaz9luIxp818gtYmjKCLblCWZt2d4w2F6dKX9f19wK7dl/X9XOmornjf6rbTxW2sNZyrfQyGI20TIYXVN2w5Zt/Gfm+Xp054ueFv8AkT9H/wCvGH/0AU+/y/X/ACFfb+u3+Zq0UUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFY/iieW30qB4JXiY39ohZGIJVrhARx2IJBHoazLvXtYih1e+iFitnpVwyNE0TtJOiqrHDBgEPzEdGz7ULX+vT/MHornV0Vyd54gfTJdaeOHdIuoQW0W1JZuXhjO4ouScAn5UAzj1JNJbeJtSltGhNtm7e6jtre5nsZ7SKTepYt5cnzfKFbgE5wORng/r77f5g9DraK5i8PiCPW9Gt21OyzJ5xl2WTqj4Xj5fN9D6nnn2plnq948KWmnrBFdXWo3kayTB5EjWOR8sVLZJOANoZRzxgDFAdLnVUVysviHVEkhsEjtGvxqQsZpCrCMgwGUSKucjjb8pJ6EZ71q6LfXs89/Z6m0ElxZSqhlt42jSQMisDtLMQeSOp6Z9qAehq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFRXMcsttIlvN5ErLhZdobYfXB61y6XN3b+DEjS8uHmk1A2f2mR90gVroxk59Qp49OKAOtorjL+a40e8utJsru5MEy2ex5p3mkg82cxuQ7ktyBkZJwc4p92tzp97e6VZz301oIra4YCeWaeNGlZZQrkmTlVyMEn72O1G4bHYUVxdjr80M0AvFvnt7NZSx6NtDcNLuIJCRsmRyxZjxlTXaUwCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcnAPsmvlvEEmpx3El2wtbhLmT7JIpb93HsVtinGF+dQSehORR1sHS51lFcZYadJdaHf6omp6jDfx3V4Y5WvpXjXZNIFBiZim3CgY29PTrWjo+pT6jrkM0hdEn0iC4MG47UZmYnj17Z9qOtv62b/QJaX/rql+p0VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFXIP9Sv+e9U6uQf6lf896AJKKKKACiiigCOf/Ut/nvWTfafFqKwLcFtkM6T7BjDspyoPHQHB7cgVrzDMJA6nH86reRJ/d/WgDG1jw7Z63u+1tMm+2ktZPKYDfG+Mg8eqgj0/Gi20EW909zJqF5cz+U0MEkxjJt0OCQgCAHlV5bcTgZJrZ8iT+7+tHkSf3f1oAwB4YhkSf8AtC+vL+aZUUXExjV4wjb02+WigENznBOaD4YgltLyO+vby8mvIxFJczFBIEBJCgKoUAEn+HnPOa3/ACJP7v60eRJ/d/WgNzA1Hwvb6jLek315bwagmy7t4GQJN8uzJJUsDtAHykZwM5qf+wYV1JLyO4uE/wBHW2mhGwpcIu7aHypPG5vulevOa2PIk/u/rR5En939aAMfS9FOlMqw6ney2kabIbSYxlIl7AMEDnA4+ZjVqHT4YdTub8FmnuESMliMKq5wo46ZZj9TV7yJP7v60eRJ/d/WgDDh8M2MN2JgZXUfaAIWIKATsrOMYzjK5HP8R9sJF4bjWxlsbjUL66tGVVihmZP3G0gqVZVDEggYLFjxW75En939aPIk/u/rQBgN4Ygmtb2K/vry9lvYPs8lxMUDrHz8qhUCjkk525PfOBVy80a0v71bi6DSbbWW1MZI2OkhUtnv/AO/c1p+RJ/d/WjyJP7v60AtHcxLXw7HBcCa4v7y9aOJooPtDIfIRsAhdqjJwB8zbj78nN/T7KPTtNtrKAs0dtEsSFzliFAAzjvxVzyJP7v60eRJ/d/WgCOipPIk/u/rR5En939aAI6Kk8iT+7+tHkSf3f1oAjoqTyJP7v60eRJ/d/WgCOipPIk/u/rR5En939aAI6Kk8iT+7+tHkSf3f1oAjoqTyJP7v60eRJ/d/WgCOipPIk/u/rR5En939aAI6Kk8iT+7+tHkSf3f1oAjoqTyJP7v60eRJ/d/WgCjqOnxanbJBOzqqTRTgoQDujcOOo6ZUZ9qqzaBazadqdm0k3l6k7vMQwypZQp28ccKOua2PIk/u/rR5En939aP6/r7g3OXstFfUhq0mp209kLy8jngUyJ5sRjjjVXyhZQdyEjk8dRyRV5tB8/TzbX2p3t3IJFliuZPLWSJl6FdiKvHuDnJByK2vIk/u/rR5En939aAMSTQXljtGl1e/a6tZGdLvEIkIYYKkCPZgj/Zz70jeG7b7MI4Lm5t5kupbqK5jZfMieRmLYypUj5yMMDx7jNbnkSf3f1o8iT+7+tAGJD4ctYvs7tNcSzQ3ZvHmdl3TSmMx5fAAxtbGAABgYq7bWEVre3l1Gzl7t1eQMRgFVCjH4Cr3kSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR1nHRLVtJk09zI0MkrS7t2GV2kMmQR0IY5H0FavkSf3f1o8iT+7+tAGGnhq3NvdJe3VzfTXWwSXM5QSDYcpt2KqrtPIwOvPNWNO0hdPknmku7i8urgKslzcbN5Vc7VARVUAZPQdznNankSf3f1o8iT+7+tAGFP4ZtJrSC38+4jWNHjkKMubhXILh8qfvEZJGD1wRmtmpPIk/u/rR5En939aAI6Kk8iT+7+tHkSf3f1oAjoqTyJP7v60eRJ/d/WgCOipPIk/u/rR5En939aAI6Kk8iT+7+tHkSf3f1oAjoqTyJP7v60eRJ/d/WgCOipPIk/u/rR5En939aAI6Kk8iT+7+tHkSf3f1oAjoqTyJP7v60eRJ/d/WgCOipPIk/u/rR5En939aAI6Kk8iT+7+tHkSf3f1oAjoqTyJP7v60eRJ/d/WgCOsh/D/n3iyXuqX11bpMJktJfKEasp3LyqBzggEAsegrb8iT+7+tHkSf3f1o63A5pfCMWye3l1bUZNPnlklksS0Sxne5dl3KgfaSx43dOKtX2gG51Jb2z1W902UQCAi1WEqygkjiSNsdT0xW35En939aPIk/u/rQG5BEjRwojyNKyqAZHA3MfU4AGT7ACn1J5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR0VJ5En939aPIk/u/rQBHRUnkSf3f1o8iT+7+tAEdFSeRJ/d/WjyJP7v60AR1cg/1K/wCe9V/Ik/u/rVmEYhAPUZ/nQA+iiigAooooAbJ938R/OlpJPu/iP51neIdV/sXw/d34UySRpiGNVLGSQ/KigDkksQMD1pN2Q0ruxpUV53o2tnQtF1exszdPJbRJdW0moWk0G5pMLISJFUsBLlzjj58Vt6zNqugaRGsV/fapdXt1HAjGO2V4s5J2DCJnAON5PJHXoW9P6+QlqdTRXA339vXOipFqcmo2ITVrRYJpxa+dKhkTO8R7kyGzjAGcDIPObPiHWb6wWefS7vU7kaXsjucRWwgZ8KSJCwDklWB/d8DP4U1r/Xp/mJu39f12O1ornbpr+bxfBa6fq115UeJ72EpCYo48EKgOzfucgn73AVvaqCarqi6bb+IH1B3invUgOneVH5ao8/lDB2794yCcsRkEYHZLW3mM62GeG4Vmt5UlVXZGKMGAZTgjjuCCCO1SVxNhePFo09pazXsd5c6tfGJbBImlYLO5bHmjYAMjk/Qcmm2Wr61qdrpFt9uls5Z768tbiYxRNKUi8wKejIH+QZIBXOeKY5aN+tvz/wAjuKRWVs7WB2nBwehrhxfa5a2c19NrUk4stVSy8k28SrPG0yIWkIXO/DnlSo4Hy9an/tC8a+msLSdbN73W5Lc3MUMe9EW3EmQCpDMduMsDx64FJaq69fy/zE9Pvt+f+R10c8MskscUqO8LBZFVgShIBAI7HBB+hFSV5+b7UdGm1yG3knvby41eC2E0aRCUg20Z3YYrHvwMc4XPOOx6TwzLrDw3Sa1b3UaxyAW0l75HnSJtGdwgYpkNnpjjHFG/9eSf6g9DcooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKo6vpOnavZGLVrC1vo0y6JcwrIFbBGQGBweetcl4etdO0bwDox0q1+w6hqlpAgk022hE87iPeclxsJwGOX469zQuvy/EdjuJJ4oTGJpUjMjbEDMBvbGcD1OAePakmnit1Vp5UiVmCKXYAFicAc9yTgCuEe91HUrCwhubiWG6ttfFsJ7hIjKFEbHLCP93vwxHHGccdRVjUri7jd9LvbuS++yalp0kdzKiK7B5h8rbAq5BU9AOCPrRHW3qvxt/mTJ2v6P8AC/8AkdvRXDW+teJNQ1V7mwstQkto9Qa2Mf8AogtfKSXY7El/O34Bb0zgbSOTq+E7a4jn1eWfUbm5U6hMgjlWPaMEc/KgOccdce1C1+6/5f5jen32/P8AyOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiq9/Da3FjLHqAU2xXModsLtHJz7cc54x1rkYdA+3aFrEeiWNtaadfmJbWxkXyYZFU/O5UKdgkHGNvIAJHNLuB21FcFOYNP0+60WLRLHQ5pLizNyumMPKkhmnEZO4IhzhWU5UcHg1taPaW2k+Lr/TtLhjtrL7FBP9mhQJHHIXkUkKOAWCjOP7ue9Vb+vxA6OiuI1jUdbQeKr211Z7ePRSHtrdYI2WTFukhWQlSxUk/wlSMnnpizdX2s6RNfQrfnUZTpUl7D9pjjQRSKQNo2hfk+boxJ4+9S/r8Ljat/Xp/mddRXMeHJdRutXnnbUtTu9M+zR+WL+zS3PmkndgeUjEAbeenJ69unp7CCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVxg0230TXvtmt6Pb3jXF9/o+sqFeaIyPiNH3AMoBYINpYdMgc0LewdLnZ0VwOneH9Fk8L6pqs1nbW18l1fyf2lHGqTxlZ5cN5gGeMDqcYGOla2hXFxdeI4bi9XZcS6HbPKuMYcu5Ix9aOtv62b/QctL/11S/U6iiiigQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSR/d/E/wA6Wkj+7+J/nQA6iiigAooooAbJ938R/OobmzgvGhNym/yJRNGNxADgHBwOuM9++D1AqaQ4TJ6Aj+dM8+P+9+lAFe80mx1CZJb22SZkjkhG/oUcAOpHQg4HB9KrJ4a0xLCayaO4mgmZWK3F3LMVKnKlC7Epg8jaRg9K0fPj/vfpR58f979KAM//AIRzTjpcmnyC6mgkcOTPezSSBgQQRIzl1IIBGCMdqrzeD9FuGc3FvNKJFVZEe7mZJCoADspfDOAo+cgtwOa2PPj/AL36UefH/e/SgDPj8O6fFqct/F9rjnmlE0uy+mCO4AGSgfaeABjGMChPDelx6l9tW3fzRIZQnnyGJZD1cRbtgbkncFzknmtDz4/736UefH/e/SgDOn8M6XPCsZhlj2zyXCvBcyxOryEs5DowYAknIzj2qS10HTLIWwtLVYhaySSwhWbCs+d5xnnO49fWrvnx/wB79KPPj/vfpQD13Kr6LYSW0tu8GYprgXTrvbmQMHDdf7yg46cVHcaBptzBNFLA2Jp/tLMkro4lwBvVlIZTgYypH61e8+P+9+lHnx/3v0o8v6/rRAZyeGdJjsbi0FpuiuXWSYvK7O7qAA5cktuG1fmznIznNWtO02DS7cw2zXDqzbibm6knbP8AvSMx/DNT+fH/AHv0o8+P+9+lAElFR+fH/e/Sjz4/736UASUVH58f979KPPj/AL36UASUVH58f979KPPj/vfpQBJRUfnx/wB79KPPj/vfpQBJRUfnx/3v0o8+P+9+lAElFR+fH/e/Sjz4/wC9+lAElFR+fH/e/Sjz4/736UASUVH58f8Ae/Sjz4/736UASUVH58f979KPPj/vfpQBJRUfnx/3v0o8+P8AvfpQA9gGUg9CMGs2bw7pk2lWmnGGRLeyCi28qeSN4tq7RtkVg4+UkZzyCc1f8+P+9+lHnx/3v0oAzP8AhFtG+x/ZRZDyvtH2rHmPnztuPMznO7vnOc89eafB4d0y3tfs6QOymdLlnlnkkkeRCCrM7MWbG0dSeAB0rQ8+P+9+lHnx/wB79KAKB8Pad/ah1BEninZ/McQ3Usccjf3mjVgjHgckHpU1tpNpZ6hcXtssiS3JzKomfy2PHzeXnaG4GSBk1Z8+P+9+lHnx/wB79KAJKKj8+P8AvfpR58f979KAJKKj8+P+9+lHnx/3v0oAkoqPz4/736UefH/e/SgCSio/Pj/vfpR58f8Ae/SgCSio/Pj/AL36UefH/e/SgCSio/Pj/vfpR58f979KAJKKj8+P+9+lHnx/3v0oAkoqPz4/736UefH/AHv0oAr6ppdprOnSWOoJI9vIQWWOZ4icEEfMhBHIHeqsPhqwgt54Vl1J0nADebqlzIwwcgqzSEofdSDWl58f979KPPj/AL36UAULfw7plvZ3FsLdpUuQBO1xM80kgHTc7kscdueO1TabpFnpKyCzSXdKQZJJp3mkfHAy7ksQOwzxVnz4/wC9+lHnx/3v0oAqTaLp9xDqMU1vuTU/+Psb2HmfIE9ePlUDjFQazoq6hbTPakRXjQeQkjMwBTcGKHB6NtwT1ANaXnx/3v0o8+P+9+lAHO6B4a/s3WDfR6VpeioIGia20s5WckqQ7ny0GV2kDg/ePPaumqPz4/736UefH/e/SncCSio/Pj/vfpR58f8Ae/SkBJRUfnx/3v0o8+P+9+lAElFR+fH/AHv0o8+P+9+lAElFR+fH/e/Sjz4/736UASUVH58f979KPPj/AL36UASUVH58f979KPPj/vfpQBJRUfnx/wB79KPPj/vfpQBJRUfnx/3v0o8+P+9+lAElFR+fH/e/Sjz4/wC9+lAElFR+fH/e/Sjz4/736UASVlJ4b01NQF4yXMsgk81UmvJpIkf+8sbMUUjsQBjtWj58f979KPPj/vfpQBjr4O0UTvI0FxIrytM1vLezPAXZixPks5T7xJ+71qxqPhzT9UvVu7k3kdwsYi32t/PbkrkkA+W655J61oefH/e/Sjz4/wC9+lACwxLBCkSFiqKFBdy7ED1Ykkn3PNPqPz4/736UefH/AHv0oAkoqPz4/wC9+lHnx/3v0oAkoqPz4/736UefH/e/SgCSio/Pj/vfpR58f979KAJKKj8+P+9+lHnx/wB79KAJKKj8+P8AvfpR58f979KAJKKj8+P+9+lHnx/3v0oAkoqPz4/736UefH/e/SgCSio/Pj/vfpR58f8Ae/SgCSio/Pj/AL36UefH/e/SgCSio/Pj/vfpR58f979KAJKKj8+P+9+lHnx/3v0oAkoqPz4/736UefH/AHv0oAkoqPz4/wC9+lHnx/3v0oAkoqPz4/736UefH/e/SgCSio/Pj/vfpR58f979KAJKKj8+P+9+lHnx/wB79KAJKKj8+P8AvfpR58f979KAJKKj8+P+9+lHnx/3v0oAkoqPz4/736UefH/e/SgCSio/Pj/vfpR58f8Ae/SgCSio/Pj/AL36UefH/e/SgCSio/Pj/vfpR58f979KAJKKj8+P+9+lHnx/3v0oAkoqPz4/736UefH/AHv0oAkoqPz4/wC9+lHnx/3v0oAkoqPz4/736UefH/e/SgCSkj+7+J/nTPPj/vfpT4zlMjoSf50AOooooAKKKKAI5/8AUt/nvVOrk/8AqW/z3rC1/VP7G0G6vgpkkjTEUaqWMkh4RQBySWIGBSeiGldmjRXn+kaz/Yej6tZWhumkt4lubeS/tJYNzPhZCRIqlgJMuccfPitrV5tT0LSo1ivr3U7m8uo4FYx24eLOSdgwiZ443k8kdehb0EtTpqQMpYgEEr1APSuGvf7cuNGSPUpNQsgmq2iwSzC286VDImd4j3Jw2cYA7ZB5zcmvry0vdRtbedRPJe2tot08KbwGjXLnAAZuuM8AkcY4o/zt+X+Yf5X/AK+466iq1nBJZWhS6vp70qSxmuFjVsenyKo4+lcxaa5e/wBu2UqSahPp2orK8X2qO3WMqELqYwmJBkD+MdD2obsB17MqKWchVHJJOAKSSRIYnlmdY40UszscBQOpJ7CuOmm1CbwHPrd1qLXBu7JZhaNBCYIt2CAoKbjgHHzE564p+uTX+pWfibydQa1h06J4Ft1jRkmzAHLOSN38eBtK9O9Kd4p+Q4+87HXqwdQyEMrDIIOQRS1X0/8A5Blr/wBcU/kKsVUlZtExd0mFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFc546i8/wyIvs8Nz5l7aL5M5xHJm4j+Vjg8HoeD9DUcMC6FozwppdnolzeTiOGLRNkjStjPG+JF3YVvvDAA60dL/10/zHY6eiuIt9Z1qSH7H9omhuI9YWyMt3HC0pjMAkO4R/JuG7jHoM9xXQavc3OjeGZJIrhri5jCxrPcKuSzMF3MFCjjdnAA6UdL/1tf8AUXWxqedELgQGRPOKlxHuG4rnGcdcZI5p9cZerfaRrl3K2pS3ksOhzyxSzxxh1YOp/gUKRwMfL65Jq4ZNV26Zavq0izamS8k6QxjyAse4pECpHJxy+7gH8Dpf+t2v0F1t/Wyf6nT0VyEuraojDTkvx50OrJZNeNEhaSNofM5GNocbgOABkDjGRUr3GtxLqemWl1LfXFqYHS4KRLMY3J3qOBGXAUkZAHIz6k6X/rp/mPZ2/r+tDqqKzNAuRc6ew+2XV3JFIUla8iWOVG4O1lVVHccgcgg5PWtOgAooooAKKKKACiiigAooooAKKKKACiiigAoqC+htrixljvwptiuZQ7YXaOTn2457Y61ykGjCXTb+TSdOWLS7ieBodORFjWeNGBkYIcKvmDjBwCACepoA7KiuDstQubFopJbJXttOS4dI2mC+Siv8+3AYMyK4jAGB8r84xXeU/MAorj9X0yPT9ftNQGl2drD9tiDajA5a6kZ22hHBUYQs2D87cfwjtQu4r3Sp7pFtGhkuIpvtMyOu65XzN3mAg5BCkIC2CDIMZC0lqD0O/orP0e7+0WskLW8dtJaSfZ3iifeikAEBTgZG0jsKwfGWu6apk0O91W1sBJbNNcedcLEzx8hY1yQSWIOcdAD6ilJ2Vxx1Ouorg5ytzp2m6xaKl9bR2tsILqCRGFs6SZkA5yS4wmFzkjBwK2PDt/P9seC9tkSW7eaQzLLuLPGyo6lcDAXIVTk5C5ODVtWbRK2TOkorL8SadNqugz2dtHBK8jR5iuWKxyKHUsrEA8EAjoetYMVnF9ju9Ht/DtjZTQSQXNzY2BQxXUTMeASqAn5GBDAdAM4NSPodlRXCWGo3Ni0M1xaCS20+KXaGmx5KBwHK4BDsoYRgcD5H5wwru6OlxX6BRRRQMKKKKACiiigAooooAKKKKACiiigAooooAKKK48afb6Nrn2zWdJt7tri9/cauoV5ojI+ER8gMoBIQbSR0yBzQt7B0udhRXC2Gg6NJ4Z1PVJrS3tr1Lq+k/tGONUmjKzyYbzBzxgd8YGOlamiTz3XiGGe8XZcS6LbvKuMYYu5Ix9aOtv62b/QJaX/rql+p01FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFXIP9Sv+e9U6uQf6lf896AJKKKKACiiigCOf/Ut/nvWbc2cF2YTcJv8iQSxjcQAwzg4HXGe/fntWnMN0RA7kfzqD7M/qtAGdd6XZX8qSXlukzLG8Q3dCjgBlI6EHA4PpVZPDumpYy2bJPNBKQxW4upZSpU5UqXYlMHkbcYPStr7M/qtH2Z/VaAMb/hH9POmSWEguZoJHDkzXk0kgYEEESMxdSCARgjHanHQdOa2ngkgaRLjZ5pkld2YoAFbcSTuG0fNnORnOea1/sz+q0fZn9VoAoWVhBYWv2eAzOhJJNxcPMxz/tOSf1qlZeGNJ0+4hntrdxJb58gyXEkghBGCqBmIVcfwjA4HHArc+zP6rR9mf1WgDDXwxpSpPGsMwhuFKPB9ql8oAnJ2x7tqc/3QKdf+HNL1K4kmvIHZpU8uVUnkRJlxjDorBX4P8QOK2vsz+q0fZn9Vo8g8yvHGsUSxxjCIAqj0Ap1TfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAGfqWm2urWTWl8jtEzK/7uVo2DKwZSGUggggHg1T/AOEZ042RtZDeyoZBKGl1Cd5EYcApIzlk7/dI6mtz7M/qtH2Z/VaAMe28PaXaAeRbbSLgXW4yOxaUJs3kk5J29c9ep55q7c20N5ay211EssMqlHRxkMD1Bq39mf1Wj7M/qtAGHD4Z0qHzcQyyNNA1vJJPcyyu0bdU3MxOPTnjnGM1avNJs76zjtriNvLiIMTRyMjxkDAKupDKcEjIOcE1pfZn9Vo+zP6rQBzd/wCF7aezsLS1jVbeC9FzLvkcu/ysN2/li+SDuJzxnPFW4/D+nw2EtpCLmNJn3yyreTCZ24GTLu3ngAfe6DHStn7M/qtH2Z/VaP6/r7gKFhp1tpluYbRGClizNJI0ju3qzsSzHgcknpVmpvsz+q0fZn9VoAhoqb7M/qtH2Z/VaAIaKm+zP6rR9mf1WgCGipvsz+q0fZn9VoAhoqb7M/qtH2Z/VaAIaKm+zP6rR9mf1WgCGipvsz+q0fZn9VoAztT0y11jT3sr9ZHgkILCOV4ycHI+ZCCOR61Hp+jW2mGQ20t6/mABvtN/PPj6eY7Y/DFav2Z/VaPsz+q0AZE2gabPb20MlufLtl2Rqsrr8vGVbB+YHAyGyDjnNT2Wnw2H2jydxa4naeRmxlmb+gAAHsBWh9mf1Wj7M/qtAGLH4d06O+F2VuJZFfzEWe7lljRvVY2Yqp57AYq3Np1pO1w00Ic3MQhl3E/Mgzx7fePT1q/9mf1Wj7M/qtHkBjwaFZW11bTxCTdbeYU8yQyEs+MuWbLFsDGSehIrQkjWaJ45BlHUqwz1Bqx9mf1Wj7M/qtG+gbFE2Fs0NvC0eY7ZlaJdxwCowv1x755weoqldeG9Nuxd745FN5G0cpWViNrY3hVJKruwM4AzW39mf1Wj7M/qtHmBRu7KG8szbTeYsRx/qZWiYY6YZSCPwNRWGkWemxSJaJIDL/rJJJnkkfjAy7EscDpk8Vp/Zn9Vo+zP6rQBkS6Dp00VrG9uQlqoSJVkZRt4+VsH5h8o4bIOK0am+zP6rR9mf1WgCGipvsz+q0fZn9VoAhoqb7M/qtH2Z/VaAIaKm+zP6rR9mf1WgCGipvsz+q0fZn9VoAhoqb7M/qtH2Z/VaAIaKm+zP6rR9mf1WgCGipvsz+q0fZn9VoAhrLTw7py3wuytxJIJPMVJruWSNG/vLGzFFI7YHHatr7M/qtH2Z/VaAOfXwjo4neRoJ5FeVpmglvJnhLs24nymcp94k/d61PqHh+w1K8W7uPtcc6x+Xvtr6a3JXJOD5brnknrWz9mf1Wj7M/qtAFaKNYYUiQsVRQoLuWYgepOST7nmn1N9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ0VN9mf1Wj7M/qtAENFTfZn9Vo+zP6rQBDRU32Z/VaPsz+q0AQ1cg/wBSv+e9Q/Zn9VqeEbYgD2J/nQA+iiigAooooAbJ938R/OlpJPu/iP51leJtRm0zw/czWUbS3kgENrGuMvM52oOcDqQeTjANJjRpQXEN1F5ltNHNHuK7o2DDIJBGR3BBB9xUlecW19d+GtL1jTobG80hfsi3Vo120TsMBY5nGx3Hy/K/J6sSRWxr0D6JoUMej3NxL9tu4Y5ZbvVJuFbPSU7zGGOFyo/i4wcEN/5f5C/r9TrJJY4VDSusalgoLHAJJwB9SSBT68/1DSdRj0RIdclKRDV7M28cGqzztEhkQMGlYI7c5IzkjPB4GLl5Nd2Ooy+Gobq53ahPE9nM0ztJHBj98A5JbKiNsHPBkWmtf69P8/wD+vzOttr23vGnW3k3m3lMMvykbXABI568EdKnrhTLIb6ay+0S21te+IJIZ5YZDGxX7OGChxyu5lUZBB7A81a1a5l8JzA2k1xcQ3lsba1jubl5sXYYmNdzkn5t5B5/gFLon3S/K4Ldr1/Ox2FNSWOQsI3VyjbW2nO0+h9DzXH3lhdaLcW13qdxf31hbpBEJYtRljeJuFLPGGCyhmOSSSecBTWe4k0bw94gvNLln+0f2qYWaa9lKRo0qBm+bcEwrE79pIHPOKOtv63S/UOi/rv/AJHe3N1BaQ+bdSrFHuVdznAyxCgfiSB+NS1wc0GvaRpV01zMtvbvc2Igji1Sa8kQm5USZkkRW2spA25I4Prik1Rbk6f4t1Q6jfLPpk8j2SR3TpHFtt43wUBAcFieGBHPSmlf+vT/ADHbbzdjvaK4HUf+Ei1fX9Xj0x4YpbExravLqs1uIg0StvaFI2WVSxYfOf4SABjJ71d20b8bsc46ZpdLiFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAjmnht0D3EqRKWVAzsFBZjhRz3JIAHcmpKwfGH/IGtv+wlZf8ApTHWDqAuf7M8TasdRvhcabdyG0VLp1jjCxo20oCFcEk8MD14xTWv9en+YPRX/rr/AJHbxXUE000UUqvJAwWVQeUJAYA/gQfxqWuF1fVNRhOuJaznnVrW3BkuWiWKN4YsgOFYxgk4yBwWzweaUxa1pliLXUrkWlpdX8EKtDqUt1JBGwO4GaRFYbmCgHkjecEcYX/A/G3+Y3p+Z27SxpIiO6q8hIRScFsDJx68Uy3uoLpGa2lWVUdo2KnOGU4YfUEEVyuoaHZxeJdAgW4vyim4ALalcM2doONxfJ/E9OOlV7e5uL77JY3d7cx291rF/FJIk7I7BHk8uIOCGUcfwkHCY6Ubi6X/AK6/5Hb0Vwck13JeW+lw6jeC0i177Is6zsZJIvsjO0ZfOWw+V3E5GBzkZre8Oq9rqOsaeJ7ia3tbiPyftEzTOgaJWI3uSxGSTyT1o8/66f5jatp/XVfob1FFFAgooooAKKKKACiiigAooooAKKKKACiiigCK5uYLK1kubyeO3giXdJLK4VUHqSeAKg03WNM1iN5NI1G0v0jO12tZ1lCn0JUnFR67YNqejTWkdxHbPIU2ySR71BDAgFcjOcYxkdaqaPqN++sXulapJa3M1rFFN9otImiU7yw2FGZiGGzP3jkMOlC3DobdRS3VvBIEmnijco0gV3AJVcbmx6DIye2RXn+vX8c3iq60q71Wa1vGu7c2rrq/2WNISELIYhKrOTiQZCtksBuGPl6O2a1utU1bVdQMf2G1X7FG02CgVPmlbn1f5T/1zo6XGalrrelXtlNeWWp2dxawAmWeK4R0jwMncwOBgetJpuuaTrPmf2Pqllf+VjzPstwkuzOcZ2k4zg/lWJJpUuuwaxezY05NSsxZQCWPLCMbsSOuRyS5wpIIGM4JIF3S9Q1GPXpdH1WazupFthcCa0haEIC23ayM74J6g55weOKfWwntc3aQkKpLEAAZJPauO1a3mvdY8Qs+o38K2NlFLbR2908SxybZCWwpG7oOGyvHSm2azWeo6aPt15cf2lpM810Li4aRWkURYZVJwn324QAc9OBUN6Py/wCD/kNK7S7/ANfqdjDNHcQpNBIssUihkdGBVgeQQR1FPrI8J/8AIl6L/wBeEH/osVr1pJcsmiIu8UwoooqSgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqL65pMeqDTZNUslv2xi1a4QSnP8AsZz+lXq5X9/4YuFK/Zb3TL/UeB92eGWaTrnkSAM3+yVUd8ULewdLmvH4l0KbUTp8OtadJehyhtlu0MgYdRtznPtWgJ4jcGASp5wUOY9w3BScA464yDz7VxtsdPHw71T+1tn2b7Xf/f6lvtMu3b33ZxjHOcYq7oQuh4jhGo5+1/2Hbefnrv3vu/XNHW39bN/oOWl/66pfqdRRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApI/u/if50tJH938T/ADoAdRRRQAUUUUANk+7+I/nTJIIpmjaaJJGibfGWUHY2CMj0OCRn3NOlO2Mn0IP61F9p/wBj9aAHyW8MsqSSwxvJGCEZlBK5GDg9s1UttC0iytp7ez0uyt4LnmeKK3RVl/3gBg/jVj7T/sfrR9p/2P1oArw6DpFtpsmnW+lWMVjLnzLVLZFifPXKgYNV7PQ/s+rLeTSQGO2hNvY29vb+UltESCR945PyqMjaMDgVofaf9j9aPtP+x+tHW4DZtNsbi3nt57O3lhuG3TRvEpWU8csCME8Dr6Vnf8I7GLyySH7LbaVYN5tvYW9qIwJcEbiwOMDcSAFHPOTWn9p/2P1o+0/7H60AQS6HpM+ppqU2mWcl8mNt09uhlXHTD4yPzqQaXYLeT3YsbYXNwnlzTCFd8q/3WbGSPY0/7T/sfrR9p/2P1oArWugaPY27wWWk2NtDI6yPHDbIisynKsQByQQCD2xVlrG0eK4ie1haO5JM6GMES5AB3D+LgAc9hR9p/wBj9aPtP+x+tAEF7omlalNFLqOmWd3LB/qnnt1do/8AdJHH4VeqD7T/ALH60faf9j9aAJ6Kg+0/7H60faf9j9aAJ6Kg+0/7H60faf8AY/WgCeioPtP+x+tH2n/Y/WgCeioPtP8AsfrR9p/2P1oAnoqD7T/sfrR9p/2P1oAnoqD7T/sfrR9p/wBj9aAJ6Kg+0/7H60faf9j9aAJ6Kg+0/wCx+tH2n/Y/WgCeioPtP+x+tH2n/Y/WgCeioPtP+x+tH2n/AGP1oAfNBDcIEuIklUMrhXUMAynKnnuCAQexFMaxtXhnia1haO4JMyGMFZSRglh34A60faf9j9aPtP8AsfrQBQ0zRGtl1FtUlhvZdRm8ycLb7IiBGsYUIWbjagzknJJ+lT22h6TZWEtjZ6XZW9pNnzLeK3RY3z1yoGDVj7T/ALH60faf9j9aAKo8PaKNPjsRpFgLOJ/Mjt/syeWj/wB4LjAPvU82l6fcWUtncWNtLbTMXkgeFWR2J3ElSMEk859af9p/2P1o+0/7H60ANi06yggt4YbO3jitTugjSJQsRwRlRj5eCRx6mpkgijlkkjiRJJSDIyqAXIGASe/AxUf2n/Y/Wj7T/sfrQBPRUH2n/Y/Wj7T/ALH60AT0VB9p/wBj9aPtP+x+tAE9FQfaf9j9aPtP+x+tAE9FQfaf9j9aPtP+x+tAE9FQfaf9j9aPtP8AsfrQBPRUH2n/AGP1o+0/7H60AT0VB9p/2P1o+0/7H60ALdWltfWr217bxXMEgw8UyB1Ye4PBplhp1lpdsLbTLO3s4AciK3iWNc+uAAKd9p/2P1o+0/7H60AYd14Zu7iG/sV1GFdN1B3aeNrTdPh/vBZN+B6AlCQPwrZk0ywm097Gayt5LSTO+3eJTG2Tk5UjByefrT/tP+x+tH2n/Y/WjpYOtyja+FvD9iJRZaFptuJ08uUQ2caeYv8AdbA5HsatafpWn6RAYNKsLaxiJ3GO2hWNSfXCgVJ9p/2P1o+0/wCx+tADja27NMzQRFp1CSkoMyKMgBvUcnr60n2O23Rt9ni3RIY4zsGUQ4yo9AcDj2FJ9p/2P1o+0/7H60AU9P8ADWhaTc/adK0XTrKfaV822tEjbB6jKgHFadQfaf8AY/Wj7T/sfrQBPRUH2n/Y/Wj7T/sfrQBPRUH2n/Y/Wj7T/sfrQBPRUH2n/Y/Wj7T/ALH60AT0VB9p/wBj9aPtP+x+tAE9FQfaf9j9aPtP+x+tAE9FQfaf9j9aPtP+x+tAE9FQfaf9j9aPtP8AsfrQBPRUH2n/AGP1o+0/7H60AT0VB9p/2P1o+0/7H60AT1nwaDo9rqL6hbaVYw3rkl7mO2RZGz1ywGTVn7T/ALH60faf9j9aAKkXhvQ4NSOoQaNp8V6zFzcpaoJCx6ncBnJ9aXUfD2i6xMkur6RYX8iLtR7q2SUqPQFgcCrX2n/Y/Wj7T/sfrQBJDDHbwpDBGsUUahURFAVQOAAB0FPqD7T/ALH60faf9j9aAJ6Kg+0/7H60faf9j9aAJ6Kg+0/7H60faf8AY/WgCeioPtP+x+tH2n/Y/WgCeioPtP8AsfrR9p/2P1oAnoqD7T/sfrR9p/2P1oAnoqD7T/sfrR9p/wBj9aAJ6Kg+0/7H60faf9j9aAJ6Kg+0/wCx+tH2n/Y/WgCeioPtP+x+tH2n/Y/WgCeioPtP+x+tH2n/AGP1oAnoqD7T/sfrR9p/2P1oAnoqD7T/ALH60faf9j9aAJ6Kg+0/7H60faf9j9aAJ6Kg+0/7H60faf8AY/WgCeioPtP+x+tH2n/Y/WgCeioPtP8AsfrR9p/2P1oAnoqD7T/sfrR9p/2P1oAnoqD7T/sfrR9p/wBj9aAJ6Kg+0/7H60faf9j9aAJ6Kg+0/wCx+tH2n/Y/WgCeioPtP+x+tH2n/Y/WgCeioPtP+x+tH2n/AGP1oAnoqD7T/sfrR9p/2P1oAnoqD7T/ALH60faf9j9aAJ6Kg+0/7H60faf9j9aAJ6Kg+0/7H60faf8AY/WgCekj+7+J/nUP2n/Y/WpYjujB9ST+tAD6KKKACiiigCOf/Ut/nvVOrk/+pb/Peuc8UXVzb6HJDp2DfXhFtagttAd+N2cHhRljweFNJjRd0/UrTVbX7Tp86zw72TeoI+ZSQRz7j8etTTziBULJI+91QeWhbGTjJx0Hqe1cFImq6LbanpzWUVkt5ZiS1TT7l5jmJVSQKTGhDGPaQAP4SetXpf8AhHfsFn/wi/8AZ/l/2pa+d9h2fe3j7+3+L681XVJeX52Jbsm/X8rnYyOI4mds4UEnFQ6fex6jpttewBljuYllQOMMAwBGcd+a5TSv7G+13f8AaX2P/hJfOuceft+07Nz7dmfm2eXtxjjHvmqNj/ZP2XSv+Es+y/2f/Y1r9j+27fK83B8zbu4348vHfHTvSW33fr/kN7/f+n+Z6DUSzhrqSAJIGjVWLFCFOc8BuhPHIHTI9a4b7TfaNpthqBWU3Oo2hsUEwbeZdxNsXzznazA55yabqWnx2EWq6fAzrHDaaZCrq2G4mcZz6980f1/X9dRX/r+v60PQKKr2Vhaadb+RYW0VtFktsiQKCT1Jx1J7nqasUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIrm5gs7WS5u5khgiUs8kjBVUepJqpp+tWepyvHai6DKN2Z7OaEMPVS6gN+Gap+LYpH0mCVInmit72CeeKNCxaNZAW+UcnH3sD+7VfVdcsdY8O3y6BqUN5LGimVbKYPIibhv4U5Dbd2O+aOjf8AX9f5B1OkorzzUDpP2DWh4S+y/wBm/wBi3X2v7DjyfOwNn3eN+PMz3xjPatC502PStSs20G3SC8utOud7oAGuJAqFC5/jbPc5PJ9TSk7R5v66/wCQ7apf10/zOzorgJP7I/4Q+4HhZrRdS2Qf2g0ab7gJvXzDMqkSE7d+QSGPPOaq/YrQeH746frGl3drNdWKGDRYfIigb7SuWwJHwzAjOMfdFVbWwlrY9EurqGytJbq6cRwwoXdyM7QOpqWuB8Q6NY20fiGxsNPgjt5NIWc28UI2mQPJ8+0DG7jr14HpV2Gx0PVvElgllFZ3WljTpXjigCtbswlXnaPlOCT9D70lrb5/hf8AyFJ2v/W9v8zsait7qG6WQ27hxHI0bEDoynBFef3N7bXfiW2vIBplvqCaolvLDFbFrxIxIUzJIGyqMADgrj5gATwaHt7S00PXLXR47O11BNRJukjgBkS2M4JLIhVimwk8EZGcUlr/AF6f5jejt/XX/I9FqhDqy3GsT2Fva3Ei25CzXI2CONyoYIctuJwwPCkc9axfBdtawm9k07V9JvbVygEGkW4iggYZycCRwC2RnGPu1ky6Xa27eKLqxsYYpv7ThSea3hAl+zlLdplBAzgguSB7nrVW1t/XT/Ma1R39Feeaj/Zh0rXx4Va3XS/7KbzWsNvkifJxt2/Lvxndjn7ue1dxY6dZ6ZatFY28cKud8hVeZHxgsx6sxwMk8mk9Fcm+tia2nFzbRzqkiCRQwWVCjD6qeQfY1W1PVV00QKLae7nuHKQ29vt3uQCx5dlUAAE8kVxvh3TbPVF8PQalbx3UA0HJgmUPGx3x4JU8HHbPSls9MsNQk8Nrf2VvdCK8vYY/PiV9qIZQi8g8DaMfQVTX9eja/QJOza/rp/md8DlQSCCR0Palrz651K0tvD+oaXLOn9of2wz/AGQHMoRrwMHK9du0g7ulXLf+y7TxwRA+k6rez3Dh3Qqb6zypJDEZJQY287doIHNRfUpq1/I7G3nFzbpMqSIHGQsqFGH1B5FSV57Y/wBl/wBnaH/wlH2b+yv7Pby/tu3yPO3j7275d237uefvY71PZWKalc6Hb6nC09oft5ihuASJIN6+UHU/eGzaQD6A9aFqrg9Gd3RWH4WjS3s761gURwW9/NHDGvCxrnIUDsBk4Hatynuk+4utiK6uobO2ee5bbGnUhSx9AABySTxgcmqCeI9MfT7m982ZIrXHnJLbSpKmemY2UPz2457VPq+rWeh6XNqGpTLDbxAbmYgZJOAOeOSQK5m3utF1jTdUu7vxBYrLceU1xJZXcTizRWzGpbkdckkjBJPbFLuHY6KDXbGaxnvD9pt4Lf8A1jXdpLbkfQSKpP4ZqXTtVtNUSQ2jSboyA8c0LwyJnplHAYZ7HHNcjNfT3tndLb6i+uaZaTWdx9uCId2Jt0qZjUK4VVVuBkZwc1s6Rd2+q+K7/UNMnjubP7HDAbiFw6SSB5GIBHB2hhnH96q/r+vyA6GivPtc0uzuIPG1/PAsl3a4e2mYZaBltYyGjPVGz3GCcD0q1qWn2ulXd/BpYXTVudFleR4AFLSBlCueRl/mIyTk560u39dLjat/Xov1O3rNn8Q6Vb2q3E14qRtcG2QlTl5A20qBjJwQeRxwT0rjNJuLCwm1DVLXSbXS9Tks0ht7JLOWEyPuwG3SRRk5d0U7QcYGT0x0eqaZDp3hCK3VQ72yxRiVh8xzIm459yMmh6K4jU1HWLLSjGLt5N8uSkcMDzOQMZO1ATgZGTjAyKtW9xFdW8dxbSLLDKodHQ5DA9CDWHqF9a6P4rW91W5jtbWWy8qOaZgqK4fJXceMkEYHfacdKTRopIvAreajR74p5ERgQVRmdlBB6YUjipbtDm/rqNK8uU6GoJ7yC3uLeCZ9sly5SJcE7mCliPbhSea4iw8OaQT4XD2EL/a7Jjdblz9qxEpHm/8APTB5G7OKS3vbPSYtGe+uobOztdavoUeeQIkaATqq5JwABgAfQVo1ZtdiE7xUkd/RVeyv7PUrVbnTruC7gYkLLBIHUkdeRxVipKCiiigAooooAKKKKACiiigAooooAKKKKACiiigArMXxBpz6kbGN55JRJ5ZeO1laJX7qZQuwEdwTxWnXHLqVrpusi38P6xb3pnvcXGkZV5IS7/vHXb8yAElzuyOoGMihb2B7XNceLtHMzxma4RUlaFp5LKZIQ6ttI80oE+8CPvda1BeQG/ayD/6QsQlKYPCkkA56dQa4vT9e0iPw1qemSXUF1fNdXyf2dE4kmkLTyYXyxzzkckYwcnirFrqFl4d1+2h8QapaWkq6Nbxl7m4WMSOrMGwWIzR1t/Wzf6fiOWjdv61SOyopkUsc8KSwSLJHIoZHRsqwPQgjqKfQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAq5B/qV/z3qnVyD/Ur/nvQBJRRRQAUUUUARz/AOpb/PeqdXZRujwe5H86j+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqr39lFqNjJazlgj4O5DhlIIIIPqCAfwrR+zJ6tR9mT1agDEstH+zXovLq+utQuVjMUclz5Y8tSQWAEaqOSo5IJ4rSqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFairP2ZPVqPsyerUAVqKs/Zk9Wo+zJ6tQBWoqz9mT1aj7Mnq1AFarkH+pX/PemfZk9WqSIbY8DsT/ADoAfRRRQAUUUUANk+7+I/nSkgAknAHUmkk+7+I/nWP4pS9uNCksNM3LcXzC2EoQsIVb78hxjou7uMnAzzSd+g15k+i67Z69ppvbEuIldkPmjaRjofoVIYezA01PEWmXUQk0y9tL8faEt3NvdRkIzHHJ3df9nqewrlb7RNdtE1OybyL6LU7IbVsrRreNXiwNjbpH5eP5ckgfIBWvqF2msWViNOsr1Bb6jbF0msZYSqhxnAZRkAdxkD1qtLr5fnYl3UW/X8rmxPremw3zWBv7U34QuLTz1EpAGfuZz09qrweJNOGh6dqWqXdrpq38KSItzcKoyyg7QWxk81maNJ9ggvNJu7O7W+lubqbzRaSNFKGdmVvNC7M7SowTnjGOlUdHWTRBp91qtheSRSaJa2qLFaSTNFIu4yIyKCVzuXkgD5eTwKS2fy/X+v6sN7/f+a/4f+rnaJcwSTPCk0bSoqu6BgWVTnBI7A4OPoaqQ6zaTTyhJ4DAkcTrcCdCr7ywA4ORyOCeDnjODXINpur6ToumvZWswu7m1fTpI413m2DsWhZscYiyQT05qTVtCZF1axtrGWS0+y6bBEqxkh1SZtwGOuFxn0FH9f1+Av6/r8Ts7S+tNQhM1hdQ3UQYoXhkDqGHBGR3HpU9IqqiBUUKqjAAGABS0DCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKmpalDpdqk9wrsrzxQAIATukdUU8kcZYZ9qZNrmlW95HaT6nZxXMr+XHC9wgd2/uhSck89Kp+KoJrjSbdLeJ5WGoWblUUsQq3EZY8dgAST2ArEvNLm/wCEb8YCKykNxdXMrxBYjulxGgUrxk8jjHcU46/16f5sJaJf13/yNI+MbJvFFxpMNzpuyzj33ck1+qSR8EnbHg7gMDcSVxnvW+1xCk6wvNGsroXWMsAzKMAkD0GRk+4rlNW068u7fxdFBbSO91bRrANuPNIiIwpPB54ps00eu+JYZH07URpq6TdwzyTWcsRJZocoFKhicA4wOe2cGpWunr+o1qzcHiTS7i0mn0y/s9Q8h1SRbe7jOwswUAndgHnoevQc1Zm1fTbfUIrC41C1ivJhmK2eZVkf6KTk/hXIO+oXui3dnbpe3tnE1r5E11p7205ImXcpUqu8BQDuCgdetP1OGZLHxFpJ0+6mv9Umd7SZLd2jfciiNjKBtTYR/EQflyM5FPrYSOqu9c0mwmWK+1OztpGcRqk1wiEtgHbgnrgg49xV6uUOlyGTxY8lo0kl1CkauYv9eBbgYHqNxPA710GlK6aPZLMGWQW6Bw45B2jOfektb/13/wAg7f12/wAy3RRRTAKKKKACiiigAooooAKKKKACiiigAooooAhu7j7LavMIZZyvSOFcsx6ADt+JIA7kVk/8JRCljezXOn3tvcWQQyWUgjMpDnCbSrlDuOQPm7HOKvazqR0jSZrxbW4u2jA2w20TSOxJwOFBOOeTg4Ga52zbTb/SdRfVIdUuZrgpJeMNNu7c4B+RYgUVyFx/Dk9SetLvYOxtDXTFpk97qel3unLEQqxzmJ3lJIChRHI4ySQACRyal0zWF1GWaCS0uLG7gCtJbXOzeFbO1sozKQdp6Hsc1yv2S8uba7bS49Ul0yCWzuIItQMpmkeObfKFE37zG0LgNxnpW3pDtqXia91aO3uILU2kNtGbm3eF5GVpGY7HAbA3AAkeuKoOho3Gu6TaXa2t1qllBcO/lrDJcIrs2AdoUnOcMDj3HrT7TV9N1Dz/ALBqFrdfZ22zeTMr+UfRsHg/WuU1bSZZtN8eFbCSSW9TbDiIkzgWqABePmw24cd81L4jsUW4uQ8EkVpJoclruiQgb2dQiAgEZ5wBg9TxS7f10uNq39ea/wA/wOisfEGjanctb6bq1jeTqu5ore5SRgPUgHOK0K5Lw1cXja/IdftZ7TU7izVY1MMccbxxNzjZNLyGlH3iOCMDrXW02rEhRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY9v4g+2X5hs9Lvp7ZZmga+URCEOpKsMFw5AIIyFI4rYrjpGEWvqfDcWrQXMl4pvLeW1lW0kQt+8fc67AcZIMbAscZzk0LdIHsXl8Yx+XPcyaPqcen280kUl+RC0a+W5Rm2rIZNoKnnZ056Vrx6nBLqrWEe5pBbrcbxgoVZiBg56/Ka5TTtSltdB1DSYtK1KbUZLq9EcTWMqRNvnkKsZmUR7cMDnceOmTxU1uy+F9btor2G/nij0eC2We2sJ7gM6M2c+WjYOMHn1o6/12f/AABy0bt/Wq/S52NFMhlWeFJUDBXUMA6FGAPqpAIPseafQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApI/u/if50tJH938T/OgB1FFFABRRRQA2T7v4j+dLTZjtiJHYj+dQfaX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNFVvtL+i0faX9FoAs0VW+0v6LR9pf0WgCzRVb7S/otH2l/RaALNQ3dpBfWkltdxiWGQYZT3/wPv2pn2l/RaPtL+i0AQWGiWWmzNNbrO8zLs825uZJ3C/3Q0jMQOAcDitCq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaKrfaX9Fo+0v6LQBZoqt9pf0Wj7S/otAFmiq32l/RaPtL+i0AWaSP7v4n+dV/tL+i1PCd0QJ7k/wA6AH0UUUAFFFFAEc/+pb/PeqZIAJJwB1NXJ/8AUt/nvXOeJ0vLjRJLHTdy3F8wthKELCFW+85x6LnuMnAzzSd+g15k+ja3aa5p5vLIuIldkPmDaRjofoQQw9iKYniDTrmIPpt5a3w89IHMFzGQjMccnPX26nsK5i90bW7VNSs28i+i1KzG1bK1aBFeLA2Nukfl4/lySB8gFat/dJq1nZf2fZ3iCDULYuktlJCVUOM4DKMgDuMj3qtG18vzsS7pN+v5GvNrOnQ3rWJvrU3wQuLTz1EpAGfu5z09qgh8RaeNFsNR1O6ttOW+iSRFuJ1UZZQdoJxk81m6PJ9hhu9KurO6W9kuLmXzRayNHKGZmVvNC7c7SBgnPGMdKpaQJNGFhc6nY3kkUmjW1sixWkkzRSLuLoyqCVzuXkgD5eTwKS2+79f6/qw3v9/6f8OdgtxC8zwpNG0qKGZAwLKDnBI7A4OPoaqxavaTTSBJoTCkcbrOJ0KtvJAHByORwTwc8Zwa5NtO1XStH057O1lF1cWz6fJHGu77MHYtEzY7R5IJ6c0/VdEZV1SytrKV7X7Np8EarGSHVJW3AeuF6+go/r+vwF/X9fidjaXtrfwmWxuYbmMMULwyBwGHBGR3HpU1IqqihUAVVGAAMACloGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUdX1RNH083UkE1x+8jiWKDbvdncIoG4gdWHUikstUa5wt7Yz6ZK7bYoruSEtLgZO3y3bOAD71n+NYDceG9nlXMqi7tnkW1WQyBFnQsV8v58gAnK88cVQnSy/4Rue80n+0w+mzC9U6n9pDkoMsoNxzhk3Lxx8xo0s2/62Hbax0dzqun2cM8t3f20EduwWZ5ZlUREgEBiTwSCDz6irEE8VzAk1tKksUg3JJGwZWHqCOtcPPp18LLSdUkkv7cyTzXd21lAk00TSr8nyMj52rhPlUn8M10fh6yitdCZLOe9kE0kkokvYfJk3OxJJQIm3kk42ijVX8haOxdg1XTrq+lsra/tZrqH/WwRzKzx/7yg5H41CNdsI7EXV9d21kh3nM1zHjar7S24HGMkd+MgHmud02KV7Xw9pken3UN5pbobqWS3ZY0AjZXIkI2ybif4SeuT0o0bTJxqmgyXNnIPs8WoEs8RHls0ybevQlc49Rmnb+vkHU3bvxRotibE3GpWqpfkiCXz02MApbdnOMcYyO5FWJNb0qK8S0l1OzS5kYqkLXCB2I6gLnJNcysM2nyWd1LZ3XkW+tXcjiG3eRlR1lCsEUFiCWHIB65pb3SGn0LxKjWDSPd6iHCmEkyqPKwQMcjg/kaS1V/K/5afiD0dvO356/gdTZarp+owyS6ffW13HExWR4JlcIR2JB4NMttZ0y9tmubPUbS4gRwjSxTqyqxOACQcZyRx71zniHSr28vtbSwgkAn0y2RSigCQrLKWQFhtLbTjB4+YZ4NUrjS49Q03UJo5ta1GeYW0EseoaeIMoswOABDHuwC2TyAKBvT+vQ6p/EmjjTbu/j1O0nt7MEzvDOrhCOxweD2watafqFpqlkl1YTxzwuOGjcMAfTIJGaw9Y0+4uNU1IWtuxE+jPArBcKz7m2rnpnnp71r6LcrdaPbukc8W1AjJcQPEwIGD8rgH8eh7Uo63f8AW7X6Cej/AK7L/MvUUUUwCiiigAooooAKKKKACiiigCG7uDa2ryrBLcFcYihUFmJOMDJA/EkCstPE0Xk3H2iwvLa6gaNTZyCMyMZDtTBVyhycj73GDnFaOo3EVtYSyTpcPHjawto3eTB4yAnzflzXNaTpcd3LqK2y6jBpsggkhnu1cXHnozEsDMDIQMJjeCOoAxQBvWus2921qkSS+ZcByUIGYthw27ns3y8Z56cc1oVwT6be2UCXUK6iJ7mOVoBGH3LLuBiEoQDAO6RmDAIC7A9BXe0+gBRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArJt9e+13xhtNMvZ7ZZmha9URiIOpKsMFw5AIIyFI4rWrkpGEWur/wj0eqQXMl2pu4JLWVbWRC37x9zrsBxkgxkFjjOcmhb2B7FxfF0eya4fSNSSwglkikviImjXY5Rm2rIX2gqedvTmtaPUoJdUaxj3NILdbjeMbSrEgYOevFcvp+oy22h3+lxaZqE2oPdXgjjaylSJt80hUmVlCbcMDnceOmelSwMvhrWraO8ivp4o9JgthNbWM1wGZGbOfLVsdjz60df67P/AIA5aN2/rVfoddRTIpFmhSVAwV1DAOhVgD6g4IPseafQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAq5B/qV/z3qnVyD/Ur/nvQBJRRRQAUUUUARz/AOpb/PeqdXpBlMHoSP50zyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKKt+RH/d/WjyI/7v60AVKqX+mWupxpHeq8kaNu8sSuqv7MoIDj2bI9q1vIj/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlFW/Ij/u/rR5Ef939aAKlXIP9Sv8AnvSeRH/d/WnxjCYHQE/zoAdRRRQAUUUUANk+7+I/nSSSJDE0krBURSzMegA6mlk+7+I/nWT4msbvVdFbTbMtGLx1hnmQqDFCfvkZ6kqCo4PLDjGaTv0GvMZoniWDVtGn1C5j+wLbs3nLM/8Aq02h1YnjGUZW9s47Uv8AwklrPbxzWfmKr3MUGbu1ng3bzj5dyfN7EfL6kVh33hPVY5L2O1v59Sj1G0CSPeeSgjkiIMYxGi/KwLKTgngdq0706jrVrabtHubJ7fULeVlnlhO5FfLMCjtwPfBPpVaXXy/PUl35X8/yHWfjLTLi0vLq58+ygtbkwPLcW8qLnzBGDuZQOWI47d8Val8TaZDbRTObr98W8uJbGcysFOCwjCb9oyPmxjkc8isO50nUpdM1HTP7OkYNqsd3HOZI/LljNykjADduBVQcggdOM1Z8S6NPca5baklpqF9Clu0DwadqDWsqksGDAiSMMOoILccYBqVflX9dP89CnbX1Lp8V2J1uy0+BZ7hby2NxHcQwSSJjcoHKqRj5uTkBcc9aE8VafFa273s4865MxhitYZZWkEb7W2qE3EjIyAPUjIGapWulzaVqmjTadpNz9jjtJbaSE3CPJbGSRH3Ozv8AMBtbOGY+gNM0bRL+11HRpbm32raxX6ynep2GSZGToe6g9Oneqtovn+tv0JV76nR2GoW2p2a3VlJ5kTEjJUqQQSCCpAIIIIIIBBFWaytAs57K3vVuo9hlvp5kG4HKM5Knj1FatLomPqwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigClq+qRaRp7XUsckx3rHHDEAXldmCqoyQMkkdTgdTUNne6r+9k1jTrW0gRC6tb3bTscdivlrg49C1M8R6bcalp0X2HyzdWtzFdQrKSFdkYHaSOmRkZwcZzVS8vtb1HRrpLPR7zTrpQhUzTQEyjcN6oVkbBK7gC23kijo/6/rqHUtJ4p0g2dxdS3EltFalfP+1W8kDRhjhSVdQ20n+LGODzwadD4m0qaG6k+0SRfZVDSpcW8kLhScBgrqGYEggEAgngZrjNR0u+tbPW77+z7m3iuYrCOCLUL43EjOlwxIY732j5l4BIwfXIrentLrVtRub7UdDuUto7JrVbMzRebcMzhiwKybVA2jaSwOSemBQ97L+tA/r8jYh1+wntknzcwo8626i5s5YWLscKNrqDznrjHvVfXNfXToJUs2R7uGa1WSORWwqTTCPOeOcbsc8Ec1j/YNbm0ks1teOttfQXFrZ3s8TXGxCC671Yqe+3cxPqfRl5pmsarc6ldvpj2wuH04wxSTRl9sU5eTdtYqCASeCcjGOeKatf5/hp/wRK9/wCu7/4B0Vx4i0y11H7FNO4lDKjMIXaONmxtV5AuxCcjAYgnI9RWnXET+GT/AG3fLf6XqmoW97d+ektrqrxQopC8SRGZBwR/CrZGO/FdvSWyY+oUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUARXM/2a1km8qSbYuRHEu5m9gPWsiLxIx8M/2pcWLRTGZrdbUSBiZPNMSruxjlsc9BnvityuafRr1/C5t1jUXcOoNeRRs4w+26MqjI6bl/LPNAGjpeq3F1fXFhqdpHaX1uiSskM5mjaNywVgxVT1RgQVGMd6hvPFui2F3cW11dOslqwW4K28jJBlQwMjhSqKQR8zEDrzwabpMN5da9d6vfWUtgr28dtDbzOjSYVnZmOxmXksABk/d7ZrP1LRL+fTfGUUNvuk1MEWo3qPN/0ZE9ePmBHOKZUUm7GvbeJdKuluSly0Yto/OkNxC8I8vn5xvUbl4PzDI96XT/ABHp+p6hJZWv2sXEcYlZJ7GaHCk4By6Ac4OPofSsbxRZsslzdXMG+zbSZLNjuAHmSSIFB5BA9+3rVXTrnV9F1R49Ws/7R1a4tV8qSK9EuUWRVw22CPYMyls7WyA2TwKFr/Xr/lcjp/Xl/wAE7C9luYrVmsbZbmfICRvL5a/Utg4H0BPtWFJ4mvItPu9+mw/2la3cNobcXZ8lmlKbSJdmcYcE/Jng8dDWlr11qVppTvotg99dswVUVkGwHq/zsoOBzjIz0yOtY9tbK/h64tr3wnfXatIJJoL9rSR7tycl/wDWlCQQOCVwMAcDFIo39Ok1GW3Y6ta2ttNuwqW1y06lcddzRoQc54x+NZ03jHQreeSOa8dRFKYZZfs8nlRyA42NJt2q2egJBORjORUfhfTJLBr6RdPGk2U7obfTgyfucLhmwhKLuPZSRxnqTVOfRL5/D15bJbAzS6yt0q71+aMXSPuznH3ATjrxij7Vv66CW3z/AMzXh8S6XPZ3NyJ5I0tSFmSe3kikUt93926hju6DA57ZqTTNesdXnuIbL7T5lsQsqz2csG0kZA/eKM8EHj1rnfEtjc/bNTkWMK1+tlBYymQKBOkkjAk87dpKnJB+jdDe8MNdQapqNnqsanUSsU806XQnDq25VBIij2kbDxs75ySTQtQ6HS0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWHY61qOp30hs9Ntzp0Vy9u88l4VmDIxViIhGRjIOMuCRzityuTurC6u/EEdxp+h3OmXa3KNPqPnxLHcRKfmDKjlpMrwA6cZByMULdA9iSLxPq0lrc6j/YkD6bbTzRs0N8zXBWKRkZhEYgp+6TjfnHqeK1rbWI7vV/scCh4ms47tJw3DK7MAMY9s5965+yXXrXSL7SLfQ5kmmubpo72eeH7OFlmdlbCuZDwwONg54461Olpe+HdZtzY6Pe6naR6XDZq9tJApUozdRJInYjpmjr/XZ/rYct3b+tV+lzq6KZC7SQo7xNEzKCY3ILIfQ4JGR7Ein0CCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKSP7v4n+dLSR/d/E/zoAdRRRQAUUUUANk+7+I/nS0yfiFse386q+Y/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALU0EVxEY7iJJYyQSrqGGQcg4PoQDT6peY/95vzo8x/7zfnQBdoql5j/AN5vzo8x/wC8350AXaKpeY/95vzo8x/7zfnQBdoql5j/AN5vzo8x/wC8350AXaKpeY/95vzo8x/7zfnQBdoql5j/AN5vzo8x/wC8350AXaKpeY/95vzo8x/7zfnQBdoql5j/AN5vzo8x/wC8350AXaKpeY/95vzo8x/7zfnQBdoql5j/AN5vzo8x/wC8350AXaKpeY/95vzo8x/7zfnQBdoql5j/AN5vzo8x/wC8350AW5I0miaKZFkjcFWRhkMD1BFVdP0nTdJR10vT7WyVyC4toVjDY6Z2gZpPMf8AvN+dHmP/AHm/OgC7RVLzH/vN+dHmP/eb86ALtFUvMf8AvN+dHmP/AHm/OgCxc2tve2z295BHcQSDDxSoGVh6EHg1HY6dZaZAYdNs7e0iLFjHbxLGpJ74A61H5j/3m/OjzH/vN+dAF2iqXmP/AHm/OjzH/vN+dAF2iqXmP/eb86PMf+8350AXaKpeY/8Aeb86PMf+8350AXaKpeY/95vzo8x/7zfnQBdoql5j/wB5vzo8x/7zfnQBdoql5j/3m/OjzH/vN+dAF2iqXmP/AHm/OjzH/vN+dAF2iqXmP/eb86PMf+8350AXaKpeY/8Aeb86PMf+8350AXaKpeY/95vzo8x/7zfnQBdoql5j/wB5vzo8x/7zfnQBdoql5j/3m/OjzH/vN+dAF2iqXmP/AHm/OjzH/vN+dAF2iqXmP/eb86PMf+8350AXaKpeY/8Aeb86PMf+8350AXaKpeY/95vzo8x/7zfnQBdoql5j/wB5vzo8x/7zfnQBdoql5j/3m/OjzH/vN+dAF2iqXmP/AHm/OjzH/vN+dAF2iqXmP/eb86PMf+8350AXaKpeY/8Aeb86PMf+8350AXaKpeY/95vzo8x/7zfnQBdoql5j/wB5vzo8x/7zfnQBdoql5j/3m/OjzH/vN+dAF2iqXmP/AHm/OjzH/vN+dAF2iqXmP/eb86PMf+8350AXaKpeY/8Aeb86PMf+8350AXaKpeY/95vzo8x/7zfnQBdoql5j/wB5vzo8x/7zfnQBdoql5j/3m/OjzH/vN+dAF2iqXmP/AHm/OjzH/vN+dAF2iqXmP/eb86PMf+8350AXaKpeY/8Aeb86PMf+8350AXaKpeY/95vzo8x/7zfnQBdoql5j/wB5vzo8x/7zfnQBdoql5j/3m/OjzH/vN+dAF2iqXmP/AHm/OjzH/vN+dAF2kj+7+J/nVPzH/vN+dWoOYVz7/wA6AJKKKKACiiigCOf/AFLf571n3NxFaWstzcMEihQu7HsoGSa0J/8AUt/nvWBr+mSazpo08OEt5pFF0Q5VmiByyqRzk4C9RwTzSd+g15lLSfEjyaLeXeuxLZzWZ3zRoCcRsodMDkk7WAOOrA4otNbu7zxVBZy2d1YRmylmaC5WPLEOgVgyMw6FuM555HSql54LxNcf2XdTRpeWphnN3dTXDB1YNEw3sxwDuBGRw1TvpWt6hfSXd49pYSf2fPaRm0meUo7lSJMlV/u9McY6nPDvrf8ArZ/8AVtLf1uv+CPvvEci2eoQ/YrvTryOymubdrgRkSBByy7WboWXhsHnpQ3iRLBLqa/aWSO2tbWR0igBbMrMuQQfm5A4wMY4znAy4vB9600s/wBi0nT3fTLiyYWrMxleTZiR3KKT905BBIz1OeL914bvJ/teySAefDZRrljwYZCzZ47g8f0o7/L83+lgfT+u3/BJm8Wbbia2Ohar9qhQTSQBYSRESQJM+ZtIyp4B3cfdrRs9Ztb66SC23v5lql2kmMKyOSB7549KhbS5j4gvb7dH5VxYx2yjJ3BlaQknjp84/Ws6z0XVtJ/s+SxWyuJI9OisrhZpnjClP41IQ7up4IXtyKP6/P8A4APfT+tv+D9xZfxXblbEWtje3U1/HLJBDEqBiIyA2SzBR97PJxx64BbaeLbe8eAjT7+K3mmNt9plRAiTAlTGRu3Z3AjIBXPeo9H8PXmny6M9zNDKbG1uIZmTI3tI6MCBjp8pz+HWli8P3SaTBamSHfHqrXpIY42G4aTHTrhh7Z796a6X/rX/ACB/Ddb/APDl+bWvs2qRWlxp93FFNIIo7s+WYmcgkLgPvHQ8lQPesrRvFLyWqnUba6aM3s1t9u2IIg3ntGiYBDf3V3bcZ6mq0fhS+OqW889vprPb35uTqBZnuZ0LMQhyg2YDAcMw+XHFTQaBrAsV0q4ayNib1rp7hZG8zb55lEYTbj0G7d68d6UfP+tv+D/W499P63/4H9bX/FWsS6LY2ssV3ZWQnulhe5vlLRRKVY5I3p6AfeHWs+18TXEunXUz3dpdww3NvFFqNhDuhm8yRVZQpkPIzgkOcZ9RitbX7K+u47GTTEt5J7S7Wfy7iZolcBWUjcFYg/N6Vlz+HtU1Bry6u/sdtcXUtmfIhlaSNVhmDli5RSWIyPujoBnvRHfXv+Gn/BG91/Xc0bjxNb29xMDaXclpbyeXcXyKnkwtxkHLbjjIyVUgdyMHEset+fq0tna6fdzpDJ5U10hjEcT7Q2CC4c8MOQpHNZl5oOpyW+o6Vbm0/s3UpHeSd5GEsKyffUIFIbPzYO5cZ6HHM13o97ceIYbq3s7KzWORC19FdP58qL1jeMIFYHkcucZyBmhdL/1/X9eafW39f1/XkReKFSC2X7PdX9zdy3KQx28KIW8qQgg7n2jA7lgDjsSBTrXxdb3LRH+zr+KCSf7K1xKiBIpt23y2G/dndxuAK5703TdAurO70+WWSErbPeM+1jk+dLvXHHYdf60i+H7oaT9l8yHf/a5vs7jjy/tPm46fe28eme/ehb6ifw36/wDD/wDABdZuJdT0+OKcmOTUri2lBiC5VI5CB1PQqOeM+g6Vfj1rOrLYXOn3dqZSwgmm8spMVGTt2uWHHPzAVnxeHrtLq2k82ICLUbm6JBOdsiSBccdQXGfx5qlo/hW9tNU0y7urbTIpLIOs11CzPPeFoyu92KAg55Kkt168ci2Xp+gPd+v6m7o2uR65CJ7Wzuo7Zlyk8yqquc4Kgbt2R64x6E1BHr2LTV9QnVRY2Mjxx7QS8hjHzn/vrKgf7Pvxa0Gwl0vQbOyuGRpYIwjFCSpPtnFYSaBPeQ3OjXCyRWS6m91K4d0M8TkyqEdcYIkIB5BAX3FLfT+uhWm/9dS7Z+JHh8M3Woa7CIrnTyy3kNuC20jBG0E5OVZT+NKfFTC6e0GhaqbtY/OWALDl4s43g+ZtAz/CSG/2apXfhCWNNSh0mdvJ1G1CSi9u5ZmEqn5WDOWOCpIPP8K4HWtw2Ev/AAkh1DcnlGz8jbk7t2/dn6Ypvpb+tH+v4E9ypJ4ptzbQTadZ3eo+dai7CWwQMsR6E+YyjnnjrwaQeKI5ba2ktdNvrl54FuWhi8otFE2drMS4XnBwASTg8cVyl3p/2H+zNM1DWLDSZLDTUhaW4eQJdljgqu2SIsF2dCT9/wC6Op0X8OtrH2PWZNB0e+kks0gez1GMosQVmKtGTG5XIY/KV/u88UP+vx/4H9bU9/68v+Cb8PibTprO8ukZxBa26XRcgDfEybldec44I5wcg1nXnim5tluHt7Ke5Zb62tjAURGiEixkgkyYY/P14wT6DJk1Dw1Lc3GnfY1tbS1WNIL23jBCtEjB1VABjAYFcHHyu30ovfD97K2qS2725ln1C3vbdJHYKfKWIbWIB25MZ5APUfSnpf8Aruv0F0+Re1HXTpdutxc6XfG3WLzbiVDERbL33fPk477A1S22oyPr13p06r8kSTwOoI3RtlSDz1DKfwZa5zXvCup64moLPa6VM99bhYprmRpGsW8sKVjBj5G4E7sqcnODjFblpBNL4ru7t42SGC1jtUZlI8xsl2Iz1Ayoz659KX9f18we2n9bf8E2KKKKACiiigDK8R391p2kiXTzCtxJcwQK08ZdF8yVUJKhlJwGzjIrO/4SabSZ7+DXmhuRZrbsZ7GFl/10hQKYyzEEEA8Mcg8DsdHxHpH9uaSLIpC6G5gkkScZR0SVWZSMHOQpGOlRah4egOhLp2jW1rZRi5gmEccYjTCSo7cKOpCn8aa8+/8AkPQdLr7xrEg0jUHu5Qzi0XyvMCKQN5Jk2AcjA3Z9uDjLvPEF3qOt6RaaOl+lndwvcPc26wbsKyLtYSnIUbjuwu7pt71Y8ReGl1TVLfUBpml6o0ULQta6mvyYJBDK2x9pGD/DzntirNpor2+q6bcxW9pZwWtlNA1tbcKjO8bAINoG35G5wOo4pR6X/re36CKC67dzSac0NwTHPYXkz5hVdzxtGFOMnGMnjPOatW3iNo9LsC9pd6jdPZRXNz9mVP3asv323Mo5Ibhcng4FQW3hq8hTTw0kB+zWV1bvhjy0rIVI46fKc/1qnP4MIktLiTSdG1mVLCG0li1EYEZjB+ZH8tzg7jkYHQHNC+H+v73/AABvp8/0/wCCa9z4ngKH+zra6vl+zLcPNbKpWFGBKM25gTkAnaoY+3Iq3oV3Nd+GdOu7ljLNNaRyyMABuYoCeBxyazjpGpWN1MdHh09Le7t44pImdoxbFFK5QKhDrgj5fk+7154sDR7tPBEejw3Kw3aWK24mQkAOEAyCMHGR160d/wCu/wDwCdbr+u3/AARreKIoIL17/Tr2yezg+0tFKIy0keSNy7HYdR0JBq3fawlldLarbzT3D2styiR7QGEZUEZJHPzj261zyeD7iZdSJtNL0oXuntaeVYguA+SQ7NsTd19ARjqc1ow6ZrF5r8OoaotlbxxWU1r5NvM8pLO0ZD7mReyHjHHqc8J3a+/9bfoUrc2u3/Df8ELDxRJPoOnXdzpl19svo1MVpF5ZaU7AxZfn2hf95gfxIzOmvR3Vzp6Q+bA8109vNBLEC6OsTOUYhsL0ByNwPGODmqNpo2s2mnaUyx2LXukxm3jT7Q/l3ERRVyW2ZjbKg4wwGMZOciW18P3i6jbahcvAJ2v5Ly5SNiVXMBiVUJHzYAXJIGeTgdKt25n2I15Vfclt/FlvctC62N6lpNObdbx0QRiTeU2kbt3LDAO3HvSw+IQLRmEVxfXD3k9vDbwRKjt5bsD959uAF+8WGeOASBUDaLNa+F7e2uLi3j+yXq3csruQixrP5p5I/u+vGe/ese10GPX9JhvorXT9SWLUb2WKC+UNBcRyTPhg21sfwkMFPH1zU9P68v8AgldP68/+AdEfE9u1vAbazu7m6meRBZRqglVozh925goCnAzuwcjBORTYtfupPEg059JuY4fsqTtKzRfuyxI+bEnQYxwDz7c1Vi0K7sPsF7pGm6VZXNtHLE9hDIY7dlkKkkOseQcopzs55+tW2sNRbXIr5orUpPaC2u089gYsEtlDs+f7xHO319qHe6t/Wj/4AdP67/5DrPxLb3lxbqLS7ht7s4tLuVU8q4OC3y4YsMgEjcq57VNpOuR6yztaWl0tupZftEiqqF1baVA3bicjrjHvnis2y0TVFj0uwvDaCw0tkaOaKRmluNilUDIVATqCcM2cds1q6Fp8umaPHa3DIzrJIxKEkYaRmHUehFPQWtzQooopDCiiigBk00dtbyTzuscUal3djgKBySa5qLxNfNYahPNaRxyLdxW9nC2QcShNhk98vkgYwOOozW1rGljWNP8AsrXVxajzFfzINhb5TkAh1ZSMgcEVhjwpfj+0Wl1qe7eaeG4tzcJFgPHsILbI17pjjjb70LfUDU0y+vf7UudM1VoJbiGJJ0nt4mjSRGLDG1mYggp6nqOlVr7xdbWNxqCNYX00WmkfbJ4kQpCpQPu5YFhhuigkYPHTNjS7G+/tS51TVlt4riaJIEht5WkREUsc7mVSSS57DoOtVL7w/dXNh4ngjkhDauCICzHC/uEj+bjjlT0zxT/r+vkNWb8iwnii2UXRv7S7sBb25uv9IVf3kQ6soRm/I4bkcU6y8QfatTmsrjS72xeGAXDPcmHaUJIGNkjH+E9uMe4ql4kspYxc6gyRywf2a9o6EZILuuWIwRtAyT9OlYml2st2LjSrDVNP1eK7twtzqFu0rGJA6gxl3llyWR5CoBXBBOOc0lrp/XX/AIcn1/rb/gm1bazq+qfZYbH7HbTTwNeM88LuFhL4iXaHU7ivJOeCDwe2rpmpyajoKXywfv8Aa4aBW/5aKSrKD/vKRmoL+wvodTj1DRY7WSQW/wBnkguJGiUruyrBlVunzcY5z1GKit9Gv7bR10qO5iWGS1mE9yoYSidzneg6Yyznk56Un8Onn+tvwsNfFqVPDviK81XUFhknsrtGhLzrawvG1i4IxFJuY5Y5bsp+Xpzxpah4gWy1I6fDp17fXIgFwUtlThNxXOXZRnI6Zyc8Z5xT0zRr6PU7Ke7tdPsksIGgQ2UjMZ1IAwQUXYoIzty3OOeOdFdPlHiSXUNyeU9mkAXJ3bg7Nnp0wwpy3VvP9bfoJbO/9bFXTvFNtqU9oIrO8it75S1pczIqpPhdxAG7cDgE/MozjjNW9Cv5dT0W3vLhUWSQNkICBwxHf6Vm6f4furTT/DcEkkJbSh+/KscN+5ZPl455YdccU/w/ba5psMFhd2en/ZIi4NxFfO0hBJIPlmIDuP4vzpv4rIZv0UUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigArntN1XUdU1i5jju9PgjtbhopbB4Wa4CBiA5beANw+YfIRgjk10Nc7faXqeranbNd2mnW8dpcrNFexTs8+1WyVCmMBdw+U/OeCeDQtwexXttU8RT2F3qkT6dNbwXFwgshbOkjJFIyf63zCNxC5+5jPHHWtSx1r+0NYWGAKbSSwiu42wdx3sw556YArLt9K8RQ6fd6XGNOgt7ie4cXq3DySKksjPxEYwNwDY++RkZ56VO+l6nperRT6FaWNxbJYx2gjubt4SmxiRjbE+eD7UdfL/gP9bDlu7f1qv0udHRTIjIYUM6qkhUb1Rtyg9wCQMj3wPpT6BBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFXIP9Sv+e9U6uQf6lf8APegCSiiigAooooAjn/1Lf571Tq9J938R/OloAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoUVfooAoVcg/1K/570+kj+7+J/nQA6iiigAooooAbJ938R/OoNQvotN025vbk4it4mlfHoBmp5Pu/iP51n61pEet2cdncsptTMj3ETJuE6Kc7Dz0JAz1yARjmkxrzMbS/EN7YaLqJ8SDzL6wCzMkKgF0kG5FUcDht0YJ67MnrUlpf6tL41trfVLZbMHTppPKgujNE58yMAklV+Yc/wAPG7gnmkuPAmk+ZJ/ZMEGkxXFu8FxHZW6R+ZkhkfjA3IwyCQepFSP4avb64lm1nVUneSxmscWtsYAqyFTuGXY7vl9cdMAY5d9b+v5P/gCtpZ+X5oz7nxg13Dq2nh7FLmPTri4ik0/UPtDJsAB34VSjZYYxnoeeKnl8RyaYl7M0NxeG2s7JhD5qgOZXZflyuQ3rkkHjpyS//hE724O7UdWhkZdOn0+Nbez8pEWTZ82C7EkbPUA9gO9i48K/aPtX+mbftEVpH/qs7fIctnrzuzj296O/y/N/pYH0+f6f8EhbxFri39zYf2FaG6toFuWxqJ8sxMWAw3lZ35Rvl24/2q0dN1+PVL2KKCFljmsIr1HZucSEgKR7Y65qRtIzrd3qHn/8fNnHa+Xs+7taQ7s55z5nT296zoPDV7p62DaXqcUUttYx2MzTWpkEqJ0ZQHXa2c9Sw56Gj+vz/wCAEt9P62/4JGviu8uv7Lj03So5rjUoZ5VEt0Y0i8plHzMEY4O7sp5wMc5CWXiy9uBbXFxpCW9lNdmxeT7XukSYOYzhNmCm9SN24HvtqzpXhj+y5NJb7a0/9m208GXjwZfMZG3E54I2enOe1Oj8NeXpkNp9rz5WpNf7/L65naXZjP8AtYz7Zx2prpf5/f8A5A/h03/4D/WxFc+KhaeJodLmGnlJ5hCoj1ANcqxBILQ7BheOu49RxWdoniHUbbSxcX9n5un/ANoTW7Xb3RMwJuWjU+WVxsGVGd+QB0xVyDwpdxSwRtqkZsbW+N7FElrtkZizMVkfeQ33zghVPAzmi38J3cUK2MurLLpn2trx4TbYlZjMZQvmb8BA2ONuTjr2pR8/6Wn/AAQe+n9b/wDAJvGOoT6fY2Jt7y7sxPepFLLZ2wnl2FWOFQo+TkDoprJt9du49PvzJe3l3BDd2kcMtxEtrdfvJVVg6GMYXnjKKWGcdmro9d0u51OG0NhdxWtxa3K3CPNAZkJCsuCodT/F61nSeFLm8FzPqepRy3ty9rukgtjHGqQS+YqhC7HJJbJLHr04xRHfXv8Ahp/wRu11/XVj7rxPcQfbLuLTkk0mwkaO5uTcbZBtxvZI9pDKvOcsp+U4B4zLBr9zd+JLjTbW1tPLtWCzGa8KT4Kg71i2HcnOMlhkg+lRXnhi4uPtlpFqKRaVfyNJdWxt90h3Y3qkm4BVbBzlWPzHBHGJr/Q7zUtWtprq7s/sdrMs0CJZEToV7eaZCAD0OEGQSKI9L/MT62KFt4kvTFZW9jYte3N7NeKpuboIsflSkfMyxn5ewwpI4HPJp1p4tvplhuLnR44LM3v2CZxd7nSbzPLyq7MMm/jcWB77au6f4b+wXNlN9q8z7K102PLxu8+Tf68benv7Ug8NY037J9r/AOYodQ3+X/08edsxn8M/jjtQt9f61/yB/Dpv/wAP+tigmpz3Gr6YEmnVDq93A6tLkOqRy4HAHy5AIBzjA5NWrbxWJPFA0eYaeWkMixfZb8TSqUGT5kewbOPdvSpI/DOy4gkN2SIb+4vMCPGfNV125zxjf1746Cq+l+Fbuxm0r7Tqkc1vpKtHbRRWnl7lMZTLnect3yNo68c8C2V+y++wnu7d/wALl7w9rF3rlml9Jp6WlpKgMRafdIxzg5XbgL6HOT6Cqkevyppet6vK3mQW9xJBa26gAsYzsxnqWaTI+m33zq6Np39kaLa2Hm+d9njCeZt27vfGTisRPC32o3GnajHHJpS6i96InRXS6V8tsYE8bZGLcjBwvvS30/rdFef9df8AgBbeIb3S/CupS6yovdS0glbhYgI/O4DKQOgyrD8QakOv69/aT6cNBtftXk/aUJ1EiMx7tuC3lZD5/hCkf7VNufA1gq3seipbaTb31r5E8NtaqqMwbKyYUgZALD3yOeK2f7N/4nx1Lzetr9n8vb/tbs5z+mKHfS39aP8AN2J7mP8A8JZPeWVtNo2nxTvNp4v2S7uTAFQ9FyEfLZznoB681TvPiBDZw2SzjS7W6uLRLySK+1MW6qj52hGZMu3B42gDuRkZzdQ8ORW76Zp2qSX5t9MsUitbmz0pbrzXJw5ZWilCEbUxwDyeT23rXStZljttUivIbHVJbVYLpbm185JFVmKkqjrtcbj0bHJ46U35f1v/AMAp2v8A15f8Edb+M7W40y8vxAyww2UV9CN2WmikQleMcNuVlxz29aoX/iDV4ftf2GBBcR6nZ20kc9z8iCRYSyoRGTglyCTk9SOwGvqfhw6pf6bdTXmxrUj7SqxcXKhlcDr8uHRT34yO+ajvPDL3P9pPDeiKa7vYLyJmh3LE8SxgAjcNwJjyeV6/jT0vf+t1+guny/Ei8ReLH8NwRzXqaYqrD5s8cmpbJTj7wiQx/vPbJXNX7W+nHie80+d/Mia3jurc4A2gkqycehUHJ5+Y+lZeo+EtQ1CLU4f7Yhhj1aAR3hSyJfeIwmYyZPlQ4+6Qx5OGGc1p2ljcHxNeahcJsiW3jtbcZB3gEsz8dMlgMHn5T60f8H+vvB7af1t/wTXooopAFFFFAGD4y1GXS/DhuIb7+z/9Jt45Lr5P3SPMiu3zgqPlJ5IIFY9v4omsIb+4gvH8SadCbVYbtPLDPJLL5boHjVUfaCp4A64J7jp9Y0z+1rKO383yfLuYLjdt3Z8uVXx1HXbjPbNGs6Z/a+nC183ycTwzbtu7/VyrJjGR1249s04+ff8ADT/gj00MTV/GLaI1tbakuk2d/Ojy7LvVRDCqBgB+8aPJY5+6FxweehNB9ZvPE+t6B/ZyL/Zd1ay3b7NSkt3JSSNTzEp3bdxwu7a2eSMDPR6npN3PqMWo6Tex2d5HE0LefAZo5EJBwVDKcgjghh1PWnppUzazZalc3SSTW1pLbuqRbVkLtG24fMdoHl9OevXilHdX/re36COdj1W5uZNJkS4uVSXTL92V5clmRowrHAAJGTg44zTG8dQaRpumWs9xp7Xf9mwXM51HUlti4Zf4NwYu5KnrgdMnmta38KeQliv2zd9ktLm2/wBVjf5zKd3XjG3p3z2oj8OXunm3l0bU4YLhLOK0nNzamaOVYwdrBRIpVvmb+IjB6cZpK/Lr5f8At3+aB9Pn+n/BIz4on1OBn0CwF1AtnHcyyyXHlMqyIWVUG0hnwM4JUcjn0n03VHs/h7ZapcLNdyR6bHM4B3PKfLBPJ6k+tOudCv2v5rmx1OO3+2QpFeK9r5m4qCN8fzjY2D3DDgcet6x0+bTfD1tp1pcJ51tbJDHNLEWUlVADFQw9OmR9afSVv63F1V/62M238RXX2Ozu7y1sTa3VykAnsb83CKHyFbJjXOX2rj/aznimXPiqZb1bay0z7SZb57GB/P2q7pEXZj8pwoZSp6ng8E8Gnf6Q+naRqrXgN9fasojVNMsHiTzAp2MRl9jZxmR2xwvTFadl4cNvbaIr3GZdNdppW2Z8+R43Vz14yzlu9PT+v6/q4a/1/X9WKl34juNLk1GW5tHmmt1sla2iuAyBpn2HYSingnqeuB92ppPE9zYLqCaxp0cM1nbrcottcmVZEZmUfMUXacrzxgA5yeal1Dw19vub2X7X5f2qS0fHl52eRJvx153dPb3qDxLpc7x399bGSU3NpHZyRRRlnSPzDvdcH5mCuxC46jv0pP8Ar7tPxKS08/8Ag/5ENx4vutLfUv7esLO0jsYoX8yK/Lq5lYogJaNAoyDkk8DBqz4Z8WW/iG4u7VJLGS4tVR3bT70XUJV9wGHCrz8pyCBjjrmsbR9AWe3udMsZb5NLKpMs1xpsdm8VyjqyFEWKPcPlBOVI4Az1FdbpsOpxI/8Aa17a3TEjYba1aAKPcGR8n8vpT0/r+v6RJdooopDCiiigAooooAKKKKAIbuKaa1eO2uPs0jcCUIGK+pAPGcdM5Hselcq2ralYwalbRX734jure0t76eJAyyyuFcEIqq2zcDwBycHoa6LWbS9vtJmttMvlsLiQALcNEZNozzwGU5IyM5GM5rLg8O3zaM+m397Y+SnltamxsWgMLo4cMd0r7vmAPbPOc5oW+oE+lT3lrrt3pF7eSX6x28dzDcTIiyEMzqynYqrwVBBwOvfFUdS8W3tlNrLwaOk9popBuZWu9jOpiWQ+WuwgsA3QlR055wNTStJubW+udQ1O7iu724RIi8MBhjSNCxVQpZj1diSWOc9qr3nhr7XZeIbf7Xs/toEbvLz5P7lYvX5vu57dce9P1/r+kVG19diF/FNxYC9/tnTVtzb2TX0Yt7jzi8a8ENlV2tyOORz1p9p4gvxq13a6xYWdpDa2a3bTw3rS/KSw5BjXGNjd/TGecJ4g0y42z6hZlpZRYtaeSiZYqzqWcYIyQoOB3NYWj6BvWTStKmvBo00YN215pSWhLB0wihYoi25N4YkNjjntSWun9df+B+RHr/W3/BNGzudZ1aW0s5NRm0+R7U38zxQxGRRJIfLi+ZWXCqCCcZOByK2tA1KTUdBhurzYsyl45iowu+NyjEegypNN1LSrua+jv9JvYrO7SIwMZrczRuhIP3QynII4OccnINQxeHFTTY9Lkuml0w2skFxAV2vOzkEv5ikFT9/gf3u2KOn9edh9dSvpOrX2o+JZGZgmmTWvmWkWwZYBwPNJ6/NngemD1JqfUda1CLW20vStMiu5VtRcmSe6MKAFiu3IRjnjjjHXJGOWWXhCy0/XotSt7rUGMUJiWKfUbiZeT1O+QgjHYjGeeorRGm41+XU/N/1lqtv5e3phmbOc/wC10x2pdFbz/W36B3+X6X/UyNJ8VXOoyaXLPpi21lqyE2sn2nfICEL4dNuFBCnBDN2zitDw1eT6h4dtbq7fzJpA25toGcMR0HHQVXsfDX2Oy0C3+17/AOxh97y8ed+6aP1+X72e/Sq9ho3iLStPa0tNW02WGNJBArae6OGO4rl/NYcMRn5OQOlOW+gdToLq5hsrSW5unEcMSF3c9gK5P+3tXgtNYnuysUpe3WzgeMf6N5zBFDY5Y5IJ565A4ror3SINU0lbDVHlnX5C8iStC7OpBDboypB3AHjFZCeB7KOTUGS81A/bI0RfNvZpjEVOQ37x2BIYAgkcYx0JoBdC1pst7Y+IJNJvr+XUEe1FzFNPGiyAhtrqdiqpHKkcZ68mquqeKb2yn1b7NpCXFtpCrJcyvdeWzIY958tdhywGeCVHTnnjQ0zSruDUJtQ1W9ivLuSJYVMFuYUSMEnAUsxySeTnsOBUd54e+122vxfatn9sRGPPl58n915eevzdM9vSlrZf1/Wg425tdiqfFNxZ/aTrGmi3WOxkv4fIuPOZ40xuVhtXa/zLwCw561LZa9qDaxLaapYWdrBFaC7M8N80uFJIwQY1A+6e/wBM80mt6XcojahYkyzwafJaLCqctvZCWGCOQEPHf1Fc/o/h8GOTSdImvl0m4hxeNeaUloeGTCLtiiLFk3qSQ2OOc8F7uy/rf/gErbX+tv8Agmna3ur6s+n2Zv5rB7u3lv3liijMkce9RFEA6sv3X5JBPy9s1raFqNzqGhvLOYzdQSz27tjarPFIybsdgdufxp+p6VcXF5b32l3cVneQRvEGmgM0bRsVJBUMp6qCCGGPeobfw+9vp8dgt8xtGjnF2vlgNcPKclw38HJY4H972ofw6f12/Apb6/13/Ew/Cuu3uoatbRS6lcXJltWluormCONEYEAfZ2VQZEzu+YFxjHzA9drUda1CLW20vStMiu5VtRcmSe6MKAFiu3IRjnjjjHXJGOW2Og3sd5ZS6nqMN1Hp6kWqw2nktyuzMjb2DHbn7oUZPTpjQGm41+XU/N/1lqtv5e3phmbOc/7XTHaiW+nn+v8AwCVs7/1t/wAEyNJ8VXOoyaXLPpi21lqyE2sn2nfICEL4dNuFBCnBDN2zitDw1eT6h4dtbq7fzJpA25toGcMR0HHQVXsfDX2Oy0C3+17/AOxh97y8ed+6aP1+X72e/Sk0PR9Z0hYbWTVLGfT4i2I1090lIJJHz+cRkE/3Ofam7c2mwzeooopAFFFFABXKWWoXMviOSDVdauLC5Fy6waa0Eaw3EQJ2lHZNzkrgna/ByMDFdXWFc6LqWo3Ua6lqdtJYQ3KXEcMNkUlyjBkBkMhBGQM4UE+1C3QPYyrI67d6Te6vBrs7TQ3N0I7OaCH7OVimdVUlYxJ91QM7+vPPStTStal1TWozGxW0n0qC7SIgZVnZu/XoAPwqrF4X1VLS60463CmmXM00jLBZFLgLLIzsvmmQr/ERkIDjpg81ZutC1CLVkvNBv7KyRbRLUw3Nk04CqxIxtlTHXHfpR1/rs/1sOWrdv61X6XN+imQiRYUE7q8oUb2RSqse5AJOB7ZP1p9AgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkj+7+J/nS0kf3fxP86AHUUUUAFFFFADZPu/iP50tMn/1Lf571ToAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0VQooAv0kf3fxP8AOqNXIP8AUr/nvQBJRRRQAUUUUARz/wCpb/Pesu/vYtO064vbg4it42kf6AZrUn/1Lf571h6xpSa1Zx2lyy/ZjMjzxMm4TKpzsPPQkDPXIBHekxrzMjTdfvLHR9QPiIeZfWIWZkiUAukg3IoHHRt0eT12ZNIuq6hD4ojOswrZQxaZPO6QXJmjYB4+eVX5gM9u/BPNSXHgfS/Mk/suCDSop7d4J0s7dI/MyQUfjA3KRkEg9SKnj0C7uL83Wt38V3utJbQxwWxhUo5Uk8uxz8uDzjpgDHLd73Xn+T/4Auln/WqMq08epqXmwWP9mS3MlrJcWyQamsxG0A4lCr8jYPQbhwRmnaDf6la6Pp8C2q3eq6hB9rYXGpyvHsATLl2QlMlx8irgdq2LLStUgtXsrvVILm0EBhixaFJRxgF33kMceirUbaBcQW+mtpt9HDe2Ft9lEs1uZI5EIXOUDKeqAjDce9PS7/rv/wAAWunz/T/gjrLxELq+traW1MBm86Ny0gOyaIjMfTnIywPcDoKzj4rby5dRFtJ5UemXN5FEJhtlRHAVvu5BZcEHPAboetWrvwq1xoJsotQeG9Nw1z9u8sFhIxO8hc8AqzKBngEdcVJqPhmO8jlignFvE+lyaciCPOwNjDdR0x0/WkvP+tH+u34laX/ruv0NHTbm7vLczXdolqr4aJBNvcqRn5xtAVvYFh71zdq+tyaHdazFrc8ssMtyVs5oYfIZY5XATKoHHyrjO48889K66JPLhRM52qBn1rm4/DOpixn0yXWYRps8krMkFmUnKyOzFPMMjD+IjIQHHTB5ol5Ex6cw1/FAhiv7+O3nuI44LSRIPMUZ80kfKMDB57k546U7U/EF5aWGpw6jafY7mGze5ha0ug+9BwcMyDawJHBUjkcnmmeIdBkGm6k9i0m67+yRpHDHlohHIOR1zwc9OMVPdeGbrUob86pqMctxc2jWkTw2xjSFGOSdpdizE4ycgfKMAU9ObyEr8uu5PN4j8i1vy1rm5tLpLVIfM/1rPt8s5xwDvGeDjB64qKTxLOomvFsEbSYJ2gluftGJAVfYzCPbgoGzk7gcAnHrYufD63Hia21X7SVSFB5lvs4ldQwRic8bRI/GOePSq8vhqdxNZpqCJpM85nltvs+ZCWfeyiTdgIWzkbScEgEcYSK6af1/WhK/iFk1k6T9jJvjKDGnmfK8HebdjgDkEf3sDuDVC21Ke51XTNss4RtSvoXV5M7gnmADgAYG3IBzjjk9avv4dL6qdV+141ATAxzeXwkA4MOM8qRkk5+9huwFFp4c+y3VrN9q3fZ7y5useXjd5xc7evGN/XvjtTW2v9f1+d+lgltp3/zNuiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFPVLWe6tcWuo3Onuh3eZbLExbjofMRhj6DPvWDol5f23gy21m/1X7dNc2sMzDUJYbaGIsoJ+dIgQOe+7oK6l13oy9MjFYB8NTRaJo1pZ30aXOkBPKmmtzJG5WMxksgYHoxIw3B9aF1+X63HpYz5/Es+pafptzp6I0y6qLWSO1ut8Uh2N0kAG5OQScdumRip9Q1q7kgW2uIvsN9b6hZrKlvOXRo5JVwQ2FJBAYEEDoR0qb/hFrj7P/wAhVvtP9o/2h53kDG7Zt2bc/d/HOOM5+apP+EbnnV5r+/SW9lureeSWO32JthYMqKhYkDryWPLE+1EdGr90/wAr/qTK7T9H+tv0KEnxAsE1r7J5tgYhdizK/b1+0+Zv2Z8jGdu7vuzjnGK0/D2oapfz6h/aMNskUN3JFG0U5ZhtwMY2DjvnOfanWmkX+nXriw1CBdPkned7eW1LyKXYswWQOAAWJPKnGTU+naZcaff3ri6jktLmUzrCYSHR2xu+fdgrxwNoPPU0Lz7f5f8ABHLy7/5/8A0qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCK58/7NJ9k8vz9vyebnaD745xXOpquoQ+EVkkuVmv5L02azmMKATcmINtHHA5x7c109ZLaCr6HJp7XDAm4a4SZVwUfzjKpx3wcfXHvQBHpc13ba5daTe3kl8qW8dxFcTIiuQzOrKdiqvBUEHA698VT1HxVeWcurtBpKzWmjkG5la62M6+Ush8tdhBYBuhKjpzzxp6ZpdxbXtxf6ldR3V7cIkReGAxIqIWKqFLMerMSc9+1V7vw59qs9fg+1bP7ZBG7y8+T+5WP1+b7ue3XHvT9f6/pDVr67EL+JrixF5/bGnLbmCza9jEFx5peNeCDlV2tyOORz1qfTdX1K41ybT7/T7W3Eduk4kgvGlyGLADBjXH3T39MZ5xHr2m3GJ7+0LSSixa08lEyxVnUs4wRkgA4Hc1n+E7L+zr82+lG8fTDCTKbzTUtCsoKhAoWKMtld2SQeg5FC1/r1/wCATrb+vL/gnXUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy9lf3MviF4dU1i4sbgXLrDpzQRrDPECdpR2Tc5K4J2vwcjAxXUViXOjajqF1Guo6lbyWMVwlwkUNmUlyjblBkMhBGQM4UE0LcHsZlkdbutKvNVh1ydpobm6EdnLDD5BWOV1VThA/RQM7uvPPStLS9Yk1PWYyjFbSfTIbtIiBlWdm79egA/CqsXhrVEtbnTzrMKadcTTSMsNmVnCyuzsvmGQj+IjITOPQ1ZudEv4tUS70O+s7NVtUtTDcWTTAKrEjG2VMdcd6Ov9dn/AMActW7f1qv0ubtFMiEghQTsryBRvZF2qT3IBJwPbJ+tPoEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVcg/1K/wCe9U6uQf6lf896AJKKKKACiiigCOfmFse386q+W/8Adb8quSfd/EfzpaAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyo8t/7rflV2igCl5b/3W/Kjy3/ut+VXaKAKXlv/AHW/Kjy3/ut+VXaKAKXlv/db8qPLf+635VdooApeW/8Adb8qPLf+635VdooApeW/91vyo8t/7rflV2igCl5b/wB1vyq1BxCuff8AnT6SP7v4n+dADqKKKACiiigBsn3fxH86Wkk+7+I/nUd1cxWdpNc3DBIoUMjseygZJobsrhvoS0Vzmj+J3k0O9vNfhWymsjvmjQE7Y2UOmBySdrBTjqwbFMi8R3UviVILiyvLCBNOmuZLe4SMs5V0CsGRmHQsMbs88gcUbOz/AK0uHS6/rodNRWFD4rguNNivotPvjFclFs1KoGuyylsIC/GACSX2jAznHNNfxfaRwRGSzvVuZLv7E1psUyxzeWZArYbbyoHIYj5hkgZIdnewb6m/RWTaa99ss7t0029W6tHEcti/l+aGIDDBD7CCGBzux+VUbnxFJcWdu9pHNZTpqkFpdQTqhdNxUlTtLLyrA5BPXrSWrt6fiJ6Js6Siudj8UxxRorxXN5PcX1zawRwQqrM0TP8ALy+OiH5iQDjJ25xU6+J4HsfNFlefavtBtfsGE87zQu7Z97Z935s7tuO9A3o7G3RVLS9Ui1WCR0ilglhkMU8EwG+JwAdp2kg8EHIJGD1q7QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWZr2pTaXp8M9uqMz3dvAQ4JG2SZEY8Ec4Y496pXHi+2glu8affSW9jMYbu6REEcBwDk5cMwwwPyhsd8ULX+vT/MHornQUViHX47efVfOMkwtbqK3jhjhAZneNGCqd3zZL9TtA5zwM0g8U2y2cz3FneW91DKkLWLqjTF3+4BtYqcg5yGwMHJGDgGblFc7ceJb+LUtMth4fvk+2GTzEd4N6bR7S7e+ep496fD4kRLMuY5724kvri1gt4IlR5DG7Agbn24AU/MWAPsTigRv0VgyeLbSK2gd7S88+a7+xG0CKZY5thcK3zbeQOoJHIOcci9pWrpqi3Cm1uLO4tpBHNb3AXehKhhyjMpBBByCaANCiiigAooooAKKKKACiiigAooooAKKKKACiiigCK5jlltZI7abyJWXCy7A2w+uDwaxND/tH/hFSlnci4vI7maNJr9mfcqzsPmI5+6OPw7V0FZw0eNNKksYLq6gV5Wl82JwsilpDIQDjpkkdOlAFLUUuovFukS/bphbyySRfZU+WPHku2W/vHIHXgY4HU1J4kll8vTrKKWWFb+9WCSWFirKmxnIDDlc7NuRzzxg81o3NjFdXlpcyM4e0dnjCkYJKFTn8GNUptCF1FdLdXlwzzXIuIZEbBtioAXYDkDG3J4wSWyMHFHb+uoLr/XQ5+aa4tdRk8PRXl4baS+gjWYzs0scTxO7J5pO7JMRGSdwD8HpgmmuLXUZPD0V5eG2kvoI1mM7NLHE8TuyeaTuyTERkncA/B6Y3F8M2/wBhlhlu7ua5mmW4a+dlE3mKAFYYUKMAAYC7cZyDk5F8M2/2GWGW7u5rmaZbhr52UTeYoAVhhQowABgLtxnIOTk9f62/4P8ATYf1+ev5DdBL2uq6ppXnzzwWrRPA08rSuiuvKF2JZsFSeSThhzVbSjd6z4bu7tdQmt3vLmZg6HJiiVyiqmeFO1BzjqSeta2l6UmlpMftE93PcP5k1zcFd8jYCjO0BQAABgACo9H0yXTLW6s3dWt2uJJLcg/MqOd5U8dmZgOvGKUk2mvIFoL4ckkm8LaXLNI8kj2cTO7sWZiUGSSeprnZPEfiEWk2oRLpv2dNUbT0t2ik3uPtHkrIX3YGCQSu05weRnA6yws49P062soSzR28SxIXOSQowM+/FUD4ctDpzWfmT+W199vJ3DPmed52On3d3Hrjv3q20536f8H/ACBfDb+tn/wDLuPEWp6ZbanDftZS3Fk9v/pSQtHCkcrYLuhdiAmGJ+bBA6rziO28RamdJ1i6kutPv1hkWDT5rKBkSeRwoXkyOD87hTjgYPuBc8QaG863NxaxT3Ju3hF3bxSrG7xx7iBGxK7WyQc7h04INQ6PoM735nul1G2sYZI5bazvr37TJ5qhwzsxZ/lwykKH6rnAqVre/wDWwbf1/X/DEb3mu2l1daXp09o0elafBM1xeo80lwxEgKkh1wT5ed3OM9DUum63q01xYf2j9j8jVLJ7mFLdHV7chUO1mLEPw/UBenTmtptIga+vrovJvvYEgkGRgKu/BHHX5z69qii0K2hOnFXlP9n27W0WSPmUqoJbjrhB0x3pSu0/673/AEBaNf12/wCCVPD4m1T4e6aJrqcT3OmxbrgSHzNxjHzbuuc85q54dv5dU8N6fe3IAmngVpAvTdjnHtnNULHw5faLpn2fTNcvbpYLbybW2vRAIkwuFyyRBzjjvVzRtD/sdY40u5ZYIbSK2jiYnauzOXxnBZieT7Crk7ybX9bgVtUS6j8UaNML6ZbeSd4vsqfKh/cyMS3djkDGeBjpnmtCSLUpmvYxcQ28bhRayxxlpE4+YsDwTnp29QalubGO6ubSeRnDWkplQKRgkoyc+2GNLDamG8ubj7RPJ55U+U75SLAx8gxxnqfepDqcvFdXcXgm1iW8uGln1D7G1y8haQIbkoTu9dvAPY4rR0YNYeJNQ0dJ7ie1itoLmL7RO8zoXaRWXe5LEfuwRknqauHQbQ6M2ms0piMrSq+7Do5kMgYEDghjkfQdarx+HDEjH+1LyW5mnikuLuQqJZUjORH+7ChV6jgcgtnrTX9f15biWi/r+tdjEuprhtO1LxCLy8S5s7544oROwi8qOUIU8rO1iwBOSC2W4I4ouprhtO1LxCLy8S5s7544oROwi8qOUIU8rO1iwBOSC2W4I4rcn8M28980xu7tLaSZbiWxVl8mWQEEMcruHKgkBgpI5Byck/hm3nvmmN3dpbSTLcS2KsvkyyAghjldw5UEgMFJHIOTlLp/Xb/g/wBNjlrf+u+n5fcYd1NcNp2peIReXiXNnfPHFCJ2EXlRyhCnlZ2sWAJyQWy3BHFbmu3Mv9p6Np0MrQi7ui0rIxVikaF9oI9WCg+2R3on8M28980xu7tLaSZbiWxVl8mWQEEMcruHKgkBgpI5Byc2NW06W8n0+6tGVbixuRKockK6FSjqcA/wsSPcChbL5A93YphLqHxzGZb6aWGeymZbf7sce14gOO7fM3zH17Ct6qz2Mb6pFfln82KF4VAI2kMVJ/H5B+tWaOiX9bh1CiiigAoorm9M1fUtV1q6jju9Nt47S4eKXT3hZrkIrEBy3mADcMMPkIwRyaOtg6XOkorkrbVvEtxp93qsT6bPbW9xcILEWzpI6RSsn+t8wjcQmfuYyccda1bDW/7R1lYbcKbSXT4ryN8Hcd7MOecYwBR1t/XV/oD03/rW36mxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSR/d/E/zpaSP7v4n+dADqKKKACiiigBsn3fxH86zPEOlSa3pg04OEt55VF0Q5VmhByyqRzlsBeo4JOc1pyfd/EfzpaAORvPBGJrn+ybuaNLy1MNw15dTXLB0YNCw8xmOAdwK5HDVaGl61faqb7U0sbfFhNaLFbzvL8zshDFii8fL0xx6nPHSUUmr/wBev+Yf1/X3HL6l4UOoeGNHsZ4bK7m0zyn8i7TfBOyxlCrZB4wxIODggHHai18NPFHpZt9K0nR/suoG6mt9PPyMvkumQRGmWyw6gcDrXUUVXM7tiSskvKxy2q+HL+5ub6e3+yzpcXkU5tJ5GSO4RYthjkIVsDPzdGB2jNQaf4RurS3mVY9PtRLq8N+ILUFY4kRYwUHyjJyh5wM5zxnA7CilH3Xdf1t/kN6qz/r+rnNWPh27tb2ymkkhKwaheXTBWOSkxkKgcdRvGfx61V1Twa+oNczTwWF6f7T+3Q2t4u+GVfIWIo+VO09SCA2MDr0rr6KP6/L/ACDd3+f9feZfh/TU0vTTEmk6bpJeQu1vpvMecAZzsTJ4/u9hWpRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZr2mzapp8MFuyKyXdvOS5IG2OZHYcA84U496z7rw9dz6D4hslkhEmpyyvCSx2qGRVG7jjlT0zXR0ULTb+tv8kD1Vv6/rU4RdLtvFi6+1o9ne251SCaFpQJrecxwRBlOMgjIZSRnB+mK0IPDMsWmo1jo+i6LeQXSXMcVicxSlQRh2EaHkMwztOOvPSuroo/4H4W/yB6nP3NprdzcaZqJtdPS7tJJBJbfa3MZR1xkSeVncMZxsx2z3qvF4e1GyjiubRrWW8t7+7uUikkZY5I5nc7SwUlSAynO08gjvmuoooDpb+v61OXi8OXz31tqF1Jbi5bVPt1zHGzFEUW7QqiEgFiPlOSFzz04Fa9hp8trrGq3UjIY7yWN4wpOQFjVTnj1FaNFAbhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBHNPFbRGW4lSKMEAu7BQCTgcn3IFZ3/CU+H/s/n/27pnk+Z5XmfbI9u/+7nOM+3WofF9m1/4Yntlga48yWENEqFty+am7j0xnPtVaTTd3jLVbg2eUk0iGFZfK4Y75soDjnjbkfSk3a5SV/wCvka2oa1pWkqjarqVnZLIMobmdYw303EZ60S6vaIlk8T/aVvpRHA0BDh8gtuznG0BSc+1cGsGq/ZrW2sLG5uGk0O3s9SQQxu8PynCgSyxhWw75+/2yo4z0+kFNW1W2v4EmGn2dii2jTKQXaQAseRyQqqM+rMKq2tv66/5EXur+X+X9fI0dN1201W8vLe1WYC027pZE2pIG3cqTyRlTzjHpkVBp/ia3v7qCMWl3BFdAmzuZlQR3QAz8mGLDjkbguRyKRLSWTxBrOUdI57SCNJcEAn97nB9RkfmKxtOS4vD4a082V1bzaMQ948tu6RqVgeLCORtfJcH5SeAc4oW/9fMOn3/8D7zp7/V9N0pN2qaha2S43ZuJ1jGMgZ+YjuQPxpsOtaXc3wsrfUrOW6ZBIIEnVnKEZDbQc496o3NkZfH2n3jW7OkOn3CCYoSqM0kXGegJAP4A1jabpMtronh+OOweJoNXlldRCVMakzfMRjgEEc+4pdF5/wCdv+CHVrt/lc6nTtTi1Oye5tkk2pNLDtYAEtG7Icc45KnH9Kfp1/DqmnxXltuEco+64wyEHBUjsQQQR6iue8LanHZxy6XdWuoxXLahdsC2m3Hl4aeRlPm7NmCCDndjmrvhH5tIuJkGIZ7+5lh90MzYYex6/jQVLRv1/wAzdooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzV/pOqavqlq13Z6bbx2d0s0V9FO73G1WyVCmMBdw+U/OeCeDXS0Udbh0sclbaT4kg0680mJdNt7a4uLhxfLcvJKqSyu/ERjA3APj75GRnnpViTStV0rV4Z9As7G4tUsI7MR3V48DJsZiMbYnzwR6dK6Wijz/rt+o3rv/WtxkJkaFDOipKVG9UYsqnuASBke+B9KfRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApI/u/if50tJH938T/OgB1FFFABRRRQA2T7v4j+dLTZjiEkdRj+dVvPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBboqp58n979KPPk/vfpQBBe+H9Pv7o3M63CSsoV2t7uWHzAOgYIwDfjnjir8EEVtbxwW8axRRqEREGFVRwAB2FV/Pk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALTKGUqwBBGCCOtNiijghSKCNY441CoiDAUDoAB0FV/Pk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdFVPPk/vfpR58n979KALdJH938T/Oqvnyf3v0qzCcwgnqc/wA6AH0UUUAFFFFAEc/+pb/PeqMkixRtJIwVEBZmPQAd6vT/AOpb/Peue8SWV1qmjtp1oWjF44hnmQrmKI/fIz3IBUcHlhxjNJ36DXmZ6+K3ufB+o6tb2vkXNmjt5E5LY+UOhOMfeRlbHbOO1TS+KILLXr6yvywjt4oZEMNvJKwDhtzPsB2qNvU4HXmsrU/DWqwRanHZ3Vzqqalp7Qv9oMMZjkT/AFeAioMEMwJxnhe1aEyapYeINTu7bSXvoryCGOIxzRqQyh879zDC/MORk9eDTltoSr31NK98QabYeV587v5qeYvkQvNhP752A7V/2jge9R3XibSrSYxPcSSyLGkxW3t5JiI2ztf5FPy8HnpXNnwrcac9qZrbUdTiXToLNl03UWtmR492SR5sYZTu9SRjpzW3pOjtp+p3bQWpgtTp9rbwK0gYjy/MypOSTjcvJ6+polonYfVF6517TrVbZnmeX7Uu+EW8LzFk4+fCAkLyPmPHI5qnp3iWKbw7b6neLI4nkkVfsVtLPkB2AIVAxxgA56VnaTp+qaHDpEx02W7ZNKisp4YZYw8Lpg5+ZgpXkg4JPAwDUNvpms2un6db3Nldy26ifzrfT71YSkjS7kYvvQlNpPQ555U9m/L+txdf68jfuvEumWdgl9LJO1q8XnCeG0llQJ6kopA/HFOu/EemWMwiuZ5FO0O7LBIyxKehkYKRGP8AeIrnLaw1e103R9Mu9IuLm0tVM1yLeeJvMkDkohMjqSo+8T3IX3FXrm21O1m1hLXS3uxq5EiSGWNVgYwrGVly2cDbnKBup49V0/r+v68ylvqaX9tLDrGpQ3bxRWlnbQzCXnPzlwc+v3BjA796s6dq1nqgk+yNIHiI3xzQPDIuehKOAwBwcHGDiuavvC19Pb31tGWcfZbBYpPOMZmaB2Zl3Kdyk8fN2zkdK1PDmnQ201zdDS9SsZ5VSNm1G/Ny8irkjB82TABY9x16U9LslXtc3qKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAparqcek2BuZI5JmLrHHFGBukdmCqozxyT1PA61Si1m/t762t9b02G0W7cxwS290Z134LBXyi7SQDjGRkYz0zNr+nz6hYRfY/LNza3EdzEshIVyjZ2kjpkZGecZzVOT+0tbvrET6XNpttaXAuJHuZYmaUqCFVBGzcZOSTjp054F+v4af8EH/Xr/Vi9b+IdNvPONrLLMsKs0jx28jKMHBXcFwW/wBkfN7VTvPE0R0h7rTNxkjuoIJIrq3kiZBJKinKOFYcMSDjH1qtFp+q2XgsWtpE6XYuGd44pFV3jM5ZgrE4DFCcHI5PUHkZy6DqMkepPHYXEK3M9hJFHdXvnyhY5Qz7mLtggAnAYj054prfUOx1uoana6XCsl4zgO2xEiieV3bBOFRAWY4BPA6A0kOrWk8ttEjyLJdRvLFHLC8bFUIDZDAFcFhwcHmq3iC3Weyjzp15fSRyBo/sMyRSxNgjcGZ0xwSOvOcEEZrJS21u2l0nUru0m1Ge3juYZYo3iWYLI6lCcsqEhUAbB6njNJeYzXn8Rabbx7mllkPmvCI4LaSWQshw2ERSxAPU4x05pLnxJplq6RyyTmV4ROsMdrLJJsJxu2KpYDI5444zjNYSabexaaXvdIvpL1r64nifTbmJHgV3yMs8iggjGV5BI5HSlt7jVrHxLE9zYvqV2NIiW4Fu8avv8xufmKrjrnBHbApJvS/X/K4Pr/XW35G/ceIdMt7W3uDO0yXS74RawvO0i8ZYKgJwMjJxgZFMn8S6VAIf9JaY3EXnQpbQvM0iZA3KqKSQMjOBxXNt4ZvbVbC5uLW9vCkEqTW+m6i1u8bvL5g2nzIwyjJXk9gQK2NK0Y2OsWUttZSW1pDp7xBJZvMeN2kVtpYsxJ4Jzkj3prf7/wBf+AS3Zfd+hdl8SaZFa204mlmW5UtEtvbSTOwHBOxFLAAkA5HB4NOXWIBdXYmliit7a2juGZ9ysitv5YEAAYX1z1yBxnB/sq6ttJgVtL1GS+S4umiuNPuIUaFXmZhuLyAMpBU7SGHHIyKdJoer3kOoG8ERup7GzHmBgI5ZomdnXjkKSQM46Gjow7GzH4m0p7S6uGnkgjtI/NmFxbyQsqf39rqGK8HkDHFS2OuWGo3T21rJJ5qrv2ywSRb1zjchZQHXpyuRyPWue1nTtU8Qw30/9ly2ZGmzWkUE8sRad5Cpz8rFQo2DGTn5jwO+3NZTt4tsLxY/9Hhsp4nfI4ZniKjHXojflTXT+u4zWooopAFFFFABRRRQAUUUUAISFUliAAMkntXPweLEn0+/u1s3CQXCQWw383O8Lsbp8oYuMdeOfatDXdOudV0p7S0uo7ZpGXe0sJlV0ByUKhlOCODyOM1gf2Dr7nUmu57Gcm6t7m3WG2aESNF5ZxkyPtBCFcEdec44oW+oGi3iSW0ju4tTsUiv7cRFYIJ/MSXzXKR7XKqeWBByvHvVzTNUuLm8uLHUbWO1vYESUpDMZUZHLBSGKqeqsCCBjHesa60vUtYuLrU2sns5UFsLa1uJELMYZTK2SjMo3Z2jk4xk1paXDeXOuXWq3tnJYq9vHbxW8zoz4VmZmOxmXksABk9O2aa8wfl/Xcdd+KtHsbqe3ubl1e2YLcFbeRlgyoYF2ClUBBHzEgdeeDUtt4j0u6W4KXDRi2j82QzwvEPL/vjeBuXj7wyPesnUdFvp9N8XxxW+6TUgRajeo8z/AEZE9ePmBHOKTxLaMslxc3EO60bS3tCdwA8x5ECjqCB79vWl2/rpf/gDdv6+X+f4GvYeIdP1K/ks7b7UJ44xKyzWU0OFPAOXQDnB/I+lUpvE8iaRDfwabJMk8xVCsgCiLzAgkLY4yCCFGSc/UjGhi1uGe50+9QS6vfWQSO7jvFl8qJXCsSPKiC480sOCTgjPAFdLqmnFvD32DT4hiPyljQEDCq6+voBQ9Ff+v6/4Ig1HVLqG/isdLs47u6aMzOJpzCiICB94KxySeBjsckVPYapDfaPHqIDRRshZ1ccoRkMDjuCCOPSqWoR3llrq6pZWEl+slt9nkihkRXUhtyt87KMctnnPTg07TdMuLPwq1nKFa6kjldwrceZIWYgH0y2M1LbUL9f+HGvit0Ik8Z6HJs8u5nfzU3w7bOY/aB1/dfJ+8wDzszjvVga/bTSaWbIefDqEzxCTlDGVR2OVIznKFSDgg/TFU7PSrqE+Gt8AUWNq0c/zL+7bylXHXnkEcVn/ANn6np/2G4TTJ7swaveXDwwSRB/Lk83aw3uo/jXjOeelaOybRCu4pnY0VXsrmW6tVlnsp7JySDDOyFh/3wzL+tWKkoKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsWy1jUNSvZDZ6dbnT4rh7d5pLsrKGRirERhCMZHGWBI5xW1XLXVjc3WvR3Fholxpt0tyjTah50SxzxKfmDKjlnyvA3rxnORihbg9iSLxJqslrc6h/Y0D6dbzTRs0V6WnKxyMjMIzGB/CTjfnHqeK1bbV47rVvskCh4mtEuknDcMGYgDGPbOfesCzXXLbSr3SYNEmSaa5ujHeTTQ+QFkldlbCuXPDA42jnjjrU62t5oGsQGy0m81K1j02K0V7eSEEFGbqJJF7EdM0df67P9bDlu7f1qv0udRRTInaSFHeNomZQTG5G5T6HBIyPYkU+gQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVyD/Ur/nvVOrkH+pX/AD3oAkooooAKKKKAI5/9S3+e9U6vScpz6j+dJ5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVM8mIXBnEaecVCGTaNxUHIGfTJPFaHlp/dX8qPLT+6v5UAUqKu+Wn91fyo8tP7q/lQBSoq75af3V/Kjy0/ur+VAFKirvlp/dX8qPLT+6v5UAUqKu+Wn91fyo8tP7q/lQBSoq75af3V/Kjy0/ur+VAFKirvlp/dX8qPLT+6v5UAUqKu+Wn91fyo8tP7q/lQBSoq75af3V/Kjy0/ur+VAFKirvlp/dX8qPLT+6v5UAUqbJGk0TRyorxuCrKwyGB7EVf8tP7q/lR5af3V/KgDHsNK0/S1ddMsLWzVyCwt4VjDY9cAZq3V3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVFXfLT+6v5UeWn91fyoApUVd8tP7q/lR5af3V/KgClRV3y0/ur+VHlp/dX8qAKVXIP9Sv+e9L5af3V/Klj4Tj1P8AOgB1FFFABRRRQA2T7v4j+dR3VzFZ2k1zcMEihQyOx7KBkmpJPu/iP51meIdKk1vTBpwcJbzyqLohyrNCDllUjnLYC9RwSc5pO/Qat1MM+JtSm8EaxdzxLY6pZRM4RVyEDIHjOGzk7WAPbcrVak8RXVr4m1O0+xXl/DbwQShLZI/3IYPuYlmXd90cDJ44FVdS8Euq3y6JcSbdQsHtbgX97NOSw5iYM5cgDLgj/azV6407XLbXL++0oWEyXsMUQS5ldDEUDfPwrbvvfd46dRTltp/X9f1YlXvqWLjxPbqsTafaXeph7dbljaKn7uJs7XO9lznBwBluDxUT+LrZ7hodNsL7U2W2iuybVUA8qTdtbLuo/hPHX0BrGn8BRW8tpJDpOj64IbGGyMerKF2eXnDo3lv13HK4HQc1vafor2Wp3k6R28EE1lb28UMHCxmPzMgDAAX5wBj06CiWidv6/rT+tn1X9f11/rdX8S27LZf2da3WpPeQC5RLYICsJxh2LsoA5HGcnnAODVXRtevLjwrbah9hu9TmmklGyBY42CiRgCRIyAYAAx1qvp2g6vokGlPYiyuZ7fTYrC6jmmeNDswQ6MEYnBLcFRnI5GKrDwpqUdpp8VxDpmqpAs6zW127LDueXesqrsYFgMjBA6nDerfl/W9v0+/7l1/ry/4JrXfiuG20SLVotNvruzki8wvD5QKHONhV3Uls8YAPPFPvPE8NpNMi2F7cJaqGvJYVQra5XdhgWDMdvJCBjjHrWRa+HdbsLbRrRItNu7TTULmNrh4A8247W2iNvlUHIHqf9kGrtzpOsxT6kNLFj5erEPM88rhrV/KWMlVCESDCg4JTnPrxPQpW6kp18W2taobiYvYwWtrJCkaAlmkaQYXHJLEIAKvaZrK6jPPbS2lzY3cCq8ltc7NwVs7WyjMpB2t0PbnFYl94K+1299ab4GtpLWzigWZfMBa3dmxIpGCpyoI7jNaPhvRk0pZ2GgaNo7yYBGlnPmAZ5Y+UnrwOe/NVpdkq9tdzcooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigClqi6k1rnSLq1tpVOWa6tmnUrjoAsiYPTnJ+lZHh/VNauPDNvq+pLBqDXdvFNFaada+S6lhkjdJMVbqOfl6V0Uil42UdSCK5aXw3qC+EtD01Vs7x9OSNbm0nlZILoLEUKlgrHAYhhlSDtHHoLZ/L9b/oPSw/UPFDi00+4tYLqF21MWlzaMiNLnYx8vgleu05DYxznGafe+I5ZLJPs8Nxp93HqFrBcW9wqF1SSRR1UspDKTyCe/QiqVt4T1GysUWz/ALOgkj1b+0EhiVkiVPL2+WMDg54zj/ax/DVmTw/qV9JLe332SG8mu7SQxQys6RxQSBsByoLMcsfugcgds0R3V+6/S/6kyvZ27P8AW36F9/FFsl75ZtLo2n2gWpvwqeSJi2zZ97f947c7dueM0aDrd1q89+lxps1qltcvCkjtGVbbgY+Vyc9+gFZFp4Misdceb+wNCvo5Lx7oX9wgF1EWcvjHltuIJODvXjHpW1pFjfafqGopMtu1ncXDXEUqyt5mWxlWTbgAYPIY59BQvPt/l/wRy8u/4a/8A16KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCOeeK2t5J7h1jiiUu7scBQBkk1zEPim/bT9Rnms44pVu4beyhbIOJQgQye+XyQMYHHUZrb1rSRrWnfZGu7i0HmJJ5lvsLEqcgEOrKRkDIIrCHhHUB/aTS65cXbz3ENxbG5SLAeLYQW8uNO6beONvbNC31D0JZ/EOpaW13Y6gLW5v0FubaWGNoo5POkMa5UsxG1hk4Y5HpWhpV/ff2tdaVq7W8txDDHcJPbRNEkiOWGNrMxBBT+8c5HSs+bw/qWqPd32om1tb5xbi2jgkaaOPyZDIpLFVJ3McHAGBjrWhpVhf/wBrXWq6utvFcTQx26QW0rSpGiFmzuZVJJLn+EYwOtNef9dv+CDt0/ruVr/xja2FzqMbafqE0WlkfbbiJEKQqUD7uXDMMNyFBIweOmZU8VWqrdHULO808W1sbr/SUX97EOrqEZvb5ThuRxVe/wDDt3daf4pgjkhDawCLcsxwv+jpH83HHKnpnj8qj8TWMsYudRZI5bcaY9m6EZILuuWIwRtAyT9OlLa39dP8xu2lv61X/B+40NO8QNfaxLp0ukX9jLHAs5a5MJUqxIGNkjHOQe3GPcZ2K4rwc4g1d7a21Kx1yKS23S39o0rmIoQEjZ3mlzkOxABGME45rtabJCiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vTNX1LVdauo47vTbeO0uHil094Wa5CKxAct5gA3DDD5CMEcmukrmr/SdU1fVLVruz023js7pZor6Kd3uNqtkqFMYC7h8p+c8E8GhboHsV7bVvEtxp93qsT6bPbW9xcILEWzpI6RSsn+t8wjcQmfuYyccda1bDW/7R1lYbcKbSXT4ryN8Hcd7MOecYwBWVbaT4kg0680mJdNt7a4uLhxfLcvJKqSyu/ERjA3APj75GRnnpViTStV0rV4Z9As7G4tUsI7MR3V48DJsZiMbYnzwR6dKOvl/wAB/rYct3b+tV+lzpaKZCZGhQzoqSlRvVGLKp7gEgZHvgfSn0CCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKSP7v4n+dLSR/d/E/zoAdRRRQAUUUUANk+7+I/nS0yfiFse386q+Y/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0VS8x/wC8350eY/8Aeb86ALtFUvMf+8350eY/95vzoAu0kf3fxP8AOqfmP/eb86tQcwrn3/nQBJRRRQAUUUUAf//Z"
    }
   },
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "![ss_list%20of%20drug.JPG](attachment:ss_list%20of%20drug.JPG)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Table Title\n",
    "- __List of Drugs (As of 1 April 2021)__"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Column Headers\n",
    "- __Active Ingredient(s)__: The ingredient in a pharmaceutical drug that is biologically active\n",
    "- __Dosage Form__:The means which drug molecules are delivered to sites of action within the body example Tablet, Injection, Ear drops\n",
    "- __Strength(s)__:The amount of drug in a given dosage form\n",
    "- __Subsidy Class__:Refers to the subsidy class in Singapore. It can be classified as Standard Drug List (SDL) or Medication Assistance Fund (MAF)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Storing the column headers into a variable \"column_headers\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Active Ingredient(s)',\n",
       " 'Dosage Form',\n",
       " 'Strength(s)',\n",
       " 'Subsidy Class',\n",
       " 'Clinical Indication']"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "column_headers=['Active Ingredient(s)','Dosage Form','Strength(s)','Subsidy Class','Clinical Indication']\n",
    "column_headers"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 4: Exploring the html<a id='html'></a>"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'<!DOCTYPE html>\\n<html class=\"no-js\" xmlns=\"http://www.w3.org/1999/xhtml\">\\n <head>\\n  <title>\\n   MOH | Drug Subsidies &amp; Schemes\\n  </title>\\n  <meta charset=\"utf-8\"/>\\n  <meta content=\"ie=edge\" http-equiv=\"x-ua-compatible\"/>\\n  <meta content=\"width=device-width, initial-scale=1.0\" name=\"viewport\"/>\\n  <meta name=\"keywords\"/>\\n  <link href=\"../../assets/MOH_Corp/img/favicon.ico\" rel=\"shortcut icon\" type=\"image/x-icon\"/>\\n  <link href=\"../../assets/MOH_Corp/img/Icon-60.png\" rel=\"apple-touch-icon\"/>\\n  <meta content=\"w4zqH9fAlbYTbkWlHAyXH85MFv78fhJhgC919EyPpko\" name=\"google-site-verification\"/>\\n  <meta content=\"Find out more about the list of drugs that is subsidised at our public hospitals, specialist outpatient clinics and polyclinics. \\n\" name=\"description\"/>\\n  <script type=\"text/javascript\">\\n   (function(h,o,t,j,a,r){\\n        h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};\\n        h._hjSettings={hjid:1465941,hjsv:6};\\n        a=o.getElementsByTagName(\\'head\\')[0];\\n        r=o.createElement(\\'script\\');r.async=1;\\n        r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;\\n        a.appendChild(r);\\n    })(window,document,\\'https://static.hotjar.com/c/hotjar-\\',\\'.js?sv=\\');\\n  </script>\\n  <script src=\"https://assets.wogaa.sg/scripts/wogaa.js\" type=\"text/javascript\">\\n  </script>\\n  <script type=\"text/javascript\">\\n   (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({\\'gtm.start\\':\\nnew Date().getTime(),event:\\'gtm.js\\'});var f=d.getElementsByTagName(s)[0],\\nj=d.createElement(s),dl=l!=\\'dataLayer\\'?\\'&l=\\'+l:\\'\\';j.async=true;j.src=\\n\\'https://www.googletagmanager.com/gtm.js?id=\\'+i+dl;f.parentNode.insertBefore(j,f);\\n})(window,document,\\'script\\',\\'dataLayer\\',\\'GTM-53N52TR\\');\\n  </script>\\n  <meta content=\"Sitefinity 12.2.7232.0 PE\" name=\"Generator\"/>\\n  <link href=\"/Telerik.Web.UI.WebResource.axd?d=PMrIT5dOWaVYIcpFWUE4nOwcRLA17O-loIxGAkl8OyYLM-olt2c7iHH0AuOhkOXnq_qArjrniyUOx-64p6X6TtWl5rR1ZK5Xr_1XvA0lVJ3rFXYihh-0F88wbvBgOcyR0&amp;t=637553983040596192&amp;compress=0&amp;_TSM_CombinedScripts_=%3b%3bTelerik.Sitefinity.Resources%2c+Version%3d12.2.7232.0%2c+Culture%3dneutral%2c+PublicKeyToken%3db28c218413bdf563%3aen%3a4ce39564-eafe-4a26-9ef6-244a21c7a8bb%3a7a90d6a\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/foundation.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/jquery-ui.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/slick.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/slick-theme.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/magnific-popup.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/font-awesome.min.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/line-awesome-font-awesome.min.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/style.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <link href=\"/assets/MOH_Corp/css/navbar.min.css\" rel=\"stylesheet\" type=\"text/css\"/>\\n  <style media=\"all\" type=\"text/css\">\\n   .az-navigation li {\\ndisplay: inline;\\n}\\n  </style>\\n  <style media=\"all\" type=\"text/css\">\\n   .tooltip{\\n   position:absolute !important; \\n}\\n\\n.tooltip.top .tooltip-arrow{\\n   border-top-color: #053c50; \\n}\\n\\n@media screen and (max-width:991px){\\n  .forms-search{\\n   \\tmargin-top:unset !important;\\n  }\\n}\\n  </style>\\n </head>\\n <body class=\"\" data-whatinput=\"mouse\">\\n  <form action=\"./drug-subsidies-schemes\" id=\"form1\" method=\"post\">\\n   <div class=\"aspNetHidden\">\\n    <input id=\"ctl08_TSM\" name=\"ctl08_TSM\" type=\"hidden\" value=\"\"/>\\n    <input id=\"ctl09_TSSM\" name=\"ctl09_TSSM\" type=\"hidden\" value=\"\"/>\\n    <input id=\"__EVENTTARGET\" name=\"__EVENTTARGET\" type=\"hidden\" value=\"\"/>\\n    <input id=\"__EVENTARGUMENT\" name=\"__EVENTARGUMENT\" type=\"hidden\" value=\"\"/>\\n    <input id=\"__VIEWSTATE\" name=\"__VIEWSTATE\" type=\"hidden\" value=\"tuUy7i80OUkrXtzPQOOV0q0K8cWsJu+pUsFaNhtHcX/ZP63Efg8o27UlCE61D8f2GQXkiY4q4wO9oLIJ10danwuMiyE49pjhxDSPw/eDZYU=\"/>\\n   </div>\\n   <script type=\"text/javascript\">\\n    //<![CDATA[\\r\\nvar theForm = document.forms[\\'form1\\'];\\r\\nif (!theForm) {\\r\\n    theForm = document.form1;\\r\\n}\\r\\nfunction __doPostBack(eventTarget, eventArgument) {\\r\\n    if (!theForm.onsubmit || (theForm.onsubmit() != false)) {\\r\\n        theForm.__EVENTTARGET.value = eventTarget;\\r\\n        theForm.__EVENTARGUMENT.value = eventArgument;\\r\\n        theForm.submit();\\r\\n    }\\r\\n}\\r\\n//]]>\\n   </script>\\n   <script src=\"/WebResource.axd?d=pynGkmcFUV13He1Qd6_TZMdYEsCHmLSovwDpxmCw0GUzX_Hr5B89aQVpxN0Q-5LwEvDbCJsFzUl8VZXQ2yJggA2&amp;t=637454356939909757\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/jquery.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/slick.min.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/foundation.min.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/bootstrap.min.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/jquery-ui.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/what-input.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/awesomplete.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/innernav.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/jquery.magnific-popup.min.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/app.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"/assets/MOH_Corp/js/main.js\" type=\"text/javascript\">\\n   </script>\\n   <script type=\"text/javascript\">\\n    //<![CDATA[\\r\\nvar __cultureInfo = {\"name\":\"en\",\"numberFormat\":{\"CurrencyDecimalDigits\":2,\"CurrencyDecimalSeparator\":\".\",\"IsReadOnly\":true,\"CurrencyGroupSizes\":[3],\"NumberGroupSizes\":[3],\"PercentGroupSizes\":[3],\"CurrencyGroupSeparator\":\",\",\"CurrencySymbol\":\"$\",\"NaNSymbol\":\"NaN\",\"CurrencyNegativePattern\":0,\"NumberNegativePattern\":1,\"PercentPositivePattern\":0,\"PercentNegativePattern\":0,\"NegativeInfinitySymbol\":\"-Infinity\",\"NegativeSign\":\"-\",\"NumberDecimalDigits\":2,\"NumberDecimalSeparator\":\".\",\"NumberGroupSeparator\":\",\",\"CurrencyPositivePattern\":0,\"PositiveInfinitySymbol\":\"Infinity\",\"PositiveSign\":\"+\",\"PercentDecimalDigits\":2,\"PercentDecimalSeparator\":\".\",\"PercentGroupSeparator\":\",\",\"PercentSymbol\":\"%\",\"PerMilleSymbol\":\"\",\"NativeDigits\":[\"0\",\"1\",\"2\",\"3\",\"4\",\"5\",\"6\",\"7\",\"8\",\"9\"],\"DigitSubstitution\":1},\"dateTimeFormat\":{\"AMDesignator\":\"AM\",\"Calendar\":{\"MinSupportedDateTime\":\"\\\\/Date(-62135596800000)\\\\/\",\"MaxSupportedDateTime\":\"\\\\/Date(253402271999999)\\\\/\",\"AlgorithmType\":1,\"CalendarType\":1,\"Eras\":[1],\"TwoDigitYearMax\":2029,\"IsReadOnly\":true},\"DateSeparator\":\"/\",\"FirstDayOfWeek\":0,\"CalendarWeekRule\":0,\"FullDateTimePattern\":\"dddd, MMMM d, yyyy h:mm:ss tt\",\"LongDatePattern\":\"dddd, MMMM d, yyyy\",\"LongTimePattern\":\"h:mm:ss tt\",\"MonthDayPattern\":\"MMMM d\",\"PMDesignator\":\"PM\",\"RFC1123Pattern\":\"ddd, dd MMM yyyy HH\\\\u0027:\\\\u0027mm\\\\u0027:\\\\u0027ss \\\\u0027GMT\\\\u0027\",\"ShortDatePattern\":\"M/d/yyyy\",\"ShortTimePattern\":\"h:mm tt\",\"SortableDateTimePattern\":\"yyyy\\\\u0027-\\\\u0027MM\\\\u0027-\\\\u0027dd\\\\u0027T\\\\u0027HH\\\\u0027:\\\\u0027mm\\\\u0027:\\\\u0027ss\",\"TimeSeparator\":\":\",\"UniversalSortableDateTimePattern\":\"yyyy\\\\u0027-\\\\u0027MM\\\\u0027-\\\\u0027dd HH\\\\u0027:\\\\u0027mm\\\\u0027:\\\\u0027ss\\\\u0027Z\\\\u0027\",\"YearMonthPattern\":\"MMMM yyyy\",\"AbbreviatedDayNames\":[\"Sun\",\"Mon\",\"Tue\",\"Wed\",\"Thu\",\"Fri\",\"Sat\"],\"ShortestDayNames\":[\"Su\",\"Mo\",\"Tu\",\"We\",\"Th\",\"Fr\",\"Sa\"],\"DayNames\":[\"Sunday\",\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\",\"Saturday\"],\"AbbreviatedMonthNames\":[\"Jan\",\"Feb\",\"Mar\",\"Apr\",\"May\",\"Jun\",\"Jul\",\"Aug\",\"Sep\",\"Oct\",\"Nov\",\"Dec\",\"\"],\"MonthNames\":[\"January\",\"February\",\"March\",\"April\",\"May\",\"June\",\"July\",\"August\",\"September\",\"October\",\"November\",\"December\",\"\"],\"IsReadOnly\":true,\"NativeCalendarName\":\"Gregorian Calendar\",\"AbbreviatedMonthGenitiveNames\":[\"Jan\",\"Feb\",\"Mar\",\"Apr\",\"May\",\"Jun\",\"Jul\",\"Aug\",\"Sep\",\"Oct\",\"Nov\",\"Dec\",\"\"],\"MonthGenitiveNames\":[\"January\",\"February\",\"March\",\"April\",\"May\",\"June\",\"July\",\"August\",\"September\",\"October\",\"November\",\"December\",\"\"]},\"eras\":[1,\"A.D.\",null,0]};//]]>\\n   </script>\\n   <script src=\"/Telerik.Web.UI.WebResource.axd?_TSM_HiddenField_=ctl08_TSM&amp;compress=0&amp;_TSM_CombinedScripts_=%3b%3bSystem.Web.Extensions%2c+Version%3d4.0.0.0%2c+Culture%3dneutral%2c+PublicKeyToken%3d31bf3856ad364e35%3aen%3af7ba41a4-e843-4f12-b442-8e407f37c316%3aea597d4b%3ab25378d2\" type=\"text/javascript\">\\n   </script>\\n   <div class=\"aspNetHidden\">\\n    <input id=\"__VIEWSTATEGENERATOR\" name=\"__VIEWSTATEGENERATOR\" type=\"hidden\" value=\"EC2C6CF5\"/>\\n    <input id=\"__VIEWSTATEENCRYPTED\" name=\"__VIEWSTATEENCRYPTED\" type=\"hidden\" value=\"\"/>\\n   </div>\\n   <script type=\"text/javascript\">\\n    //<![CDATA[\\r\\nSys.WebForms.PageRequestManager._initialize(\\'ctl00$ctl00$ctl08\\', \\'form1\\', [], [], [], 90, \\'ctl00$ctl00\\');\\r\\n//]]>\\n   </script>\\n   <input id=\"ctl08\" name=\"ctl00$ctl00$ctl08\" type=\"hidden\"/>\\n   <script type=\"text/javascript\">\\n    //<![CDATA[\\r\\nSys.Application.setServerId(\"ctl08\", \"ctl00$ctl00$ctl08\");\\r\\nSys.Application._enableHistoryInScriptManager();\\r\\n//]]>\\n   </script>\\n   <nav class=\"navbar navbar-default navbar-sticky-top\">\\n    <div class=\"masthead\">\\n     <div class=\"container\">\\n      <div class=\"row\">\\n       <div class=\"col\">\\n        <a href=\"https://www.gov.sg\" rel=\"noreferrer noopener\" target=\"_blank\">\\n         <span class=\"sgds-icon sgds-icon-sg-crest\">\\n         </span>\\n         <span>\\n          A Singapore Government Agency Website\\n         </span>\\n        </a>\\n       </div>\\n      </div>\\n     </div>\\n    </div>\\n    <div class=\"container\">\\n     <div class=\"navbar-header\">\\n      <button aria-controls=\"navbar\" aria-expanded=\"false\" class=\"navbar-toggle collapsed\" data-target=\"#navbar\" data-toggle=\"collapse\" type=\"button\">\\n       <span class=\"sr-only\">\\n        Toggle navigation\\n       </span>\\n       <span class=\"sgds-icon sgds-icon-menu\">\\n       </span>\\n      </button>\\n      <a href=\"/\">\\n       <img alt=\"Ministry of Health\" class=\"navbar-brand\" src=\"/assets/MOH_Corp/img/moh-logo.png\"/>\\n      </a>\\n     </div>\\n     <div class=\"navbar-collapse collapse\" id=\"navbar\">\\n      <ul class=\"nav navbar-nav navbar-right\">\\n       <li class=\"search-box--mobile\">\\n        <div class=\"container\">\\n         <div class=\"inputWrapper\">\\n          <div class=\"form-group\">\\n           <label class=\"sr-only\" for=\"searchBoxMobile\">\\n            Search\\n           </label>\\n           <div class=\"input-group\">\\n            <div class=\"input-group-addon\">\\n             <span class=\"sgds-icon sgds-icon-search\">\\n             </span>\\n            </div>\\n            <div class=\"form-control search-input\" id=\"mainSearchInputBlock2\" placeholder=\"What are you looking for?\" style=\"padding:0\" type=\"text\">\\n            </div>\\n           </div>\\n          </div>\\n         </div>\\n        </div>\\n       </li>\\n       <li class=\"dropdown\">\\n        <a aria-expanded=\"false\" aria-haspopup=\"true\" class=\"dropdown-toggle\" data-toggle=\"dropdown\" href=\"javascript:void(0)\" role=\"button\">\\n         For Public\\n         <span class=\"caret\">\\n         </span>\\n        </a>\\n        <div class=\"dropdown-menu\">\\n         <div class=\"container\">\\n          <ul class=\"level2\">\\n           <li>\\n            <a href=\"/news-highlights\">\\n             News Highlights\\n            </a>\\n           </li>\\n           <li>\\n            <a href=\"/cost-financing/healthcare-schemes-subsidies\">\\n             Healthcare Schemes &amp; Subsidies\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/cost-financing/healthcare-schemes-subsidies\">\\n               <strong>\\n                Healthcare Schemes &amp; Subsidies\\n               </strong>\\n               <div>\\n                View all healthcare financing schemes &amp; subsidies available in Singapore such as MediShield Life, CareShield Life, MediSave, CHAS and ElderShield.\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/cost-financing/fee-benchmarks-and-bill-amount-information\">\\n               <strong>\\n                Fee Benchmarks and Bill Amount Information\\n               </strong>\\n               <div>\\n                Search for fee benchmarks for private sector professional fees and bill amount information for public and private hospitals.\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n           <li>\\n            <a href=\"/home/healthcare-locator\" rel=\"noopener noreferrer\" target=\"_blank\">\\n             Healthcare Locator\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/home/search-for-healthcare-institutions\">\\n               <strong>\\n                Search for Healthcare Institutions\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/search-for-healthcare-professionals\">\\n               <strong>\\n                Search for Healthcare Professionals\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/resources-statistics/listing-of-suspensions-revocations-from-the-ministry-of-health-s-healthcare-financing-schemes/suspensions-revocations-from-healthcare-financing-schemes\">\\n               <strong>\\n                Suspensions/Revocations from Healthcare Financing Schemes\\n               </strong>\\n               <div>\\n                List of suspensions and revocations taken by MOH under CHAS, MediSave and MediShield Life\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/listing-of-enforcement-actions-taken-by-the-ministry-of-health-on-breaches-of-regulatory-requirements/enforcement-actions-for-breaches-of-regulatory-requirements\">\\n               <strong>\\n                Enforcement Actions for Breaches of Regulatory Requirements\\n               </strong>\\n               <div>\\n                List of enforcement actions taken by MOH under the PHMCA, MRA and DRA\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/upcoming-and-completed-healthcare-facilities\">\\n               <strong>\\n                Upcoming and Completed Healthcare Facilities\\n               </strong>\\n               <div>\\n                View all upcoming and completed healthcare facilities.\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n           <li>\\n            <a href=\"/diseases-updates/disease-updates\">\\n             Disease Updates\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/resources-statistics/infectious-disease-statistics/2021/weekly-infectious-diseases-bulletin\">\\n               <strong>\\n                Weekly Infectious Diseases Bulletin\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/diseases-updates/being-prepared-for-a-pandemic\">\\n               <strong>\\n                Being Prepared for a Pandemic\\n               </strong>\\n               <div>\\n                Learn more about how Singapore is prepared to prevent &amp; respond to disease outbreaks.\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/diseases-updates\">\\n               <strong>\\n                Overview of Diseases\\n               </strong>\\n               <div>\\n                Learn more about the various infectious diseases that Singapore has overcome.\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n           <li>\\n            <a href=\"/resources-statistics\">\\n             Resources &amp; Statistics\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/e-consultation\">\\n               <strong>\\n                E-Consultation\\n               </strong>\\n               <div>\\n                Through E-Consultation, MOH aims to gather feedback and suggestion from members of the public to further improve policies, programmes and services.\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/research-grants\">\\n               <strong>\\n                Research Grants\\n               </strong>\\n               <div>\\n                Search for various available grants\\xa0to drive the translation of basic research to advance human healthcare, and to increase the translational and clinical research capabilities of public hospitals, research institutions and medical researchers.\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/resources-statistics\">\\n               <strong>\\n                Resources &amp; Statistics\\n               </strong>\\n               <div>\\n                Search for publications, education brochures, statistics on admission rates, waiting times, bed occupancy rates, diseases and more.\\n                <br/>\\n                <div>\\n                 <br/>\\n                </div>\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n           <li>\\n            <a href=\"/home/my-health-record\" rel=\"noopener noreferrer\" target=\"_blank\">\\n             My Health Record\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/home/appointments\">\\n               <strong>\\n                Appointments\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/children\\'s-health\" rel=\"noopener noreferrer\" target=\"_blank\">\\n               <strong>\\n                Children\\'s Health\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/personal-health\">\\n               <strong>\\n                Personal Health\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n          </ul>\\n         </div>\\n        </div>\\n       </li>\\n       <li class=\"dropdown\">\\n        <a aria-expanded=\"false\" aria-haspopup=\"true\" class=\"dropdown-toggle\" data-toggle=\"dropdown\" href=\"javascript:void(0)\" role=\"button\">\\n         For Healthcare Professionals\\n         <span class=\"caret\">\\n         </span>\\n        </a>\\n        <div class=\"dropdown-menu\">\\n         <div class=\"container\">\\n          <ul class=\"level2\">\\n           <li>\\n            <a href=\"/licensing-and-regulation\">\\n             Licensing and Regulation\\n            </a>\\n           </li>\\n           <li>\\n            <a href=\"/home/health-professional-portal\">\\n             Health Professional Portal\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/home/dentist\" rel=\"noopener noreferrer\" target=\"_blank\">\\n               <strong>\\n                Dentist\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/tcm-practitioner\">\\n               <strong>\\n                TCM Practitioner\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/pharmacist\">\\n               <strong>\\n                Pharmacist\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/allied-health-professional\">\\n               <strong>\\n                Allied Health Professional\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/nurse\">\\n               <strong>\\n                Nurse\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/doctor\">\\n               <strong>\\n                Doctor\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/home/all-heathcare-professionals\">\\n               <strong>\\n                All Heathcare Professionals\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n           <li>\\n            <a href=\"/policies-and-guidelines\">\\n             Policies and Guidelines\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/home/guidelines\">\\n               <strong>\\n                Guidelines\\n               </strong>\\n               <div>\\n               </div>\\n              </a>\\n             </li>\\n             <li>\\n              <a href=\"/policies-and-legislation\">\\n               <strong>\\n                Legislation\\n               </strong>\\n               <div>\\n                Acts regulating drugs, healthcare professionals, medical practices, research and more.\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n          </ul>\\n         </div>\\n        </div>\\n       </li>\\n       <li class=\"dropdown\">\\n        <a aria-expanded=\"false\" aria-haspopup=\"true\" class=\"dropdown-toggle\" data-toggle=\"dropdown\" href=\"javascript:void(0)\" role=\"button\">\\n         Who We Are\\n         <span class=\"caret\">\\n         </span>\\n        </a>\\n        <div class=\"dropdown-menu\">\\n         <div class=\"container\">\\n          <ul class=\"level2\">\\n           <li>\\n            <a href=\"/about-moh\">\\n             About Us\\n            </a>\\n            <ul class=\"level3\">\\n             <li>\\n              <a href=\"/careers\">\\n               <strong>\\n                Careers\\n               </strong>\\n               <div>\\n                Join Us. Together, we can protect the health of this nation.\\n               </div>\\n              </a>\\n             </li>\\n            </ul>\\n           </li>\\n           <li>\\n            <a href=\"/home/our-healthcare-system\">\\n             Singapore\\'s Healthcare System\\n            </a>\\n           </li>\\n           <li>\\n            <a href=\"/about-moh/senior-management\">\\n             Senior Management\\n            </a>\\n           </li>\\n          </ul>\\n         </div>\\n        </div>\\n       </li>\\n       <li class=\"hidden-xs\">\\n        <a aria-controls=\"searchBoxCollapse\" aria-expanded=\"false\" class=\"searchToggle\" data-toggle=\"collapse\" href=\"#searchBoxCollapse\" role=\"button\">\\n         <span class=\"sgds-icon sgds-icon-search\">\\n         </span>\\n        </a>\\n       </li>\\n      </ul>\\n     </div>\\n    </div>\\n    <div aria-expanded=\"true\" class=\"collapse\" id=\"searchBoxCollapse\">\\n     <div class=\"container\">\\n      <div class=\"inputWrapper\">\\n       <div class=\"form-group\">\\n        <label class=\"sr-only\" for=\"searchBox\">\\n         Search\\n        </label>\\n        <div class=\"input-group\">\\n         <div class=\"input-group-addon\">\\n          <span class=\"sgds-icon sgds-icon-search\">\\n          </span>\\n         </div>\\n         <div class=\"form-control search-input\" id=\"mainSearchInputBlock\" placeholder=\"What are you looking for?\" style=\"padding:0\" type=\"text\">\\n         </div>\\n        </div>\\n       </div>\\n      </div>\\n     </div>\\n    </div>\\n    <div class=\"alert alert-warning alert-dismissible\" style=\"margin-bottom:0px\">\\n     <div class=\"container\">\\n      <a aria-label=\"close\" class=\"close\" data-dismiss=\"alert\" href=\"#\" style=\"transform:translateY(40%)\">\\n       \\n      </a>\\n      <p style=\"margin-bottom:0\">\\n       We are aware of scam calls and emails impersonating MOH officers. Please note that MOH officers will not make any calls via automated voice machines. When in doubt, please verify the authenticity of phone calls and emails by calling the\\n       <strong>\\n        <span style=\"text-decoration: underline;\">\\n         MOH hotline at 1800-333-9999\\n        </span>\\n       </strong>\\n       .\\n      </p>\\n     </div>\\n    </div>\\n   </nav>\\n   <main class=\"page-container\">\\n    <section class=\"body-wrap\">\\n     <div class=\"well\">\\n      <div class=\"well-content\">\\n       <div class=\"container\">\\n        <div class=\"bread-crumbs\">\\n         <ul>\\n          <li>\\n           <a href=\"/\">\\n            Ministry of Health\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"/cost-financing/healthcare-schemes-subsidies\">\\n            Healthcare Schemes &amp; Subsidies\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"/cost-financing/healthcare-schemes-subsidies/drug-subsidies-schemes\">\\n            Drug Subsidies &amp; Schemes\\n           </a>\\n          </li>\\n         </ul>\\n        </div>\\n        <h1>\\n         Drug Subsidies &amp; Schemes\\n        </h1>\\n        <p>\\n        </p>\\n        <span class=\"last\">\\n         01 Apr 2021\\n        </span>\\n       </div>\\n      </div>\\n     </div>\\n     <section class=\"body-content\">\\n      <div class=\"sf_colsIn container\" data-sf-element=\"Container\" id=\"ContentPlaceHolder_contentPlaceholder_TB03B381D008_Col00\">\\n       <div class=\"sfContentBlock\">\\n        <p>\\n         The Ministry of Health (MOH) provides subsidies for drugs at our public hospitals, specialist outpatient clinics and polyclinics to ensure that patients have access to effective medications for common medical conditions in Singapore.\\n        </p>\\n       </div>\\n       <div class=\"sfContentBlock\">\\n        <div class=\"accordion-list\">\\n         <p style=\"margin-top:25px\">\\n          <a class=\"expand\" href=\"#\">\\n           Expand All\\n          </a>\\n          |\\n          <a class=\"collapses\" href=\"#\">\\n           Collapse All\\n          </a>\\n         </p>\\n         <h4 class=\"accordion\">\\n          Who is Eligible?\\n         </h4>\\n         <div class=\"show-more\">\\n          <br/>\\n          <p>\\n           Patients receive drug subsidies and assistance based on their subsidy and means-test status, and the scheme under which the drug is covered (e.g. Standard Drug List (SDL), Medication Assistance Fund (MAF)).\\n          </p>\\n         </div>\\n         <h4 class=\"accordion\">\\n          What drugs can I claim for?\\n         </h4>\\n         <div class=\"show-more\">\\n          <br/>\\n          <p>\\n           If you need financial support to pay for the medications you are taking, check the following list to see if they are included.\\n          </p>\\n         </div>\\n        </div>\\n        <br/>\\n        <p>\\n        </p>\\n       </div>\\n       <div class=\"sfContentBlock\">\\n        <h2>\\n         List of Drugs* (as of 1 April 2021)\\n        </h2>\\n        <p>\\n         * The drug availability at each healthcare institution varies, depending on the clinical conditions commonly managed by the institution and the drugs usually prescribed by the doctors.\\n        </p>\\n       </div>\\n       <div class=\"sfContentBlock\">\\n        <div class=\"text\">\\n         <p>\\n         </p>\\n        </div>\\n        <div class=\"az-navigation\">\\n         <ul>\\n          <li class=\"selected\" id=\"li-A\">\\n           <a href=\"javascript:\" title=\"A\">\\n            A\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-B\">\\n           <a href=\"javascript:\" title=\"B\">\\n            B\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-C\">\\n           <a href=\"javascript:\" title=\"C\">\\n            C\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-D\">\\n           <a href=\"javascript:\" title=\"D\">\\n            D\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-E\">\\n           <a href=\"javascript:\" title=\"E\">\\n            E\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-F\">\\n           <a href=\"javascript:\" title=\"F\">\\n            F\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-G\">\\n           <a href=\"javascript:\" title=\"G\">\\n            G\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-H\">\\n           <a href=\"javascript:\" title=\"H\">\\n            H\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-I\">\\n           <a href=\"javascript:\" title=\"I\">\\n            I\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-K\">\\n           <a href=\"javascript:\" title=\"K\">\\n            K\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-L\">\\n           <a href=\"javascript:\" title=\"L\">\\n            L\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-M\">\\n           <a href=\"javascript:\" title=\"M\">\\n            M\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-N\">\\n           <a href=\"javascript:\" title=\"N\">\\n            N\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-O\">\\n           <a href=\"javascript:\" title=\"O\">\\n            O\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-P\">\\n           <a href=\"javascript:\" title=\"P\">\\n            P\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-Q\">\\n           <a href=\"javascript:\" title=\"Q\">\\n            Q\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-R\">\\n           <a href=\"javascript:\" title=\"R\">\\n            R\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-S\">\\n           <a href=\"javascript:\" title=\"S\">\\n            S\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-T\">\\n           <a href=\"javascript:\" title=\"T\">\\n            T\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-U\">\\n           <a href=\"javascript:\" title=\"U\">\\n            U\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-V\">\\n           <a href=\"javascript:\" title=\"V\">\\n            V\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-W\">\\n           <a href=\"javascript:\" title=\"W\">\\n            W\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-Y\">\\n           <a href=\"javascript:\" title=\"Y\">\\n            Y\\n           </a>\\n           |\\n          </li>\\n          <li class=\"unselected\" id=\"li-Z\">\\n           <a href=\"javascript:\" title=\"Z\">\\n            Z\\n           </a>\\n           |\\n          </li>\\n         </ul>\\n        </div>\\n        <div class=\"tableList\" id=\"A\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Abacavir &amp; Lamivudine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Abacavir 600 mg + Lamivudine 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Abacavir, Dolutegravir &amp; Lamivudine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Abiraterone Acetate (Abiranat)\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Absolute Alcohol\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Acetazolamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Acetic acid\\n            </td>\\n            <td>\\n             Ear drops\\n            </td>\\n            <td>\\n             2%, 3%, 4%, 5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Acetylcysteine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             5 g/25 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aciclovir\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             250 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aciclovir\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aciclovir\\n            </td>\\n            <td>\\n             Eye ointment\\n            </td>\\n            <td>\\n             3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Acitretin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10 mg, 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Adalimumab Biosimilar (Amgevita)\\n            </td>\\n            <td>\\n             Prefilled autoinjector\\n            </td>\\n            <td>\\n             40 mg/0.8 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Adalimumab Biosimilar (Amgevita)\\n            </td>\\n            <td>\\n             Prefilled syringe\\n            </td>\\n            <td>\\n             20 mg/0.4 mL, 40 mg/0.8 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Adefovir Dipivoxil\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Adrenaline\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1:1,000 (1 mg/mL), 1:10,000 (1 mg/10 mL)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Albendazole\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             400 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Albendazole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Alendronic Acid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 70 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Alendronic Acid &amp; Colecalciferol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Alendronic Acid 70 mg + Colecalciferol 2,800 international units, Alendronic Acid 70 mg + Colecalciferol 5,600 international units\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) For patients with osteoporosis (T-score  -2.5)\\n             <br/>\\n             2) For patients with osteopenia (T-score  -1.5) and a history of non-trauma induced fracture\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Alfacalcidol\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             0.25 mcg, 1 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Alfacalcidol\\n            </td>\\n            <td>\\n             Oral drops\\n            </td>\\n            <td>\\n             2 mcg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Alfacalcidol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.25 mcg, 1 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Alfuzosin Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Allopurinol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg, 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Alteplase\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             50 mg/50 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aluminium Hydroxide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             600 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aluminium Hydroxide, Magnesium Trisilicate &amp; Simeticone\\n            </td>\\n            <td>\\n             Chewable tablet\\n            </td>\\n            <td>\\n             Aluminium Hydroxide 250 mg + Magnesium Trisilicate 250 mg + Simeticone 30 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aluminium Hydroxide, Magnesium Trisilicate &amp; Simeticone\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             Aluminium Hydroxide 400 mg/5 mL + Magnesium Trisilicate 400 mg/5 mL + Simeticone 30 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aluminium Oxide\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ambrisentan\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies:\\n             <br/>\\n              Idiopathic PAH\\n             <br/>\\n              Heritable or familial PAH\\n             <br/>\\n              PAH associated with connective tissue disease\\n             <br/>\\n              Anorexigen-induced PAH\\n             <br/>\\n              PAH associated with HIV infection\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amikacin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amiloride &amp; Hydrochlorothiazide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Amiloride Hydrochloride 5 mg + Hydrochlorothiazide 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amino Acids\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             5%, 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aminophylline\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             250 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amiodarone Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amiodarone Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amitriptyline\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amlodipine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amoxicillin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amoxicillin\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             125 mg/5 mL, 250 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amoxicillin &amp; Clavulanic Acid\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Amoxicillin 500 mg + Clavulanic Acid 100 mg, Amoxicillin 1 g + Clavulanic Acid 200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amoxicillin &amp; Clavulanic Acid\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             Amoxicillin 200 mg/5 mL + Clavulanic Acid 28.5 mg/5 mL, Amoxicillin 600 mg/5 mL + Clavulanic Acid 42.9 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amoxicillin &amp; Clavulanic Acid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Amoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 875 mg + Clavulanic Acid 125 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amphotericin B\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Amphotericin B\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ampicillin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.5 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Anastrozole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Antazoline Hydrochloride &amp; Tetryzoline Hydrochloride\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             Antazoline Hydrochloride 0.5 mg/mL + Tetryzoline Hydrochloride 0.4 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Anti-Rabies Immunoglubulin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             300 units/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Apixaban\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2.5 mg, 5 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA\\n             <sub>\\n              2\\n             </sub>\\n             DS\\n             <sub>\\n              2\\n             </sub>\\n             -VASc score of 1 or more for men, and 2 or more for women\\n             <br/>\\n             *This excludes patients with rheumatic mitral stenosis or prosthetic heart valves\\n             <br/>\\n             2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aprepitant\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             80 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aprepitant\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             80 mg &amp; 125 mg (Tripack)\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aqueous Cream\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Emulsifying Ointment 30% with either Chlorocresol 0.1% or Phenoxyethanol 0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ascorbic Acid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ascorbic Acid\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 g/20 mL, 500 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Aspirin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg, 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Atazanavir\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             200 mg, 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Atenolol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Atorvastatin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 20 mg, 40 mg, 80 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Atracurium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             25 mg/2.5 mL, 50 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Atropine Sulfate\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.5%, 1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Atropine Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.6 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Azathioprine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg, 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Azithromycin\\n            </td>\\n            <td>\\n             Extended-release oral suspension\\n            </td>\\n            <td>\\n             2 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Azithromycin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Azithromycin\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             200 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Azithromycin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"B\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Bacillus Calmette-Guerin\\n            </td>\\n            <td>\\n             Solution for intravesical use\\n            </td>\\n            <td>\\n             12.5 mg, 40 mg, 80 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Baricitinib\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg, 4 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Checklist to be completed\\n             <br/>\\n             Treatment of adult patients with rheumatoid arthritis\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Beclomethasone\\n            </td>\\n            <td>\\n             Inhaler\\n            </td>\\n            <td>\\n             250 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Beclomethasone Dipropionate\\n            </td>\\n            <td>\\n             Inhaler\\n            </td>\\n            <td>\\n             50 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzalkonium Chloride &amp; Cetrimide\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Benzalkonium Chloride 0.01% + Cetrimide 0.2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzathine Benzylpenicillin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2.4 million international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benztropine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2 mg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benztropine Mesilate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzhexol Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzoyl Peroxide\\n            </td>\\n            <td>\\n             Gel\\n            </td>\\n            <td>\\n             2.5%, 5%, 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzoyl Peroxide\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             5%, 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzyl Benzoate\\n            </td>\\n            <td>\\n             Topical emulsion\\n            </td>\\n            <td>\\n             25%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzylpenicillin Sodium\\n            </td>\\n            <td>\\n             Eye drops (preservative-free)\\n            </td>\\n            <td>\\n             2,500 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Benzylpenicillin Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 million international units, 5 million international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betaine\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             180 g\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of classic homocysteinuria\\n             <br/>\\n             2) Treatment of homocysteinuria secondary to sulfite oxidase deficiency, methionine synthase deficiency or cobalamin-related remethylation pathway defect\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betahistine Mesilate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             6 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betamethasone (as Valerate)\\n            </td>\\n            <td>\\n             Scalp lotion\\n            </td>\\n            <td>\\n             0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betamethasone (as Valerate)\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             0.0125%, 0.025%, 0.05%, 0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betamethasone (as Valerate)\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             0.025%, 0.05%, 0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betamethasone (as Valerate) &amp; Clioquinol\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Betamethasone 0.025% + Clioquinol 3%, Betamethasone 0.05% + Clioquinol 3%, Betamethasone 0.1% + Clioquinol 3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betamethasone Sodium Phosphate\\n            </td>\\n            <td>\\n             Eye/ear drops\\n            </td>\\n            <td>\\n             0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betamethasone Sodium Phosphate\\n            </td>\\n            <td>\\n             Eye/ear drops\\n            </td>\\n            <td>\\n             0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Betaxolol\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.25%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bethanechol Chloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bevacizumab\\n            </td>\\n            <td>\\n             Intravitreal injection\\n            </td>\\n            <td>\\n             25 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration\\n             <br/>\\n             2) Treatment of adults with visual impairment due to macular oedema secondary to central or branch retinal vein occlusion\\n             <br/>\\n             3) Treatment of adults with visual impairment due to diabetic macular oedema\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bisacodyl\\n            </td>\\n            <td>\\n             Enteric-coated tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bisacodyl\\n            </td>\\n            <td>\\n             Rectal suppository\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bismuth Subcitrate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             120 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bismuth Subgallate\\n            </td>\\n            <td>\\n             Rectal suppository\\n            </td>\\n            <td>\\n             Bismuth Subgallate 200 mg + Zinc Oxide 120 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bismuth Subsalicylate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             262.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bisoprolol Fumarate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2.5 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bleomycin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             15,000 international units (USP 15 units)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Blinatumomab\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             35 mcg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) for a maximum of 2 cycles for induction in a lifetime. Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor.\\n             <br/>\\n             Patients who achieve a complete response after induction can receive up to three additional cycles for consolidation in a lifetime.\\n             <br/>\\n             <br/>\\n             Complete response is defined as a patient who:\\n             <br/>\\n             a) has 5% or less bone marrow blasts; and\\n             <br/>\\n             b) has no evidence of disease; and\\n             <br/>\\n             c) has platelet count of more than 50,000 per microlitre; and\\n             <br/>\\n             d) has absolute neutrophil count of more than 500 per microlitre.\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Boric Acid, Resorcinol &amp; Phenol\\n            </td>\\n            <td>\\n             Paint\\n            </td>\\n            <td>\\n             Boric Acid 0.8% + Resorcinol 8% + Phenol 4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bortezomib\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             3.5 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Checklist to be completed.\\n             <br/>\\n             For primary induction in newly diagnosed patients with symptomatic multiple myeloma\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Botulinum toxin type A complex (Botox)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 units, 100 units\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) For adults with focal spasticity of the upper limbs due to stroke, who have Modified Ashworth Scale of 2 or more at the target muscle intended for botulinum toxin A treatment, and do not have the affected joint permanently fixed in position due\\n          to fibrotic shortening of the target muscle and are concurrently receiving physiotherapy\\n             <br/>\\n             <br/>\\n             2)\\xa0For adults with cervical dystonia, blepharospasm or hemifacial spasm\\n             <br/>\\n             <br/>\\n             3)\\xa0For children aged 2 years or older, with focal spasticity of the upper or lower limbs (including dynamic equinus foot deformity) due to cerebral palsy, and who do not have significant joint contractures (i.e. the affected joint is not permanently fixed in position due to shortening of the target muscle); and are concurrently receiving supportive therapy (e.g. physiotherapy or occupational therapy)\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Brimonidine Tartrate\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.15%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bromocriptine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Buclizine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Budesonide\\n            </td>\\n            <td>\\n             Powder inhaler\\n            </td>\\n            <td>\\n             100 mcg/dose, 200 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bupivacaine Hydrochloride (hyperbaric)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.5% (in dextrose 8%)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Bupivacaine Hydrochloride (isobaric)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Buprenorphine\\n            </td>\\n            <td>\\n             Sublingual tablet\\n            </td>\\n            <td>\\n             0.2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Busulfan\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             60 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Busulfan\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"C\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             C1 Esterase Inhibitor (Human)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 international units/10 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of hereditary angioedema\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cabergoline\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.5 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             As a 2nd line agent for the management of hyperprolactinaemia in patients who have failed to respond or who are unable to tolerate bromocriptine\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calamine\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             Calamine 15%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calamine &amp; Menthol\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             Calamine 15% + Menthol 0.4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcipotriol\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             50 mcg/g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcipotriol\\n            </td>\\n            <td>\\n             Scalp solution\\n            </td>\\n            <td>\\n             50 mcg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcipotriol &amp; Betamethasone\\n            </td>\\n            <td>\\n             Gel\\n            </td>\\n            <td>\\n             Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcipotriol &amp; Betamethasone\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             Calcipotriol 50 mcg/g + Betamethasone (as Diproprionate) 0.5 mg/g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcitriol\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             0.25 mcg, 0.5 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcium\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             20 mg to 23 mg Ca2+/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcium Acetate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             667 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcium Carbonate\\n            </td>\\n            <td>\\n             Chewable tablet\\n            </td>\\n            <td>\\n             1.25 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcium Carbonate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             625 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcium Carbonate &amp; Colecalciferol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Calcium Carbonate 450 mg + Colecalciferol 5 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcium Chloride Dihydrate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calcium Gluconate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calf Blood Extract (deproteinised)\\n            </td>\\n            <td>\\n             Eye gel\\n            </td>\\n            <td>\\n             8.3 mg/g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Calfactant\\n            </td>\\n            <td>\\n             Intratracheal suspension\\n            </td>\\n            <td>\\n             105 mg/3 mL, 210 mg/6 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Candesartan Cilexetil\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             4 mg, 8 mg, 16 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of patients with heart failure who cannot tolerate angiotensin converting enzyme inhibitors\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Capecitabine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             150 mg, 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Captopril\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             12.5 mg, 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Carbamazepine\\n            </td>\\n            <td>\\n             Controlled-release tablet\\n            </td>\\n            <td>\\n             200 mg, 400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Carbamazepine\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             100 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Carbamazepine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Carbimazole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Carboplatin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             150 mg/mL, 10 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Carmustine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Carvedilol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             6.25 mg, 12.5 mg, 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cefalexin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cefalexin\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             125 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cefazolin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ceftazidime\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ceftriaxone\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             250 mg, 1 g, 2 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Celecoxib\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cetirizine\\n            </td>\\n            <td>\\n             Solution\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cetrimide\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cetrimide\\n            </td>\\n            <td>\\n             Shampoo\\n            </td>\\n            <td>\\n             5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Charcoal (activated)\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Charcoal (activated)\\n            </td>\\n            <td>\\n             Granules\\n            </td>\\n            <td>\\n             50 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Charcoal (activated)\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             200 mg/mL (in sorbitol 70%)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Charcoal (activated)\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg, 250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chloral Hydrate\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             200 mg/5 mL, 500 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorambucil\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chloramphenicol\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chloramphenicol\\n            </td>\\n            <td>\\n             Eye ointment\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlordiazepoxide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorhexidine Gluconate\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorhexidine Salt\\n            </td>\\n            <td>\\n             Mouthwash\\n            </td>\\n            <td>\\n             0.2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorhexidine Salt\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             0.05%, 0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorhexidine Salt\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorhexidine Salt\\n            </td>\\n            <td>\\n             Mouthwash\\n            </td>\\n            <td>\\n             0.2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorhexidine Salt &amp; Alcohol\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             Chlorhexidine Salt 0.1% + Alcohol 70%, Chlorhexidine Salt 0.5% + Alcohol 70%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorhexidine Salt &amp; Cetrimide\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             Chlorhexidine Salt 0.015% + Cetrimide 0.15%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chloroquine Phosphate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             150 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorpheniramine\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             4 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorpheniramine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             4 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorpromazine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorpromazine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlorpropamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Chlortetracycline\\n            </td>\\n            <td>\\n             Eye ointment\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Choline Salicylate &amp; Cetylpyridinium Chloride\\n            </td>\\n            <td>\\n             Oral gel\\n            </td>\\n            <td>\\n             Choline Salicylate 8.7% + Cetylpyridinium Chloride 0.01%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ciclosporin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10 mg, 25 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ciclosporin\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ciclosporin\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cimetidine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             200 mg/2 mL, 150 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cimetidine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ciprofloxacin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg, 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ciprofloxacin\\n            </td>\\n            <td>\\n             Eye/ear drops\\n            </td>\\n            <td>\\n             0.3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ciprofloxacin\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             2 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cisplatin\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             50 mg/50 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Citric Acid Monohydrate &amp; Potassium Citrate\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             Citric Acid Monohydrate 0.25 g/5 mL + Potassium Citrate 1.5 g/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clarithromycin\\n            </td>\\n            <td>\\n             Modified-release tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clarithromycin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg, 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clarithromycin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clarithromycin\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             125 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clidinium &amp; Chlordiazepoxide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Clidinium Bromide 2.5 mg + Chlordiazepoxide 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clindamycin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             150 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clindamycin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             150 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clobetasol propionate\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             0.05%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clobetasol propionate\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             0.05%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clomiphene\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clomipramine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clonazepam\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.5 mg, 2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clopidogrel\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             75 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clotrimazole\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clotrimazole\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clotrimazole\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clotrimazole\\n            </td>\\n            <td>\\n             Vaginal tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cloxacillin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cloxacillin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             250 mg, 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cloxacillin\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             125 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Clozapine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Coal Tar\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             5%, 10%, 15%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Coal Tar\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             20%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Coal Tar\\n            </td>\\n            <td>\\n             Shampoo\\n            </td>\\n            <td>\\n             25%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Coal Tar &amp; Salicylic Acid\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             Coal Tar 5% + Salicylic acid 2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cocaine\\n            </td>\\n            <td>\\n             Solution\\n            </td>\\n            <td>\\n             10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cocois Compound\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             Coal Tar Solution 10% + Camphor 2% + Sulphur 4% + Salicylic Acid 2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Codeine &amp; Promethazine\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             Codeine Phosphate 18 mg/10 mL + Promethazine 7.2 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Codeine Phosphate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             30 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Coenzyme Q10\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of mitochondrial disorders\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Colchicine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Colecalciferol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1,000 units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Colestyramine\\n            </td>\\n            <td>\\n             Powder for oral suspension\\n            </td>\\n            <td>\\n             4 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Compound Diphenhydramine\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             Ranging from\\n             <br/>\\n             5 mg/5 mL to\\n             <br/>\\n             14 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Compound Polyethylene Glycol (Fortrans)\\n            </td>\\n            <td>\\n             Oral powder\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Compound Sodium Lactate\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Conjugated Oestrogens\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.3 mg, 0.625 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Conjugated Oestrogens\\n            </td>\\n            <td>\\n             Vaginal cream\\n            </td>\\n            <td>\\n             0.625 mg/g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cyanocobalamin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cyclophosphamide\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             200 mg, 1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cyclophosphamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cyproheptadine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             4 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Cytarabine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 mg/mL, 100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"D\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Dacarbazine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dactinomycin\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             500 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dantrolene Sodium\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             25 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dapagliflozin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             <p>\\n              1) Treatment of type 2 diabetes mellitus, as a dual therapy\\n              <br/>\\n               In combination with metformin for patients with HbA1c &gt; 7% despite treatment with metformin monotherapy;\\n              <br/>\\n               In combination with a sulfonylurea for patients with HbA1c &gt; 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated;\\n              <br/>\\n              2) Treatment of type 2 diabetes mellitus as a triple therapy\\n              <br/>\\n               In combination with metformin and a sulfonylurea for patients with HbA1c &gt; 7% despite treatment with optimal doses of dual therapy\\n              <br/>\\n              3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin\\n             </p>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dapsone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Darunavir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             600 mg, 800 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Daunorubicin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Deferasirox\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             90 mg, 360 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Deferiprone\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Deferiprone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Deferoxamine Mesilate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Denosumab\\n            </td>\\n            <td>\\n             Prefilled syringe\\n            </td>\\n            <td>\\n             60 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of post-menopausal women with osteoporosis (T-score  -2.5) at high risk of fracture and eGFR &gt; 30 mL/min and who are unable to tolerate or follow the administration instructions for oral bisphosphonates\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dequalinium Chloride\\n            </td>\\n            <td>\\n             Lozenge\\n            </td>\\n            <td>\\n             0.25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Desmopressin Acetate\\n            </td>\\n            <td>\\n             Nasal drops\\n            </td>\\n            <td>\\n             0.1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Desmopressin Acetate\\n            </td>\\n            <td>\\n             Nasal spray\\n            </td>\\n            <td>\\n             10 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Desmopressin Acetate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.1 mg, 0.2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dexamethasone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mcg, 4 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dexamethasone Phosphate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             4 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dexmedetomidine\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             200 mcg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dextromethorphan Hydrobromide\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             15 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dextromethorphan Hydrobromide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             15 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dextrose &amp; Potassium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             Dextrose 5% + Potassium Chloride 0.15%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dextrose &amp; Sodium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             Dextrose 2.5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.2%, Dextrose 5% + Sodium Chloride 0.45%, Dextrose 5% + Sodium Chloride 0.9%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dextrose Monohydrate\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             5%, 10%, 20%, 50%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dextrose Monohydrate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dextrose, Potassium Chloride &amp; Sodium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.33%, Dextrose 5% + Potassium Chloride 0.22% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.30% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.45%, Dextrose 5% + Potassium Chloride 0.15% + Sodium Chloride 0.9%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diazepam\\n            </td>\\n            <td>\\n             Enema\\n            </td>\\n            <td>\\n             5 mg/2.5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diazepam\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diazepam\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg, 5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dibasic Sodium Phosphate &amp; Monobasic Sodium Phosphate\\n            </td>\\n            <td>\\n             Enema\\n            </td>\\n            <td>\\n             Dibasic Sodium Phosphate 7 g/118 mL + Monobasic Sodium Phosphate 19 g/118 mL, Dibasic Sodium Phosphate 3.5 g/59 mL + Monobasic Sodium Phosphate 9.5 g/59 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diclofenac Sodium\\n            </td>\\n            <td>\\n             Enteric-coated tablet\\n            </td>\\n            <td>\\n             25 mg, 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diclofenac Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             25 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diclofenac Sodium\\n            </td>\\n            <td>\\n             Rectal suppository\\n            </td>\\n            <td>\\n             12.5 mg, 25 mg, 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diclofenac Sodium\\n            </td>\\n            <td>\\n             Gel\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diethylcarbamazine Citrate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Digoxin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mcg/mL, 250 mcg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Digoxin\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             50 mcg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Digoxin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             62.5 mcg, 250 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Digoxin-specific Antibody Fragments\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             40 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diltiazem Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg, 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diltiazem Hydrochloride\\n            </td>\\n            <td>\\n             Sustained-release capsule\\n            </td>\\n            <td>\\n             90 mg, 100 mg, 200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diltiazem Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             30 mg, 60 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dimercaprol\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diosmin &amp; Hesperidin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Diosmin 450 mg + Hesperidin 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diphenoxylate &amp; Atropine Sulfate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Diphenoxylate Hydrochloride 2.5 mg + Atropine Sulfate 25 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diphtheria &amp; Tetanus Vaccine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Diphtheria Toxoid Vaccine minimum 2 international units/0.5 mL + Tetanus Toxoid Vaccine minimum 20 international units/0.5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Diphtheria Antitoxin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10,000 units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dipyridamole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg, 75 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Disodium Edetate\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.38%, 3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dobutamine\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             250 mg/5 mL, 250 mg/20 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Docetaxel\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             20 mg, 80 mg, 160 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Donepezil Hydrochloride\\n            </td>\\n            <td>\\n             Oral disintegrating tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             For patients with mild to moderately severe Alzheimer\\'s Disease who have swallowing difficulties and are unable to receive a film-coated tablet\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Donepezil Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dopamine Hydrochloride\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             200 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dolutegravir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dothiepin Hydrochloride\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Doxorubicin Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg, 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Doxycycline\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Droperidol\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2.5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dutasteride\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             0.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Dydrogesterone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"E\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Efavirenz\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg, 600 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Empagliflozin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 25 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of type 2 diabetes mellitus, as a dual therapy\\n             <br/>\\n              In combination with metformin for patients with HbA1c &gt; 7% despite treatment with metformin monotherapy;\\n             <br/>\\n              In combination with a sulfonylurea for patients with HbA1c &gt; 7% despite treatment with sulfonylurea monotherapy and when metformin is contraindicated or not tolerated;\\n             <br/>\\n             2) Treatment of type 2 diabetes mellitus as a triple therapy\\n             <br/>\\n              In combination with metformin and a sulfonylurea for patients with HbA1c &gt; 7% despite treatment with optimal doses of dual therapy\\n             <br/>\\n             3) Treatment of type 2 diabetes mellitus in combination with insulin, with or without metformin\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Emtricitabine &amp; Tenofovir Disoproxil Fumarate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             In combination with other antiretroviral agents for the treatment of HIV-1 infection\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Emulsifying Ointment\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Enalapril Maleate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg, 20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Enoxaparin Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Entacapone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Entecavir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Entecavir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of nucleos(t)ide-nave patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection and evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically\\n          active disease\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ephedrine Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             30 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Epoetin Alfa\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2,000 international units/0.5 mL, 4,000 international units/0.4 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Epoetin Beta\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2,000 international units/0.3 mL, 4,000 international units/0.3 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Epoprostenol (Veletri)\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             1.5 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of pulmonary arterial hypertension (idiopathic or heritable PAH or PAH associated with connective tissue diseases) in patients with WHO Functional Class III-IV symptoms\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Eptifibatide\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Eptifibatide\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             75 mg/100 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ergometrine Maleate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mcg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ergotamine &amp; Caffeine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Caffeine 100 mg + Ergotamine Tartrate 1 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Erythromycin (as Ethyl Succinate)\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Erythromycin (as Ethyl Succinate)\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             200 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Erythromycin (as Lactobionate)\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             500 mg, 1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Erythromycin Stearate\\n            </td>\\n            <td>\\n             Enteric-coated tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Estradiol\\n            </td>\\n            <td>\\n             Vaginal tablet\\n            </td>\\n            <td>\\n             10 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Etanercept\\n            </td>\\n            <td>\\n             Prefilled syringe\\n            </td>\\n            <td>\\n             25 mg/0.5 mL, 50 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Checklist to be completed\\n             <br/>\\n             1) Treatment of adult patients with non-radiographic axial spondyloarthritis\\n             <br/>\\n             2) Treatment of juvenile idiopathic arthritis\\n             <br/>\\n             3) Treatment of adult patients with chronic plaque psoriasis\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Etanercept\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             25 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Checklist to be completed\\n             <br/>\\n             1) Treatment of adult patients with non-radiographic axial spondyloarthritis\\n             <br/>\\n             2) Treatment of juvenile idiopathic arthritis\\n             <br/>\\n             3) Treatment of adult patients with chronic plaque psoriasis\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ethambutol Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg, 400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ethanol\\n            </td>\\n            <td>\\n             Solution\\n            </td>\\n            <td>\\n             Minimum 95%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ethionamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ethyl Chloride\\n            </td>\\n            <td>\\n             Topical spray\\n            </td>\\n            <td>\\n             88 g/100 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Etoposide\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Etoposide\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             20 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Etoricoxib\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             60 mg, 90 mg, 120 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Etravirine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Everolimus\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.25 mg, 0.75 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ezetimibe\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"F\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Factor Eight Inhibitor Bypassing Activity (FEIBA)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Famotidine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fenofibrate\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             100 mg, 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fentanyl\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mcg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fentanyl\\n            </td>\\n            <td>\\n             Transdermal patch\\n            </td>\\n            <td>\\n             12 mcg/hr, 25 mcg/hr, 50 mcg/hr\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ferric Carboxymaltose\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ferrous Fumarate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ferrous Gluconate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ferrous Gluconate, Multivitamins &amp; Minerals\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             Ferrous Gluconate 250 mg + Vit B12 7.5 mcg + Vit C 50 mg + Folic Acid 1 mg + Sorbitol 25 mg + Copper Sulfate 200 mcg + Manganese Sulfate 200 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ferrous Sulphate &amp; Vitamin B1 &amp; Riboflavin &amp; Nicotinamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Ferrous Sulphate 200 mg + Vitamin B1 3 mg + Riboflavin 1.5 mg + Nicotinamide 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fexofenadine\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             6 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Filgrastim\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             30 million units/0.5 mL (300 mcg/0.5 mL), 30 million units/mL (300 mcg/mL)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Finasteride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Flecainide Acetate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluconazole\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             50 mg, 100 mg, 150 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluconazole\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             100 mg/50 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fludrocortisone Acetate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.1 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Flumazenil\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluocinolone Acetonide\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             0.003125%, 0.00625%, 0.0125%, 0.025%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluorescein Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluorescein Sodium\\n            </td>\\n            <td>\\n             Single-use eye drops\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluorouracil\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluoxetine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10 mg, 20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Flupenthixol Decanoate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 mg/mL, 40 mg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluphenazine Decanoate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             25 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluticasone Propionate\\n            </td>\\n            <td>\\n             Inhaler\\n            </td>\\n            <td>\\n             50 mcg/dose, 125 mcg/dose, 250 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Fluvoxamine Maleate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Folic Acid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Folinic Acid\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Formoterol &amp; Budesonide\\n             <br/>\\n            </td>\\n            <td>\\n             Inhaler\\n            </td>\\n            <td>\\n             Formoterol Fumarate Dihydrate 2.25 mcg/dose + Budesonide 80 mcg/dose (120 doses), Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 80 mcg/dose (120 doses), Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 160 mcg/dose (120 doses)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Formoterol &amp; Budesonide\\n            </td>\\n            <td>\\n             Powder inhaler\\n            </td>\\n            <td>\\n             Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 80 mcg/dose (60 doses), Formoterol Fumarate Dihydrate 4.5 mcg/dose + Budesonide 160 mcg/dose (120 doses), Formoterol Fumarate Dihydrate 9 mcg/dose + Budesonide 320 mcg/dose (60 doses)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Furosemide\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Furosemide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             40 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"G\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Gabapentin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             100 mg, 300 mg, 400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ganciclovir\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Gelatin Succinylated &amp; Sodium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             Gelatin Succinylated 4 g/100 mL + Sodium Chloride 0.701 g/100 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Gemcitabine\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             200 mg, 1000 mg, 2000 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Gemfibrozil\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Gentamicin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             40 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Gentamicin\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Gentian Violet\\n            </td>\\n            <td>\\n             Paint\\n            </td>\\n            <td>\\n             0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glecaprevir &amp; Pibrentasvir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Glecaprevir 100 mg + pibrentasvir 40 mg tablet\\n             <br/>\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of chronic hepatitis C (all genotypes) infection in treatment-nave, pegylated interferon plus ribavirin (with\\xa0or without sofosbuvir)-experienced and sofosbuvir plus ribavirin-experienced adults.\\n             <br/>\\n             <br/>\\n             Glecaprevir/Pibrentasvir should be used in line with the recommended treatment regimen and duration:\\n             <br/>\\n             <br/>\\n             Treatment-naive\\n             <br/>\\n              8 weeks treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or compensated cirrhosis (Child-Pugh A);\\n             <br/>\\n             <br/>\\n             Treatment-experienced\\n             <br/>\\n              8 weeks treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotypes 1,2,4,5,6) without cirrhosis\\n             <br/>\\n              12 weeks treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotypes 1,2,4,5,6) with compensated cirrhosis (Child-Pugh A)\\n             <br/>\\n              16 weeks treatment of glecaprevir/pibrentasvir for patients with hepatitis C virus (genotype 3) without cirrhosis or with compensated cirrhosis (Child-Pugh A)\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glibenclamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Gliclazide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             80 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glipizide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glucagon\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glycerol\\n            </td>\\n            <td>\\n             Rectal suppository\\n            </td>\\n            <td>\\n             1 g, 1.5 g, 2 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glycerol, Methyl Salicylate, Sodium Salicylate &amp; Thymol Compound\\n            </td>\\n            <td>\\n             Mouthwash\\n            </td>\\n            <td>\\n             Glycerol 10% + Methyl Salicylate 0.03% + Sodium Salicylate 0.52% + Thymol 0.05%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glyceryl Trinitrate\\n            </td>\\n            <td>\\n             Oral spray\\n            </td>\\n            <td>\\n             0.4 mg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glyceryl Trinitrate\\n            </td>\\n            <td>\\n             Patch\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glyceryl Trinitrate\\n            </td>\\n            <td>\\n             Sublingual tablet\\n            </td>\\n            <td>\\n             0.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Glycine\\n            </td>\\n            <td>\\n             Irrigation solution\\n            </td>\\n            <td>\\n             1.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Golimumab\\n            </td>\\n            <td>\\n             Prefilled syringe\\n            </td>\\n            <td>\\n             50 mg/0.5 mL, 100 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Checklist to be completed\\n             <br/>\\n             1) Treatment of adult patients with rheumatoid arthritis\\n             <br/>\\n             2) Treatment of adult patients with ankylosing spondylitis\\n             <br/>\\n             3) Treatment of adult patients with psoriatic arthritis\\n             <br/>\\n             4) Treatment of adult patients with non-radiographic axial spondyloarthritis\\n             <br/>\\n             5) Treatment of adult patients with ulcerative colitis\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Goserelin\\n            </td>\\n            <td>\\n             Subcutaneous injectable implant\\n            </td>\\n            <td>\\n             3.6 mg, 10.8 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             LHRH agonist is recommended:\\n             <br/>\\n             1) As primary therapy for men with locally advanced or metastatic prostate cancer\\n             <br/>\\n             2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy\\n             <br/>\\n             3) For men with prostate cancer who have a biochemical relapse\\n             <br/>\\n             LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Griseofulvin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             125 mg, 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Guaifenesin\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             100 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"H\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Haemodialysis Concentrate 35X (Acetate Salt)\\n            </td>\\n            <td>\\n             Solution\\n            </td>\\n            <td>\\n             The diluted solution contains: Na+ 140.0 mmol/L, K+ 2.60 mmol/L, Ca2+ 1.38 mmol/L, Mg2+ 0.62 mmol/L, Cl- 102 mmol/L, HCO3- 45 mmol/L\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Haemodialysis Concentrate 35X (Bicarbonate)\\n            </td>\\n            <td>\\n             Solution (comprised 2 separate 10 L canisters: acidic &amp; basic)\\n            </td>\\n            <td>\\n             Acidic concentrate: KCl 5.5 g/L, NaCl 161.0 g/L, CaCl2.2H2O 9.7 g/L, MgCl2.6H2O 3.7 g/L, CH3COOH (glacial) 8.8 g/L; Basic concentrate: NaCl 30.5 g/L, HCO3- 66.0 g/L; Final diluted solution contains: Na+ 140 mmol/L, K+ 2.0 mmol/L, Ca2+ 1.8 mmol/L,\\n          Mg2+ 0.5 mmol/L, Cl- 107.2 mmol/L, CH3COO- 4.0 mmol/L, HCO3- 35.0 mmol/L\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Haloperidol\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Haloperidol\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             2 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Haloperidol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.5 mg, 1.5 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Heparin Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1,000 units/mL, 5,000 units/mL, 25,000 units/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Heparinised Saline\\n            </td>\\n            <td>\\n             Injection (in sodium chloride 0.9%, preservative-free)\\n            </td>\\n            <td>\\n             50 international units/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hepatitis B Immunoglobulin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n              200 international units/mL (adults), 100 international units/mL (children)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Homatropine Hydrobromide\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Human Hemin\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             250 mg/10 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of acute attacks of hepatic porphyria (acute intermittent porphyria, porphyria variegata, hereditary coproporphyria)\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydralazine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 25 mg, 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydralazine Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrochlorothiazide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocolloid (carboxymethylcellulose-containing)\\n            </td>\\n            <td>\\n             Dressing\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocolloid (carboxymethylcellulose-containing)\\n            </td>\\n            <td>\\n             Gel\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocortisone\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             0.5%, 1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocortisone\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocortisone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocortisone (as Sodium Succinate)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocortisone Acetate\\n            </td>\\n            <td>\\n             Rectal foam\\n            </td>\\n            <td>\\n             10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrocortisone Acetate &amp; Clioquinol\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Hydrocortisone Acetate 1% + Clioquinol 3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrogen Peroxide\\n            </td>\\n            <td>\\n             Mouthwash\\n            </td>\\n            <td>\\n             3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydrogen Peroxide\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydroxocobalamin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of cobalamin-related remethylation pathway defect causing cobalamin C deficiency\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydroxychloroquine Sulphate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydroxychloroquine Sulphate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydroxyprogesterone Caporate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             250 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydroxyurea\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydroxyzine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hydroxyzine Hydrochloride\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             10 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hyoscine Butylbromide\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hyoscine Butylbromide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hyoscine Hydrobromide Trihydrate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             400 mcg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Hypromellose\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"I\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Ibuprofen\\n            </td>\\n            <td>\\n             Oral liquid\\n            </td>\\n            <td>\\n             100 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ibuprofen\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ifosfamide\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Imatinib (Generic)*\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             100 mg, 400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             *Generic formulation cannot be used for gastrointestinal stromal tumours (GIST) due to patent protection\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Imatinib (Generic)*\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg, 400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             *Generic formulation cannot be used for gastrointestinal stromal tumours (GIST) due to patent protection\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Imipenem &amp; Cilastatin\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             Imipenem 500 mg + Cilastatin 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Imipramine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Indometacin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Infliximab (Remsima)\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Aspart\\n            </td>\\n            <td>\\n             Injection, penfill\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Type 1 &amp; 2 diabetes mellitus\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Aspart\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Aspart &amp; Insulin Aspart Protamine\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             Insulin Aspart 30% + Insulin Aspart Protamine 70%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Detemir\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Glargine (Basaglar)\\n            </td>\\n            <td>\\n             Injection, cartridge\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Glargine (Lantus)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Glargine (Lantus)\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Glulisine\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Isophane (Human)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Isophane (Human)\\n            </td>\\n            <td>\\n             Injection, penfill\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Lispro\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Type 1 &amp; 2 diabetes mellitus\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Lispro\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Type 1 &amp; 2 diabetes mellitus\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Lispro &amp; Insulin Lispro Protamine\\n            </td>\\n            <td>\\n             Injection, penfill\\n            </td>\\n            <td>\\n             Insulin Lispro 25% + Insulin Lispro Protamine 75%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Lispro &amp; Insulin Lispro Protamine\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             Insulin Lispro 25% + Insulin Lispro Protamine 75%\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Type 1 &amp; 2 diabetes mellitus\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Lispro &amp; Insulin Lispro Protamine\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             Insulin Lispro 50% + Insulin Lispro Protamine 50%\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Type 1 &amp; 2 diabetes mellitus\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Soluble &amp; Insulin Isophane (Human)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Insulin Soluble 30% + Insulin Isophane 70%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Soluble &amp; Insulin Isophane (Human)\\n            </td>\\n            <td>\\n             Injection, penfill\\n            </td>\\n            <td>\\n             Insulin Soluble 30% + Insulin Isophane 70%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Soluble (Human)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Insulin Soluble (Human)\\n            </td>\\n            <td>\\n             Injection, penfill\\n            </td>\\n            <td>\\n             100 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Interferon Alfa-2a\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             3 million international units/0.5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Intraperitoneal Dialysis\\n            </td>\\n            <td>\\n             Solution\\n            </td>\\n            <td>\\n             Dextrose 1.5%, 2.5% or 4.25% with Ca2+ 1.25 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 95 mmol/L, Lactate 40 mmol/L; Dextrose 1.5%, 2.5% or 4.25% with Ca2+ 2.57 mmol/L, Na+ 132 mmol/L, Mg2+ 0.25 mmol/L, Cl- 96 mmol/L, Lactate 40 mmol/L\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Iodine\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             0.5%, 1.0%, 2.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Iodine Aqueous\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             Iodine 5% + Potassium iodide 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ipratropium Bromide\\n            </td>\\n            <td>\\n             Inhaler\\n            </td>\\n            <td>\\n             20 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ipratropium Bromide\\n            </td>\\n            <td>\\n             Nebulisation solution\\n            </td>\\n            <td>\\n             0.025%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Irinotecan Hydrochloride Trihydrate\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             20 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Iron (as Polymaltose)\\n            </td>\\n            <td>\\n             Oral drops\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Iron (as Polymaltose)\\n             <br/>\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Iron (as Sucrose)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Isoniazid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg, 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Isoprenaline Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.2 mg/mL, 1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Isoprenaline Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.2 mg/mL, 1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Isosorbide Dinitrate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Isosorbide Mononitrate\\n            </td>\\n            <td>\\n             Sustained-release tablet\\n            </td>\\n            <td>\\n             60 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Itraconazole\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Itraconazole\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             10 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ivabradine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 7.5 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more,\\n          and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ixekizumab\\n            </td>\\n            <td>\\n             Injection, prefilled pen\\n            </td>\\n            <td>\\n             80 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Checklist to be completed\\n             <br/>\\n             1) Treatment of adult patients with psoriatic arthritis\\n             <br/>\\n             2) Treatment of adult patients with chronic plaque psoriasis\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"K\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Kanamycin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Kaolin, Magnesium Carbonate (light) &amp; Sodium Bicarbonate\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             Kaolin 20% + Magnesium Carbonate (light) 5% + Sodium Bicarbonate 5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ketoprofen\\n            </td>\\n            <td>\\n             Enteric-coated tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ketoprofen\\n            </td>\\n            <td>\\n             Gel\\n            </td>\\n            <td>\\n             2.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"L\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             L-Arginine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)\\n             <br/>\\n             2) Treatment of urea cycle defects\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             L-Arginine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             4.2 g/20 mL, 5 g/10 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)\\n             <br/>\\n             2) Treatment of urea cycle defects\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             L-Arginine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)\\n             <br/>\\n             2) Treatment of urea cycle defects\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             L-Asparaginase\\n             <br/>\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10,000 international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             L-Citrulline\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             750 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of hyperammonemia secondary to urea cycle disorders (proximal urea cycle defect, ornithine transcarbamylase deficiency or carbamoyl phosphate synthetase deficiency).\\n             <br/>\\n             2) Acute treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             L-Citrulline\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             5 g\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of hyperammonemia secondary to urea cycle disorders (proximal urea cycle defect, ornithine transcarbamylase deficiency or carbamoyl phosphate synthetase deficiency).\\n             <br/>\\n             2) Acute treatment of mitochondrial diseases including MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes)\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             L-Isoleucine\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             100 mg/1.5 g\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of Maple Syrup Urine Disease\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             L-Valine\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             100 mg/1.5 g\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of Maple Syrup Urine Disease\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lactulose\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             3.3 g/5 mL, 3.35 g/5 mL\\n             <br/>\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lamivudine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg, 150 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lamotrigine\\n            </td>\\n            <td>\\n             Dispersible tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lamotrigine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Land Snakes Antivenom\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Latanoprost\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.005%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Leflunomide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             20 mg, 100 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of active psoriatic arthritis where other disease modifying drugs are ineffective and/ or inappropriate\\n             <br/>\\n             2) Treatment of active rheumatoid arthritis where other disease modifying drugs are ineffective and/ or inappropriate\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Letrozole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Leuprorelin Acetate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             3.75 mg, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg, 5 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             LHRH agonist is recommended:\\n             <br/>\\n             1) As primary therapy for men with locally advanced or metastatic prostate cancer\\n             <br/>\\n             2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy\\n             <br/>\\n             3) For men with prostate cancer who have a biochemical relapse\\n             <br/>\\n             LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levetiracetam\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) As a 2nd line agent for the management of epilepsy in adults and children\\n             <br/>\\n             2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levetiracetam\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) As a 2nd line agent for the management of epilepsy in adults and children\\n             <br/>\\n             2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levetiracetam\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg, 500 mg, 1 g\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) As a 2nd line agent for the management of epilepsy in adults and children\\n             <br/>\\n             2) As adjunctive therapy or monotherapy in patients who have inadequate seizure control or intolerable adverse effects with 1st line agents, or where the use of 1st line agents is contraindicated\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levocarnitine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of primary and secondary carnitine deficiency due to detoxification\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levocarnitine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 g/5 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of primary and secondary carnitine deficiency due to detoxification\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levocarnitine\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             500 mg/10 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of primary and secondary carnitine deficiency due to detoxification\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levodopa &amp; Benserazide\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             Levodopa 100 mg + Benserazide 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levodopa &amp; Benserazide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Levodopa 200 mg + Benserazide 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levodopa &amp; Benserazide\\n            </td>\\n            <td>\\n             Controlled-release capsule\\n            </td>\\n            <td>\\n             Levodopa 100 mg + Benserazide 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levodopa &amp; Carbidopa\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Levodopa 100 mg + Carbidopa 25 mg, Levodopa 250 mg + Carbidopa 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levodopa &amp; Carbidopa\\n            </td>\\n            <td>\\n             Sustained-release tablet\\n            </td>\\n            <td>\\n             Levodopa 200 mg + Carbidopa 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levodopa, Carbidopa &amp; Entacapone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Levodopa 50 mg + Carbidopa 12.5 mg + Entacapone 200 mg, Levodopa 100 mg + Carbidopa 25 mg + Entacapone 200 mg, Levodopa 150 mg + Carbidopa 37.5 mg + Entacapone 200 mg, Levodopa 200 mg + Carbidopa 50 mg + Entacapone 200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levonorgestrel &amp; Ethinylestradiol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Levonorgestrel 0.15 mg + Ethinylestradiol 0.03 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Levothyroxine Sodium\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mcg, 50 mcg, 75 mcg, 100 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine\\n            </td>\\n            <td>\\n             Topical spray\\n            </td>\\n            <td>\\n             10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine &amp; Adrenaline\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Lidocaine 2% + Adrenaline 1:80,000 (12.5 microgram/mL)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine &amp; Prilocaine\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Lidocaine 2.5% + Prilocaine 2.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine Hydrochloride\\n            </td>\\n            <td>\\n             Gel\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine Hydrochloride\\n            </td>\\n            <td>\\n             Oral solution (viscous)\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lidocaine Hydrochloride\\n            </td>\\n            <td>\\n             Injection (preservative-free)\\n            </td>\\n            <td>\\n             1%, 2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Linagliptin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             For patients with type 2 diabetes mellitus and chronic kidney disease stages 3b, 4 or 5\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Linezolid\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             2 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of patients with culture-positive vancomycin-resistant\\xa0enterococci (VRE) bloodstream\\xa0infections\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Linezolid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             600 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of patients with culture-positive vancomycin-resistant enterococci (VRE) bloodstream infections\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Liothyronine Sodium\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             20 mcg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Liquid Paraffin\\n            </td>\\n            <td>\\n             Oral emulsion\\n            </td>\\n            <td>\\n             2.5 mL/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Liquid Paraffin\\n            </td>\\n            <td>\\n             Liquid\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lisinopril\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg, 20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lithium Carbonate\\n            </td>\\n            <td>\\n             Controlled-release tablet\\n            </td>\\n            <td>\\n             400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lomustine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             40 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lopinavir &amp; Ritonavir\\n             <br/>\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             Lopinavir 80 mg/mL + Ritonavir 20 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lopinavir &amp; Ritonavir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Lopinavir 200 mg + Ritonavir 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Loratadine\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             5 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Loratadine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lorazepam\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.5 mg, 1 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Losartan Potassium\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Lovastatin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"M\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Magnesium Carbonate &amp; Sodium Bicarbonate\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             Magnesium Carbonate 150 mg/5 mL + Sodium Bicarbonate 250 mg/5 mL + Aromatic Cardamom Tincture 0.15 mL/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Magnesium Chloride Hexahydrate, Potassium Chloride &amp; Procaine Hydrochloride\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             Magnesium Chloride Hexahydrate 162.5 mg/mL (0.8 mmol/mL) + Potassium Chloride 59.5 mg/mL (0.8 mmol/mL) + Procaine Hydrochloride 13.64 mg/mL (0.05 mmol/mL)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Magnesium Sulfate\\n            </td>\\n            <td>\\n             Crystal\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Magnesium Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             49.3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Magnesium Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             49.3% (2 mmol Mg2+/mL)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Magnesium Sulfate &amp; Glycerin\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             Magnesium Sulfate 35.4% + Glycerin 1.1%\\n             <br/>\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Magnesium Trisilicate\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             Magnesium Trisilicate 5% + Magnesium Carbonate 5% + Sodium Bicarbonate 5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Malathion\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mannitol\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             20%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mebeverine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             135 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Medroxyprogesterone Acetate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Medroxyprogesterone Acetate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mefenamic Acid\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mefloquine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Melphalan\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Melphalan\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Memantine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mercaptopurine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Meropenem\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg, 1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mesalazine\\n            </td>\\n            <td>\\n             Enema\\n            </td>\\n            <td>\\n             2 g/30 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mesalazine\\n            </td>\\n            <td>\\n             Enteric-coated tablet\\n            </td>\\n            <td>\\n             250 mg, 400 mg, 500 mg, 800 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mesalazine\\n            </td>\\n            <td>\\n             Granules\\n            </td>\\n            <td>\\n             2 g, 4 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mesalazine\\n            </td>\\n            <td>\\n             Prolonged-release tablet\\n            </td>\\n            <td>\\n             500 mg, 1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mesalazine\\n            </td>\\n            <td>\\n             Suppository\\n            </td>\\n            <td>\\n             250 mg, 500 mg, 1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mesna\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mesna\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             400 mg, 600 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Metformin Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg, 500 mg, 850 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methadone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methionine\\n            </td>\\n            <td>\\n             Oral powder\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methotrexate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/2 mL, 1 g/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methotrexate\\n            </td>\\n            <td>\\n             Injection (preservative-free)\\n            </td>\\n            <td>\\n             50 mg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methotrexate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methoxsalen\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             0.01%, 0.05%, 0.1%, 0.75%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methoxsalen\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methoxsalen\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methyl Salicylate\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             10%-20%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methyl Salicylate\\n            </td>\\n            <td>\\n             Solution\\n            </td>\\n            <td>\\n             25%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methylated Spirit\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             70%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methyldopa\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             125 mg, 250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methylphenidate Hydrochloride\\n            </td>\\n            <td>\\n             Extended-release tablet\\n            </td>\\n            <td>\\n             18 mg, 27 mg, 36 mg, 54 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Attention deficit hyperactivity disorder in children and adolescents aged &lt; 18 years old\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methylphenidate Hydrochloride\\n            </td>\\n            <td>\\n             Long-acting capsule\\n            </td>\\n            <td>\\n             20 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Attention deficit hyperactivity disorder in children and adolescents aged &lt; 18 years old\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methylphenidate Hydrochloride (Medikinet)\\n            </td>\\n            <td>\\n             Modified-release capsule\\n            </td>\\n            <td>\\n             5 mg, 10 mg, 20 mg, 30 mg, 40 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methylphenidate Hydrochloride\\n            </td>\\n            <td>\\n             Sustained-release tablet\\n            </td>\\n            <td>\\n             20 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Attention deficit hyperactivity disorder in children and adolescents aged &lt; 18 years old\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methylphenidate Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Methylprednisolone (as Sodium Succinate)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             62.5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Metoclopramide Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             5mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Metoclopramide Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Metronidazole\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Metronidazole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Miconazole\\n            </td>\\n            <td>\\n             Oral gel\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Miconazole Nitrate\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Midazolam\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             5 mg/mL, 5 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Midodrine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mirtazapine\\n            </td>\\n            <td>\\n             Oral disintegrating tablet\\n            </td>\\n            <td>\\n             15 mg, 30 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mirtazapine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             30 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mitomycin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mitoxantrone\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Moclobemide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             150 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mometasone Furoate\\n            </td>\\n            <td>\\n             Nasal spray\\n            </td>\\n            <td>\\n             0.05%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Morphine Sulfate\\n            </td>\\n            <td>\\n             Controlled-release tablet\\n            </td>\\n            <td>\\n             10 mg, 30 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Morphine Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Morphine\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             1 mg/mL, 2 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Morphine\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Multivitamin for Paediatrics\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             A combination preparation of vitamins, minerals and/or nutrients, which includes at least 3 of the following: Ascorbic acid, Riboflavine, Nicotinamide, Thiamine, Pyridoxine, Calciferol, Cyanocobalamin, Vitamin A\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mycophenolate Mofetil\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mycophenolate Mofetil\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mycophenolate Mofetil\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Mycophenolate Sodium (Myfortic)\\n            </td>\\n            <td>\\n             Enteric-coated Tablet\\n            </td>\\n            <td>\\n             180 mg, 360 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of organ rejection in patients who have received a kidney transplant and are unable to tolerate mycophenolate mofetil due to gastrointestinal adverse effects\\n             <br/>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"N\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Naloxone Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.4 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nandrolone Decanoate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             25 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Naphazoline Hydrochloride &amp; Pheniramine Maleate\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             Naphazoline Hydrochloride 0.025% + Pheniramine Maleate 0.3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Neomycin Sulfate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Neomycin, Polymyxin B &amp; Dexamethasone\\n            </td>\\n            <td>\\n             Ear drops\\n            </td>\\n            <td>\\n             Neomycin Sulfate 6,500 international units/mL + Polymyxin B Sulfate 10,000 international units/mL + Dexamethasone Sodium Metasulfobenzoate 1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Neostigmine Metilsulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2.5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Netupitant &amp; Palonosetron\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             Netupitant 300 mg &amp; Palonosetron 0.5 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nevirapine\\n            </td>\\n            <td>\\n             Extended-release tablet\\n            </td>\\n            <td>\\n             400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nevirapine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nicotinic Acid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nifedipine\\n            </td>\\n            <td>\\n             Extended-release tablet\\n            </td>\\n            <td>\\n             30 mg, 60 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nifedipine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nifedipine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nitrazepam\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nitrofurantoin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Norepinephrine\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             4 mg/4 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Norethisterone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nortriptyline\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10 mg, 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nystatin\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             100,000 units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Nystatin\\n            </td>\\n            <td>\\n             Vaginal tablet\\n            </td>\\n            <td>\\n             100,000 units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"O\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Olanzapine\\n            </td>\\n            <td>\\n             Oral disintegrating tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Olanzapine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Olive Oil\\n            </td>\\n            <td>\\n             Ear drops\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Omalizumab\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             150 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Checklist to be completed.\\n             <br/>\\n             As an add-on therapy to H\\n             <sub>\\n              1\\n             </sub>\\n             -antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS7) of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H\\n             <sub>\\n              1\\n             </sub>\\n             -antihistamines.\\n             <br/>\\n             <br/>\\n             A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Omeprazole\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Omeprazole\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             40mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ondansetron\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ondansetron\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             8 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oral Rehydration Salts\\n            </td>\\n            <td>\\n             Effervescent tablet\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oral Rehydration Salts\\n            </td>\\n            <td>\\n             Oral powder for reconstitution\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oxaliplatin\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             50 mg/10 mL, 100 mg/50 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oxaliplatin\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             50 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oxybutynin Chloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oxymetazoline Hydrochloride\\n            </td>\\n            <td>\\n             Nasal drops\\n            </td>\\n            <td>\\n             0.01%, 0.025%, 0.05%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oxymetazoline Hydrochloride\\n            </td>\\n            <td>\\n             Nasal spray\\n            </td>\\n            <td>\\n             0.025%, 0.05%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oxytocin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 international units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Oxytocin &amp; Ergometrine Maleate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Oxytocin 5 international units/mL + Ergometrine Maleate 0.5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"P\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Paclitaxel\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             6 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pamidronate Disodium\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             30 mg, 90 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of metastatic bone lesions from breast cancer and advanced multiple myeloma\\n             <br/>\\n             2) Treatment of hypercalcaemia of malignancy\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pancuronium Bromide\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             2 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pantopazole\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             40 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Paracetamol\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             500 mg/50 mL, 1,000 mg/100 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Paracetamol\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             120 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Paracetamol\\n            </td>\\n            <td>\\n             Rectal suppository\\n            </td>\\n            <td>\\n             125 mg, 250 mg, 325 mg, 650 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Paracetamol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             120 mg, 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Paracetamol &amp; Orphenadrine Citrate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Paracetamol 450 mg + Orphenadrine Citrate 35 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Paraffin\\n            </td>\\n            <td>\\n             Liquid\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Paraffin Soft &amp; Paraffin Liquid\\n            </td>\\n            <td>\\n             Emulsion\\n            </td>\\n            <td>\\n             Soft Paraffin 50% + Liquid Paraffin 50%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Peginterferon Alfa-2a\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             135 mcg/0.5 mL, 180 mcg/0.5 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment, in combination with ribavirin, of chronic hepatitis C infection in naive adult patients and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin\\n             <br/>\\n             2) Treatment for a duration of up to 48 weeks, in adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B infection with compensated liver disease and evidence of viral replication and liver inflammation.\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Penicillamine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pethidine Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenazopyridine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenobarbital Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             200 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenobarbitone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 30 mg, 60 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenol (in almond oil)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenoxymethylpenicillin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenylephrine Hydrochloride\\n            </td>\\n            <td>\\n             Single-use eye drops\\n            </td>\\n            <td>\\n             2.5%, 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenylephrine Hydrochloride\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             2.5%, 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenytoin\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             125 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenytoin Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phenytoin Sodium\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             30 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Physostigmine Salicylate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Phytomenadione\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pilocarpine Hydrochloride\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             2%, 4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pilocarpine Nitrate\\n            </td>\\n            <td>\\n             Single-use eye drops\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Piperacillin &amp; Tazobactam\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Piperacillin 4 g + Tazobactam 0.5 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Piroxicam\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10 mg, 20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Plasma-derived Factor VIII\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             250 international units, 500 international units, 1000 international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Plasma-derived Factor VIII &amp; Von Willebrand Factor\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Plasma-derived Factor VIII 250 international units, 500 international units, 1000 international units + Von Willebrand Factor range 100 international units to 3200 international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Podophyllum Resin\\n            </td>\\n            <td>\\n             Paint\\n            </td>\\n            <td>\\n             0.25%, 0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Poractant alfa\\n            </td>\\n            <td>\\n             Intratracheal suspension\\n            </td>\\n            <td>\\n             120 mg/1.5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Posaconazole\\n            </td>\\n            <td>\\n             Delayed-release tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Posaconazole\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             40 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             For prophylaxis of invasive fungal infections in high risk patients (such as anticipated to have prolonged neutropenia) and haematopoietic stem cell transplant recipients\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Chloride\\n            </td>\\n            <td>\\n             Slow-release tablet\\n            </td>\\n            <td>\\n             600 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Chloride\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             500 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Chloride\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             7.45%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             0.1 mmol/mL, 0.2 mmol/mL, 0.4 mmol/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Chloride &amp; Sodium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             Potassium Chloride 0.15% + Sodium Chloride 0.9%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Citrate\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             500 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Permanganate\\n            </td>\\n            <td>\\n             Crystals\\n            </td>\\n            <td>\\n             100%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Permanganate\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Potassium Phosphate Monobasic\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             1 mmol/mL (0.1361 g/mL)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Povidone-Iodine\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pralidoxime Chloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg/20 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pramipexole Dihydrochloride Monohydrate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.125 mg, 1 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pravastatin Sodium\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Prazosin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Prednisolone\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             10 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Prednisolone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1 mg, 5 mg, 20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Primaquine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             7.5 mg, 15 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Probenecid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Procainamide Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Procaine Hydrochloride\\n            </td>\\n            <td>\\n             Lotion (in spirit 70%)\\n            </td>\\n            <td>\\n             2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Procarbazine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Prochlorperazine Maleate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Prochlorperazine Mesilate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             12.5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Progesterone\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Promethazine Hydrochloride\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             5 mg/5mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Promethazine Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             25 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Promethazine Hydrochloride\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             5 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Promethazine Theoclate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Propantheline Bromide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             15 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Propafenone Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             150 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Proparacaine Hydrochloride\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Propofol\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Propranolol Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Propranolol Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 40 mg, 80 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Propylene Glycol\\n            </td>\\n            <td>\\n             Solution\\n            </td>\\n            <td>\\n             40%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Propylthiouracil\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Protamine Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1% (10 mg/mL)\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pyrazinamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pyridostigmine Bromide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 60 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pyridoxine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Pyrimethamine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"Q\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Quetiapine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg, 100 mg, 200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Quinine Sulfate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"R\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Rabies Virus Vaccine (Inactivated)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Minimum 2.5 international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ranitidine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Raltegravir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             400 mg, 600 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             In combination with other antiretroviral agents for the treatment of HIV-1 infection\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Recombinant Factor VIII (Xyntha)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             250 international units, 500 international units, 1000 international units, 2000 international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ribavirin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of chronic hepatitis C infection (all genotypes)\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ribavirin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of chronic hepatitis C infection (all genotypes)\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rifampicin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             150 mg, 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rifampicin\\n            </td>\\n            <td>\\n             Suspension\\n            </td>\\n            <td>\\n             100 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rifaximin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             550 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rilpivirine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Risedronate Sodium\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg, 35 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) For patients with osteoporosis (T-score  -2.5)\\n             <br/>\\n             2) For patients with osteopenia (T-score  -1.5) and a history of non-trauma induced fracture\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Risperidone\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Risperidone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.5 mg, 1 mg, 2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ritonavir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rituximab (MabThera)\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             100 mg/10 mL, 500 mg/50 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of patients with CD20 positive diffuse large B cell lymphoma\\n             <br/>\\n             2) Treatment of patients with CD20 positive follicular non-Hodgkin\\'s lymphoma\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rituximab biosimilar (Truxima)\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             100 mg/10 mL, 500 mg/50 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rivaroxaban\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             15 mg, 20 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1)\\xa0Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA\\n             <sub>\\n              2\\n             </sub>\\n             DS\\n             <sub>\\n              2\\n             </sub>\\n             -VASc score of 1 or more for men, and 2 or more for women\\n             <br/>\\n             *This excludes patients with rheumatic mitral stenosis or prosthetic heart valves\\n             <br/>\\n             2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Rivastigmine\\n            </td>\\n            <td>\\n             Transdermal patch\\n            </td>\\n            <td>\\n             4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hr\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Rivastigmine patch formulation (4.6 mg/24 hr and 9.5 mg/24 hr) for the treatment of moderately severe dementia associated with Parkinson\\'s disease in patients who have behavioural symptoms\\n             <br/>\\n             2) Rivastigmine patch formulation (4.6 mg/24 hr, 9.5 mg/24 hr and 13.3 mg/24 hr) for the treatment of moderately severe dementia associated with Alzheimer\\'s disease in patients who have behavioural symptoms\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ropinirole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.25 mg, 1 mg, 2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"S\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Salbutamol\\n            </td>\\n            <td>\\n             Inhaler\\n            </td>\\n            <td>\\n             100 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salbutamol\\n            </td>\\n            <td>\\n             Nebulisation solution\\n            </td>\\n            <td>\\n             0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salbutamol\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             5 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salbutamol\\n            </td>\\n            <td>\\n             Oral liquid\\n            </td>\\n            <td>\\n             2 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salbutamol\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salicylic Acid\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             2%, 20%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salicylic Acid\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             1%, 2%, 5%, 10%, 20%, 40%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salicylic Acid &amp; Lactic Acid\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             Salicylic Acid 16.7% + Lactic Acid 16.7% Collodion\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salmeterol &amp; Fluticasone Propionate\\n            </td>\\n            <td>\\n             Inhaler\\n            </td>\\n            <td>\\n             Salmeterol 25 mcg/dose + Fluticasone Propionate 50 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 125 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 250 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Salmeterol &amp; Fluticasone Propionate\\n            </td>\\n            <td>\\n             Powder inhaler\\n            </td>\\n            <td>\\n             Salmeterol 50 mcg/dose + Fluticasone Propionate 100 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 250 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 500 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sea Snake Venom Antiserum\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             1,000 units/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Selenium Sulfide\\n            </td>\\n            <td>\\n             Topical suspension\\n            </td>\\n            <td>\\n             2.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sennosides\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             7.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sertraline\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sevelamer Carbonate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             800 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of hyperphosphataemia in patients with chronic kidney disease who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia.\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Silicone Cream\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Dimethicone 10%, Chlorocresol 0.1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Simeticone\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Simvastatin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sirolimus\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             0.5 mg, 1 mg, 2 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             For kidney transplant immunosuppression in patients with:\\n             <br/>\\n             1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR\\n             <br/>\\n             2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR\\n             <br/>\\n             3) History of CNI drug hypersensitivity\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sirolimus\\n            </td>\\n            <td>\\n             Oral solution\\n            </td>\\n            <td>\\n             1 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             For kidney transplant immunosuppression in patients with:\\n             <br/>\\n             1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR\\n             <br/>\\n             2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR\\n             <br/>\\n             3) History of CNI drug hypersensitivity\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Alginate, Sodium Bicarbonate &amp; Calcium Carbonate\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             Sodium Alginate 500 mg/10 mL + Sodium Bicarbonate 267 mg/10 mL + Calcium Carbonate 160 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Benzoate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2 g/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Benzoate\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             5 g, 1 kg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Benzoate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Bicarbonate\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             4.2%, 8.4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Bicarbonate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             4.2%, 8.4%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Bicarbonate\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Bicarbonate\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             Minimum 99%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Bicarbonate &amp; Sodium Chloride\\n            </td>\\n            <td>\\n             Powder\\n            </td>\\n            <td>\\n             9 parts Sodium Bicarbonate + 1 part Sodium Chloride\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Calcium Edetate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             500 mg/10 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             0.45%, 0.9%, 3%, 20%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Chloride\\n            </td>\\n            <td>\\n             Irrigation solution\\n            </td>\\n            <td>\\n             0.9%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Chloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.45%, 0.9%, 3%, 20%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Chloride\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.9%, 5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Chloride\\n            </td>\\n            <td>\\n             Eye ointment\\n            </td>\\n            <td>\\n             5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Chloride &amp; Dextrose\\n            </td>\\n            <td>\\n             Sustained-release tablet\\n            </td>\\n            <td>\\n             Sodium Chloride 500 mg + Dextrose 200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Chloride, Calcium Chloride Dihydrate &amp; Potassium Chloride\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             Sodium Chloride 8.6 g/L + Calcium Chloride Dihydrate 0.33 g/L + Potassium Chloride 0.3 g/L\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Nitrite\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Nitroprusside\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/2 ml\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Polystyrene Sulfonate\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             15 g/60 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Polystyrene Sulfonate\\n            </td>\\n            <td>\\n             Powder for oral suspension\\n            </td>\\n            <td>\\n             99%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Tetradecyl Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1%, 3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Thiosulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             25%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Valproate\\n            </td>\\n            <td>\\n             Controlled-release tablet\\n            </td>\\n            <td>\\n             200 mg, 300 mg, 500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Valproate\\n            </td>\\n            <td>\\n             Enteric-coated tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Valproate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sodium Valproate\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             200 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sofosbuvir &amp; Velpatasvir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Sofosbuvir 400 mg + Velpatasvir 100 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of chronic hepatitis C infection (all genotypes) in treatment-nave, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults.\\n             <br/>\\n             <br/>\\n             Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration:\\n             <br/>\\n              12 weeks treatment of sofosbuvir/velpatasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or with compensated cirrhosis (Child-Pugh A). For patients with genotype 3,\\xa0the addition of ribavirin may be considered in patients who are treatment-experienced or have compensated cirrhosis (Child-Pugh A).\\n             <br/>\\n              12 weeks treatment of sofosbuvir/velpatasvir in combination with ribavirin for patients with hepatitis C virus (all\\xa0genotypes) with decompensated cirrhosis (Child-Pugh B or C).\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Solifenacin Succinate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Somatostatin (as Acetate)\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             3 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Somatropin\\n            </td>\\n            <td>\\n             Prefilled pen\\n            </td>\\n            <td>\\n             5 mg/1.5 mL, 10 mg/1.5 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of children with short stature due to conditions associated with growth failure\\n             <br/>\\n             *Somatropin is not recommended for the treatment of idiopathic short stature\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Somatropin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             3.33 mg, 4 mg, 6 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of children with short stature due to conditions associated with growth failure\\n             <br/>\\n             *Somatropin is not recommended for the treatment of idiopathic short stature\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sotalol hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             80 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Spironolactone\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Stiripentol\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg, 500 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of status epilepticus in Dravet syndrome\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Stiripentol\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             250 mg, 500 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Treatment of status epilepticus in Dravet syndrome\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Streptokinase\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             1.5 million international units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Streptomycin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulfadiazine Silver\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulfamethoxazole &amp; Trimethoprim\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             Sulfamethoxazole 80 mg/mL + Trimethoprim 16 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulfamethoxazole &amp; Trimethoprim\\n            </td>\\n            <td>\\n             Suspension\\n            </td>\\n            <td>\\n             Trimethoprim 40 mg/5 mL + Sulphamethoxazole 200 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulfamethoxazole &amp; Trimethoprim\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Trimethoprim 20 mg + Sulphamethoxazole 100 mg, Trimethoprim 80 mg + Sulphamethoxazole 400 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulfasalazine\\n            </td>\\n            <td>\\n             Enteric-coated tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulphur &amp; Salicylic Acid\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Sulphur 4% + Salicylic Acid 2%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulphur, Resorcinol &amp; Calamine\\n            </td>\\n            <td>\\n             Lotion\\n            </td>\\n            <td>\\n             Sulphur 4% + Resorcinol 2% + Calamine 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulphur, Zinc Oxide, Resorcinol &amp; Calamine\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             Sulphur 4% + Zinc Oxide 8% + Resorcinol 2% + Calamine 8%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sulpiride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Sumatriptan\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Suxamethonium Chloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"T\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Tacrolimus\\n            </td>\\n            <td>\\n             Prolonged-release capsule\\n            </td>\\n            <td>\\n             0.5 mg, 1 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tacrolimus\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             0.5 mg, 1 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tacrolimus\\n            </td>\\n            <td>\\n             Concentrate for infusion\\n            </td>\\n            <td>\\n             5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tamoxifen\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg, 20 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Telmisartan\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             40 mg, 80 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Temozolomide\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             20 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tenofovir Disoproxil Fumarate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Terazosin\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             2 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Testosterone Cipionate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tetanus Immunoglobulin (Human)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             250 units/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tetanus Toxoid Vaccine\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Minimum 40 international units/0.5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tetracycline Hydrochloride\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             3%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tetracycline Hydrochloride\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Thalidomide\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Theophylline\\n            </td>\\n            <td>\\n             Sustained-release tablet\\n            </td>\\n            <td>\\n             125 mg, 200 mg, 250 mg, 300 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Theophylline\\n            </td>\\n            <td>\\n             Syrup\\n            </td>\\n            <td>\\n             80 mg/15 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Thiamine Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg/2 mL, 100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Thiamine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Thiopental Sodium\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             0.5 g, 1 g\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Thrombin\\n            </td>\\n            <td>\\n             Topical solution\\n            </td>\\n            <td>\\n             5,000 international units/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ticagrelor\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             90 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             Prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in adults with\\xa0acute coronary syndromes, that is, people:\\n             <br/>\\n              with ST-segment-elevation myocardial infarction (STEMI); or\\n             <br/>\\n              with non-ST-segment-elevation myocardial infarction (NSTEMI); or\\n             <br/>\\n              with unstable angina requiring hospitalisation - defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the following characteristics:\\n             <br/>\\n             - age 60 years and older;\\n             <br/>\\n             - previous myocardial infarction;\\n             <br/>\\n             - previous coronary artery bypass grafting (CABG);\\n             <br/>\\n             - coronary artery disease with stenosis of 50% or more in at least two vessels;\\n             <br/>\\n             - previous ischaemic stroke;\\n             <br/>\\n             - previous transient ischaemic attack;\\n             <br/>\\n             - carotid stenosis of at least 50%;\\n             <br/>\\n             - cerebral revascularisation;\\n             <br/>\\n             - diabetes mellitus;\\n             <br/>\\n             - peripheral arterial disease; or\\n             <br/>\\n             - chronic renal dysfunction, defined as a creatinine clearance of less than 60 ml per minute per 1.73m\\n             <sup>\\n              2\\n             </sup>\\n             of body surface area.\\n             <br/>\\n             <br/>\\n             Ticagrelor should be used in combination with low-dose aspirin for up to 12 months.\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ticlopidine Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Timolol Maleate\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.25%, 0.5%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tioguanine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             40 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tolbutamide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tolterodine Tartrate\\n            </td>\\n            <td>\\n             Extended-release capsule\\n            </td>\\n            <td>\\n             4 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tolterodine Tartrate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1 mg, 2 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Topiramate\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             25 mg, 50 mg, 100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tramadol Hydrochloride\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tramadol Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tranexamic Acid\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             100 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tranexamic Acid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Trastuzumab Biosimilar (Ogivri)\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             440 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n             <br/>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tretinoin\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Triamcinolone Acetonide\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Triamcinolone Acetonide\\n            </td>\\n            <td>\\n             Nasal spray\\n            </td>\\n            <td>\\n             55 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Triamterene &amp; Hydrochlorothiazide\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Triamterene 50 mg + Hydrochlorothiazide 25 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Trifluoperazine\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Trimethoprim\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             50 mg/5 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Trimethoprim\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tropicamide\\n            </td>\\n            <td>\\n             Eye drops\\n            </td>\\n            <td>\\n             0.5%, 1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Tropicamide\\n            </td>\\n            <td>\\n             Single-use eye drops\\n            </td>\\n            <td>\\n             1%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"U\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Umeclidinium\\n            </td>\\n            <td>\\n             Powder inhaler\\n            </td>\\n            <td>\\n             62.5 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Umeclidinium &amp; Vilanterol\\n            </td>\\n            <td>\\n             Powder inhaler\\n            </td>\\n            <td>\\n             Umeclidinium 62.5 mcg/dose + Vilanterol 25 mcg/dose\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Urea\\n            </td>\\n            <td>\\n             Cream\\n            </td>\\n            <td>\\n             5%, 10%\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ursodeoxycholic Acid\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             250 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ursodeoxycholic Acid\\n            </td>\\n            <td>\\n             Suspension\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Ursodeoxycholic Acid\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"V\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Valganciclovir\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             450 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Valsartan\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             80 mg, 160 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Vancomycin\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             500 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Vasopressin\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             20 pressor units/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Venlafaxine\\n            </td>\\n            <td>\\n             Extended-release capsule\\n            </td>\\n            <td>\\n             75 mg, 150 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Verapamil Hydrochloride\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             2.5 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Verapamil Hydrochloride\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             40 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Vinblastine Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             10 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Vincristine Sulfate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             1 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Vitamin A\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             10,000 units\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Vitamin B Complex\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             Thiamine Hydrochloride 10 mg/2 mL + Sodium Riboflavin Phosphate 4 mg/2 mL + Nicotinic Acid 40 mg/2 mL + Panthenol 6 mg/2 mL + Biotin 5 mg/2 mL + Pyridoxine Hydrochloride 4 mg/2 mL + Cyanocobalamin 8 mcg/2 mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Vitamin B Complex\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             Thiamine 3 mg + Riboflavine 1.5 mg + Nicotinamide 10 mg + Pyridoxine 0.5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Voriconazole\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             200 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1)\\xa0Treatment of invasive aspergillosis\\n             <br/>\\n             2) Treatment of candidaemia in non-neutropenic patients\\n             <br/>\\n             3) Treatment of fluconazole-resistant candidiasis\\n             <br/>\\n             4) Treatment of serious infections from Scedosporium and Fusarium species\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Voriconazole\\n            </td>\\n            <td>\\n             Oral suspension\\n            </td>\\n            <td>\\n             40 mg/mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1)\\xa0Treatment of invasive aspergillosis\\n             <br/>\\n             2) Treatment of candidaemia in non-neutropenic patients\\n             <br/>\\n             3) Treatment of fluconazole-resistant candidiasis\\n             <br/>\\n             4) Treatment of serious infections from Scedosporium and Fusarium species\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Voriconazole\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             50 mg, 200 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1)\\xa0Treatment of invasive aspergillosis\\n             <br/>\\n             2) Treatment of candidaemia in non-neutropenic patients\\n             <br/>\\n             3) Treatment of fluconazole-resistant candidiasis\\n             <br/>\\n             4) Treatment of serious infections from Scedosporium and Fusarium species\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"W\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Warfarin Sodium\\n            </td>\\n            <td>\\n             Tablet\\n            </td>\\n            <td>\\n             1 mg, 3 mg, 5 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             White Soft Paraffin\\n            </td>\\n            <td>\\n             Ointment\\n            </td>\\n            <td>\\n             -\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"Y\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n          </tbody>\\n         </table>\\n        </div>\\n        <div class=\"tableList\" id=\"Z\">\\n         <table>\\n          <thead>\\n           <tr>\\n            <th width=\"23.19%\">\\n             Active Ingredient(s)\\n            </th>\\n            <th width=\"15.51%\">\\n             Dosage Form\\n            </th>\\n            <th width=\"19.92%\">\\n             Strength(s)\\n            </th>\\n            <th width=\"10.67%\">\\n             Subsidy Class\\n            </th>\\n            <th>\\n             Clinical Indication (where applicable)\\n            </th>\\n           </tr>\\n          </thead>\\n          <tbody>\\n           <tr>\\n            <td>\\n             Zidovudine\\n            </td>\\n            <td>\\n             Capsule\\n            </td>\\n            <td>\\n             100 mg\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Zoledronic Acid\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             5 mg/100 mL\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) For patients with osteoporosis (T score  -2.5) and who are unable to tolerate or follow the administration instructions for oral bisphosphonates\\n             <br/>\\n             2) For patients with FRAX of  20 for major osteoporotic fractures and  3 for hip fractures and who are unable to tolerate or follow the administration instructions for oral bisphosphonates\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Zoledronic Acid\\n            </td>\\n            <td>\\n             Infusion\\n            </td>\\n            <td>\\n             4 mg\\n            </td>\\n            <td>\\n             MAF\\n            </td>\\n            <td>\\n             1) Treatment of metastatic bone lesions from solid tumours and multiple myeloma\\n             <br/>\\n             2) Treatment of hypercalcaemia of malignancy\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Zuclopenthixol Acetate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             50 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n           <tr>\\n            <td>\\n             Zuclopenthixol Decanoate\\n            </td>\\n            <td>\\n             Injection\\n            </td>\\n            <td>\\n             200 mg/mL\\n            </td>\\n            <td>\\n             SDL\\n            </td>\\n            <td>\\n            </td>\\n           </tr>\\n          </tbody>\\n         </table>\\n        </div>\\n       </div>\\n       <div class=\"sfContentBlock\">\\n        <h2>\\n         Frequently Asked Questions\\n        </h2>\\n        <div class=\"accordion-list\">\\n         <p style=\"margin-top:25px\">\\n          <a class=\"expand\" href=\"#\">\\n           Expand All\\n          </a>\\n          |\\n          <a class=\"collapses\" href=\"#\">\\n           Collapse All\\n          </a>\\n         </p>\\n         <h4 class=\"accordion\">\\n          What if my drug isn\\'t listed?\\n         </h4>\\n         <div class=\"show-more\">\\n          <p>\\n           In exceptional cases, MAF can also support HSA-registered drugs that are not on the SDL or MAF list, on a case-by-case basis.\\n          </p>\\n         </div>\\n         <h4 class=\"accordion\">\\n          How do I apply?\\n         </h4>\\n         <div class=\"show-more\">\\n          <p>\\n           Please approach a Medical Social Worker (MSW) at the public acute hospital, specialist outpatient clinic or polyclinic where you are receiving treatment. They will be able to advise you further.\\n          </p>\\n         </div>\\n        </div>\\n        <br/>\\n       </div>\\n      </div>\\n     </section>\\n     <div class=\"scroll-top--container\">\\n      <div class=\"row\">\\n       <div class=\"columns large-12 medium-12 small-12\">\\n        <a class=\"scroll--top\" href=\"javascript:void(0)\">\\n         <i aria-hidden=\"true\" class=\"fa fa-chevron-up\">\\n         </i>\\n        </a>\\n       </div>\\n      </div>\\n     </div>\\n    </section>\\n   </main>\\n   <footer>\\n    <div class=\"sfContentBlock\">\\n     <div class=\"footer__top-section\">\\n      <div class=\"container\">\\n       <div class=\"row\">\\n        <div class=\"col-md-12\">\\n         <h4>\\n          Ministry of Health\\n         </h4>\\n        </div>\\n       </div>\\n       <div class=\"row\">\\n        <div class=\"col-md-9\">\\n         <ul class=\"footer__links\">\\n          <li>\\n           Public\\n           <ul>\\n            <li>\\n             <a href=\"/news-highlights\">\\n              News Highlights\\n             </a>\\n            </li>\\n            <li>\\n             <a href=\"/cost-financing/healthcare-schemes-subsidies\">\\n              Schemes &amp; Subsidies\\n             </a>\\n             <ul>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/cost-financing/fee-benchmarks-and-bill-amount-information\">\\n                Fee Benchmarks and Bill Amount Information\\n               </a>\\n              </li>\\n             </ul>\\n            </li>\\n            <li>\\n             <a href=\"http://hcidirectory.sg/hcidirectory/ \">\\n              Healthcare Locator\\n             </a>\\n             <ul>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/home/search-for-healthcare-institutions\">\\n                Search for Healthcare Institutions\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/hpp/all-healthcare-professionals/healthcare-professionals-search \">\\n                Search for Healthcare Professionals\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/suspensions-revocations-from-healthcare-financing-schemes \">\\n                Suspensions/Revocations from Healthcare Financing Schemes\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/enforcement-actions-for-breaches-of-regulatory-requirements \">\\n                Enforcement Actions for Breaches of Regulatory Requirements\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/upcoming-and-completed-healthcare-facilities\">\\n                Upcoming and Completed Healthcare Facilities\\n               </a>\\n              </li>\\n             </ul>\\n            </li>\\n            <li>\\n             <a href=\"https://www.moh.gov.sg/diseases-updates/being-prepared-for-a-pandemic \">\\n              Disease Updates\\n             </a>\\n             <ul>\\n              <li>\\n               <a class=\"\" href=\"https://www.moh.gov.sg/resources-statistics/infectious-disease-statistics/2021/weekly-infectious-diseases-bulletin\" target=\"\" title=\"\">\\n                Weekly Infectious Diseases Bulletin\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/diseases-updates\">\\n                Overview of Diseases\\n               </a>\\n              </li>\\n             </ul>\\n            </li>\\n            <li>\\n             <a href=\"/resources-statistics\">\\n              Resources &amp; Statistics\\n             </a>\\n             <ul>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/e-consultation\">\\n                E-Consultation\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/research-grants\">\\n                Research Grants\\n               </a>\\n              </li>\\n             </ul>\\n            </li>\\n            <li>\\n             <a href=\"https://saml.singpass.gov.sg/spauth/login/eservloginpage?URL=%2FFIM%2Fsps%2FSingpassIDPFed%2Fsaml20%2Flogininitial%3FRequestBinding%3DHTTPArtifact%26ResponseBinding%3DHTTPArtifact%26PartnerId%3Dhttps%3A%2F%2Fhealth1.auth.sg%2Foam%2Ffed%26Target%3Dhttp%253A%252F%252Feservices.healthhub.sg%252Fidp%252F%253Fs%253Dappointments%2526target%253D%252FAppointments%252FProfiles%253Frel%253Dself%2526ssaf%253D0%26NameIdFormat%3Demail%26esrvcID%3DHPB-HH-SP&amp;TAM_OP=login \">\\n              My Health Record\\n             </a>\\n             <ul>\\n              <li>\\n               <a href=\"https://www.healthhub.sg/myhealth#ChildrenHealth\">\\n                Children\\'s Health\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.healthhub.sg/myhealth#PersonalHealth\">\\n                Personal Health\\n               </a>\\n              </li>\\n             </ul>\\n            </li>\\n           </ul>\\n          </li>\\n          <li>\\n           Healthcare Professionals\\n           <ul>\\n            <li>\\n             <a href=\"/licensing-and-regulation/regulations-guidelines-and-circulars\">\\n              Licensing &amp; Regulation\\n             </a>\\n            </li>\\n            <li>\\n             <a href=\"/hpp/all-healthcare-professionals\">\\n              Healthcare Professionals Portal\\n             </a>\\n             <ul>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/hpp/dentists\">\\n                Dentist\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/hpp/tcm-practitioners\">\\n                TCM Practitioner\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/hpp/pharmacists\">\\n                Pharmacist\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/hpp/allied-health-professionals\">\\n                Allied Health Professionals\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/hpp/nurses\">\\n                Nurse\\n               </a>\\n              </li>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/hpp/doctors \">\\n                Doctor\\n               </a>\\n              </li>\\n             </ul>\\n            </li>\\n            <li>\\n             <a href=\"https://www.moh.gov.sg/hpp/all-healthcare-professionals/guidelines \">\\n              Policies &amp; Guidelines\\n             </a>\\n             <ul>\\n              <li>\\n               <a href=\"https://www.moh.gov.sg/policies-and-legislation\">\\n                Legislation\\n               </a>\\n              </li>\\n             </ul>\\n            </li>\\n           </ul>\\n          </li>\\n          <li>\\n           Who We Are\\n           <ul>\\n            <li>\\n             <a href=\"/about-moh\">\\n              About MOH\\n             </a>\\n            </li>\\n            <li>\\n             <a href=\"/home/our-healthcare-system\">\\n              Our Healthcare System\\n             </a>\\n            </li>\\n            <li>\\n             <a href=\"https://www.moh.gov.sg/about-moh/senior-management \">\\n              Senior Management\\n             </a>\\n            </li>\\n           </ul>\\n          </li>\\n         </ul>\\n        </div>\\n        <div class=\"col-md-3\">\\n         <ul class=\"footer__social-links\">\\n          <li>\\n           <a href=\"https://www.facebook.com/sghealthministry/\" rel=\"noreferrer noopener\" target=\"_blank\">\\n            <i aria-hidden=\"true\" class=\"sgds-icon sgds-icon-facebook-alt\">\\n            </i>\\n            <span style=\"display:none\">\\n             facebook\\n            </span>\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"https://www.instagram.com/moh_singapore/\" rel=\"noreferrer noopener\" target=\"_blank\">\\n            <i aria-hidden=\"true\" class=\"sgds-icon sgds-icon-instagram\">\\n            </i>\\n            <span style=\"display:none\">\\n             youtube\\n            </span>\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"https://twitter.com/sporemoh?lang=en\" rel=\"noreferrer noopener\" target=\"_blank\">\\n            <i aria-hidden=\"true\" class=\"sgds-icon sgds-icon-twitter\">\\n            </i>\\n            <span style=\"display:none\">\\n             twitter\\n            </span>\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"https://www.youtube.com/user/MOHSingapore?gl=SG&amp;hl=en-GB\" rel=\"noreferrer noopener\" target=\"_blank\">\\n            <i aria-hidden=\"true\" class=\"sgds-icon sgds-icon-youtube-alt\">\\n            </i>\\n            <span style=\"display:none\">\\n             youtube\\n            </span>\\n           </a>\\n          </li>\\n         </ul>\\n        </div>\\n       </div>\\n       <div class=\"row\">\\n        <div class=\"col-md-12\">\\n         <ul class=\"footer__right-links\">\\n          <li>\\n           <a href=\"/forms\">\\n            Forms\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"/contact-us\">\\n            Contact Us\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"https://crms.moh.gov.sg/mohfeedback.aspx\" target=\"_blank\">\\n            Feedback\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"https://www.jusfeedback.asia/Community/se/705E3ECB2B7C0A8E?Agency=MOH&amp;Svc=MOH%20Wesbite&amp;eLnk=www.moh.gov.sg&amp;Cat=Citizen\">\\n            Rate This Website\\n           </a>\\n          </li>\\n         </ul>\\n        </div>\\n       </div>\\n      </div>\\n     </div>\\n     <div class=\"footer__bottom-section\">\\n      <div class=\"container\">\\n       <div class=\"row\">\\n        <div class=\"col-md-7\">\\n         <ul class=\"footer__links\">\\n          <li>\\n           <a href=\"https://www.tech.gov.sg/report_vulnerability\" target=\"_blank\">\\n            Report Vulnerability\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"/covid-19/privacy-statement\">\\n            Privacy Statement\\n           </a>\\n          </li>\\n          <li>\\n           <a href=\"/terms-of-use-of-website\">\\n            Terms of Use\\n           </a>\\n          </li>\\n         </ul>\\n        </div>\\n        <div class=\"col-md-5\">\\n         <ul class=\"footer__right\">\\n          <li class=\"footer__copyright\">\\n            2019 Government of Singapore\\n          </li>\\n          <li class=\"footer__lastupdated last-updated\">\\n           Last Updated DD MM YYYY\\n          </li>\\n         </ul>\\n        </div>\\n       </div>\\n      </div>\\n     </div>\\n    </div>\\n    <div class=\"scripts\">\\n     <script>\\n      if (self !== top) {\\r\\n                            document.documentElement.style.display = \\'none\\';\\r\\n                            top.location = self.location;\\r\\n                        }\\n     </script>\\n    </div>\\n   </footer>\\n   <script type=\"text/javascript\">\\n    //<![CDATA[\\r\\nwindow.__TsmHiddenField = $get(\\'ctl08_TSM\\');//]]>\\n   </script>\\n   <script type=\"text/javascript\">\\n    $(document).ready(function () {\\n\\t\\t\\t$(\\'.tableList\\').hide();\\n\\t\\t\\t$(\\'#A\\').show();\\n\\t\\t\\t//click event on Alphabets\\n\\t\\t\\t$(\\'li\\').click(function () {\\n\\t\\t\\t\\tvar clickAlpha = $(this).attr(\\'id\\');\\n\\t\\t\\t\\tvar newAlpha = switchToMatch(clickAlpha);\\n\\t\\t\\t\\tvar elem = $(\\'#\\'+newAlpha);\\n\\t\\t\\t\\t$(\\'.tableList\\').hide();\\n\\t\\t\\t\\telem.show();\\n\\t\\t\\t});\\n\\t\\t});\\n\\n\\t\\tfunction switchToMatch(clickAlpha){\\n\\t\\t\\tswitch(clickAlpha){\\n\\t\\t\\t\\tcase \\'li-A\\': return \"A\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-B\\': return \"B\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-C\\': return \"C\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-D\\': return \"D\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-E\\': return \"E\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-F\\': return \"F\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-G\\': return \"G\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-H\\': return \"H\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-I\\': return \"I\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-J\\': return \"J\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-K\\': return \"K\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-L\\': return \"L\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-M\\': return \"M\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-N\\': return \"N\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-O\\': return \"O\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-P\\': return \"P\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-Q\\': return \"Q\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-R\\': return \"R\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-S\\': return \"S\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-T\\': return \"T\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-U\\': return \"U\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-V\\': return \"V\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-W\\': return \"W\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-X\\': return \"X\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-Y\\': return \"Y\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t\\tcase \\'li-Z\\': return \"Z\";\\n\\t\\t\\t\\tbreak;\\n\\t\\t\\t}\\n\\t\\t}\\n   </script>\\n   <!-- Global site tag (gtag.js) - Google Analytics -->\\n   <script async=\"\" src=\"https://www.googletagmanager.com/gtag/js?id=UA-56164365-1\">\\n   </script>\\n   <script>\\n    window.dataLayer = window.dataLayer || [];\\n        function gtag(){dataLayer.push(arguments);}\\n        gtag(\\'js\\', new Date());\\n \\n        gtag(\\'config\\', \\'UA-56164365-1\\');\\n   </script>\\n   <script src=\"https://va.ecitizen.gov.sg/CFP/Script/Jquery/jquery.min.js\" type=\"text/javascript\">\\n   </script>\\n   <script src=\"https://va.ecitizen.gov.sg/CFP/VA/MOH/js/custom_widget.js\" type=\"text/javascript\">\\n   </script>\\n   <script type=\"text/javascript\">\\n    function myFunction() {\\n  var dots = document.getElementById(\"dots\");\\n  var moreText = document.getElementById(\"more\");\\n  var btnText = document.getElementById(\"myBtn\");\\n\\n  if (dots.style.display === \"none\") {\\n    dots.style.display = \"inline\";\\n    btnText.innerHTML = \"Read more\"; \\n    moreText.style.display = \"none\";\\n  } else {\\n    dots.style.display = \"none\";\\n    btnText.innerHTML = \"Read less\"; \\n    moreText.style.display = \"inline\";\\n  }\\n}\\njQuery(document).ready(function(){\\n  jQuery(\\'.navbar-default > .container\\').wrap(\\'<div style=\"position:relative\"></div>\\');\\n});\\n   </script>\\n   <script type=\"text/javascript\">\\n    //<![CDATA[\\r\\n;(function() {\\r\\n                        function loadHandler() {\\r\\n                            var hf = $get(\\'ctl09_TSSM\\');\\r\\n                            if (!hf._RSSM_init) { hf._RSSM_init = true; hf.value = \\'\\'; }\\r\\n                            hf.value += \\';Telerik.Sitefinity.Resources, Version=12.2.7232.0, Culture=neutral, PublicKeyToken=b28c218413bdf563:en:4ce39564-eafe-4a26-9ef6-244a21c7a8bb:7a90d6a\\';\\r\\n                            Sys.Application.remove_load(loadHandler);\\r\\n                        };\\r\\n                        Sys.Application.add_load(loadHandler);\\r\\n                    })();//]]>\\n   </script>\\n  </form>\\n </body>\\n</html>'"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "source=requests.get('https://www.moh.gov.sg/cost-financing/healthcare-schemes-subsidies/drug-subsidies-schemes').text\n",
    "soup=BeautifulSoup(source,'lxml')\n",
    "soup.prettify()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### (i) Finding the title of table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'List of Drugs* (as of 1 April 2021)'"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "title=soup.find('div',{\"id\":{\"ContentPlaceHolder_contentPlaceholder_TB03B381D008_Col00\"}}).h2.text\n",
    "title"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### (ii) Finding the table data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- Data for drugs with name starting with different alphabet letters are arranged into different div id(s) as per picture below for example:\n",
    "    - Information for Active Ingredient Aciclovir is in div id \"A\"\n",
    "    - Information for Active Ingredient Benztropine is in div id \"B\"\n",
    "    \n",
    "    \n",
    "- There are some alphabet letters that do not have any div id(s) (i.e. \"J\" and \"X\")\n",
    "    - There is no drug  with active ingredient starting with alphabet \"J\" or \"X\" in the List of Drugs and thus there are no div id(s) with \"J\" and \"X\""
   ]
  },
  {
   "attachments": {
    "ss_1.JPG": {
     "image/jpeg": "/9j/4AAQSkZJRgABAQEAYABgAAD/4RD4RXhpZgAATU0AKgAAAAgABAE7AAIAAAAPAAAISodpAAQAAAABAAAIWpydAAEAAAAeAAAQ0uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAFRlbyBDaG9uZyBKdW5uAAAABZADAAIAAAAUAAAQqJAEAAIAAAAUAAAQvJKRAAIAAAADMzMAAJKSAAIAAAADMzMAAOocAAcAAAgMAAAInAAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADIwMjE6MDY6MjAgMTc6MTg6MTEAMjAyMTowNjoyMCAxNzoxODoxMQAAAFQAZQBvACAAQwBoAG8AbgBnACAASgB1AG4AbgAAAP/hCyFodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIxLTA2LTIwVDE3OjE4OjExLjMyOTwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5UZW8gQ2hvbmcgSnVubjwvcmRmOmxpPjwvcmRmOlNlcT4NCgkJCTwvZGM6Y3JlYXRvcj48L3JkZjpEZXNjcmlwdGlvbj48L3JkZjpSREY+PC94OnhtcG1ldGE+DQogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgIDw/eHBhY2tldCBlbmQ9J3cnPz7/2wBDAAcFBQYFBAcGBQYIBwcIChELCgkJChUPEAwRGBUaGRgVGBcbHichGx0lHRcYIi4iJSgpKywrGiAvMy8qMicqKyr/2wBDAQcICAoJChQLCxQqHBgcKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKir/wAARCALsBuQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6K+w2n/PrD/37FH2G0/59Yf8Av2KnooAg+w2n/PrD/wB+xR9htP8An1h/79ip6KAIPsNp/wA+sP8A37FH2G0/59Yf+/YqeigCD7Daf8+sP/fsVSk8MaDLI0kuiaa7uSzM1pGSxPUk4rUoqozlH4XYmUYy3Rk/8Ir4e/6AOmf+Acf+FH/CK+Hv+gDpn/gHH/hWtVXU7l7PSby5iwXhgeRdw4yFJGfyq/bVf5n95Psqf8qKf/CK+Hv+gDpn/gHH/hTW8I+HGkVzoWnZTOMWqAc+oxg/jVPwf4xt/Fdo5WCSC5hA85MEp9Q3T8Dz/OtwXsTXxtIwzyKu6QqPlj9Ax9T6de/Sj21X+Z/eHsofyoxLf4f+FbV5Gj0W3YyFifNLSAbsZwGJx04xjHbGabp/w78KaZI722jQuXG0i5d7gD6CQsB9RToPFkF/4mtLDTd01rLbTzPO1tKquUaMKYnICyKd7cru7c88zab4iSbTb3UNQkRLaG7MSFLaaNkTKhRIjqGDfNycYA56ZrT2tf8Amf3vvY1dGy1iOtvBvhu1t1hi0OwZVzgywLI3JzyzAk/nS3Hg3w3c27wyaFYKjjBMdusbD6MoBH1BrTjvYJb6azjcmeBEeRdpwobO3npn5Tx16eopL6+ttNtGubyTy4lIGcFiSTgAAckk8ADJNZyr1Le9J/eR7KN9I6+hhD4eeFltYYE0lEEMnmJIksiyhv8AroG3H6E4FX28MaU8FvEYp9tuSUIu5Qx5z8zBsv8A8CJqHV9XuU8NzappBWPyAXZL6zlUuo6jaxRlPuQfoa0L/U4NNiR7lLlg/T7Payz4+oRTj8awnNS1m+2/4GsYyjpHzKsvhjSppIHeKcG3UKmy7lUEDpuAbDn1LZJ70+Xw7pk2oJevDIJUxhUuJFjOPWMNsP4inTa9YQvbrvmmNxGJIxbW0k3yHox2KdoPqcd/Q0+fWLS31FLF/tDzsFOIbWWRUDEgbmVSq9D94il7l+m/4/5j9/z/AOAT/YbT/n1h/wC/Yo+w2n/PrD/37FMOp2AuPs5vrYTbtvl+cu7PpjOc1FFLqh1DbNBCtr5kg3j720Bdh69yW7du1WZkGn+GdL0yaaW2imdpvvC5upZ1H+6JGYL17Yq1FpNjDE0aW6lWZmJcljliSeTkgc8DoBgDAAqvbeIrC7Nz9mW9dbZWZ3Gnz7HAOD5bbMSewQtntXPaT42nvodT1SVJPsFq0kcVn/ZU8Mzssnlr++kZY2ZiD8gUFSwBIwc7ezqTu3f+tg2Nq18I6RaWdxbRR3bR3Aw5lv55HH+67OWTr1UirFr4d0y0toIIoZGSBy6GW4kkYk5+8zMS45PDEjpxwMRR6veWOnzXnie1s9OjQqIxbXT3LOWOAuPKUliSAFXcSTge8beMdEjsVupLmaNWuPswie0mWYS7SwQxFd4YqMgFecjGcjI1Vd93+IlYty6Bp01lNavAwjmZmZkmdXGTk7XB3KM9ACMDgYHFVrjwlpF1YQWckd0sUH3Givp45D/vSK4Z/wDgRNVtS8badY6bY30EV5dw3lwIF8mznYp8+xtwVCVYHI2MASQQOau3XiXTrO0gnnF5i4UukSWE7zBR1ZolQuoGRywHUetCjVWqT3/ELq9iVtB050lQwNiWEQtiVwQozyCDlW5PzDDHjJ4GG3nh3TL+a3lnhkVrdtyCC4khUnI+8qMA446NkdfU1Be+L9EsLhIbi8JdoUn/AHMEkqrExIEjMikKnB+YkAdyM1FJ4utIvFL6I9rfl1jRhNHYXDoWZiMZWMrt6fPnb1GeDRGFW90mF1YsxeGdLh1V9QSKYzyZyj3UrRDPpEWKD8FqO38JaRa6kb6OO6aZmZist9PJFk9f3bOUA54GMDtis218atc+LpNGWDT2Edy1uyx6juulCru8xoPL4Ttnd3FaWm6hft4k1XT9RltZIbaKGeB4YWjKq5kG18uwYjYORt69Kco1Yq7fTv0FdXsTWPhvTNPuJ5oIZXa4OXFxcyTKOSflV2ITr0UDt6CorbwppNotysUdywucb/NvZpCvX7hZzs6/w47egp1h4p0fU5mjtbp8iMzK80EkSSxjq8buoWRRkfMpIwQc4IqpeeLYH8OajqOjLNI1pEJEe5s5oopM9CrMqhxx1UkdPUUuWrezv0/4ANpK7NWPRrCK7muVtwXmChgzFkG3ONqE7V68kAZ75xUj6bZybd1tGNrbhtXHPvjqPaqp1YXsd2miYuZ7aQRsWjYRk7sMA5wrEYIO0nBGDzxUq3k9tYtPqUJBWRg3kru2puOGIyTjGCcflWTv1KG3GhaddTLJLAysoAAileMcMG5CkA8qOvbI6Eguj0awitPsy24KYIyzMz8nP3yd3f147VcR1ljV42V0YZVlOQR6g1Dd3sVmimTczudscSDLSH0A/wAgd6XkBDFo9nHezXOzeZVVfLcAogXP3VxwTk5PU8egqGXw5pkt8btoZRIQo2pcSLH8pBHyBtvUDPHIyDkEipNWvprSO2js0R7q6nSKNXBIAzl2OPRAx+oA71m694rg02aO0st092by2t5QLeR44xJKikNIo2q21sgMwPK8HIzUVJtWLjGTehaXwrpKal9uEdx524ttN5MYsn/pmX2Y9sYq4mk2MdxLMtupaXG4MSyjAxwp4X8AM96qWurS3Piq809TGLe2t0bY1vKku8swJDMoRkwBgqTzmrMGtWFzHZPDMzC+ZlgHlsCxAJOQRlcBTndjnjrxQ+awS5r6/wBdSWPTbOKMIttGQP7y7j+Z5p32G0/59Yf+/YpLW9iuzIqhklibbJFIMMnpx6HsRwasVJBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79ij7Daf8APrD/AN+xU9FAEH2G0/59Yf8Av2KPsNp/z6w/9+xU9FAEH2G0/wCfWH/v2KPsNp/z6w/9+xU9FAEH2G0/59Yf+/Yo+w2n/PrD/wB+xU9FAEH2G0/59Yf+/Yo+w2n/AD6w/wDfsVPRQBB9htP+fWH/AL9ij7Daf8+sP/fsVPRQBB9htP8An1h/79ij7Daf8+sP/fsVPRQBB9htP+fWH/v2KPsNp/z6w/8AfsVPRQBB9htP+fWH/v2KPsNp/wA+sP8A37FT0UAQfYbT/n1h/wC/Yo+w2n/PrD/37FT0UAQfYbT/AJ9Yf+/Yo+w2n/PrD/37FT0UAQfYbT/n1h/79ij7Daf8+sP/AH7FT0UAQfYbT/n1h/79iip6KACis6ir5CeY0aKzqKOQOY0aKzqKOQOY0aKzqKOQOY0aiubdLu0mt5smOZGjfBwcEYNU6iurhbSzmuZASsMbSMF6kAZo5A5i7p+nWmlWSWmnwJBAnREH6n1PuajXTViuJGt3McEykSwAfKSf4l/un17H681naVq9lrVmt1p06yxnqBwVPoR2NWzIiuqM6hnztUnk464o5LhzNGdpXhe8sL2xnuNWW5Gn2klnbILXYAjbMM53Hc37sZIwD2A7zaboN7FDqVvrN7Z31tqDO0kcNm0PLqFYZMj5GB0x+NOl1GKHVrbTmVzNcxSSowA2gIUBzz1+cY/GnWd59s8//RriDyZmi/fx7fMx/EvqpzwatqT3/rX/ADNHUna5a0fTH0y2cXFx9quZn3zT7Nu8hQo4ycfKoHX1PenatpzalaxrDP5E8EyzwyFN4V19VyMggkEZHXgg80yiolDm3IU2ncranpWq6p4fk0+TUbNJpgUlmWybaUPZU83IPTksfpVXV/C9xrYs2vrqxmeCORJEmsPMiYsR86ozna4AwCS3U8VNq2pDSbFrt7We4jTmTydmUX+8dzDI+mT7VdrJ0YTun+poqs4pNefYyZvCc7adp1nb3tvD9itUtxdi1cXIwACUkWRdmcdCGHrkcVb1LQJ7/WIbyO5t7YRlMyRW7rcsqnJTzVkAKH+6VI9s4It0Vboxbv8AMXtpE50+E3Hn77nfu3Y+1Sbc/wC7uxj2xirVZ1UotUilvfsqxyh97pkgYyoBPf8A2hVcvQz5mM0Xw3c6XrVxfS3dqsUqsBaWFq9tEzMwYyOhldWk4xvAUnJznjEi+Fom8M3Wjz3LstxcTXCzRqFaNnmaZSAcjKsR14O3p2q5WRb+IoJ5LyRraeDT7QyB9SmeJYCY22uB8+8YIYZKgfKeemdv3ktb7foHNb7/AMS1Lo+t3umtDqOr2bXUcsc1tPbae0aoyHPzo0rbwehAKnBOCDgiKDwvcG7t77UNRSe8TUBeytFbeXG2IWhVFUsxUANnJZiTnsQBJpmsWuro72aXaqmMm4s5oN2em3zFXd+GavUN1Itp6fJCUl0M9/DEg0WWzt75Un/tF9QhmeDcqOZzKFZNw3AZweRn2qrrng2TXZrK7vX0e6vYIWhkF9pAuIHBIO5IzIGQjH98jBOQeCNO6vILJY2uX2CWVYk4Jy7HCjj3qeiM6kXzJ/gDkm23u/8AO/5mZe+EVu7fVokuY7ddR0qPTgkVvhIAgl+ZV3dP3vC8Y29au3Wk3v8AbkGo6be28GIRBcxz2zS+YgbcNpDrsbluTuHI44qaoRdwG+azD/6QsYlKYPCkkA56dQaV5t3uPm0t/XT/ACRSTwxdnVWkn1GB9P8At/29IEtCsyydgZTIQV9ggJ6Z65fb6Dqq+I76/vNTspbW9iWB7eOxdHVF37MSGUjP7w5O3nHAFRJ4l0yTVjpyyXHniUw7mtJREXAyVEpXYTjtuqSx1cXuqXtg9nc2s1mEYmbYVlViwVl2s3B2Hrg+1U1Utr27Lb+upN1e/Uhg8I3M8Qt9d1Rb61isZLGBIbbyG8twFZpG3NufaoGVCDljt6Ynm0DU9Q8OX2j6xqdpcxXEAhikisDGyjoS4MjByRjoFHXjnjQqrqWoRaVps99cK7RQJvYIAWI9s4pc05Pf8EDasWdH0l9GWW1huFbTlI+yW5jw1sO6Bs8p02jA2jjJGALl3DLcQGOGdoNx+Z1GW29wPQ+/NZt3dJZWzTyKzKpAwgyeSB/Wkt76G4hEuTGGkaNRIQCWBIwOfY1m05O7ZSdloOudIvg8KaNqg022RQGhW2WTefMVmbc3OSoZf+B7uop8Wk3AtYmub7zdSi3AXqwhNwLEhWQcFcEDHtng80+mu6RRs8jKiKMszHAApcoc2o9bCaTxA1/ctG0UUAitlXO5SxzIx+uEA9lPPNZN74Uu7q8k8vVhDYyX8N+1v9lDOZEZCV37vuHZnG3IJ+8R8puX19Fp9us0od98iRIkYyzMzBQB+J/AZNN1HUYtMtkmnV2V54oAEAJ3SOEB5PTLDPtVRi000XGcr6Cx6Tqq+Kn1RtRszbvEITbiyYPsBZh8/m43Zbrtx7CprHQks9XnvBKGjYuYIQmPJMhDSnOedzDPQYyfWoVvd2qyWX2a4GyFZftBj/dNkkbQ3dhjJHoRVqlZilOXXyJrawEVw9zcP59y2R5hGNi/3VHYfqe9W6zI5ElQPE6up6MpyDTqXKTzGjRWdRS5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5jRorOoo5A5goq79ni/u/qaPs8X939TT5kLlZSoq79ni/u/qaPs8X939TRzIOVlKirv2eL+7+po+zxf3f1NHMg5WUqKu/Z4v7v6mj7PF/d/U0cyDlZSqvf25u9OubZWCmaJowx7ZBFav2eL+7+po+zxf3f1NHMg5Wcv4b8K2Phq2K22ZbiQASzv1b2A7D2q2lrPDfzP8A63zkIW4YjdF6KR029+B9R3rd+zxf3f1NH2eL+7+ppcyHZnnmgaBc2ms2N3LoSWjwWM0N7ceZG0l5MxjO4kHLA7WIZyDycgd7Gk6O8+karpUmiTaPbzzNNbE+RtjPy7Sqxu2GVl3dMcV27fZEuEgZ0WaRWZIy/wAzBcZIHUgZGfqKSBrO58z7NJHN5TmOTy5N2xh1U4PBHpWrqt/15m0qk3r/AJmFo1rceZc6jqMHkXl1sVo8gmNEGAuQSDyXb/gVL4hs5r3TVjhhNwizI81sGC+fGD8yZJA59CQDjB4NdD9ni/u/qaPs8X939TWU2pqzM02pcxx+o28n/CITWWk+H5rdp1ZFtI/Ij8sn+I4fbg+xJ56VX8SWF7rcdiG0mQw7JC8bJavJFJwFyZNyhcZJKZPSuvvbnTdNjSTUbq3tEdtitPMEDN6Ak8n2qz5EX939TWM4QnFxb7djSM5Ralbv36nn93o99JZ6S8ultfajb2ccbfaUgmt0fjdu3OHByPvJntw2MVd1bTJpvE1ve22mfaZV8tTNcxQSQxqGJJUlhKjjPUAj2PUdn9ni/u/qaPs8X939TVOEW7+dw9pIwTp05vvP+1fJv3bMy9M9P9Zt/wDHce1aNXfs8X939TUKyWTzeUk0TSZK7BJk5HUYz2yK15kYtNnDeHtBa31nUFm0JIrC6jkE81/b2xnnZnztLxMfMjxniRQ3TJbJwyx8GLZeE9QttP02ysNRmuppFKRonmxi5aSNGZQflKhR32g9OMV6F9ni/u/qapxahpE+qS6ZBf2kl/Cu+W0S4UyxrxyUByB8w6juPWuj6xOW3l+AuX8zmdTe/wBd0OSOXQLyHZLE0tnczwj7XGGBdAUkYHIGMOVDdDwTWTH4Ve7W2jfRFsdLbVhOdMZ49sMIt3Q7lRigDOeUUkENk9WA9I+zxf3f1NH2eL+7+ppRxDimoq33/wCYcr/r+vM85uvCKzeGYre50O2vWsNTkltrV0iY/ZvtBby03HaoMePlJAwADimeI/DcmqR6Ysei3aaZFbsg021jsS1vISMEpMGi6ZGUbI9wTj0n7PF/d/U0fZ4v7v6mnHFSTv53+8HG7v8A1vc851jwlPff2lL9je7nj0aGHTZbqRGkW5XzTuznAkBKfPx1OD1q7feHbNPGUOqv4Zg1EzxIr3CQwb4JVfPmsXZSeCOVyfl6dK7n7PF/d/U0fZ4v7v6ml9alcOXS39dP8vzPPbfRb9PFMsyWF7Ef7RNx9rlvFa1aIjBCw+YcORkZ2Kf9r1v2p1OTxbqkjaPeWsFzbRwRXbyQFA0Zl+bCyFsHeuPlz6gV2f2eL+7+pqpZ3ulahNcQ2F5bXUtq+ydIZw7QtzwwB+U8Hg+lDrOS1XS3X/P/AIAuXW5wWleHr6NiLDSP7Aul06WC4vfNjc3dwwULJlGLSYYM2+QBvm6fM2Jl0PzPCOq2Om+GG0a+nt1jaXNvm6fn5t6uxYg5OZACd3ua9C+zxf3f1NRzi1toHmuXSGJBlpJH2qo9ST0pvFSb2/P/ADE4aWOa8O6dLpsl7Fd2m64Zwz6nlS18OcFudwZRwRgKONmB8q6d/G01m8SQLOZPl2ucKPc9+PbmtOVbaCMyTssaAgFnfAGeByaIltplLQssigkEo+RkdRWMqnM7spRa1Oenn1bT/It7TT21Ndi77h7lY9pLqpGCMnClm7k7cZJOaXy769t7e7urPypY2JewaVXXhjhgw4LYwRnj6Hmuj+zxf3f1NH2eL+7+pqeZDs7nPSRy3viKPzIpFtrGPzFZl+WSVwQMeu1c+3z+1c5q2g3l3rTynRI7qcanbXEWpSSR5it0eMlEydykYb5QApBJyScH0T7PF/d/U0fZ4v7v6mqjU5XdGkZyi7o460t5rbxvd3UOgTQW91CsUl2hgCyOrMd7APuIIIGSM+1P0zRZrbUYYZYttjprSNZn5cHzOgAByNil05HQiuu+zxf3f1NH2eL+7+po9oKUpP8Ar5fkYllaypdT3Lj7Okp4t1IIJ/vN23H2/HNXqu/Z4v7v6mj7PF/d/U1PMiLNlKirv2eL+7+po+zxf3f1NHMhcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TR9ni/u/qaOZByspUVd+zxf3f1NH2eL+7+po5kHKylRV37PF/d/U0fZ4v7v6mjmQcrKVFXfs8X939TRRzIOVklFFFZlhRRRQAUUUUAFFFFABVfULKPUdPntJiypMhUshwy+4PqOtWKKAOK8D+Er/Rru7u9ZupJ5Q7RW6mQsuzP38E9T29B9a6BJ5/7WlF4XR1Qm2gQ/u5Rjk7v4m9iBj0PWtWigaPPNB1M6p4r0m9n1l7yU6bdNcx+XGkdjIWhJjGFBUjnKuzMAoz15u6DqSXmja3beH9atb7UYbp5opIjb75gApBcRqFIY5Uvtzz1yK7aitHNPp/V7mrqJ9P6+4yND1CXV5bm/jlLae+xLVMDBwMu+evLNtwemz3NL4kvp7DS1kgmFqjTJHNdFQ32eMnBkweOPU8DOTwDWtRWU1zLTQzTSlc5LXtT0+L4f3jtr0N8k0bxxXUs0P71uflBQKpI9AM8U3xN4jCRWA0fVYoRcxySJcrdRJFKF2jaGaKXe2TwqjJwea6+isp05Si0nb+vU0jUimm1ff8fkcPeeJbhbHRr241VbZbiyjnks7WaBbmZ2x92OVTvXqMKVbrjccCr2s6zJZeKbaFtU2wv5SrY2s0HnsxY5LxyLuKYxyjZH93qR1VFU4O979b/8APaR/lMtp9V/tHYsH+jeZjd5Kfdz1z52fx2/hVpNNtIrr7SkWJtzNu3HqwAP/oI/KrVFaGRxXhzWZ9U1vUdOk1972cxyOsmnz2s9vajfhQMRh0k5+7IGXg8tg4ztMs9RtPh/rE0Op6lfM97dK0YEauqi7cSOhijV95QMeCefugcV6NRXQ6y6R7fgL/O5xH2/wxp3h24n8D3Wj2cRmhS9vNNSJ/s8bNgyPtyAQCfmcEDkkEAiq8WtaneLbWuleIWurWfVxaRassMLtNF9md3CkKI2KuMBlXAIwQ2GB7+ij2y1ur+uvbyElb+vU871WW9v/CdtdX+u3NqunayYZ7pEgUMkd0UEsm6MqpUAHIAXOSRjgP8AE3iG9tI9Lh0vxJZxWc9u0o1e7vYYFuWBAAEn2eSI8HO0KpPUcA16DRTjWirXjfVv716A1eTa/rW5wOtaxrsX9pzx6qkA0rRYNQMVpEjx3Ex80sNzqT5Z8vtg8jBHexfBbL4iRT3/AIouNNjvLWMW8EjWyJMwkOYVLxlj94cA7vm69MdtRSVZJ/D+X+QW0t/XT/L8Ty+zjsV+Ic08UmkzagusOGt4IAuoKhTaXeQMSYgDkqUA6fN2PQWPiDS5viBrkFlqVlcXn2KBI7eO4RneSMzlk2g5yOMjtnmuwoolWU1Zrpb+tP67i5fev5nAaT4lv52L6brH/CQ3TabLc3Nj5UaiznUKUiwiho8sWXZIWf5evysSl3qMN/4A1yS28Trr1z9kVpYd0Ci1c5+XbGgdATkYcsRt9Qc+gUU3Wje6j+Xf0/y+YON1Y5zQ521hb+31q533qSL9o0zCqtngkptIAZ1bGQ7HDYOAvKjRvYbex0xlhkltv3haPycszSEk4C/xZJPHT6dRpUVhKSbutP6/r/glIhs2uHtEa9jSOYj5lRsgf59OfqetTUUVIBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxnj3VNY0y+0U6BvkuJZJFMCruEowvBHp79vUV2dIVUsGIG4DAOORQBTW+mt9GW71S38mZY90sUJ8zafQH+vQeuOaqXWs3FnY2jtBDNd384itYVlwmSpcbpMHgKrEkA+gB77FZ9zoWn3dl9klhZYRL5y+VK8bRvnOUZSCn/ASOp9TTVr6lRtfU5e6vdWfwVrUs4ZZo7uZZjb6i8bwRjn91IYySR2BVRyeldNd6sun30UN1HttpLeSX7SX6MgBKke65bP+yagl8KaPLpTab9nmitHkaR44LqWLezfe3FWBbPUg8E89asyaHYz6fDZXCTTQwOHTzbiR3yM9XLFmHJBBJBBIPHFU2mv67FuUH97/ABJ9OuZbzTLa5uLc2ss0Su0BbcYyRnaT3IqnJql5LrMtjptlDMtts+0zT3Bi27uQFARtxxzztHI5641aoXOi2V1freuJ47hQoLwXMkW8A5AYIwDgZPDZ6n1rKd2/dIi463KewweOE8ua42XFjI8kTTu0e5XjAIQnavBPQDrVeDxX5viVdMNqpgkmkgjuYjKwLopJBJiCfwsCFdiCPrjRfQLGTWF1Njd/al6ML2YKBxxsD7ccDIxg4pkHhnSrfUEvIreQTRyvNHm4kZI3fO4qhbaudxyABn8BUJTVrba/mac1Np3vexDpGvzajd3ENxaw2rxKzLbmdvtJUHALRMi4B/vAsCehPWo9K8TNe2dzPewW1s9uqs1st0fOjz2kSVI/LPTGeD2PTN+10OytJ3mj+0vK6FN895LKVU8kKXY7c4H3cdB6CnWGkWmmySSW3nvJIArSXFzJO2B0AaRiQOTwOKIqorcz9RSdPWy9CCO9TXrG4hs5XtnAA81Jo3K5/wCubnHTvis/xPPq+heEtQutJkjublWeUPcylPKUnPy/K4bHAwQB9K6Wobu0gv7Oa0u4xLBOhjkQ9GUjBFdEZJSTaMnqrGBq/iXUdF022N5pMcuo3MjIlvaST3EYUDJYskBccekZ5I5xzTLjxm1hotjqup6XNbWlwGSbdvWSGbOFXy3RWKMQcMdpGVJUAkroS+FtLn0+GzmF5ItvIZYZnv5zPGxBBKzF/MHBIwG6EjpU40HTz9n82OS4+zwvDH9puJJvlbhs72O5iONxycEjOCa15qNtuv4ff/n89idf6/r+vxMbUNW8URa9pVvaabpu24t5Hlhl1BlG8bcjcIGOFzwR1ycgYGdq5064uLxZ1vpYFHl5iQnb8rEnuOoOOnaorjw3p11YWtpKLoJaf6iSO+mjlTjGPNVw5GOxPp6VqAbVAGeBjk5qJyg0uVbf13Y9SlLfPa6nHb3Cq0dxxC0YJYEDkMvXH+0OB3x1N4nAzUSW0MdzJcKn72QAM5OTgdB7D2FZFt4N0G0uY7i3sNksbIyN5znBRpGXq3YyyH/gXsMZDL1hfSX8sskaqlsjGNQ3+sLDqSP4R7Hn6Vlrq7QrqmtS+bJaxyC1tYFJAcq2wtg8AtIxXP8AdUHNbUllE7zSxloZpo/LaWM4b2PPBI7Eg1EdHsm0QaS8W+zEIh2FiDtAx1HIPfI5zzTVik11MWwutbm1DXEuLe3W6jjg8m3S+dolyGyd5iBUn2Q9BTtC1dovCfh24aO4mhvUijkmubnzJIi6/KWbaN5LYXOBywOK0IfDWmW9tcwwJcRfatvnypeTCaQr0Jl3b89s5yRx04otPDemWOivpNvHcCyYACN7uVygGMBGZiyYwMbSMHkVd42fyNHKDX9dvUSLVp7nS31CGCNIY5pAFkkA82JWK7w3Rc4yM8YxkjPGlbTpdWyTxhwrjIDqVP5Go/7Ptfs8EHkr5Nvt8qP+FcDA47496sVGhkwooopCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmfF/i0+FJtOkkt/PtrhnWUKcMoG3BXt3PHf2rpqo3+jWGp3VrPf26ztaFmiD8qCcc479KAJbS/t7zTY76JitvInmBpFKYX1IPSoZNZtIdP+2zmWOAttjzEzNLnpsRcs2ewAyfSrVxbQ3cDQ3MayRt1U/z9j71l6holzd2loItQC3Vjci4tp54fMA+Vlw6hl3fK7DOR2Pblq19So2vqZk/i2Y+F9Q1G3VYZY7mSC2a4srjYu3oZUVS6DGckgDpXRm/t0vkspJQty8JmVCCNyKQGIPTgsPfkVh3HhjUH8O3umQatD5l9NJJPcT2e/hxyFVXXGD0Jzx69auX+i3epafbx3F9Gl5EWV7iCAqrIwKuoUuSuVPB3HBAPPSqfLbT+tC3ydO7/wCAaVleQahYw3lnJ5lvOgkjfBG5TyDzVe51qytb9LKRppLhgCY4LeSbYCcAtsU7AeeWwOD6GrscaRRLHGoVEUKqjsB0FZkml3sWsy32m3sEKXOz7RFPbGXdt4ypDrtJHHO4cDjrnKbd/dIjyu9wF7ex+KhYyvbvaS2zTRhYmWRCrIuC24hs7iegqdNZs31P7AftCTkkL5trKiOQMkK7KFY4yeCeh9Kqy6XqT+Jo9TTULVYI4zCIDZsWKMVJ+fzMZyvB249jWbaeC/s3iKLVHurZ3iuZZw4sgJ5A4cbXl3EsF3DGABhenTEJz0Vu9/vNLU2m2+n4m3ZazZ6g8gtTOVjBJle2kSNgDjKuyhWH0JpLPXLG+t5J4nmjgjAYy3NvJAhB6ENIoDD3Ge3rVLS9AubC/nuWurVVkjZRb2ls8MJZjneyGRgW46jaTk5J4waP4dfTvtInuY/KmVVW3sI5LaGLGSSqeY20nPO3bnuCeaIuppzL1FJU1ez9C/LqAubGZtFmtru4QDaqyBhnPfB4796Rr+WysLi51SGQLHKwVbWB5mZM4U7EDMT64H5VYtrOO13eU0zbuvmzvJ+W4nFZ/ibQ28Q6OLJZoY8TJKVubfz4ZQpzskj3LuU+mRyB9K3jyuST2MxX8S6culpqAW+kgdzHti064eRGGcho1QunT+IDt6ir9jewalYQ3loXME6B4y8bRkqeh2sAR+Irmbbwdead4ZbSdL1CwtxLdGeYf2aRCytyYliSRdq5/wBo8cHOSTtT6Ja6tpsFv4ns9O1Z4zuJksx5e71VHL7eOOprWUaS+F9fw/rzIV+pFqnivR9GvTaahcuk6xCd1S3kk2RkkeYxVSFUFTljgDjJGRU97r1jp17FbXf2pWl27ZUs5nhG44G6VVKLz6kVS1PwwuoSasUuRAuo6WNOCiLIiA8z5uoz/rOnHTrzWVrfw/8A7a1f7XLdWRXy4VVrjThNPCYySPKkL4jBPJG0nryOMOEaLa5m1/XoVLTb+tv+CdIdc08QvIZyFS6Fmw8tsiYsFC4xnqRz0wc5xzVSx1mS88WahpwaMW9pbxNse3mjl3szgtuZQjodowVJ5DZ7VI2hKfEP9o+aBDkStbhPvThDGJN2f7h24x2BzxVWPRdYi8WXOsNqdlJbzQrAbVbBlfy0LsgEhmI3Zk5O3Bx0FSvZ2evT8fu9Q7/11/yJrHxbpGpakljZS3Mk0iPJG32KYRSIvBZZCmxl5HIJByMdRQvirTpLS7mjj1DNqgd4pNNuEkYE4BVGjDMM91BA71xXgrTb6K9ihNvcQtLZSQztNZXcL6dkA7YpZpGib5uCIVVTtDYAAFdF4W8Cp4dupZ2ksC0lqLVlsNPFqHAOd7fOxZzzkk+nA5ztVpUYXV35ee/l/W4k9fn+Ghf0jxZbav4ZGrR2t9DiBJXiewuCQWXOEHlgygeqA0af4kiTwlpuqaxPE8t5EhH2GCZxM7LnEUe0yHjJxtyACT0NLpekaxpXh8abFqllI1vGkNnM9g/yIox+8US/OcDqCgz27VRsPCuq2OgaZZLrNq13pLj7JcCwYRlPLMZWSPzSWJDNyrLzjjggy1RvKz0urb7a+X9dmKN+VX3/AK/r/I0ZfF+ixWVvctcylbl2jhjS1leVnX7yeUFLhhg5UjIweODUs2oXd3Z293oKRXME0DSK0gK5OAUGCQRnnIPT2qvYeG3tLizuZ73z7iKaeedxDsWV5Rg7Rk7VHAAyTgcknmtDR9O/snSobLzfN8vd8+3bnLE9Mn1rKappe7/X4DTdySS9S3nhhuQyGYYWQj5C393PY+mevarNVLux+2yILiQm2XloAOJD/tHuPb889KzrnSddknma18R/ZomL+VELGNvKB2bRk9du1/r5n+yKyHsjUa9iF8togaSXGXCDIjHYse2e3c/nVd7+ZtfWyhVPIitzNcyNnKknEaj64cn/AHR61KtgIb43Fq/krISZogMrIf72Oze/fv2Ir6fpbx2t5/aBje5vpXedos42n5VUE+iBRn1BPejoUrGfb+LYL/xLBZaeJJbNrKe4eY2sq7yjxhTExAEikO3K7s/Lg88zaV4hWbRZtR1KWNYlu3hVoreZCi+ZsQOjqGVuRuOMDk9Kr6b4Z1Gy1C1u7jWI7lrKwksrdPsexQpMZDth8s37vnBAPGAvOZ9L0C8t7HULLWL21vbe9eR2WC0aEqZCS3JkbI546EeprV8iWn9a/wCRrL2dtPL9fI05NSgWS4ijEk0tsFaWOJCSobp9TgE4HOO3IzYgniuYEmgdZI3GVZTkGs7T9JnsdNljN4r31w/mT3aw43tgLkKScfKoAyT071dtLOGyh8u3XAJ3MxOWdu7E9z71m7GLt0J6KKKQgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqrdanZ2V1bW93cJDLdEiEOcByMcZ9eRx3q1XK+NPCc3iubTYknW3ggd2mkxlsELgKPXigDqqKpLZS2ejLZ6dO3mRR7I5bgmRj9T6+/OPQ9Kw9U8+30O1WG31CGA3YXUvIEj3BQqcsrR/O2X2fMnO3OMY4aV3YqMbs2brXdNs9MvNQubnZa2TMlxJ5bHYVODwBk9e2a0AcgEdDXn00D2fgjUBHb67BO17NJZLEbl5ySMoXKEsQf9skdAeeK6DUb26UWmr6XHezJJE9ubVoZE+ZuY3aNlDLhl2liBgOSeBkU46af1oW6a6d3+B0NVp9Rtba/tbKeXbcXe/wAlNpO/aMtyBgYHrRp1q9lpltbTTyXMkUSo80rbmkYDlifUmsTVbtbTxdp0iLqrDDrcCGG5kg2lTtyFBTO7v1Hespvl+8mMeZs3rm7gtBEbh9glkWJOCcs3QcVNXEXUV1da7H9pt9Ulu4dVVgV80W0duD8rAZEbcEZPLA5zgDjo4YNVXUA80+bfcTt85Dx248kH/wAe/E0qcnNX/rZfiOcFEs22qWl5N5VvLvfaWxsYcBip6j1BFOXUrKS3uZobqKWO1ZknMTh/LZfvKcZwR6dah1Erpml3V5Y2PnXEMLtHFDHlpG5IUY9W/nmuf8NWer6dqTWet6fapFeWa75LWZ7iN5U4dnLRIFLhxxznYfSt4w5otmbtc6i1vre9Dm1k3iMgN8pGCQD39iKnpkcMUO7yo0TccttUDJxj+QArM8Sfav7LX7L9oEfnILn7ID53k5+bZt+bP+782M45xWUnZXHFXdi1qWqWukWv2m+Mqw5wXjgeTb7nYDge54q51rldZlt08C3UNhDqswuEeOJJbe6mmLHPUOC4Hu3FReJ7q6v4rBbCPUIYZY5H85Le7DBxtCoyRPGy5yTuchRj3zWUqvKm99v6/wAjZU726bnX0Vw95NqLWOjXNyupT3gsozJYRJdQh5TjJaWL5VbPG2QEe6gk1e1lrhPFNtJEL66H7pBaxi6hjj+Ykv5ifum4PKOO33h0NOpZ287C9mdVVSPVLSW7+ypLmbcybdjdVALc4x3H51WaDVf7R3rP/o3mZ2+cn3c9MeTn8N341eNpb7iwhRXO471XDZPBORzk4HPtWhkPininDGGVJArFGKMDhhwQfcelR3t7b6dYy3d5J5cEK7nfaTgfQc1yPhzT4NDvtWgig1qW+jknkjSee7kgmQkMu13JiLnIGc7s5965yzTXJvD+uRuNTnin00OqyWd4GScHlEW5kkZyAf4VCt6HBx1KhFvR6afiRJtJnqV3dR2VpJczLKyRjLCGF5XP0RAWP4A03T7+21TTre/sZPMtrmMSROVK7lIyDggEfiK53RLlLGPU71P7ak0vEZjW9gupZzLyJCkbqZdvKcBdvDEADNYMU2pSfC/RbWwj1Kya3MVvqG7TroTRqIznaiGOVhu2ZMZ9eoBFJUb3Xml9/wCpSs1c9EkuIYZIkmljjeZtkSswBkbBOAO5wCcDsDUGo6pZ6TFDJqE3lJPPHbxnaW3SOwVV4B6kgZ6Vx264stL8MXd1JqOpRWuoyvJKumXQlRDDOi7on3zYBZRubJOQc81c8U6nE9rpF/Zx66JftUUira2l4P3QlXzfNiRf7ucCQZPOBR7H30tWm7f1/Wgm7K/lf8zsKZ58RuDAJU84KHMe4bgpOM464yDzXHeKbiV9U0+6tF1W6/dK0enwx31urlmGGaWIbFOOqSjHqUBJLtR0q0tvH8eoXa60VuoUWNrSe8eNZVk6OsRKomCDhgE+970o0k0r31v07A3vbyOn/tS0+3fZPN/f79mzY3Xbu64x05q3Uf2aDzvN8mPzN27fsGc4xnPrjj6VJXOMKZDNFcQpNbyJLE4yrowZWHqCOtcp4eiluLi8tbk6lcRyREvfSveWxJLfdEchAQ9fmjOOOi8CovD+mPF4TksLNtTtdUt41DfaJLhYxIhJAQv8pQkYOzgg1gqr0dtLX+42dNK6v2OsvbyKwtHubgSmNPveVC8rf98oCT+VOtriK8tYrm3bfDMgdGwRlSMg4Nc9p2pm88P3muzC7aG/H+j26RvKUjA2rhEBPzHLEgdCM9Kzp5b+bwTo0VkL60SLy4b3FlceagWPH3EKSkb9vKH8xmqdS1/l/X5AqV9Dt6K5y1t5z4ds4zLdXt4HYwXDQyW7R8nG7zNzAAcfNuLAdyauXGtS2N5HZT6df3chEW64tbb9zl2Zepbjbty3oCPWtL6GTVrmvUN1eQ2UaPcMVEkixLhSxLMcAYA9T17Dk8Csl5ptTt7C+mtLpbGVVkezkj2TRscEeYnO7HdR0/2uzyU1XxQFG14NJGTxn/SHXjn1WNj/AN/BVW11GkadzdwWnk/aH2edKIo+CdzHoOPpUcOp2lxql1p0Mu66tER5o9pGwPnac4wc7T09K46SK8u/EMDXltqsl7Bq5YsvnLaR2wLeWwGRG3ylckAsCTnFaOlXCHxVq1mo1kW9wi+W1xFdeWsmX8zZI42oPu42kDptquXS/wDXQ0dNK/p+v+W33nVUVzmjJqEtyqak10YtNt2tpDIpxeOT/rCMfP8AIqnIyMyMOo40tHiuIoW3horYn9xBKd0ka+57D0Xkj17CWjJqxo0UUUhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFGecd6K4vx7ba1cX+if8I55ou1kkO9DgIML949MfXrQB2lFUllvrTRlku41u7xI/3i242qzewPOP19B2rNutWurfTbD7NcQT3OpXQgjnaMmGAlWblQQSBsIwSCWPUdmlcaVzforz2ZZ7r4f68ZJ7C9QXtwbr9y/lTqDyq7ZQUOR13NjB4rq9S1aTSbuBp1j+wPBISwB3rKi7gPQgqH98r3zTcbL+uxbhZ2Xn+Br0VW057uTTLZ9SSNLtolaZIs7VYjkDPOB0rK1KJ/+Ey0aSVbeSPEyxZRxJE2zLHcH2kEADBXj1qJXiTFXN6iuN1LU7q/vrNmntIbSPWktkt2jJmkZG5bduAHrt2njnPPG9DqlzLqAt2s9qbivmbZug78xBf/AB7HvU05c6uv60T/AFHKDialFYlzpMGl6dfXVo8qyraTKrbh8uSz5GBwcmuf8I2915kunaq06m+0yOUJ/ac18CDlWfdMAY2O4fKBt46nHG8Yc0HLsQ2l/Xp/md3RVSx06HThKICx81gzbjnooX+QqDXNQm0+ziNqI/OuJ0t0ebPlxlzgM2MEj2yMkgZGc1lJpDSu7GlRXNeKLFp/BN7/AGyLS9uIY2kSRLbYqMOjKrMxBAPXNS+JNZvdOa3g0oK9y8Ukzo1usgEaYyxLTRBQCw7k89OKiVTlTbRpGnzWSfc6CiuWn8Q6k2m6dqkSR2mnTWi3FzcNatc+WSAdu1HVlGP4sMPXAHNvVNU1Gy1mEN5dvpTeWpuGtGn3uzEbcrIDHxjDFCvPJ6Cm5JO3nYXs2b1FZbapcjUfs4s8x+Zt8zbN0z1/1W3/AMex709NGghvjeQswm3yON2CoZwAeOOPlHf1qyLGjRXJ+GZ9agh1O513VrOe1trm4DhLORHTa2c7jK2EA6LjoRz64F14m1bU/DuuWesWqqx0xby3/cpblkZiBkLPMRnjk7T14NdCoNtpNdPxIlKybPS6KwLM3OpT6no3iSPT9QjjSNyIrYiNlfd+7dHZskbc54yGHArB0/WLzRvhj4YTSbUT3d5DDbQrtQhT5Zb7rSRhuEIA3r174wZVK+ifVfjf/Ipaq53tFckdQ1iSTwudWhksLmbUZY7iFWVRKot5ypKo7gA7VbbubBA54qx4zikkh0p2W2ltY9TtTJDNG5YsZkCMrq67SpOcEMD6Uez99Rb3E3ZX8r/n/kdLRXO+I9W1XS7yGWHy7fSkTfc3b2T3W07gNu1JFZBjndtcDqdoHMD/APCQN8QJYoNVs0sfskcgt5LKRiV8whgCJgN/+1t6EcccqNO6vfv+AN2udTRVD+xrb+0/t2ZPN8zzMZGM7Nnp6frV+shhVe+sodRs3trnzfKf7wimeMn23KQce2eaxtN1HWLqa4tL94LK+MZkhgexchAGxu8wSlZRyOAVPPIGcVT0O712HwNFfzXNvfSrAsiobd/MKg5cFjIdzEAgcDnsax9omtVpa5t7Np6PU6uKKOCFIoUWONFCoijAUDoAKdWCJ4fEWm6n9ogtbrS/uW++PeJSq5Zjng4bgccFTVD+1rzTPB/h+LTLcTXV5FFEmQrBcRbj8rSRhj8uMbh1zzjBtztdvy/ElU76HW0Vhw6tqsWm273+mbLp9wkQBzjBwDiJZQMjBxuOOmT1qxcaZDrdvFNeLJE5iZNqEjAbGfvKD27gfSrWquQ1Z2ZqUVwXxC1a8bQ/Een2t1Y2VtZaXvuGuoy7zeaHVVTDqE+5gE7sk4xxzsXUEn/CeaPNMLaSP7JOsB8txLEcJu+bftYHjgpkY61v7L3U297/AIK4un9eX+Z0tFc4+ratB4wFpfCO002WQR2pNk8puTsyf3yyYiIbs8Yzj5Sc8V9I17WLu8sJb37B9kvp7i3WCGJ/NTyy+JC5bBB2YK7RgsPmNT7J2uJtJ2OrorkNG/s/w9ceMZoooLGztboTuIoQFT/RYmZtq4zzknHJqrpXirxFcLqtve2US3tjbQXkaNbLGZI2Z9y7EuJcMVQ7SWHJ5XA5r2LabT00/H/Ippr+v67nc0ViWetS6laanfWMtn9iiBWznkJCOyrlnds/cDHbxgja34aWmzS3Gl2s1xJbyyyQozyWrFomYgElCeq+ntWTi1uTcs0Vga5qOrx67p2l6K9lE13BPK813C8oTyzHjCqy5zvI6j1zxg5lv4o1XV7C2l059P09/wCyotRna8iaVW37souHTaAUOWJONy8Vaptx5un/AA/+TKszsqK4ifxbrUkU19aw2dtZ2dla3s8E8TvM4lBLRghlCkBT8xDcn7vFTzeI/EM/i24stJ0kXGn2V1Hb3DYiyQyozPvM6smA+QvlNnb1+b5a9hK9rr+rf5ohTUldHYUVnxXdyfElxaPPYm2W2jkjhRz9pDFmDMy9NnCgH1DUtro1tZ3puojJ5h8zqRj523Ht61i1Yov0VlW2qCH7SL+eNre2ODfMwSPrjaxOBuHQ44+h4qVtZtJIZv7Omhv54lYmC3mVm+Vip4B7MCD3yCMZ4pAaFFZX9pm08PS6lNKt4wUuqwgKGY8LGue+cLzzk9ugzgb7R7XTdKtZbWO/vPNmuLu4iLxhx88h2BlJJLHA3DAHfGKdilG501FefMZJfhzpU5ezu7f7fEZQ0b7Zd12ArIyyDbgncM7geBXS6vrN5pl1cxiKGQPah7EHcC827YUY+hLx4xzy3pVcv5tFOn2Nyisy5u7mzurYbluHmUK9tGuGyOrqew9dxx05zwdOoMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5Hxz4nvvDNxpUtjGs6TyOksBH+sHy4weoPPH8jQB11VrnTbG9tZba8sre4gmbdJFLErK54OSCME8D8qZFqKf2VHfXsb2SsgZo58BkJ7EDv7daguNaFnYxz3NpMJbiXyra1QqZZmIJAwSApwCeTgAckU1e+hSvfQkudB0e8tVtrvSrGe3Rt6xS2yMgbGMgEYzjjNSJpOnR2MVmlharawsHigEKhEYHIIXGAQecjvXMXGv6o3hHVbzy720uI7qWJXSK3kks0X+JlLhHA9ix5710supw2+oRWc4kVpIHnWUqNhCEbhnsfmBx6Z9DVO6W5TUkrX7/AIF2qF1oWkX12Lq+0qyubgYxNNbo7jHTkjPFT6feLqOnW95HHLElxGsipMu1wCMjI7H2rPvb65j8U6baIbiG3kWQsRFG0c5C5C7t29SuM8Lg561lNJaSQo3u7Mu/2Vp325737Ba/apNu+fyV3ttxjLYycYGPoKt1zmo+IpTfW0GnW9wYv7QjtprvEflZzhk5bcT2yFxnvWymoQyXHkqlyGyRlrWQL/30Vx+tEGpL3f62f6hKMluWXRZI2SRQ6MCGVhkEehFU9N0bS9FiePR9Ns9Pjkbc62sCxBj6kKBk1Snub7RbG81LVblJrW0tZZWRAATtLMOw/gwPrRp6+Ip7KWbULvTkeeAtBDbWzgwORkAyM5DgdM7Fz1wOlapPkbvoQ1qbVR3FvDd27wXUMc8Mg2vHIoZWHoQeDUFjFexiX7fOsxLDy9oAwNoz2H8WTRqWoxaZaiaVJJWZxHHFEuXlc9FGcDP1IA6kgVnKyWo1e+hC/h7RpLGOyfSLBrWNi6QG2Qxqx6kLjAPJ5pzaDpDwW8L6VZNFakmCM26FYjnOVGPl59Kz9dvL7/hFbi/tzd6TcW6tII3ELs2OzffXB68EH3FWdd8Q23h+2hmvELrKSoxPDFggZ/5ayID+Gayk6cU3Jaaf8A1Sm7JPuTy6DpE8kEk2lWUj2yhYGe3QmIDoFOPlA7Yp8uj6bPqCX82nWkl5HjZcPApkXHTDYyKov4ntjcWENnbT3kl9ALiJYmiU+Wcc/vHXPXouSO/bM0+uxx68ukQ2k9xceWsrmN4gI0LEbiGcMQMclQfz4qvcv8/xJtP8PwNSiqp1CEXHkbLnfu25+yybc/723GPfOKgSLU0vjJJcLJbB5GESgbipA2DOByDu79xzWhFiRdG0xNUl1JNOtFvpk2SXQgUSuvHBfGSOBxnsKht/DOg2dpNa2miadBbzgrLDFaRqkgOMhlAwc4HX0FUPDfiK/wBZkulvdCvLJYZ5Y1mkeDZ8rYCELKzbvU428HmsqX4hWmqaBrT6Q5trzT7fzc+db3OBnGcQySDjHQ8+gNdHs6t7J7W6/cS2krnTR+HtFi0l9Li0iwTT5Due0W2QRMcg5KYweQO3amReGdBh0yXTodE06OxmYPLapaRiKRuOWTGCeByR2FRW2pvrcd7ZLHqGi3cIU7pFhMgVs7ZF5kXB2sMMMjByBWXaeMIdK+Hmkaz4guBJPdQRAkvFCZpGXJ5cpGvAJ5KjjjsKEqruk9br73t+Q0tNDak8NaFLpcWmS6Lpz2ELF47RrRDEjc8hMYB5POO5plx4U8O3drb211oOmTQWoKwRSWcbLCCckKCMLn2qhb+L4tUj0G40ny3ttSvZLaXcyuU2RSsQGRipO6MDILDGcetWPE+o3diNOW0NzAk19BHLcwxRSKqmRRsYO4ID5xuUMR1otVU1Fuzv3E7JX8v6/ItzeG9DuLi2nuNG0+Wa0VVtpHtUZoVU5UISPlAPTHSpr3SNN1Ke3m1HTrW7ltW3wSTwK7RNkHKkj5TkDkegqnqPiKOw1u10qKyuLy7uIzKEhkhXYgOC2JJFLAd9oYjvjIzVk8R6gnjGTSE0G8mtlhRxcRvAB8zEFzulB2DHTbuyDx0pKNR2d+/UNFc6KiqHkal/afmfao/snmZ8raM7NmMZx/e569O/ar9YDKdho+maWXOmadaWZkxvNvAse7HTOAM9ahk0iO3iuX0OKy068uTmS4FoG3nOSWClSx5PJPU96g07xENWs57qw066lhjz5bCSA+cQcYUeZlT7Ptx35qrpHiie58Mx6rqel3NuuxGd18sowY4LKBISFXqc4OPWseam7Ly/A2tUTbZo22gabb6DBoz2sVzZQIqCK4QSBsdyCME55+tPXQtIXT2sF0qyFm7b2thbp5bN6lcYzwKiurw30Oo21lPc2ktmADcxqh+baH2ruDA8EZyO/HPSk3ie30rwnpmo6vLulu4owBvjj8xym48uyoOATyQOw5IFNuGra/r+kJKbtZm5a2tvZWyW9lBFbwIMJFEgRV+gHAqWsqx8RWOoabDfW4neKYsB5cLS7Sp2kEx7l6jqCQeoJFSXq6hdxpJpVyLdWibiWPB3cbThlyO/+FarUzad7MkvNG0vUbiOfUNNs7qaNGjSSeBXZVYYZQSMgEEgjvmobrw1oV7qC395oun3F4hUrcy2qPIu37uGIzx29KyPGXiifSNG1WPSbS7ub+1sXneaBYtlrlW2O/mMAeVJwoY4HI5Gbk+oXn/CY6dZA3MNq9tK7fuomiuWG3+LfvUrnptwc9eK3jGokmnbfr21/ET21/rYvpoWkRas2qx6VZJqL/evFt0EzcY5fGenHWqnh/wtp3h9JHtrW1+2TPI013HbLHJKGkL4ZhycZA5Palg8SRXfiS50e0sriZ7QqLm4WSHZCWXcu5TJ5mD0BCEE9+DiLT/FdvqN9DDHYX0UNw8kUN3MiLHJJGW3IBu3Z+RiCV2nHBpWq8tulvw6f8MS7XLNl4X0DTZ5JtO0PTbSWRDG8kFpGjMp6qSByD6Un9gwadpssHhW203R53ACyJYgoOecojJnv36+vSqugXN4t/r9tfX01+ljdqsLTLGrKhgjk2/IqjqxwT+JqppfxD0nVrO+ntopT9hEbTpHPbzlUdiN+6KV1wMMSM7gBnHIzTjVld3vt+O25T03NzS9Fs9J0G30e3jD2kMPk7ZADvHfd2Ockn61chhit4Eht40iijUKkaKFVVHAAA6Cqf8Aa8bSaikVvcS/2eo3mNAfMYru2IM5LY28cfeHvizZ3H2yxgufJlg86NZPKnXa6ZGdrDsR0IrKXM7ti0HNbwvcJO8UbTRqypIVBZQ2MgHqAcDP0FUrnw9ot7DbQ3mj2FxFacWyS2qMsPT7gI+XoOnoKh1jxAmk31rZJp97qF1dxySRRWipkhNu7JdlUffHU9sdSAazeL7aS1t5tMsL7U/OtUvGS2WMNFC2drN5jqOcMMDJ+U8VUY1LKUf63/4P4j6GzJY2k3nedawyeeoWbdGD5gHQN6gZPX1qvc6FpF5qUWo3elWU99DjyrqW3RpUwcjDkZGCSeKyp/G9jFMBb2d9d26ww3E13CiCKGKX7rsXZSR1JCgsAOlR33xB0TT/ABMuiTyg3HmxwSMJ4R5cj42r5bOJGzuXlUYDPJ4bFRp1b2incm8WrmvBotvF4guNZeSSa7miWBDIFxDGDnYuFBwW5O4k57gcVo1Ujv8AfrE1h9kul8qFJftLR4hfcWG1W7sNuSOwI9ajtYNTS9L3V1HJb/vMIFAPLfJ27Lx/jWUrvcosSWVrNZm0ltoXtiADC0YKY9NvSm2+m2NnKZLSyt4JCCC8USqSCxY8gd2JY+5JptpfieVredPIuoxloWOcj+8p/iX3/PBqa4uYbSBprmRY416sf5e59qkPIjm0+0uNnmwKQkwnAHAMg6MQOp+vcA9hRfabY6nCkWpWdveRo4kVLiJZArDowBHB5PPvTVvxHp0t9fp9jhjVpGMrcrGBnc3pxzjtWZBrNzaaXZvfW1zd6hfFpYrKARh0X723JKqNikAktyfXIqlfoWlLdF688P6NqMcUeoaTY3SQljGs9sjhCxy2ARxk8n1qddNsUjto1s7dUtCDbKIlxCQMfIMfLwSOOxrl5Nf1E+ENOvHN1BNcXiRy3EcMMnkg3AQI6lwOchcrux1rfu9ctrGa9juY5l+x2oumYJkSJ83Cc8kFcY919adpWKcZ2saAjQStIEUSMAGYDkgdBn8TTqpS6kLd42u4Wgt5FGJmIwjH+F/7vbnkZ444zdqDIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACoZbS3muIZ5YUeWDPlOy5KZ649OlTVheIvFVp4ZuLEagj+RdMytKnPlkY5I7jn/wDXQBuOiyRskihkYYZWGQR6Vl3fh+G6sYbdLq6t2tphPbTRspeBgCMLuUgjBYYYHgn2xoW11Be2sdxaSpNDINySIchhUR1OxWylvJLqKO1hJDzyNsjXHU7jxj36U1dPQpXvoZU/hKGXQ59Li1PUIIrmV5J5FeN5Jd33gS6NgE88AY7YHFWrvQY7/TYLS+vbqdoWybg+WskgIKsrbVC4KsVOAOOmDzWfL40tP+EeutUtGspglw9vaq9/HHHdsOgWRvlBPPr0roRcRGcQGVBOU8zytw3bc4zj0zxmqfMlqVLnW/n/AMEkACqAowBwAO1ZV/ob3+qW98NVvbZrbJjihWHYMjB+9GTyPf6YrShmiuIVmt5ElicZV0YMrD2IqhcawkWv2mlxfZ5ZJkd5QbpFkiUD5T5Z+ZgTkZHTFZSt1JjdbFc+F7Y3/wBo+2XgiF0LxbUOoiWXOS33dxycnBJGSSAOMaCaZYR3Hnx2Nsk2SfMWFQ2fXOM1U1LxDY6df2tibi3kvLidIxbeeokCsfvbepArVpQ5UrR6f8D/AIA5c2nMR3FvDd2sttcxrLDMhjkjYZDKRgg/hWfpGjS6T8n9sahe26oEit7rymEQHTDKgdiBxlmYnvk81FNr8lnZXd5f6dNDb2ltLcOynJIQt8oBAGSFyMkdfxpln4lN2ZoZNKvrK8S3NzFbXXlkzoOMq0bOvUgEZyMjjkVvHm5G1sQ13/rb/gG5VTUtOj1O1EMkkkTI6yRTREB43U5DDII/AgggkEUWN3NdCXz7VrbYwChjndlQc9B3OPwqeeeG1t3nuZUhhjUs8kjBVUDuSeAKyklbUavfQzL7QpNQ0U6dc6xflXyJZgsAkkU/wn93tA+gB96bc+HPtUlrLJqt+Li3ieEzp5QaVHILBvkwPujlQp96NS19YdAfVtG+yanbxZZ2S6wpUddrKrAnPbj61evtW07S40fU7+1slkOENxMsYY+2SM1m1C2ppeatbz/4JmXPhSC60m10t766FhbwpCbfbCwkC9CS0ZYNx1UrjqMHmrGpaBHqt1BJd3lw0EEiSpa7IigdejbihcH3DD9atXesabYNCL7UbS2M/wDqRNOqeZ0+7k89R09aW41bTrO8itLvULWC5mx5UMsyq8mTgYUnJ544ptRb17/j/XQXNMU6ZYG4+0GxtjNu3eZ5K7s+ucZzVqis5NSnN8YprFooVeQGdmO0KoBDdOhye/Y9a0I1ZDH4eSK6vmF/eG0vg/mWP7sRKzgbmUhPMBPJ+/jk8VnR+BbYWFxbXGralc+dZiyWSRogYohggKqxhQRjqVJOec4GLui+MNB8QTTQ6VqtncTRM4MUdxGzlVOC4CsTt6YPuKSfxZpb6LfX+i3tnq5sky8dpdK+CegJXOM10fvou1rbdPuIly21/r+rEkGgSQWt0BrF+97c7Q2oOsHnKq9FA8vywBlv4P4j35qpa+DY7TQbXTE1nUz9hkV7O6JhEtvhdu0YjCsNpIIdWzuPtjSTV4NRsLibw7c2OpywsYyq3Y8sOOqs6Btpx7E+1Q6b4itbnwnaa9qTwabbz26TSGacBItwHBc4HU4zxSvUs/Vdt+n9bFJEd54be+s7CObW9RF1YzmeK+VYBKWKumCPK8vG1yPuenfmm6n4Zm1WxtLafxBqcf2aRZTLGltumdWDKzZhI4IHCgA9wauPr1jnTDbyi6i1SUxW81uyvGSI3kzuB6YQ8jPOKi1vXY9HksYF+zSXV7cxwxwTXiQMylgHdQ33yoOdo5PTvQnU5kktfRf1/kJ2tr2/Ag1jwwNcght9Q1S8e1RUEtv5VuVnKnO5iYiysfVCuOoweatXmi/adWg1C31C7spo0EcggEZWdA27a+9G4znldp5PNS3+t6VpU0EOqanZ2UtwcQpcXCxtKeBhQxGeo6eoqlL4y8PweIm0SfVrOK+VV/dyXMaksxwEALZ39DjHQj1pR9q7cq79PvB26m3RVD7fc/2n9m+wSeV5mzz8nGNm7d09fl69av1iMytP0FLLVJdRmvLi9u5IxEZZ0iUhc5x+7Rc/8CzjtjJzCulHR9Hube2W81a3ZTHFYMYQEU5+UEhfl5/iYnA71cXXtHf7Ts1Wxb7KCbjFyh8nBx83Py88c1X0rxTo2sWC3dnqFvtOzcjTJujLHCqwBOCTwB3NY2pv3U+//BNr1Pia7f8AAItL0Ce08KQ6ZLfzR3RTNxdQ7SzueWxvVhjtyOmOlLH4aWPS7SzXVL/fZMDbXIMQkiAXbt4Taw25HzKevrir97evFb3H9ni3ubuBQ7QST+XgH1IViOAccc4qODWLU6Db6rfyw2ME0KSs00oVU3AYBY4HU4qmo3d/L/gCvP7x40u3lt4o9RC6i8YIE11FGWOfooA/ADpVuKKOCJY4UWONRhUQYAHsKbBcQ3Vuk9rLHNDIu5JI2DKw9QRwRVTUr+5siPs1hJdgxu52EjBGMDoeuf0rTyM9WzO1zwfa67LdtNf39rHfWwtruK1lVVnUbtuSVJBG8/dIz0bcOKmvfDsl3rltqS63qFubUbY7eJYDHg43A7oi3zbRn5vpik8UeKtO8K6NPeahdWscywPJBbT3KxNcMozsXPJPQcA9alfXox4mtdHh+zSySQPNOPtaCWADG39195g2TyOBj3roj7Wya21/4P8Al+BL2/ryGT+G47vxDb6teX1zcG0dntrd4oNkBK7TtYRiQZ7jfg98jiqPhjw1cWMcU+q3l1LJFPPJBaSGLyrcvI/zLsUMSVb+JmxuPStltb0pNXXSn1OzXUXGVszcIJmGM5CZz0BPToKWDWtLudQNhbalZzXip5ht451aQLnG7aDnGe9TzVOW1tLdun9dRNK9zJg8HIh1VbzWtSvotWjZLqKcQKrEoI9wMcSsCFUDrj1BPNNGgf2Lb3t4o1HxDdT2yWrQyvApeNS2FAxGgA3tnuR6mr2j6zcX1xqkGo2sFnJp1wImMVwZUZTGsgbJRccPyMcY6mprTxFol/bPcWGsWFzAkixNLDdI6q7EBVJBwCSQAO+aqUqmz20/4GxXXUqeH9Bl0vwjFpd3dyPdNERcXUbneZGHLKx54zgHsAK1rO3+x2MFt50s/kxrH5s7bnfAxuY9yepNDXtqjzI9zCrW6CSZTIAY1OcM3oODyfQ0+GaK4gSa3kSWKRQySIwZWU8ggjqKylKUm2+okkitNpkM+sWupO0gmtYZYUUEbSJChOeM5+QY59ayB4Mt4bO1t9P1TUbDyLRbN3gaLdPEudofchwRlsFdp+Y81r6hrGmaRGH1XUbSxQgsGuZ1jBAIBPzEd2UfiPWm32uaTpkMEupapZWkdwcQvcXCRiXv8pJ5/Cqi6lly/wBb/wCbKvpYpyeFNOe0vbaPzYYby2itWSNhiNIwQoXIPY980/8AsBo9akv7PVr+0SeRZZ7SPymhmYALk70ZlyAAdrL0z1yas3Wt6VY3kNpe6nZ29zOwSKGa4RHkY9Aqk5JORwPWnTaxplvqkWm3Go2kV9MN0Vq86rLIOeVQnJ6HoOxoTqb9/wCv0I5YpaFS3sNR/wCEsutRuLkpY/Zlt4LVJ2dXIYsZWUqAjc7eCcjqe1a9RLd27Xj2i3ERuY0EjwhxvVSSAxXqASDz7GqtrqFzPemGWwkhjHmfvSSQdrYHbuOf8aiTb3K8xsujRSadPapc3UElxgyXcMm2YkHruxx0x0wBwKZY6EllPK76hf3iyq6tFdz+YmGkZ+mO27aPRQB2q/bXMN3CJbdw6ZI6YII6gg8g+xqWpAzLjRhNp6WMdxItsJld0f5i0YOfKB7KSAOc8ZH0dqmjrqcttMl5c2VxbM2ya2KbtrDDKd6sMHjtngYIq5b3UN1GZLdw6Biu4DgkdcHv9RWfbeILNtEXVr+e3sLKRj5U084VXTdhGycAbhgge4pq5a5r6FS68IQz6JbaVBqeoWlrbyCQCNo3aRhIJFLNIjE4YZ9++au3OhQ3v2Jru4nmktcbpDsBnGQcPhQMFlVsKF5X0yDnt4vgOhWN/CLVpL+4EUEEl8kfmr5mwsjNgNgfNgcnoOtbxu7dXmQzxBoFDyqXGY1OcFvQcHk+lU3JLXv+I3zpWYx7KKW8S5lLSNGP3aMflQ/3gPX3P4Y5qxUKXlvJOsKSqXZBIg7OvqD0P4eo9amqDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsjW/DVh4huLJ9TVpI7RmYRA4VycdfbjpWvVW61Ozsrq2t7u4SGW6JEIc4DkY4z68jjvQA6exgnsGs9pihK7AsR2bR6DHb26Vk6lpWpXFjYfZ/sstxp12s0cbsYop1CsoDYVtpAbIwCMqOnbeopp2dxp2OTutE1xvC+pWES6fNd6jPK7s07xRxq47fIxJHTtnrx0q9qOmalf21pcxLa2mpxq8LlZmdVjkGG2vsBJBCMAVGSuOOtXrrXdNs9MvNQubnZa2TMlxJ5bHYVODwBk9e2a0AcgEdDTvpsW5SWtu/wDwSK0tYbGzhtbVBHDBGscaAYCqBgD8qydUtdXm16wubG2spLe0LEma7dHbcu0/KI2HHXrz7Vt1Wn1G1tr+1sp5dtxd7/JTaTv2jLcgYGB61nPXdkxbT0Rgf2DqgvjGjWf2P+0xfmZnYyyDOShXbgY6A5OQAMDtqQ6DbQagLtW+cMWx5EI5PuEDd/XNXrm7gtBEbh9glkWJOCcs3QcVNRCKgrL+tF+lhyk5bmfr9hLqvhvUtPt2RZbu0lgRnJChmQgZxnjJqhpWmapJq8Op63HZ28lratawQWk7TAhihZ2dkTk+WoCheME5OcDUt9Vs7qQxwTbmCFzlSMAMVJ5HqDVey8TaHqUVxJpmsWN8tsm+b7JcLMY155IUk9jW8ZSUXZfPt0Ifb+un+Rp1ma7p02o2UItvKaW3uI7hI5yRHIVOdrEA49jg4IBwcVctb63vQ5tZN4jIDfKRgkA9/Yip6xkrjTs7mFrNtrWqeGZrNLSwjurhWjdTeOY0U9CG8rLHpxtH1qDWNM1vVFsyDDCqxyLPbxajNCockbXDxqGcABvlO0HPXvWxqWqWukWv2m+Mqw5wXjgeTb7nYDge54q51rOUFO6b/r+v+AaKbjZpdzkzoGsW+n6ZFp7QRXttZR20l8Lx12kdf3RjZZF7/Ng8nBXrV7UNM1OTXY7vTDHag+Ws1z9rbMiKSSpgMZQ9Thgyt7gcHeoquS7vfrcXtGZbaDbNqP2wt+88zzMeRD1zn72zd+Oc+9alFVI9UtJbv7KkuZtzJt2N1UAtzjHcfnV+RG5mWNhrFlPqVtEtmlpcSSz2935zNKjvyA0WzbgEnnfzgcc1zUPgjXJNL1OO9e3aa8077IEn1S5vFkcHO9mlX5Acn5VXA984HoEU8U4YwypIFYoxRgcMOCD7j0qO9vbfTrGW7vJPLghXc77ScD6Dmt41ZR0S7fgTJJp3MazstYt/t+otZacl/PHFDFZx3b+SFTdgmXys5+c/wdgPesZPCuuS+C9J0y6SzS60mSMoltqdxElyixlDmVEV4z8xPAYcAHOeOzu7qOytJLmZZWSMZYQwvK5+iICx/AGm6ff22qadb39jJ5ltcxiSJypXcpGQcEAj8RQqkknJLqu/Tb+txrRWOYbw9qdtpujPpllZpdWF9JdS21xqk8qPvjlQ/v3jZyf3gblfUe9WtftfEWp6ZYx2thpgnS4iuJ1k1CQKhjkVwqsICWztxkhcehroZLiGGSJJpY43mbZErMAZGwTgDucAnA7A1BqOqWekxQyahN5STzx28Z2lt0jsFVeAepIGelCqSlJO13fTf/PuJq6s+39fqYetaXrl5fW11pUdvZXfkrHLeLqL5j+bLL5JhZJVHOC208nBTOau3dnqUXiWLUdOhtLiKWBbe4We4aJo1D7tyYRtxwzcHb0HNbVM8+I3BgEqecFDmPcNwUnGcdcZB5qfaPRW2uFtx9FVP7UtPt32Tzf3+/Zs2N127uuMdOat1kMwdA0zU9PuHScRW1gse2K0ju2uQrZ6hnjVlGONuWHPAXHNVLT+y/CE+m+IpbO1sIIvJivFuCWbk7WKsgCt90gAtzXUUyGaK4hSa3kSWJxlXRgysPUEday9mrWT6WNfaO92jn9It9VPhd7qW2hOr6iPNnjnkMSrkBQCQrEYUDjHXPSq0vh/Vbnw7pNtOlstzpjriOG/mjWVRGUz5qKrIeSehHbvx0t7eRWFo9zcCUxp97yoXlb/AL5QEn8qdbXEV5axXNu2+GZA6NgjKkZBwabgndX7f8AFOS1sY9v4agbTLeCeJbZoy7MiyC7G5m3E+ZMhY5PPbrWxa262trHBGcrGMD5VX9FAA/AVLVW81O008gXcvl5RnHyMeBjPQe4rRbWM23JnM+J/Des6jNrK6S2n+Xq+nraPLdM4e3KiToqqdwbf6rtOThulX9QtNdfxPp91Z2enyWdojozy3rpI2/buIQRMONvHzc+1bN9fW+m6dPfXsnl21vG0sr7SdqgZJwOTx6UyXVbODU7XT5Ztt1do8kEe0neqY3HOMDG4dfWt1UlZK19/y/yF0/ryMZNI1aLxe95Z+VZ2E0vmXRW/eX7VhNozA8W2M8DlHGcDO7gDL8H6de3ENnNLa2VtZWd7dzRSQzM0s7tJKh3LsAT7xPDNnAruKKXtXy8tiXG7ucnZab4nW48QPJHpti+p5kt54Lx52gkEKRrlWhUEfJuzn2wetZtr4f8A7EtNYvvFd9BY2V3ZRWzvLq0115bKz4fzZwMElxhQBgjjJNdhpms2Wrm5Fk0261l8mZJreSFkbAbGHUEjDA5HBzV6qdWUbxtbb7lsU9d/6/qxzfh211GfwnLdanbwDVtTjM00U6HywxTaiMvXAUKCPXdW3psMtvpdrDcR28UscKK8dqpWJWAAIQHovp7VZorKU+ZsSRkX2jteeKdM1MiForK3uI8OMsHk8vBXj0VgTkdfc1hWfhrW9I0+zjso9NvJv7Ki064FzO6LFs3fMmI23g7zlTtztXmu0opxqNLl6f8AD/5sq7tY49vBc0Wn6lbW0sLyT6da2UE8mQ/7kNyxA4GSCMZptz4QuZPFlxevAl5ZXV3DdMW1i6tzEyBAP3CAxyYMasCSvoema7KirVeafNf+tP8AIzUFFWRh20txL44vRHp0K2kdnGkl81u0cry7iRGHIxIgU5+XIBJGcmtyiqkGqWlzdG3gl3SjdldjDG07W6j1rKT5i/MpvY6jFDdXlm1qdUnACrJuEC4I4O3ljj+I8/QcU2G11m98+31xrEWsiuFNk0iyA+Y2zOeCPL259W3cYrZoqQMa/tNQl0H+zkCM0zC3eaE+XshPDPjja23IAXPJB6dE1XTLz7Xpl1o8VrI1jvQQXMjRoFZcbgQrfMMYxjkE8itqobW7hvY2ktn3osjRk7SPmUlWHPXkEZ6U0ylJo5a80HXB4Ss9JtV0+4nS5WeeWSd4VylwJQFUI55xjk8f7VX9U0S61R4pWS2ha6gFrqSCQsGizuIU7Ru/jUZC8SE9sHQm17TYNMTUJbnbaySrCsnlscuX2AYxn73H/wBatCq5nb5lOcktihd2DXtxCshWO1hIdRHw5b2P8IHtyfYdb9FFQZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvjTwnN4rm02JJ1t4IHdppMZbBC4Cj14rqqM8470AUlspbPRls9OnbzIo9kctwTIx+p9ffnHoelYeqefb6HarDb6hDAbsLqXkCR7goVOWVo/nbL7PmTnbnGMcdTRTTsyoyszz6aB7PwRqAjt9dgna9mksliNy85JGULlCWIP+2SOgPPFdBqN7dKLTV9LjvZkkie3Nq0MifM3MbtGyhlwy7SxAwHJPAyOhoqnK+5bqX1fn+JW061ey0y2tpp5LmSKJUeaVtzSMByxPqTWJqt2tp4u06RF1Vhh1uBDDcyQbSp25Cgpnd36jvXSUVnNOWpEZW3OIuorq612P7Tb6pLdw6qrAr5oto7cH5WAyI24IyeWBznAHHRwwaquoB5p82+4nb5yHjtx5IP/j34mtSippx5Fb+tkv0KnPmK0trDHbymCCNXMbKCiAE5ycce5z9a5f4fqx8P29neXesXDxWcMctrqem/Z44TtwVQmFN/pyzcAeuT2NFbxnaLjbe34X/zMmrtP+un+QyOGKHd5UaJuOW2qBk4x/IAVmeJPtX9lr9l+0CPzkFz9kB87yc/Ns2/Nn/d+bGcc4rWorGS5lYqLs7nK6zLbp4FuobCHVZhcI8cSS291NMWOeocFwPduKi8T3V1fxWC2EeoQwyxyP5yW92GDjaFRkieNlzknc5CjHvmuvorOdPnjytmsanK00u/4nD3k2otY6Nc3K6lPeCyjMlhEl1CHlOMlpYvlVs8bZAR7qCTV7WWuE8U20kQvrofukFrGLqGOP5iS/mJ+6bg8o47feHQ9VRVOF3fzuHtPIy2g1X+0d6z/wCjeZnb5yfdz0x5Ofw3fjV42lvuLCFFc7jvVcNk8E5HOTgc+1TUVoZXOK8OafBod9q0EUGtS30ck8kaTz3ckEyEhl2u5MRc5AzndnPvXOWaa5N4f1yNxqc8U+mh1WSzvAyTg8oi3MkjOQD/AAqFb0ODj1iiupYh6t63t+BEo3VjldEuUsY9TvU/tqTS8RmNb2C6lnMvIkKRupl28pwF28MQAM1gxTalJ8L9FtbCPUrJrcxW+obtOuhNGojOdqIY5WG7Zkxn16gEV6RRUqsk726p/d8ildKxwe64stL8MXd1JqOpRWuoyvJKumXQlRDDOi7on3zYBZRubJOQc81c8U6nE9rpF/Zx66JftUUira2l4P3QlXzfNiRf7ucCQZPOBXYUUe2TkpNbf12E1dW8rf195xfim4lfVNPurRdVuv3StHp8Md9bq5ZhhmliGxTjqkox6lASS7UdKtLbx/HqF2utFbqFFja0nvHjWVZOjrESqJgg4YBPve9dlRSjWcUkr6X69wavfzt+BH9mg87zfJj8zdu37BnOMZz644+lSUUVgM5Hw9FLcXF5a3J1K4jkiJe+le8tiSW+6I5CAh6/NGccdF4FReH9MeLwnJYWbana6pbxqG+0SXCxiRCSAhf5ShIwdnBBrs6r31lDqNm9tc+b5T/eEUzxk+25SDj2zzWHsrJW3Ssb+1u3fbT+v6sYOnambzw/ea7MLtob8f6PbpG8pSMDauEQE/McsSB0Iz0rOnlv5vBOjRWQvrRIvLhvcWVx5qBY8fcQpKRv28ofzGa7WKKOCFIoUWONFCoijAUDoAKdVShdNd7fgJVEndI56wttW/sS0W3v5Z2G/dJMjWzkbvlBWVJH4HGWOTjJznNbEdqJbaMahHHNKEKsXAfOeoztHBwOwqzRWq0VjJu7ueefECC7vk1izktdauVfTMabFpxmWJ5CH8zzDGQpIwnyyHBHCgkkHXvr1LLx1p7KmtMGgaK4EVvdy2wJ2+XwqmIH72WHI7musoroVb3VFrRX69/6+8l6/wBehxoNynxGJX+0b2OSTGCL23htFEeD6284J/3SCerHGKfhWee+1O1uIrnWZ50uLpb1rrzxbeSHkCKm4CNiCEwUy2Acmu+qCysrfT7UW9nH5cSszBdxPLMWPJ9yTR7Zctra2t/X9erE027/ANf1/VjkdM1d/t3iuWz0zU5ZpW+0Wsc1hcWwn2W8abQ7oACWUjrnuBWb4ZtNduIdWt/tmoeU1tBNaTXEV5b7bhWcsv8ApMryFeEDDIUjtySfR6rahp8GqWMlpdmYQyY3eRO8LH23IQw/Pmn7ZJNJWvbz2Kepg6LfSa34dv8AXX+3pFqERNvBEx8yOJVIBRegdjuYHvlc9K29H/5Adj/x9/8AHvH/AMfv+v8Auj/Wf7fr75qzDDFbW8cFvGsUUahEjQYVVAwAB2FPrKck27LQSWxzmvafc6n4l0u38/UYdP8As1y1wbO4khDODFsDOhBB+8RggnBHTIPPmXUJdK0w+I11/LaVEYhpy3Cyfa+fM83ycEHHl48zCfer0OiqjV5YqP8AXX/P8Cr6HA3ljr8sV5eXk+pm/srC0kgitZpEhe4wTL8iYEmSACpyMduaS+i1qX4gOZtSvrOJbmE2iRaddzQvDhdyl45RCMt5gJlQsuc5xtx39FWsQ072/rT+vmzNRaVrmJFcwr47ubXzdRM76fHL5bHNqqiRhlR2kJPPqAvpWsltBHJvjhjV+fmVADycn8zzTYbK1trme4t7aGKa5IaeVIwrSkDALEctgcc1PWEmnaxfUw4p5tLs7q8S0unsUwYbKOPfMecEquRtHfac49ulPh1e41Tz7ezsL6wmVXKTXtttjO2Rk4OTydu4cfdKnBzitmipAwZ7ptO8OstpFJBfzyeREs43lp243E/xgfeJH8KnpjAqataf2ZaaRp6rqJ0qMNHOdP8ANMzMF+Tc0XzgEhiSCOcZODz1NFUnYuMrM8+uFn07wRpCC31qC+iu1dYrdLiRlQXIMgl8rcG/dk/fJzzjNbmqvfvN5ultfeXq1qIE/duv2STPEu1hmP5WYndjlFGMnnpaKfNdFOp5GVcW0wv4Bp4kSaNFEtxISUZB/C3989ehBHXIzg6tFFQZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxfj221q4v9E/4RzzRdrJId6HAQYX7x6Y+vWu0ooApLLfWmjLJdxrd3iR/vFtxtVm9gecfr6DtWbdatdW+m2H2a4gnudSuhBHO0ZMMBKs3KggkDYRgkEseo7b9VrnTbG9tZba8sre4gmbdJFLErK54OSCME8D8qatfUqLSepw0yz3Xw/14yT2F6gvbg3X7l/KnUHlV2ygocjrubGDxXV6lq0mk3cDTrH9geCQlgDvWVF3AehBUP75XvmrFzoOj3lqttd6VYz26NvWKW2RkDYxkAjGccZqRNJ06Oxis0sLVbWFg8UAhUIjA5BC4wCDzkd6pyTX9di3OL37v8R2nPdyaZbPqSRpdtErTJFnarEcgZ5wOlZWpRP8A8Jlo0kq28keJliyjiSJtmWO4PtIIAGCvHrW9VC60LSL67F1faVZXNwMYmmt0dxjpyRnisppy27kxaTdznNS1O6v76zZp7SG0j1pLZLdoyZpGRuW3bgB67dp45zzxvQ6pcy6gLdrPam4r5m2boO/MQX/x7HvVn+ytO+3Pe/YLX7VJt3z+Su9tuMZbGTjAx9BVulTi4r3v60S/Qc5KWyMuPSLfTlmuLdpBIIXUZI4BYv2Hqa5/wLpt7P4Wjk1ZJMX9jFmZtZuLxpNycsUlULGec/LnrjsK7MgMpDAEEYIPemwwxW8CQ28aRRRqFSNFCqqjgAAdBW8Z2hKPe36mTu2n/XQr2OnQ6cJRAWPmsGbcc9FC/wAhUGuahNp9nEbUR+dcTpbo82fLjLnAZsYJHtkZJAyM5rSqO4t4bu3eC6hjnhkG145FDKw9CDwayldrQqLSepz3iixafwTe/wBsi0vbiGNpEkS22KjDoyqzMQQD1zUviTWb3Tmt4NKCvcvFJM6NbrIBGmMsS00QUAsO5PPTir7+HtGksY7J9IsGtY2LpAbZDGrHqQuMA8nmnNoOkPBbwvpVk0VqSYIzboViOc5UY+Xn0rKUJNNLTb+v63NlOKtfW1zFn8Q6k2m6dqkSR2mnTWi3FzcNatc+WSAdu1HVlGP4sMPXAHNvVNU1Gy1mEN5dvpTeWpuGtGn3uzEbcrIDHxjDFCvPJ6Cr8ug6RPJBJNpVlI9soWBnt0JiA6BTj5QO2KfLo+mz6gl/Np1pJeR42XDwKZFx0w2MiqcZX07/ANf8MLmh2K7apcjUfs4s8x+Zt8zbN0z1/wBVt/8AHse9PTRoIb43kLMJt8jjdgqGcAHjjj5R39a0aK0MrnJ+GZ9agh1O513VrOe1trm4DhLORHTa2c7jK2EA6LjoRz64F14m1bU/DuuWesWqqx0xby3/AHKW5ZGYgZCzzEZ45O09eDXfLo2mJqkupJp1ot9MmyS6ECiV144L4yRwOM9hUNv4Z0GztJrW00TToLecFZYYrSNUkBxkMoGDnA6+grqVaF7tdui6ESV00inZm51KfU9G8SR6fqEcaRuRFbERsr7v3bo7NkjbnPGQw4FYOn6xeaN8MfDCaTaie7vIYbaFdqEKfLLfdaSMNwhAG9evfGD1kfh7RYtJfS4tIsE0+Q7ntFtkETHIOSmMHkDt2pkXhnQYdMl06HRNOjsZmDy2qWkYikbjlkxgngckdhSVSCvfuvw+ZS21MY6hrEknhc6tDJYXM2oyx3EKsqiVRbzlSVR3AB2q23c2CBzxVjxnFJJDpTsttLax6namSGaNyxYzIEZXV12lSc4IYH0rSk8NaFLpcWmS6Lpz2ELF47RrRDEjc8hMYB5POO5plx4U8O3drb211oOmTQWoKwRSWcbLCCckKCMLn2o9pDnUlpZ9v+D/AMMJ3at5W/Mp+I9W1XS7yGWHy7fSkTfc3b2T3W07gNu1JFZBjndtcDqdoHMD/wDCQN8QJYoNVs0sfskcgt5LKRiV8whgCJgN/wDtbehHHHOvN4b0O4uLae40bT5ZrRVW2ke1RmhVTlQhI+UA9MdKmvdI03Up7ebUdOtbuW1bfBJPArtE2QcqSPlOQOR6ClGpGKXz6IGr3+Qz+xrb+0/t2ZPN8zzMZGM7Nnp6frV+iiucZz2m6jrF1NcWl+8FlfGMyQwPYuQgDY3eYJSso5HAKnnkDOKp6Hd67D4Giv5rm3vpVgWRUNu/mFQcuCxkO5iAQOBz2NdDYaPpmllzpmnWlmZMbzbwLHux0zgDPWoZNIjt4rl9DistOvLk5kuBaBt5zklgpUseTyT1PesOSSSfWxvzxba6adCmJ4fEWm6n9ogtbrS/uW++PeJSq5Zjng4bgccFTVD+1rzTPB/h+LTLcTXV5FFEmQrBcRbj8rSRhj8uMbh1zzjB27bQNNt9Bg0Z7WK5soEVBFcIJA2O5BGCc8/WnroWkLp7WC6VZCzdt7Wwt08tm9SuMZ4FU4y1t1t+H/DiU4opQ6tqsWm273+mbLp9wkQBzjBwDiJZQMjBxuOOmT1qxcaZDrdvFNeLJE5iZNqEjAbGfvKD27gfSr9ra29lbJb2UEVvAgwkUSBFX6AcCpa1WiM29bo4L4hateNofiPT7W6sbK2stL33DXUZd5vNDqqph1CfcwCd2ScY452LqCT/AITzR5phbSR/ZJ1gPluJYjhN3zb9rA8cFMjHWti80bS9RuI59Q02zupo0aNJJ4FdlVhhlBIyAQSCO+ahuvDWhXuoLf3mi6fcXiFStzLao8i7fu4YjPHb0rpjViopev4q39fcQ9v68v8AIz31bVoPGAtL4R2mmyyCO1JsnlNydmT++WTERDdnjGcfKTnivpGvaxd3lhLe/YPsl9PcW6wQxP5qeWXxIXLYIOzBXaMFh8xrcTQtIi1ZtVj0qyTUX+9eLboJm4xy+M9OOtVPD/hbTvD6SPbWtr9smeRpruO2WOSUNIXwzDk4yBye1Lnp8u2tu39ff+Qne+n9f1/TMrRv7P8AD1x4xmiigsbO1uhO4ihAVP8ARYmZtq4zzknHJqrpXirxFcLqtve2US3tjbQXkaNbLGZI2Z9y7EuJcMVQ7SWHJ5XA56Sy8L6Bps8k2naHptpLIhjeSC0jRmU9VJA5B9KT+wYNO02WDwrbabo87gBZEsQUHPOURkz379fXpVOpBp9Xpq/Ip6/1/XmRWetS6laanfWMtn9iiBWznkJCOyrlnds/cDHbxgja34aWmzS3Gl2s1xJbyyyQozyWrFomYgElCeq+ntUOl6LZ6ToNvo9vGHtIYfJ2yAHeO+7sc5JP1q5DDFbwJDbxpFFGoVI0UKqqOAAB0FYzcbtREr6GHrmo6vHrunaXor2UTXcE8rzXcLyhPLMeMKrLnO8jqPXPGDmW/ijVdXsLaXTn0/T3/sqLUZ2vImlVt+7KLh02gFDliTjcvFdc1vC9wk7xRtNGrKkhUFlDYyAeoBwM/QVSufD2i3sNtDeaPYXEVpxbJLaoyw9PuAj5eg6egqozgopNfP7/APgfcVpY5mfxbrUkU19aw2dtZ2dla3s8E8TvM4lBLRghlCkBT8xDcn7vFTzeI/EM/i24stJ0kXGn2V1Hb3DYiyQyozPvM6smA+QvlNnb1+b5epksbSbzvOtYZPPULNujB8wDoG9QMnr61XudC0i81KLUbvSrKe+hx5V1Lbo0qYORhyMjBJPFWqlNP4f609PP7zNKSVmxIru5PiS4tHnsTbLbRyRwo5+0hizBmZemzhQD6hqW10a2s703URk8w+Z1Ix87bj29abBotvF4guNZeSSa7miWBDIFxDGDnYuFBwW5O4k57gcVo1hK2luxfcyrbVBD9pF/PG1vbHBvmYJH1xtYnA3DoccfQ8VK2s2kkM39nTQ388SsTBbzKzfKxU8A9mBB75BGM8VZksrWazNpLbQvbEAGFowUx6belNt9NsbOUyWllbwSEEF4olUkFix5A7sSx9yTUgU/7TNp4el1KaVbxgpdVhAUMx4WNc984XnnJ7dBnA32j2um6Vay2sd/eebNcXdxEXjDj55DsDKSSWOBuGAO+MVuzafaXGzzYFISYTgDgGQdGIHU/XuAewovtNsdThSLUrO3vI0cSKlxEsgVh0YAjg8nn3qk0XGSW5w7GSX4c6VOXs7u3+3xGUNG+2XddgKyMsg24J3DO4HgV0ur6zeaZdXMYihkD2oexB3AvNu2FGPoS8eMc8t6VcvPD+jajHFHqGk2N0kJYxrPbI4QsctgEcZPJ9anXTbFI7aNbO3VLQg2yiJcQkDHyDHy8EjjsarmTXzZbnFoq3N3c2d1bDctw8yhXto1w2R1dT2HruOOnOeDp00RoJWkCKJGADMByQOgz+Jp1ZmIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcj458T33hm40qWxjWdJ5HSWAj/AFg+XGD1B54/ka66oZbS3muIZ5YUeWDPlOy5KZ649OlAEMWop/ZUd9exvZKyBmjnwGQnsQO/t1qC41oWdjHPc2kwluJfKtrVCplmYgkDBICnAJ5OAByRWk6LJGySKGRhhlYZBHpWXd+H4bqxht0urq3a2mE9tNGyl4GAIwu5SCMFhhgeCfbDVr6lRtfUwrjX9Ubwjqt55d7aXEd1LErpFbySWaL/ABMpcI4HsWPPeull1OG31CKznEitJA86ylRsIQjcM9j8wOPTPoazZ/CUMuhz6XFqeoQRXMryTyK8byS7vvAl0bAJ54Ax2wOKtXegx3+mwWl9e3U7Qtk3B8tZJAQVZW2qFwVYqcAcdMHmqdmtP60Lbg/vf/ALun3i6jp1veRxyxJcRrIqTLtcAjIyOx9qz72+uY/FOm2iG4ht5FkLERRtHOQuQu7dvUrjPC4OetbAAVQFGAOAB2rKv9De/wBUt74are2zW2THFCsOwZGD96Mnke/0xWU/7vcmNru5R1HxFKb62g063uDF/aEdtNd4j8rOcMnLbie2QuM962U1CGS48lUuQ2SMtayBf++iuP1rPPhe2N/9o+2XgiF0LxbUOoiWXOS33dxycnBJGSSAOMaCaZYR3Hnx2Nsk2SfMWFQ2fXOM0qfNb3/60X4XuOfL9kzrm7vtD0691TVZ1uLWztZZmjjUBmKlmHYfw4H1/Oqenapq1xqFzpuoXtpHfvaGeG2h06ZFiPHS4dikwUsoJVRz2HSuiubaG8tJrW6jEsEyGORG6MpGCPyrJ0zw0NO1NL2XVdQv2it2toEujERFGSpIBVFZj8i8sWPHXvXRBw5Wn/X9f155y8v62/4JoWMV7GJft86zEsPL2gDA2jPYfxZNGpajFplqJpUklZnEccUS5eVz0UZwM/UgDqSBVuqmpadHqdqIZJJImR1kimiIDxupyGGQR+BBBBIIrGV7aDja+pl67eX3/CK3F/bm70m4t1aQRuIXZsdm++uD14IPuKs674htvD9tDNeIXWUlRieGLBAz/wAtZEB/DNJfaFJqGinTrnWL8q+RLMFgEkin+E/u9oH0APvTbnw59qktZZNVvxcW8TwmdPKDSo5BYN8mB90cqFPvWUuez5d9P6/z/A2XJpzeYj+J7Y3FhDZ2095JfQC4iWJolPlnHP7x1z16Lkjv2zNPrscevLpENpPcXHlrK5jeICNCxG4hnDEDHJUH8+Kq3PhSC60m10t766FhbwpCbfbCwkC9CS0ZYNx1UrjqMHmrGpaBHqt1BJd3lw0EEiSpa7IigdejbihcH3DD9ap899O/4f18xe4XDqEIuPI2XO/dtz9lk25/3tuMe+cVAkWppfGSS4WS2DyMIlA3FSBsGcDkHd37jmpzplgbj7QbG2M27d5nkruz65xnNWq0MjnfDfiK/wBZkulvdCvLJYZ5Y1mkeDZ8rYCELKzbvU428HmsqX4hWmqaBrT6Q5trzT7fzc+db3OBnGcQySDjHQ8+gNdBH4eSK6vmF/eG0vg/mWP7sRKzgbmUhPMBPJ+/jk8VnR+BbYWFxbXGralc+dZiyWSRogYohggKqxhQRjqVJOec4GOpOje7Xbv8yJJ2aRfttTfW472yWPUNFu4Qp3SLCZArZ2yLzIuDtYYYZGDkCsu08YQ6V8PNI1nxBcCSe6giBJeKEzSMuTy5SNeATyVHHHYVqwaBJBa3QGsX73tztDag6wecqr0UDy/LAGW/g/iPfmqlr4NjtNBtdMTWdTP2GRXs7omES2+F27RiMKw2kgh1bO4+2EvZ632uv+Dr2KW2o238XxapHoNxpPlvbaleyW0u5lcpsilYgMjFSd0YGQWGM49aseJ9Ru7EactobmBJr6COW5hiikVVMijYwdwQHzjcoYjrTrzw299Z2Ec2t6iLqxnM8V8qwCUsVdMEeV5eNrkfc9O/NN1PwzNqtjaW0/iDU4/s0iymWNLbdM6sGVmzCRwQOFAB7g0fu+dNWtfz/wAv66oTvbTt+OpLqPiKOw1u10qKyuLy7uIzKEhkhXYgOC2JJFLAd9oYjvjIzVk8R6gnjGTSE0G8mtlhRxcRvAB8zEFzulB2DHTbuyDx0qXWPDA1yCG31DVLx7VFQS2/lW5Wcqc7mJiLKx9UK46jB5q1eaL9p1aDULfULuymjQRyCARlZ0Dbtr70bjOeV2nk80o+zSV7de/y/r+kO+vyJPI1L+0/M+1R/ZPMz5W0Z2bMYzj+9z16d+1X6KK5xmNp3iIatZz3Vhp11LDHny2EkB84g4wo8zKn2fbjvzVXSPFE9z4Zj1XU9LubddiM7r5ZRgxwWUCQkKvU5wcetXtP0FLLVJdRmvLi9u5IxEZZ0iUhc5x+7Rc/8CzjtjJzCulHR9Hube2W81a3ZTHFYMYQEU5+UEhfl5/iYnA71h+8STfb8f6/rqb+420vL+v+HJ7q8N9DqNtZT3NpLZgA3Maofm2h9q7gwPBGcjvxz0pN4nt9K8J6ZqOry7pbuKMAb44/McpuPLsqDgE8kDsOSBUul6BPaeFIdMlv5o7opm4uodpZ3PLY3qwx25HTHSlj8NLHpdpZrql/vsmBtrkGISRALt28JtYbcj5lPX1xVPn1t5f8ES5OpNY+IrHUNNhvrcTvFMWA8uFpdpU7SCY9y9R1BIPUEipL1dQu40k0q5FurRNxLHg7uNpwy5Hf/CpBpdvLbxR6iF1F4wQJrqKMsc/RQB+AHSrcUUcESxwoscajCogwAPYVqtjN2vocv4y8UT6Ro2qx6TaXdzf2ti87zQLFstcq2x38xgDypOFDHA5HIzcn1C8/4THTrIG5htXtpXb91E0Vyw2/xb96lc9NuDnrxTdc8H2uuy3bTX9/ax31sLa7itZVVZ1G7bklSQRvP3SM9G3Dipr3w7Jd65bakut6hbm1G2O3iWAx4ONwO6It820Z+b6Yrpi6fKl6/l/X/DkPb+vIWDxJFd+JLnR7SyuJntCoubhZIdkJZdy7lMnmYPQEIQT34OItP8V2+o30MMdhfRQ3DyRQ3cyIsckkZbcgG7dn5GIJXaccGpZ/Dcd34ht9WvL65uDaOz21u8UGyAldp2sIxIM9xvwe+RxVHwx4auLGOKfVby6lkinnkgtJDF5VuXkf5l2KGJKt/EzY3HpStT5b9bee/wDXy9RNu+n9f1/SJ9Aubxb/AF+2vr6a/Sxu1WFpljVlQwRybfkVR1Y4J/E1U0v4h6Tq1nfT20Up+wiNp0jnt5yqOxG/dFK64GGJGdwAzjkZsQeDkQ6qt5rWpX0WrRsl1FOIFViUEe4GOJWBCqB1x6gnmmjQP7Ft728Uaj4hup7ZLVoZXgUvGpbCgYjQAb2z3I9TVP2VnfV6eWvX7yn5f1/Wprf2vG0mopFb3Ev9nqN5jQHzGK7tiDOS2NvHH3h74s2dx9ssYLnyZYPOjWTyp12umRnaw7EdCKyfD+gy6X4Ri0u7u5HumiIuLqNzvMjDllY88ZwD2AFa1nb/AGOxgtvOln8mNY/Nnbc74GNzHuT1JrGaim0hK+hnax4gTSb61sk0+91C6u45JIorRUyQm3dkuyqPvjqe2OpANZvF9tJa282mWF9qfnWqXjJbLGGihbO1m8x1HOGGBk/KeK1JtMhn1i11J2kE1rDLCigjaRIUJzxnPyDHPrWQPBlvDZ2tvp+qajYeRaLZu8DRbp4lztD7kOCMtgrtPzHmqj7PlV9/+H/4BWlhJ/G9jFMBb2d9d26ww3E13CiCKGKX7rsXZSR1JCgsAOlR33xB0TT/ABMuiTyg3HmxwSMJ4R5cj42r5bOJGzuXlUYDPJ4bF6Twppz2l7bR+bDDeW0VqyRsMRpGCFC5B7Hvmn/2A0etSX9nq1/aJPIss9pH5TQzMAFyd6My5AAO1l6Z65NWnRvqtP8Ahv8Ag/gZrmtqXI7/AH6xNYfZLpfKhSX7S0eIX3FhtVu7DbkjsCPWo7WDU0vS91dRyW/7zCBQDy3yduy8f41Xt7DUf+EsutRuLkpY/Zlt4LVJ2dXIYsZWUqAjc7eCcjqe1a9YSsrW7F90VLS/E8rW86eRdRjLQsc5H95T/Evv+eDU1xcw2kDTXMixxr1Y/wAvc+1U5dGik06e1S5uoJLjBku4ZNsxIPXdjjpjpgDgUyx0JLKeV31C/vFlV1aK7n8xMNIz9Mdt20eigDtUgWVvxHp0t9fp9jhjVpGMrcrGBnc3pxzjtWZBrNzaaXZvfW1zd6hfFpYrKARh0X723JKqNikAktyfXIq3caMJtPSxjuJFthMruj/MWjBz5QPZSQBznjI+jtU0ddTltpkvLmyuLZm2TWxTdtYYZTvVhg8ds8DBFUrFx5epz8mv6ifCGnXjm6gmuLxI5biOGGTyQbgIEdS4HOQuV3Y61v3euW1jNex3Mcy/Y7UXTMEyJE+bhOeSCuMe6+tUbrwhDPoltpUGp6haWtvIJAI2jdpGEgkUs0iMThhn375q7c6FDe/Ymu7ieaS1xukOwGcZBw+FAwWVWwoXlfTINe7b5stuDRNLqQt3ja7haC3kUYmYjCMf4X/u9ueRnjjjN2q72UUt4lzKWkaMfu0Y/Kh/vAevufwxzViszEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsLxF4qtPDNxYjUEfyLpmVpU58sjHJHcc/wD663ayNb8NWHiG4sn1NWkjtGZhEDhXJx19uOlAGlbXUF7ax3FpKk0Mg3JIhyGFRHU7FbKW8kuoo7WEkPPI2yNcdTuPGPfpTp7GCewaz2mKErsCxHZtHoMdvbpWTqWlalcWNh9n+yy3GnXazRxuxiinUKygNhW2kBsjAIyo6dmtXqVFJvUgl8aWn/CPXWqWjWUwS4e3tVe/jjju2HQLI3ygnn16V0IuIjOIDKgnKeZ5W4btucZx6Z4zXL3Wia43hfUrCJdPmu9Rnld2ad4o41cdvkYkjp2z146Ve1HTNSv7a0uYltbTU41eFyszOqxyDDbX2AkghGAKjJXHHWqaVtP60/zLcY9O7/4BtwzRXEKzW8iSxOMq6MGVh7EVQuNYSLX7TS4vs8skyO8oN0iyRKB8p8s/MwJyMjpirtpaw2NnDa2qCOGCNY40AwFUDAH5Vk6pa6vNr1hc2NtZSW9oWJM126O25dp+URsOOvXn2rKbtt3Jik27k2peIbHTr+1sTcW8l5cTpGLbz1EgVj97b1IFatcv/YOqC+MaNZ/Y/wC0xfmZnYyyDOShXbgY6A5OQAMDtqQ6DbQagLtW+cMWx5EI5PuEDd/XNKm5NXl/Wi/W45qK+Eim1+Szsru8v9Omht7S2luHZTkkIW+UAgDJC5GSOv41Pca1HDdJaxQSy3EtnJdxqBwwQqNueuSXHY96dr9hLqvhvUtPt2RZbu0lgRnJChmQgZxnjJrL0zwfY6L4itr/AEjT9PsIlsZLecWsCxNI5aMqTtUZA2tyfWuiKg46vXX8jOW11/Wq/wCCbNjdzXQl8+1a22MAoY53ZUHPQdzj8Knnnhtbd57mVIYY1LPJIwVVA7kngCpKzNd06bUbKEW3lNLb3Edwkc5IjkKnO1iAcexwcEA4OKxk2loOKTepDqWvrDoD6to32TU7eLLOyXWFKjrtZVYE57cfWr19q2naXGj6nf2tkshwhuJljDH2yRms3WbbWtU8MzWaWlhHdXCtG6m8cxop6EN5WWPTjaPrUGsaZreqLZkGGFVjkWe3i1GaFQ5I2uHjUM4ADfKdoOevespSkk+XV6dP6/4Bsoxdr+fU2LvWNNsGhF9qNpbGf/UiadU8zp93J56jp60txq2nWd5FaXeoWsFzNjyoZZlV5MnAwpOTzxxXPHQNYt9P0yLT2givbayjtpL4XjrtI6/ujGyyL3+bB5OCvWr2oaZqcmux3emGO1B8tZrn7W2ZEUklTAYyh6nDBlb3A4NOUr/P+v62FyR7/wBf18zerOTUpzfGKaxaKFXkBnZjtCqAQ3Tocnv2PWmNoNs2o/bC37zzPMx5EPXOfvbN345z71qVoZaGJovjDQfEE00OlarZ3E0TODFHcRs5VTguArE7emD7ikn8WaW+i31/ot7Z6ubJMvHaXSvgnoCVzjNNsbDWLKfUraJbNLS4klnt7vzmaVHfkBotm3AJPO/nA45rmofBGuSaXqcd69u015p32QJPqlzeLI4Od7NKvyA5PyquB75wOpQpN3vbbr95Er2djsk1eDUbC4m8O3NjqcsLGMqt2PLDjqrOgbacexPtUOm+IrW58J2mvak8Gm289uk0hmnASLcBwXOB1OM8VWs7LWLf7fqLWWnJfzxxQxWcd2/khU3YJl8rOfnP8HYD3rGTwrrkvgvSdMuks0utJkjKJbancRJcosZQ5lRFeM/MTwGHABznhKENU+66/f8ApqUtVqdQ+vWOdMNvKLqLVJTFbzW7K8ZIjeTO4HphDyM84qLW9dj0eSxgX7NJdXtzHDHBNeJAzKWAd1DffKg52jk9O9YzeHtTttN0Z9MsrNLqwvpLqW2uNUnlR98cqH9+8bOT+8Dcr6j3q1r9r4i1PTLGO1sNME6XEVxOsmoSBUMciuFVhAS2duMkLj0NHJDnVtr91/X+fQTemm9vx1/4Br3+t6VpU0EOqanZ2UtwcQpcXCxtKeBhQxGeo6eoqlL4y8PweIm0SfVrOK+VV/dyXMaksxwEALZ39DjHQj1qnrWl65eX1tdaVHb2V35Kxy3i6i+Y/myy+SYWSVRzgttPJwUzmrt3Z6lF4li1HTobS4ilgW3uFnuGiaNQ+7cmEbccM3B29BzSjCFlfz6oHfW3kW/t9z/af2b7BJ5XmbPPycY2bt3T1+Xr1q/RRXOMoLr2jv8Aadmq2LfZQTcYuUPk4OPm5+Xnjmq+leKdG1iwW7s9Qt9p2bkaZN0ZY4VWAJwSeAO5qDQNM1PT7h0nEVtYLHtitI7trkK2eoZ41ZRjjblhzwFxzVS0/svwhPpviKWztbCCLyYrxbglm5O1irIArfdIALc1hzzSUn2/r+v+GN+SF2l5f1/wxuXt68Vvcf2eLe5u4FDtBJP5eAfUhWI4Bxxzio4NYtToNvqt/LDYwTQpKzTShVTcBgFjgdTiszSLfVT4Xe6ltoTq+ojzZ455DEq5AUAkKxGFA4x1z0qtL4f1W58O6TbTpbLc6Y64jhv5o1lURlM+aiqyHknoR278U5SV7eX/AARKMep1EFxDdW6T2ssc0Mi7kkjYMrD1BHBFVNSv7myI+zWEl2DG7nYSMEYwOh65/SqNv4agbTLeCeJbZoy7MiyC7G5m3E+ZMhY5PPbrWxa262trHBGcrGMD5VX9FAA/AVqtrszdk9DJ8UeKtO8K6NPeahdWscywPJBbT3KxNcMozsXPJPQcA9alfXox4mtdHh+zSySQPNOPtaCWADG39195g2TyOBj3rF8T+G9Z1GbWV0ltP8vV9PW0eW6Zw9uVEnRVU7g2/wBV2nJw3Sr+oWmuv4n0+6s7PT5LO0R0Z5b10kbft3EIImHG3j5ufaumMafKu+vXy0/H+rEPb+vI021vSk1ddKfU7NdRcZWzNwgmYYzkJnPQE9OgpYNa0u51A2FtqVnNeKnmG3jnVpAucbtoOcZ71kJpGrReL3vLPyrOwml8y6K37y/asJtGYHi2xngco4zgZ3cAZfg/Tr24hs5pbWytrKzvbuaKSGZmlndpJUO5dgCfeJ4Zs4FL2cOXmv0/H+um/oJys7HQ6PrNxfXGqQajawWcmnXAiYxXBlRlMayBslFxw/IxxjqamtPEWiX9s9xYaxYXMCSLE0sN0jqrsQFUkHAJJAA75rEstN8TrceIHkj02xfU8yW88F487QSCFI1yrQqCPk3Zz7YPWs218P8A9iWmsX3iu+gsbK7sorZ3l1aa68tlZ8P5s4GCS4woAwRxkmqdOFnffTRa69Sn5f1/X6HcNe2qPMj3MKtboJJlMgBjU5wzeg4PJ9DT4ZoriBJreRJYpFDJIjBlZTyCCOornvDtrqM/hOW61O3gGranGZpop0Plhim1EZeuAoUEeu6tvTYZbfS7WG4jt4pY4UV47VSsSsAAQgPRfT2rGcVFtX2EnewzUNY0zSIw+q6jaWKEFg1zOsYIBAJ+Yjuyj8R602+1zSdMhgl1LVLK0juDiF7i4SMS9/lJPP4VWvtHa88U6ZqZELRWVvcR4cZYPJ5eCvHorAnI6+5rCs/DWt6Rp9nHZR6beTf2VFp1wLmd0WLZu+ZMRtvB3nKnbnavNVGMHFXev/D/AOS+8qyte5011relWN5DaXup2dvczsEihmuER5GPQKpOSTkcD1p02saZb6pFptxqNpFfTDdFavOqyyDnlUJyeh6Dsa5tvBc0Wn6lbW0sLyT6da2UE8mQ/wC5DcsQOBkgjGabc+ELmTxZcXrwJeWV1dw3TFtYurcxMgQD9wgMcmDGrAkr6HpmrUKTdr/1p/XyM1Jtao61bu3a8e0W4iNzGgkeEON6qSQGK9QCQefY1VtdQuZ70wy2EkMY8z96SSDtbA7dxz/jVK2luJfHF6I9OhW0js40kvmt2jleXcSIw5GJECnPy5AJIzk1uVhJctvQvuiK2uYbuES27h0yR0wQR1BB5B9jUtZD2OoxQ3V5ZtanVJwAqybhAuCODt5Y4/iPP0HFNhtdZvfPt9caxFrIrhTZNIsgPmNszngjy9ufVt3GKkDUt7qG6jMlu4dAxXcBwSOuD3+orPtvEFm2iLq1/Pb2FlIx8qaecKrpuwjZOANwwQPcVHf2moS6D/ZyBGaZhbvNCfL2QnhnxxtbbkALnkg9Oiarpl59r0y60eK1kax3oILmRo0CsuNwIVvmGMYxyCeRVJIuKT0ZWbxfAdCsb+EWrSX9wIoIJL5I/NXzNhZGbAbA+bA5PQda3jd26vMhniDQKHlUuMxqc4Leg4PJ9K5W80HXB4Ss9JtV0+4nS5WeeWSd4VylwJQFUI55xjk8f7VX9U0S61R4pWS2ha6gFrqSCQsGizuIU7Ru/jUZC8SE9sGrK3zZbjG1zaS8t5J1hSVS7IJEHZ19Qeh/D1HrU1ULuwa9uIVkKx2sJDqI+HLex/hA9uT7DrfrMxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqrdanZ2V1bW93cJDLdEiEOcByMcZ9eRx3q1XK+NPCc3iubTYknW3ggd2mkxlsELgKPXigDqqKpLZS2ejLZ6dO3mRR7I5bgmRj9T6+/OPQ9Kw9U8+30O1WG31CGA3YXUvIEj3BQqcsrR/O2X2fMnO3OMY4aV3YqMbs2brXdNs9MvNQubnZa2TMlxJ5bHYVODwBk9e2a0AcgEdDXn00D2fgjUBHb67BO17NJZLEbl5ySMoXKEsQf8AbJHQHniug1G9ulFpq+lx3sySRPbm1aGRPmbmN2jZQy4ZdpYgYDkngZFOOmn9aFumund/gdDVafUbW2v7Wynl23F3v8lNpO/aMtyBgYHrRp1q9lpltbTTyXMkUSo80rbmkYDlifUmsTVbtbTxdp0iLqrDDrcCGG5kg2lTtyFBTO7v1Hespvl+8mMeZs3rm7gtBEbh9glkWJOCcs3QcVNXEXUV1da7H9pt9Ulu4dVVgV80W0duD8rAZEbcEZPLA5zgDjo4YNVXUA80+bfcTt85Dx248kH/AMe/E0qcnNX/AK2X4jnBRLEOr2NwzLHOPkRpGLKVCqrFSSSMDBBqCy8TaHqUVxJpmsWN8tsm+b7JcLMY155IUk9jV0Q29sGlSBEKqcmOP5sZyQABk8849a5/wpeRX/8Aa8TWl7Gsl5JKBeWE0CvG2AMeYgB6Hjr61vGN4t22M3p95v2t9b3oc2sm8RkBvlIwSAe/sRU9Mjhih3eVGibjltqgZOMfyAFZniT7V/Za/ZftAj85Bc/ZAfO8nPzbNvzZ/wB35sZxzispOyuOKu7FrUtUtdItftN8ZVhzgvHA8m33OwHA9zxVzrXK6zLbp4FuobCHVZhcI8cSS291NMWOeocFwPduKi8T3V1fxWC2EeoQwyxyP5yW92GDjaFRkieNlzknc5CjHvmspVeVN77f1/kbKne3Tc6+iuHvJtRax0a5uV1Ke8FlGZLCJLqEPKcZLSxfKrZ42yAj3UEmr2stcJ4ptpIhfXQ/dILWMXUMcfzEl/MT903B5Rx2+8Ohp1LO3nYXszqqqR6paS3f2VJczbmTbsbqoBbnGO4/OqzQar/aO9Z/9G8zO3zk+7npjyc/hu/GrxtLfcWEKK53Heq4bJ4JyOcnA59q0Mh8U8U4YwypIFYoxRgcMOCD7j0qO9vbfTrGW7vJPLghXc77ScD6DmuR8OafBod9q0EUGtS30ck8kaTz3ckEyEhl2u5MRc5AzndnPvXOWaa5N4f1yNxqc8U+mh1WSzvAyTg8oi3MkjOQD/CoVvQ4OOpUIt6PTT8SJNpM9Su7qOytJLmZZWSMZYQwvK5+iICx/AGm6ff22qadb39jJ5ltcxiSJypXcpGQcEAj8RXO6JcpYx6nep/bUml4jMa3sF1LOZeRIUjdTLt5TgLt4YgAZrBim1KT4X6La2EepWTW5it9Q3addCaNRGc7UQxysN2zJjPr1AIpKje680vv/UpWaueiSXEMMkSTSxxvM2yJWYAyNgnAHc4BOB2BqDUdUs9Jihk1Cbyknnjt4ztLbpHYKq8A9SQM9K47dcWWl+GLu6k1HUorXUZXklXTLoSohhnRd0T75sAso3NknIOeaueKdTie10i/s49dEv2qKRVtbS8H7oSr5vmxIv8AdzgSDJ5wKPY++lq03b+v60E3ZX8r/mdhTPPiNwYBKnnBQ5j3DcFJxnHXGQea47xTcSvqmn3Vouq3X7pWj0+GO+t1cswwzSxDYpx1SUY9SgJJdqOlWlt4/j1C7XWit1CixtaT3jxrKsnR1iJVEwQcMAn3velGkmle+t+nYG97eR0/9qWn277J5v7/AH7Nmxuu3d1xjpzVuo/s0Hneb5Mfmbt2/YM5xjOfXHH0qSucYUyGaK4hSa3kSWJxlXRgysPUEda5Tw9FLcXF5a3J1K4jkiJe+le8tiSW+6I5CAh6/NGccdF4FReH9MeLwnJYWbana6pbxqG+0SXCxiRCSAhf5ShIwdnBBrBVXo7aWv8AcbOmldX7HWXt5FYWj3NwJTGn3vKheVv++UBJ/KnW1xFeWsVzbtvhmQOjYIypGQcGue07UzeeH7zXZhdtDfj/AEe3SN5SkYG1cIgJ+Y5YkDoRnpWdPLfzeCdGishfWiReXDe4srjzUCx4+4hSUjft5Q/mM1TqWv8AL+vyBUr6Hb1VvNTtNPIF3L5eUZx8jHgYz0HuKyLC21b+xLRbe/lnYb90kyNbORu+UFZUkfgcZY5OMnOc1sR2oltoxqEcc0oQqxcB856jO0cHA7CtVqrmbVnYW+vrfTdOnvr2Ty7a3jaWV9pO1QMk4HJ49KZLqtnBqdrp8s226u0eSCPaTvVMbjnGBjcOvrXD/ECC7vk1izktdauVfTMabFpxmWJ5CH8zzDGQpIwnyyHBHCgkkHXvr1LLx1p7KmtMGgaK4EVvdy2wJ2+XwqmIH72WHI7mumNFOKfV3/LT+vkQ9F/XkdZRXGg3KfEYlf7RvY5JMYIvbeG0UR4Prbzgn/dIJ6scYp+FZ577U7W4iudZnnS4ulvWuvPFt5IeQIqbgI2IITBTLYByan2Pu81+l/6/z+4TlZ2Ow0zWbLVzciyabday+TMk1vJCyNgNjDqCRhgcjg5q9XFaZq7/AG7xXLZ6Zqcs0rfaLWOawuLYT7LeNNod0ABLKR1z3ArN8M2mu3EOrW/2zUPKa2gmtJriK8t9twrOWX/SZXkK8IGGQpHbkk06KSbelkt/Pf7inp/X9dz0eiuY0W+k1vw7f66/29ItQiJt4ImPmRxKpAKL0DsdzA98rnpW3o//ACA7H/j7/wCPeP8A4/f9f90f6z/b9ffNZSg43T6CuXKK5zXtPudT8S6Xb+fqMOn/AGa5a4NncSQhnBi2BnQgg/eIwQTgjpkHnzLqEulaYfEa6/ltKiMQ05bhZPtfPmeb5OCDjy8eZhPvVUaXNFO/9a/5FW0ueh0VwN5Y6/LFeXl5PqZv7KwtJIIrWaRIXuMEy/ImBJkgAqcjHbmkvotal+IDmbUr6ziW5hNokWnXc0Lw4XcpeOUQjLeYCZULLnOcbcWqKbtzf1p/n+Zmppq539VINUtLm6NvBLulG7K7GGNp2t1HrWfFcwr47ubXzdRM76fHL5bHNqqiRhlR2kJPPqAvpWsltBHJvjhjV+fmVADycn8zzWDVi/IlorDinm0uzurxLS6exTBhso498x5wSq5G0d9pzj26U+HV7jVPPt7OwvrCZVcpNe222M7ZGTg5PJ27hx90qcHOKkDZqG1u4b2NpLZ96LI0ZO0j5lJVhz15BGelY8902neHWW0ikgv55PIiWcby07cbif4wPvEj+FT0xgVNWtP7MtNI09V1E6VGGjnOn+aZmYL8m5ovnAJDEkEc4ycHmkrlxjfQ2Zte02DTE1CW522skqwrJ5bHLl9gGMZ+9x/9atCvPrhZ9O8EaQgt9agvortXWK3S4kZUFyDIJfK3Bv3ZP3yc84zW5qr37zebpbX3l6taiBP3br9kkzxLtYZj+VmJ3Y5RRjJ5rk007st01a50tFZVxbTC/gGniRJo0US3EhJRkH8Lf3z16EEdcjODq1mYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUZ5x3ori/HttrVxf6J/wAI55ou1kkO9DgIML949MfXrQB2lFUllvrTRlku41u7xI/3i242qzewPOP19B2rNutWurfTbD7NcQT3OpXQgjnaMmGAlWblQQSBsIwSCWPUdmlcaVzforz2ZZ7r4f68ZJ7C9QXtwbr9y/lTqDyq7ZQUOR13NjB4rq9S1aTSbuBp1j+wPBISwB3rKi7gPQgqH98r3zTcbL+uxbhZ2Xn+Br0VW057uTTLZ9SSNLtolaZIs7VYjkDPOB0rK1KJ/wDhMtGklW3kjxMsWUcSRNsyx3B9pBAAwV49aiV4kxVzeorjdS1O6v76zZp7SG0j1pLZLdoyZpGRuW3bgB67dp45zzxvQ6pcy6gLdrPam4r5m2boO/MQX/x7HvU05c6uv60T/UcoOJqUViXOkwaXp19dWjyrKtpMqtuHy5LPkYHByay/CUsviDS7iTVpbmG6aBbZ7J5OYYyvyuRkqzOPm38/3f4WzsoNxcuxDdmvM6+iqljp0OnCUQFj5rBm3HPRQv8AIVBrmoTafZxG1EfnXE6W6PNny4y5wGbGCR7ZGSQMjOazk0hpXdjSormvFFi0/gm9/tkWl7cQxtIkiW2xUYdGVWZiCAeual8Saze6c1vBpQV7l4pJnRrdZAI0xliWmiCgFh3J56cVEqnKm2jSNPmsk+50FFctP4h1JtN07VIkjtNOmtFuLm4a1a58skA7dqOrKMfxYYeuAObeqapqNlrMIby7fSm8tTcNaNPvdmI25WQGPjGGKFeeT0FNySdvOwvZs3qKy21S5Go/ZxZ5j8zb5m2bpnr/AKrb/wCPY96emjQQ3xvIWYTb5HG7BUM4APHHHyjv61ZFjRork/DM+tQQ6nc67q1nPa21zcBwlnIjptbOdxlbCAdFx0I59cC68Tatqfh3XLPWLVVY6Yt5b/uUtyyMxAyFnmIzxydp68GuhUG20mun4kSlZNnpdFYFmbnUp9T0bxJHp+oRxpG5EVsRGyvu/dujs2SNuc8ZDDgVg6frF5o3wx8MJpNqJ7u8hhtoV2oQp8st91pIw3CEAb1698YMqlfRPqvxv/kUtVc72iuSOoaxJJ4XOrQyWFzNqMsdxCrKolUW85UlUdwAdqtt3Nggc8VY8ZxSSQ6U7LbS2sep2pkhmjcsWMyBGV1ddpUnOCGB9KPZ++ot7ibsr+V/z/yOlornfEerarpd5DLD5dvpSJvubt7J7radwG3akisgxzu2uB1O0DmB/wDhIG+IEsUGq2aWP2SOQW8llIxK+YQwBEwG/wD2tvQjjjlRp3V79/wBu1zqaKof2Nbf2n9uzJ5vmeZjIxnZs9PT9av1kMKr31lDqNm9tc+b5T/eEUzxk+25SDj2zzWNpuo6xdTXFpfvBZXxjMkMD2LkIA2N3mCUrKORwCp55Aziqeh3euw+Bor+a5t76VYFkVDbv5hUHLgsZDuYgEDgc9jWPtE1qtLXNvZtPR6nVxRRwQpFCixxooVEUYCgdABTqwRPD4i03U/tEFrdaX9y33x7xKVXLMc8HDcDjgqaof2teaZ4P8PxaZbia6vIookyFYLiLcflaSMMflxjcOuecYNudrt+X4kqnfQ62isOHVtVi023e/0zZdPuEiAOcYOAcRLKBkYONxx0yetWLjTIdbt4prxZInMTJtQkYDYz95Qe3cD6Va1VyGrOzNSiuC+IWrXjaH4j0+1urGytrLS99w11GXebzQ6qqYdQn3MAndknGOOdi6gk/wCE80eaYW0kf2SdYD5biWI4Td82/awPHBTIx1rf2Xupt73/AAVxdP68v8zpagsrK30+1FvZx+XErMwXcTyzFjyfck1hvq2rQeMBaXwjtNNlkEdqTZPKbk7Mn98smIiG7PGM4+UnPFfSNe1i7vLCW9+wfZL6e4t1ghifzU8sviQuWwQdmCu0YLD5jU+zly3vpv8A15ktpM6uq2oafBqljJaXZmEMmN3kTvCx9tyEMPz5rmdG/s/w9ceMZoooLGztboTuIoQFT/RYmZtq4zzknHJqrpXirxFcLqtve2US3tjbQXkaNbLGZI2Z9y7EuJcMVQ7SWHJ5XA5pUn8UXtZ9t/8AItpr+v67nbQwxW1vHBbxrFFGoRI0GFVQMAAdhT6xLPWpdStNTvrGWz+xRArZzyEhHZVyzu2fuBjt4wRtb8NLTZpbjS7Wa4kt5ZZIUZ5LVi0TMQCShPVfT2rOUWtyVboWaKwNc1HV49d07S9Feyia7gnlea7heUJ5ZjxhVZc53kdR654wcy38Uarq9hbS6c+n6e/9lRajO15E0qtv3ZRcOm0AocsScbl4qlTbjzdP+H/yZVmdlRXET+LdakimvrWGztrOzsrW9ngnid5nEoJaMEMoUgKfmIbk/d4qebxH4hn8W3FlpOki40+yuo7e4bEWSGVGZ95nVkwHyF8ps7evzfLXsJXtdf1b/NEKakro6mGytba5nuLe2himuSGnlSMK0pAwCxHLYHHNT1nxXdyfElxaPPYm2W2jkjhRz9pDFmDMy9NnCgH1DUtro1tZ3puojJ5h8zqRj523Ht61k79Si/RWVbaoIftIv542t7Y4N8zBI+uNrE4G4dDjj6HipW1m0khm/s6aG/niViYLeZWb5WKngHswIPfIIxnipA0KKyv7TNp4el1KaVbxgpdVhAUMx4WNc984XnnJ7dBnA32j2um6Vay2sd/eebNcXdxEXjDj55DsDKSSWOBuGAO+MU7FKNzpqK8+YyS/DnSpy9nd2/2+Iyho32y7rsBWRlkG3BO4Z3A8Cul1fWbzTLq5jEUMge1D2IO4F5t2wox9CXjxjnlvSq5fzaKdPsblFZlzd3NndWw3LcPMoV7aNcNkdXU9h67jjpzng6dQZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVyPjnxPfeGbjSpbGNZ0nkdJYCP9YPlxg9QeeP5GgDrqrXOm2N7ay215ZW9xBM26SKWJWVzwckEYJ4H5UyLUU/sqO+vY3slZAzRz4DIT2IHf261Bca0LOxjnubSYS3EvlW1qhUyzMQSBgkBTgE8nAA5Ipq99Cle+hJc6Do95arbXelWM9ujb1iltkZA2MZAIxnHGakTSdOjsYrNLC1W1hYPFAIVCIwOQQuMAg85HeuYuNf1RvCOq3nl3tpcR3UsSukVvJJZov8TKXCOB7Fjz3rpZdTht9Qis5xIrSQPOspUbCEI3DPY/MDj0z6Gqd0tympJWv3/Au1QutC0i+uxdX2lWVzcDGJprdHcY6ckZ4qfT7xdR063vI45YkuI1kVJl2uARkZHY+1Z97fXMfinTbRDcQ28iyFiIo2jnIXIXdu3qVxnhcHPWsppLSSFG93Zl3+ytO+3Pe/YLX7VJt3z+Su9tuMZbGTjAx9BVuuc1HxFKb62g063uDF/aEdtNd4j8rOcMnLbie2QuM962U1CGS48lUuQ2SMtayBf++iuP1og1Je7/AFs/1CUZLcsuiyRskih0YEMrDII9CKhSxtI7hJ47WFZki8lJFjAZY852A9QuQOOlVbWLU4JGe9uo5YhG2FCgfNvJB6D+HA/zmodFv7vWvBtjqGY4by9sUmyg+RJGQHgHPAJ75rRJ8ra/rf8AyJsa9R3FvDd27wXUMc8Mg2vHIoZWHoQeDUFjFexiX7fOsxLDy9oAwNoz2H8WTRqWoxaZaiaVJJWZxHHFEuXlc9FGcDP1IA6kgVErJagr30IX8PaNJYx2T6RYNaxsXSA2yGNWPUhcYB5PNObQdIeC3hfSrJorUkwRm3QrEc5yox8vPpWfrt5ff8IrcX9ubvSbi3VpBG4hdmx2b764PXgg+4qzrviG28P20M14hdZSVGJ4YsEDP/LWRAfwzWUnTim5LTT/AIBqlN2Sfcnl0HSJ5IJJtKspHtlCwM9uhMQHQKcfKB2xT5dH02fUEv5tOtJLyPGy4eBTIuOmGxkVRfxPbG4sIbO2nvJL6AXESxNEp8s45/eOuevRckd+2Zp9djj15dIhtJ7i48tZXMbxARoWI3EM4YgY5Kg/nxVe5f5/iTaf4fgalFVTqEIuPI2XO/dtz9lk25/3tuMe+cVAkWppfGSS4WS2DyMIlA3FSBsGcDkHd37jmtCLEi6NpiapLqSadaLfTJskuhAoldeOC+MkcDjPYVDb+GdBs7Sa1tNE06C3nBWWGK0jVJAcZDKBg5wOvoKoeG/EV/rMl0t7oV5ZLDPLGs0jwbPlbAQhZWbd6nG3g81lS/EK01TQNafSHNteafb+bnzre5wM4ziGSQcY6Hn0Bro9nVvZPa3X7iW0lc6aPw9osWkvpcWkWCafIdz2i2yCJjkHJTGDyB27UyLwzoMOmS6dDomnR2MzB5bVLSMRSNxyyYwTwOSOwqK21N9bjvbJY9Q0W7hCndIsJkCtnbIvMi4O1hhhkYOQKy7TxhDpXw80jWfEFwJJ7qCIEl4oTNIy5PLlI14BPJUccdhQlVd0nrdfe9vyGlpobUnhrQpdLi0yXRdOewhYvHaNaIYkbnkJjAPJ5x3NMuPCnh27tbe2utB0yaC1BWCKSzjZYQTkhQRhc+1ULfxfFqkeg3Gk+W9tqV7JbS7mVymyKViAyMVJ3RgZBYYzj1qx4n1G7sRpy2huYEmvoI5bmGKKRVUyKNjB3BAfONyhiOtFqqmot2d+4nZK/l/X5Fubw3odxcW09xo2nyzWiqttI9qjNCqnKhCR8oB6Y6VNe6RpupT282o6da3ctq2+CSeBXaJsg5UkfKcgcj0FU9R8RR2Gt2ulRWVxeXdxGZQkMkK7EBwWxJIpYDvtDEd8ZGasniPUE8YyaQmg3k1ssKOLiN4APmYgud0oOwY6bd2QeOlJRqOzv36hornRUVQ8jUv7T8z7VH9k8zPlbRnZsxjOP73PXp37VfrAZTsNH0zSy50zTrSzMmN5t4Fj3Y6ZwBnrUMmkR28Vy+hxWWnXlycyXAtA285ySwUqWPJ5J6nvUGneIhq1nPdWGnXUsMefLYSQHziDjCjzMqfZ9uO/NVdI8UT3PhmPVdT0u5t12IzuvllGDHBZQJCQq9TnBx61jzU3ZeX4G1qibbNG20DTbfQYNGe1iubKBFQRXCCQNjuQRgnPP1p66FpC6e1gulWQs3be1sLdPLZvUrjGeBUV1eG+h1G2sp7m0lswAbmNUPzbQ+1dwYHgjOR3456Um8T2+leE9M1HV5d0t3FGAN8cfmOU3Hl2VBwCeSB2HJAptw1bX9f0hJTdrM3LW1t7K2S3soIreBBhIokCKv0A4FS1lWPiKx1DTYb63E7xTFgPLhaXaVO0gmPcvUdQSD1BIqS9XULuNJNKuRbq0TcSx4O7jacMuR3/AMK1Wpm072ZJeaNpeo3Ec+oabZ3U0aNGkk8CuyqwwygkZAIJBHfNQ3XhrQr3UFv7zRdPuLxCpW5ltUeRdv3cMRnjt6VkeMvFE+kaNqsek2l3c39rYvO80CxbLXKtsd/MYA8qThQxwORyM3J9QvP+Ex06yBuYbV7aV2/dRNFcsNv8W/epXPTbg568VvGNRJNO2/Xtr+Intr/WxfTQtIi1ZtVj0qyTUX+9eLboJm4xy+M9OOtVPD/hbTvD6SPbWtr9smeRpruO2WOSUNIXwzDk4yBye1LB4kiu/Elzo9pZXEz2hUXNwskOyEsu5dymTzMHoCEIJ78HEWn+K7fUb6GGOwvoobh5IobuZEWOSSMtuQDduz8jEErtOODStV5bdLfh0/4Yl2uWbLwvoGmzyTadoem2ksiGN5ILSNGZT1UkDkH0pP7Bg07TZYPCttpujzuAFkSxBQc85RGTPfv19elVdAubxb/X7a+vpr9LG7VYWmWNWVDBHJt+RVHVjgn8TVTS/iHpOrWd9PbRSn7CI2nSOe3nKo7Eb90UrrgYYkZ3ADOORmnGrK7vfb8dtynpubml6LZ6ToNvo9vGHtIYfJ2yAHeO+7sc5JP1q5DDFbwJDbxpFFGoVI0UKqqOAAB0FU/7XjaTUUit7iX+z1G8xoD5jFd2xBnJbG3jj7w98WbO4+2WMFz5MsHnRrJ5U67XTIztYdiOhFZS5ndsWg5reF7hJ3ijaaNWVJCoLKGxkA9QDgZ+gqlc+HtFvYbaG80ewuIrTi2SW1Rlh6fcBHy9B09BUOseIE0m+tbJNPvdQuruOSSKK0VMkJt3ZLsqj746ntjqQDWbxfbSWtvNplhfan51ql4yWyxhooWztZvMdRzhhgZPyniqjGpZSj/W/wDwfxH0NmSxtJvO861hk89Qs26MHzAOgb1AyevrVe50LSLzUotRu9Ksp76HHlXUtujSpg5GHIyMEk8VlT+N7GKYC3s767t1hhuJruFEEUMUv3XYuykjqSFBYAdKjvviDomn+Jl0SeUG482OCRhPCPLkfG1fLZxI2dy8qjAZ5PDYqNOre0U7k3i1c14NFt4vEFxrLySTXc0SwIZAuIYwc7FwoOC3J3EnPcDitGqkd/v1iaw+yXS+VCkv2lo8QvuLDard2G3JHYEetR2sGppel7q6jkt/3mECgHlvk7dl4/xrKV3uUWJLK1mszaS20L2xABhaMFMem3pTbfTbGzlMlpZW8EhBBeKJVJBYseQO7Esfck020vxPK1vOnkXUYy0LHOR/eU/xL7/ng1NcXMNpA01zIsca9WP8vc+1SHkRzafaXGzzYFISYTgDgGQdGIHU/XuAewovtNsdThSLUrO3vI0cSKlxEsgVh0YAjg8nn3pq34j06W+v0+xwxq0jGVuVjAzub045x2rMg1m5tNLs3vra5u9Qvi0sVlAIw6L97bklVGxSASW5PrkVSv0LSlui9eeH9G1GOKPUNJsbpISxjWe2RwhY5bAI4yeT61Oum2KR20a2duqWhBtlES4hIGPkGPl4JHHY1y8mv6ifCGnXjm6gmuLxI5biOGGTyQbgIEdS4HOQuV3Y61v3euW1jNex3Mcy/Y7UXTMEyJE+bhOeSCuMe6+tO0rFOM7WNARoJWkCKJGADMByQOgz+Jp1UpdSFu8bXcLQW8ijEzEYRj/C/wDd7c8jPHHGbtQZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDLaW81xDPLCjywZ8p2XJTPXHp0qaszVvEOn6Jc2cWpy+Qt2zKkrD5VIx949uvXpQBpOiyRskihkYYZWGQR6Vl3fh+G6sYbdLq6t2tphPbTRspeBgCMLuUgjBYYYHgn2xqKwdQykMpGQQeCKRJUk3eW6vsba2052n0PvTWjGm0YU/hKGXQ59Li1PUIIrmV5J5FeN5Jd33gS6NgE88AY7YHFWrvQY7/AE2C0vr26naFsm4PlrJICCrK21QuCrFTgDjpg806XXYk0y+vIbS8ufsUrxNBbxB5ZGUgHYueevtWmDkA9PrTu7FOUuvn/wAEAAqgKMAcADtWVf6G9/qlvfDVb22a2yY4oVh2DIwfvRk8j3+mK1arT3vkX9ra/ZriT7Rv/fRx5ji2jPzntnoPWs5JPcUW1sZx8L2xv/tH2y8EQuheLah1ESy5yW+7uOTk4JIySQBxjQTTLCO48+OxtkmyT5iwqGz65xmlvb+KwWAzK7efOkC7QOGY4BPtVmiKUVaP9f0rBKUnuIy7lKnoRisjw/4ffw/bR2qaxf3trDCsMMF0sG2JVwBgpGrE4GOSaeviKzMc8kqzRRwQSTyOyZwqMVbhckn5ScAU5vEGnCTy0maSX7Gb1UVD80Q75IxnkcE5rVOSi7bP9CWujNOqmpadHqdqIZJJImR1kimiIDxupyGGQR+BBBBIIosdQj1ASmJJE8pgp3gDJKhvX0YVbqGr6MadndGRfaFJqGinTrnWL8q+RLMFgEkin+E/u9oH0APvTbnw59qktZZNVvxcW8TwmdPKDSo5BYN8mB90cqFPvVrWNUGj6e15JaXFzFHzJ5GzKL3Y7mXI+mT7VfByKz5Iu6ZfNJJMwbnwpBdaTa6W99dCwt4UhNvthYSBehJaMsG46qVx1GDzVjUtAj1W6gku7y4aCCRJUtdkRQOvRtxQuD7hh+ta1FU4p7i55FU6ZYG4+0GxtjNu3eZ5K7s+ucZzVqiqEWsQTah9jWKYP5kibiBtygUnv/tCq8iCvH4eSK6vmF/eG0vg/mWP7sRKzgbmUhPMBPJ+/jk8VnR+BbYWFxbXGralc+dZiyWSRogYohggKqxhQRjqVJOec4GOhtbyC9WRrZ94ilaJ+CMMpwRz71HqmoxaTpdxf3Ku0Vum9hGAWI9skVqpzTsvIUrdf6/qxSg0CSC1ugNYv3vbnaG1B1g85VXooHl+WAMt/B/Ee/NVLXwbHaaDa6Yms6mfsMivZ3RMIlt8Lt2jEYVhtJBDq2dx9sbt3PJbWkk0NrLdugyIISgd/Yb2VfzIqHSNTi1nRrTUrZJI4ruFZkSUAMoYZwcEjP0JoU52bXfy+X9bbj2KF54be+s7CObW9RF1YzmeK+VYBKWKumCPK8vG1yPuenfmm6n4Zm1WxtLafxBqcf2aRZTLGltumdWDKzZhI4IHCgA9wa1bm+trS4tYbiTZJdymKBdpO9gjORx0+VGPPpTNR1D+zooX+yXV15s8cO22j3lN7Ab2HZRnJPYUKc7q3y0Qmu/b8DN1jwwNcght9Q1S8e1RUEtv5VuVnKnO5iYiysfVCuOoweatXmi/adWg1C31C7spo0EcggEZWdA27a+9G4znldp5PNadQC8gN+1kH/0hYhKUweFJIBz06g0lOXToFieiqH9sQ/2n9h8qbzPM8vdgbc7N/XPpV+sxmVp+gpZapLqM15cXt3JGIjLOkSkLnOP3aLn/AIFnHbGTmFdKOj6Pc29st5q1uymOKwYwgIpz8oJC/Lz/ABMTgd626hs7yDULOK7tH8yCZdyPgjI+h5rNwjbl/rXc055XuZOl6BPaeFIdMlv5o7opm4uodpZ3PLY3qwx25HTHSlj8NLHpdpZrql/vsmBtrkGISRALt28JtYbcj5lPX1xWnfXTWVlJcJbTXRjGfKhKBiO+NzKOOvWlsbtL/T7e8hDLHcRLKoccgMMjPvzT5Ytv5f8AADmla5CNLt5beKPUQuovGCBNdRRljn6KAPwA6VbiijgiWOFFjjUYVEGAB7CnVQ1LV4dMIE8cr5jeT92AeFxnqR6ir8iNWzO1zwfa67LdtNf39rHfWwtruK1lVVnUbtuSVJBG8/dIz0bcOKmvfDsl3rltqS63qFubUbY7eJYDHg43A7oi3zbRn5vpir2q6lDpGjXep3KyNDaQNO6xgFiqjJAyQM8etEuoeXqdrZi0un+0xu/npHmKLbjh2zwTngd8GtlOpZW8/wDg/gLp/Xl/wClP4bju/ENvq15fXNwbR2e2t3ig2QErtO1hGJBnuN+D3yOKo+GPDVxYxxT6reXUskU88kFpIYvKty8j/MuxQxJVv4mbG49K6eip9pLl5Rcqbuc5B4ORDqq3mtalfRatGyXUU4gVWJQR7gY4lYEKoHXHqCeaaNA/sW3vbxRqPiG6ntktWhleBS8alsKBiNABvbPcj1Naeka0urTX0JsrmzmsZxBLHceWSSUVwQUZhgqw759q0qqVSa0l5f1p5D1MPw/oMul+EYtLu7uR7poiLi6jc7zIw5ZWPPGcA9gBWtZ2/wBjsYLbzpZ/JjWPzZ23O+Bjcx7k9SamoqJTcm2+okrFObTIZ9YtdSdpBNawywooI2kSFCc8Zz8gxz61kDwZbw2drb6fqmo2HkWi2bvA0W6eJc7Q+5DgjLYK7T8x5ro6KFOSVl/W/wDmyru1jFk8Kac9pe20fmww3ltFaskbDEaRghQuQex75p/9gNHrUl/Z6tf2iTyLLPaR+U0MzABcnejMuQADtZemeuTWvRR7SXchRSVkZFvYaj/wll1qNxclLH7MtvBapOzq5DFjKylQEbnbwTkdT2rXoqha6xBd3ptkimVx5nzMBj5G2nv6mpbuV5jZdGik06e1S5uoJLjBku4ZNsxIPXdjjpjpgDgUyx0JLKeV31C/vFlV1aK7n8xMNIz9Mdt20eigDtWlHIk0ayROrowyrKcgj606kBmXGjCbT0sY7iRbYTK7o/zFowc+UD2UkAc54yPo7VNHXU5baZLy5sri2Ztk1sU3bWGGU71YYPHbPAwRV9JUk3eW6vsba2052n0PvUGn38epWpuIFcReY6KzY+faxXcMHocce1PUpNrUyLrwhDPoltpUGp6haWtvIJAI2jdpGEgkUs0iMThhn375q7c6FDe/Ymu7ieaS1xukOwGcZBw+FAwWVWwoXlfTIKf27E2jx6jBZ3lwkkwiEUMQaQfvNhYgH7oPJPYDNalPmlYblK1mV3sopbxLmUtI0Y/dox+VD/eA9fc/hjmrFNEiGVow6mRQCyg8gHocfgadUkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz3ijwnD4pnsBeTNHb2rOzog+aTOMDPbpXQ0xp4kmSF5FWSQEohPLY64HfGaAK39mxwaSNP05jZRomyMxD7g/H/9fuDzWLq+nXc2h2VummLPDb3Sm7sIXTbdxYYEDeQCNxViGIztIOe/TUU07O5UZOLucDdeHZl8EX1gvheOSaa7lltLWAwFbXcPlcFmUKR0+XkE8ZHNbuowahOLTVdOsJYL/wAp7Z4Znj3Ij9Gba5U7WVW4JOC2OTitmXULOC1muZruCOCAkSyvKAsZHUMc4H41YznpVOTa1LdRvfz/ABK2nWMWmaZbWNvnyreJY1yckgDGSfWsTVbaZfF2nX9poM1w0AdZryIwKWVlIC5ZwxAJzjGPTNdJUUlzBFcRQSzRpNNnyo2cBnxycDvj2rKa5tWyYyaZyEuhXkuvLNLo6TXEeprcDVJHjz9nzkInO8bQcFcAcEgknnoIdLuYtQFw15uTcW8vdN0PbmUr/wCO49q0ZJoodvnSJHvYIu5gNzHoB7+1PpU4qCsv60X+Q5zctzN8RWs994Z1G1tE8yee3eNEyBkkY6niqUOhtY+K7S6tEdrb7PcrM7OPkZ2hKKB1xhGxgHH41sxXdtO+yC4ikbBbajgnAOCePfipHdIo2kkZURRlmY4AHqTWym4/j+Ohn1HVk+JLKe+0tY4ITcosyPPahwv2iMH5kySBz6EgHGDwa0oriGfd5Escm04bYwOOM9vapKzlHmVmVGXK7nManbS/8IXPY6P4cmtmuFeNbOL7PH5RP8RxJtwfYk89Kr+J9PvteisFbR5Wg2SF42jtJJYpPlC5Mu9QpG4kplun0rp73UbLTY0k1G8t7RHbYrTyqgZvQEnk+1WKylSjNOLZpGpKLUrd/wATh7zRdQlsdGeXSWv9StrKONvtSW81sknG7ducOGyPvJntw2MVe1nSp5/FNtfWulfapl8pTNdQwSQRKGJJQlhKjjPUAj/ZPUdVRVOmm7+dw9q/0MttLuTqP2gXmI/M3eXum6Z6f63b/wCO49q02VXUq4DKwwQRkEUtQrd2zzeUlxE0mSuwOCcjqMe2RWhld7nJ6D4dh0C/1SPTfCtrbXDGZ7bUUhgSJ0YhliO1vMAB4I24+Xr0rndM8I6zbaLrUcGlXNqbzThGYCLK3aS4BySgttqgcnazMW65xwT6pTJ54raB5rmVIYkGWkkYKqj1JPSulYmevW9vwIaTRzGiWUmkR6nfWPhuewinEezS4mgEsjjIaU4k8vJDLyXydnPOBWK2iazffDfSdKudJvbdrFoo7yzD2jvcxqhGUDl4mAYqcPj7vY4rvru8trC0kur64itreIZkmmcIiD1JPAp1vcwXltHc2k0c8Eqh45YmDK6noQRwR70lWkvet1Xfp8ylorHFx6Re6Xo/h1rDStTuRp9/JNJZyvaJPGjRTIAAjLCAC64VTwD+FWPFMFzqlrpF1D4Uurm9guorhSxtfNtFSVWddzS4BZVP3CQe5FdhUNzd21miNd3EUCySLEhlcKGdjhVGepJ4A70e2k5qVtb+f+Ymrq3lY5HxTpVzqeqaffW3h+S8u44lEYvobWe2tyWBO4NIJFcY+9ESOnD4AqbUfDdinjiLVz4Vt9S8+NFa4jht99vKr5ErGRlJ4I5XLfJ06V11FJV5RSS6X79Qavfz/QKKh+123n+T9oi83dt2bxuzjOMeuOamrAZyPh7QvJuLyC50RI7GeMiR7+3tzPOxbOGaJmEi9fvAHOOWycM0jw3DbeFrjTJdIj0u4jjG6+CRBZnQkpLlG3HBAb5gD+tdjUN3ZWt/bm3v7aG5hYgmOaMOpI5HB4rD2MUkl0Vjf20m3frb8DndIlubnw5ca22nTS3uqqH+zxMgZU27UGXZRjHzdf4j1qleaTqWoeD9Js5tOu4/sZRLq0DWzPMqx7cgOXjYBiDhsdM8ECuvu7y10+1a4vriG1gTAaWZwirk4GSeKkilSaJJYXWSN1DK6HIYHoQe4qnTUrq/YSqOOqRgWGhTR6JaW9vNc2gi3/u7psOuWzj/AEeRUAHYDIAwBity1iaC1jikfzGUYLfNz/30SfzJqWopru3tji4uIojtLfvHC8Dqee3NarRWMm3J3OF8deHL7WptVRdAi1k3OniLT5ppIgllLh95w5yrHKYZAckAMVABrTv7WeHx1p+o2nhmecxwPBcahCbZSwbbgEtIHIXByMfTNdRPcQ21vJcXMscMMal3kkYKqKOSSTwB7017u2juorZ7iJZ5lZooi4DSBcZIHUgZGcetdCrSslba/fqteonr/XocmNFnT4jHU7fRi4kkzLf30Fs4jUR7f9HkV/OTPQhlYHnG3JJoeDtM8++tb+HRpLWW3ubvz9TlaMm6jMkiiJSHL7QSpwwUDZwK9BqOGCK2iEdvEkUYJIRFCgEnJOB6kk0e3ly8vlb5EuN3c5KwbXDdeJnj8P3FrLfEzWb3stu0TMsCRhXCSseWUnpjHUjpWR4b8HXNtb6xDc2kum2VzawmIXEdnGY7iNnbzNlsAgwdhBOSdvJ4ArvrDVNP1WOR9Lvra9SJzHI1vMsgRx1U7ScH2p19p9nqlm1pqdpBeWzkFobiISI2DkZUgg880/bSinG1r2/DbdlPX+v67HOeH1l1jwtd61eaeHutZg3m18zbuiCbY49/YEZbPYyGt/R4fs2h2MH2T7F5dvGn2bzPM8nCgbN38WOme+KuDjpRWU58zdloJLY5zXvDkWu+JdLk1CwivdPgtrlZUmwyb2MWwFD977rHoQCAeDiufPh6/wD7K0yPXPDra+yaVFbrC8sLfY7hc7nJkcD5gVG9NzDZ716HRVRrSjFR6L/g/wCf5FX0scDeeDLueK8nu7ZNQ1OCwtEsbuRlZhcRg73TcfkbIU7uCeOeKS+8LXdz8QH1G8t9TmX7TDLa3dp9iKQRqFBQtKvnoNysWWMkEOe7MK7+irWJmnf+un+RmoJKyOdtLmyl+ImoR2tkr3CWES3N9HcbghDsVhdOithiwPUg+wroqKhju7aWTy4riJ35+VXBPBwePY8VhKXNYvrcyxFqFjb3l9aWXmSyYaPTUmVFJzyxY5AY8k44+p5pYZ9Y1Lz7a705tKQq+y5S5SU5EjKowBkbkCv7bsZBGa2aKkDDuheW/h37FZ2rW11Kwtka3G5Y93BmzzgAZb5u4xznmtrmjYh0q2g0gappdqDFJp4MYU/KBGxVyFYLjp2yCAcV0tMininDGCRJArFGKMDhgcEHHcHtVJtFxk46o4S+0G8j8G6TYr4cF1fWt0kyfZ2gK2gW4VyFZ2UjcgIG0exxWzqumXl7N59naywf2rai0vlaRQ0C5yHOGIyFaRflJOSvYZG6+oWUdqtzJdwLAzhFlaUBSxbaBnOM7uMevFWKfO7fMp1JWMy5sHmurZLZBax2yjFwpG4D+4o9OOd2R04J5GnRRUGQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcd478P6n4gutITSW8loZHd7jdt8n7uDxznjjFdjRQBSWK9s9GWOOX7ddxx48ybCeYfUgcfhx9e9Yeqas1hodrIuoyW6T3Yhvb+cKrWYKkk4cFU+YKoyCBuB579TRTWjKi0nqebXV5bQfD/AFaW41rarX05jkvY4B9tPUIyPHtYHr8qgkAEcV0+oa+totpqlneRXelzxPEqwlWV5usZVx6lWTGeSy9+vRUVTkmv69C3NPp3/EradHdRaZbJqEwnu1iUTSBQoZ8ckAdBmuf1nU7Cy8baSLvVrWNsSK1vO0IMWUOGBI3qWOB97BxjFdTRWU05bExkk9Thb7U3vddhhuNSdJ7fWEjGmRomFjDfLI/ylxuBBB3BTkD69NDPqragEmgxb7iN3koOO3PnE/8Ajv4CtSilTi4Kzd/+GS/Qc5qWyOb8VabaWngrXpbeHY/9mXK53E8FWY9fck1j6NEqeMLXQ7gbktdInWMZPzW7vDs59sMnX+DPeu8orojU5Y8tu/5WM5e8kv63X+RBbWcFmHFtHsEhDNgk5IAH8gKoeJL6ew0tZIJhao0yRzXRUN9njJwZMHjj1PAzk8A1rUVjJNrccWk7nJa9qenxfD+8dtehvkmjeOK6lmh/etz8oKBVJHoBnim+JvEYSKwGj6rFCLmOSRLlbqJIpQu0bQzRS72yeFUZODzXX0VlOnKUWk7f16msakU02r7/AI/I4e88S3C2OjXtxqq2y3FlHPJZ2s0C3Mztj7scqnevUYUq3XG44FXtZ1mSy8U20LapthfylWxtZoPPZixyXjkXcUxjlGyP7vUjqqKpwd7363/4Ae0j/KZbT6r/AGjsWD/RvMxu8lPu56587P47fwqyNMtUuDPHHsmJdvMBOQWABPPH8I/KrdFaGVzhvC8selXusW114kur28t5riV9Lf7N5pXduEoRI1fJBGOdvzdK52HxPfap4Y19LvVLe/t/7MFykouo7hYGzyjtFDCoIBG5csRxyMjPrdFdSrxu2466fh8iJRumcromvW6R6ndXXiSDUtIgEbLqcrwpEjtkPGHQKpA+Trkjdgk1ztn4mMHwn0J9C1OyTAhtbu8N0ipZ/u8/O/lyLGchV+dCPm7ZBr0yipVWCbbj1X4fLzKWisefya0seneE9T17WNMliXVJQ2oRXiPAV8idVJlCopPQHCqM9qt+Mtf0dbLRb7/hIbBLd76B443kt3iuUEyBnBdSfkGTuQjaeSa7Wij2sedS5dn/AF0E02reVvz/AMzi/FPiMWOqafJBr8cVpLEsi2ljdW32m6LMNpVJlPmIR/cZW643EgBNQVbH4jpNfeKLjTo7u2jW3hkNsiTsJDmFS8e49RwDu+br0x2tFEasYpJR79uvyBq9/kVf7NtPtn2ryf3+/fv3Hrt2/wAuKtUUVzjOR8PanPqtxeWb6491cGIv59hLbTQQ/NxtITcrf7MgPAOC2CareGWuE8GtDpmtPdalaRLvsm8gmBkJzEQFBG7BX5iSO1dvVe+tXvLN4I7ue0L8ebBt3ge25SP0+lYezaSd9Umjf2ibelk7GJba5FdaLqGs3V9HDpc3yWhmKxqFC7Scnuz5AyegGOtZD688PgTQ30fULSONliguLs3CqluRFnBcpIqHcAPmU9ccEg12lnaQafZQ2lnGIoIECRoP4QBgVNVShJppPewlOKexz1he6xLolpLHLbahI+/dPa7J0cBvlO7fECcdSFxkHgdK02sItRtom1SDdL5bIw+7gNjIwGPoO5+tXqK1WisZt3d0ecfEfVmFprmmXGry6aiaUXtbWGJGe/ZlkDj5kYsqhRnZgqCWY4wRq6jq+l2PxD0qO81yzSV7aSMWlw9uGhZtm3aSvmAv6bsHA44rsqK6FWiopW2v26r0Jeq/ry/yONGuzJ8Rjp8usieN5NkWn2NxbOYgI8k3EbIJl55DIzDpkKOtfw34gutT1i2A8QR6hMZ7mK806JYsWsaM4R22jerZVB8zYO7gV3VVNM06LSrBbS3Z2jV3cFyCcs5Y9AO7Gj2kOW3Lra3/AAdv67ktO5yOkeKdH/tPxhPY6lb30kcguVhsp0llkRLWIEooJz8wx6Z4NUvDOva9q0OrQQarDqEkFtBdWs8FxDcqzbn3Ql0giTkIAQASu7O7pj0aq2o2kl9YyW8N7cWLvx59sE8xfpvVhz06fTFP2sLNKPZXetrfIt6mLpusvq+i6lrUN80GnSI32OQwhvKVFIaXbjLHfu4PBCDHXnX0eb7TodjP9r+2+Zbxv9p8vy/OyoO/b/DnrjtmpbGxt9N0+CysoxFb28YjjQHO1QMDr1qespyi2+VaEq+hzmvSalP4l0vTNP1SXTobi2uZZnhhjdyUMW3BdWA++ex4J74I58+Kri40rTJtW8QLoHn6VFdRzIkQ+2TnO9AJFYHGEO1cMd/WvQ6KqNSKik1+Xn5ea37FaWOBvNY8QNFeX0t89g2m2FpdSWEcEZV5HBMiOzKzbflxhSCMnmkvvEGs/wDCwHsI9W0ywiiuYY4rK7vVie6iYKWYRtAWkJJcKUlUZUAjg57+irVaKd3Ff1b+vmZqLStcyIr0DxlcWL6qHY2UcyacbfHljewMvmfxZ4G3ttz3q7Dptpb3Bnhi2ynfltx/ibc3f1pIdMtbfUri/jRzc3AVXkeVnwo6KoJIQd8LgE8nmrdYSadrFmHFqyadZ3V3eTs2kwYKXUoYucnGAACXXJ4bg/XrT4fElnqfnwaHKt1eRq7CN0dB8kjRtyQAcOjDrzjrjmtmipAxG1L7D4cluoZHurrOxUuMqWnYhVjI/hG4gYHQc89Tn6lL/wAI7Y6RpsurHTLeXeJ9Sby9zSgbsAupQM7FjyDnBAHp1EkMUxQzRJIY23oWUHa2MZHocE8+9Pqk7FxkkebXeo2th8P9Hku9Wjt2+3IRDepCPtK/agHZkkTIKglsrtKnnjFdJqus3ME2/TryKeHVLUJprKFdRcZwCCPvgqwbHpGx6V0tFPmVrW6lOomtjKuJLiG/gjs5nuLnYomjfiMr/fYj7hznGBz0wcZGrRRUGQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcZ491TWNMvtFOgb5LiWSRTAq7hKMLwR6e/b1FdnSFVLBiBuAwDjkUAU1vprfRlu9Ut/JmWPdLFCfM2n0B/r0Hrjmql1rNxZ2No7QQzXd/OIrWFZcJkqXG6TB4CqxJAPoAe+xWfc6Fp93ZfZJYWWES+cvlSvG0b5zlGUgp/wEjqfU01a+pUbX1OXur3Vn8Fa1LOGWaO7mWY2+ovG8EY5/dSGMkkdgVUcnpXTXerLp99FDdR7baS3kl+0l+jIASpHuuWz/ALJqCXwpo8ulNpv2eaK0eRpHjgupYt7N97cVYFs9SDwTz1qzJodjPp8NlcJNNDA4dPNuJHfIz1csWYckEEkEEg8cVTaa/rsW5Qf3v8SfTrmW80y2ubi3NrLNErtAW3GMkZ2k9yKzdQluF8XaSjeYlswlCmK6IDtsyQ8WzDAY4O7gnpW3Wbe6BY6hqEV7cm78+L/VmO9mjVfoquBz34571lO7+HuTBpN3MjUdavrq8thZQrFYx6oltJP9pKyOythgIwuCueOWHTpWrDr1tPqAtFX5yxXPnwnkewct29M0N4b0ptRN61sxm84TjMz7FkGPnCZ2q3HJAyec5ya1KVNSS97f/gIc3F/Cjn9SNz4c0XUdWN3JeG0s5ZFhlYhSQWcEnJ6DA+gqtCNUs9bi0i71me/Go2E0vnSRRo1vIhjGU8tV+U+b0YkjaPm6108sSTRPFMiyRupVkYZDA9QRWdpXh7TtFkd7FJ97oE33F1LOyoOiqZGYqvsMCuiMoqLT/r/K2/mZve5YsbOS0EolupLjewILk/KAoGOvqCfxpmrakdNtY2ig+0TzyrDDFv2BnbplucDgknB6cAnir1V76xt9RtWt7yPfGSG4YqVIOQQwIIIIyCCCKxldrQcbX1MXxGLyTwfd3F5usry3RpU+w3smFI6fMAhYexGPrU+v69Joy2621vHdTTBm8ombdtXGWAiikOORkkADI55qe48PWF3pY0+5N5JbAkkNfz7mz2Z9+5hz0JIpJ/Dem3KW6zpcObdGjRzeTbyjEFlZt2XU4HDEjisZRqWfLo9P62NlKnpzba/1uUbjxWyw6dcQWsKWt7brObm9naGKMNjC7xGy7uejFc8Yz2sX+vS2WuwWJt7eOCQJ/pV3O8KuzEjZGfLKs+BnaWBPpjmppPDemy29vbslwLe3iEKQJeTLGUHAVkDAOMcHcDkcGprnRbO8vEubj7Q7IVIj+1SiI7TkZiDbDz6iranfR9fwFen2Im162XUfsZX955nl58+HrnH3d+78MZ9qemnXEV8bkXski75HEDMQp3AAL1PAwe3fpWjRWhkcx4Z1bXrsX0muW2nw20FxOnnRXrOybWwF2mFRtAz8xOeOlYs/je51Xw3rK/ZJLGaGyFzby2xnHmITjKtNDDz0wVyOeorr18P6el9dXQjm3Xass8RuZTC+QAT5RbYCQOoXPX1NU4fBWhQWtxAttcSLcwfZ5GmvZ5HMXZA7OWUDsARjJxjJrqU6N7tdv+D1Ikm07DrW7udYbUNK1mz+wyxoj/6HfOS0b7tp8xQjK2UYED8Cc1j2HiWbSPhvoF3JFcale3cEUaBvNkaRyhYs5RJH6KTkKxz+Y6CHw5p8Gnz2cRvAlwQZZTfzmdsdP3xfzABjpu9fU1Xh8G6LBoyaXHDdfZYpFkhDX07PAyjAMchffHgcYUjqfU0lOlqne11p+fX+u5S21KUfiK9vf+Ecl+zy6eb2/kguYJYmUsqwTNx5iK+CyKQSqkjtVjxbNdwx6Z5IkW2bUbdZpYLwwSDMqhV27GDoSfmUlcjvzVq48Mabdafa2dwb10tJTLDJ/aNwJkYhgT5u/eeGYct0OKZe+E9L1GztbW8bUHitTuixqlyrZBDBmYSAuQQCCxJHbFHNSU01sn+H3id2rLt+OpFrviOfR9Ttrdba1W2lXdLeX1y9vCmWChQ4jdd/orFc8YzziB9T8Rf8JxLYQWdhJp620cmXvWRwpcgvgQn5uMbd2OByM8aN54b0+/aH7W186wxiMR/2hOEkUdpED7ZM994Oe+amvdEsr++t7ycXCXFvwjwXUsORkHawRgHXI6NkdeOTSjKkktO9/wBOoO+vyD+zpv7T+1fbpvL8zf5GTtxs27evr83+c1foornGYGma/ean9qjWztILmNN0drNduk2M4BkQxAoP9obgexPWquj67q//AAhseraraW8u2FJWeK5O50z87FfLAUhcnAznGOK2rHRbPT52mg+0SSsu3fc3Us5UZyQDIzbQcDOMZwPSoP7J/suzuBoUCvLN0huryXyVyTnAO4KOTwoAPTisOWokm3rZ/f0N7022ku39bjZrldYttTgCyx29vhUuILlo2kYKGOChBAGQOvPI+tEa/LpnhLRpvIlvru7hiVRiR9x8vczMUR26A8hTyR2yRf0/w5bWXhi30V5JnijQB5I5nieRs5Y7kIIyST170o8M6WNMisPLuDBA4eEm7lMkRAwNkm7cvHGAQMEjvVOM9eXyEpU9nsQw+Jk/s23ub2zltZJtwMUrrERtOMgSlGIPUHaDgjIHSrFxbSaxbxXFrey2itEwAjcHJOMHKtg4weh79av2tslpbJBE0rIg4MsrSN+LMST+JqWtVsZtq+hxvjfXdSg0XXLTQ7dDJZac01xdyXbQNDuV9pj2oxZhsJ5Kjpz1xo3Et3/wm+lJJ5iWrWsxQxXhCyNhM+ZDswcfwtv4yeKsav4T0XXZpJdUszMZYfJlUTSIsqDOA6qwD7SxKlgSpORg0+78M6de6tDqU5vRcwYEZj1C4jRRxxsVwuDgZGOe+a6YzpqKXr+K9SXt/XkVR4lm/wCEvOjy2ttbQ7tsct1cvFLcnZuJhQxbZQOh2yZXkkDjMemeKLy/vLTz9KS3sbyaa3hm+1b5DJGXzlNuApEbYO4npkCtL+wbE6v/AGk5u5Jw25VkvZmiU4xkRF9gOO4WqHhvwrBoyefcGSa9MkzbmupZI0DyM3yI52ocEA7QO9K9Ll21t+P3/wBdiXe+hDoUq6beeKFlu5mtbO7V1N5dvIIlNvG7fM5YquST6DPSqmmeO7i9tdRebSDFNYQxXLIGnQPC7MGYedBGxICMcBSDwN3XGtbeDtGtZLxkju5RfIyXKXOoXE6TAgKdyu5BOABnGQBgUieH49Ftbmbw7ZpcahNGsRbUb+Zg6gnAaRvMbA3NgY744qnKk09G3pbptvfXqU/L+v61LUOrS3bal9itBOloAsLCYD7RJs3FRxgDlRuyeSfTm7ZyzzWMEt3b/Zp3jVpIN4fy2I5XcODg8Z71m6L4ctdI8JwaCxM8CwGKVjlfNLZ3nrkZJJ68ZrSs7SCwsYLO0Ty4LeNYo0yTtVRgDJ5PArGfIm1ESvp/X9f18srWtbvrHVrHTdL02K9uLyKaUGa68lIxGUzkhGPO/sDzjsSRSi8WXepWltLoWlxXDyWEV/Ml1dGERpJu2qCEfc2UbsBx15roJLG2l1CC9kjzcQRvHG+4/KrlSwx0Odi/lWZN4P0Wa1tbc280cVrD9njEF3NETF/ccowLr7NkdfU1UZU+VKS1/wCH815dupWljMm8bzsGubDSll0+G1t7y4nmuvLdYpeRtQK25gASQSo6c0+68aTQ+KG0u10a6uoIbiO3nuI4bhirMFOV2wmMqocElpFIw3HAztzaFps8d1HJarsu4khmVWZQyJnaAAeMZPTFRyeHdOfWDqarcw3TMrOYLyaJJSvALxowRzjAywPAA6CrUqN9Y6f8N/wTNc9tdyzHcXjaxNbvY7LJIUeO784HzHJYMmzqMAKc9Du9qjtdOnt70zvfTTIfM/dMTgbmyO/Ycf4VXt9DKeLLrXZ51eSS2W1ijjQoEjDFvn+Yh23E4OFwOMHrWvWEraW7F9yjZXzy3M1ncqouIMFmiyUYHof9k/7J59MjmrF3dJZWklxKHKRjJCLk/wCfc8DvVe40awutKk02e3DWkv8ArE3MC3Oclgck5HXNRad4d0vSbp7nT7XyZXDhm8xmyHkaRupPV3Y/jjpxUgSf2gbXRZdR1HYsccbTFYcvhAMgZH3j9OuePU5sV7qWnWNhaGBbzV77zJmjnuGSKP8Aicb9rEKu4KAF9OnJrSm0e1mt47cB4oEuFuDFG2FZgdwBB6LuAOBjkfXLtS0ez1ZYftqSEwuXjeKd4mUkYI3IQcEHkZwe9Umi049TlJb/AFH/AIQfTbicykvfxpcyw37RyJm6CAKxQ71ycEHbla6DUdeOm3F5HNaFhDafaYCsgzcHJUxgHoQdg9PnFJc+EtHutNt9PaCaKztm3RQW13LCqncGHCMM4YAjP3e2KtyaPZSrZiaOSX7EwaFpJnZsjpuJOX6A/NnkA9QDVXjb5styg1t/X3jbi/mspIGuol8mYBCsZ3OknoB/GPoMjGcY6aFRfZoftX2kpmbbsDE5wPQen4dePSpazMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5nxf4tPhSbTpJLfz7a4Z1lCnDKBtwV7dzx39q6aqN/o1hqd1az39us7WhZog/KgnHOO/SgCW0v7e802O+iYrbyJ5gaRSmF9SD0qGTWbSHT/ALbOZY4C22PMTM0uemxFyzZ7ADJ9KtXFtDdwNDcxrJG3VT/P2PvWXqGiXN3aWgi1ALdWNyLi2nnh8wD5WXDqGXd8rsM5HY9uWrX1Kja+pmT+LZj4X1DUbdVhljuZILZriyuNi7ehlRVLoMZySAOldGb+3S+SyklC3LwmZUII3IpAYg9OCw9+RWHceGNQfw7e6ZBq0PmX00kk9xPZ7+HHIVVdcYPQnPHr1q5f6Ld6lp9vHcX0aXkRZXuIICqsjAq6hS5K5U8HccEA89Kp8ttP60LfJ07v/gGlZXkGoWMN5ZyeZbzoJI3wRuU8g81Ru9Uki8SWGnRGNUmWRpfNgly2FyoRwNmeDkE5xWnHGkUSxxqFRFCqo7AdBWTqWl6ld6zZ3lrqFrBFaFisUlm0jMWG1ssJF7dOOPesp3+z3Jhy3dyPUvEsNtqFtZWe6aZ7uOCU/Z5GjTd1BkA2BsY4Jz7VpJqdhJceRHfWzzZI8tZlLZ9MZzWQfDNz9tyupKtkt/8AblgFv8+8ncyl93K5JIwARkcnGDrpp8Mdx5yvclsk4a6kK/8AfJbH6UqfNb3/AOtF+txz5PslMXup20NxPfW0Iihgkk+Q4LMrHA6nGVAPTqfwqhpniPVL6VrS70u3truWw+22vkXZnRgeArkpGVOSOOQeeeK3723+12FxbbtnnRNHuxnGRjOKp6HoGneHtPS10uytbUbVErW8CxeawGNzBep+tbxcORp79DKV7q39bf8ABJ7F75xL/aEUcZDAR7O42jJ6nvkfhT76+ttNtGubyTy4lIGcFiSTgAAckk8ADJNWKo6tpzalaxrDP5E8EyzwyFN4V19VyMggkEZHXgg81lJu2hUbX1KOr6vcp4bm1TSCsfkAuyX1nKpdR1G1ijKfcg/Q1oX+pwabEj3KXLB+n2e1lnx9QinH41R1PStV1Tw/Jp8mo2aTTApLMtk20oeyp5uQenJY/Squr+F7jWxZtfXVjM8EciSJNYeZExYj51RnO1wBgElup4rGTqJPlWun9bmyVN25npr/AMDoac2vWEL2675pjcRiSMW1tJN8h6MdinaD6nHf0NPn1i0t9RSxf7Q87BTiG1lkVAxIG5lUqvQ/eIrGm8Jztp2nWdve28P2K1S3F2LVxcjAAJSRZF2Zx0IYeuRxVvUtAnv9YhvI7m3thGUzJFbutyyqclPNWQAof7pUj2zgi25326/gLlp9zSOp2AuPs5vrYTbtvl+cu7PpjOc1Ak+pi+PnwRi0DyZdRltoA2cA9Sd3bt0FTnT4Tcefvud+7dj7VJtz/u7sY9sYq1WhloYOgeLbXX5biKG1v4HhkkTM1jPGpCNjO541UMf7mcj8Ki1DxfbJoOp3eniWO4sYfNKahZzWwxn72JFQleDyOB61YttFvrW41COPUolsLxpJEjS2Inhkfqwl34IByQNmeRzxXP2Hw1+xaffwpd6dBNd2Is99lpYgXggiRx5hZ3znJLc8YxznqSoN3vbb/g9CJXs7HTW+sx61aXaaHceVdQ4GbyylAQnkN5bbGZSM4IOD2PFVtK8RrJ4M03WdX+WW6t43ZLWB5CzsM4SNdznucDJwCe2afb6TqsMd5cyalZyarcqkYnFiwgREJIHlebuJ+Zud/cemKxz4FuJ/COn6NqV9p162myI1s82l74WVUKbZYmkO/gtyGXBxjpykqWqb0uvXz6f12KW2ptt4jt3fSPskbTR6ldPb7nDRNEVjkc7kYbgcx4KnBGfbFN8Q6zLpbafFbNGkt1eRRFp7eZ49hcBhvjUhHIOF3kAmqLeFLqLS9Jh0y40rT7rTbp7lfs2llLZiySIR5IlBHEmc7+oz3xU+s6LrmradZQLq2nwywTRzzSHTnZZHRw6bV88bR8uCCWz6ii1LnVnpfz/yE7203t+Ov/ANC+1yy069htJ/tTzzDIS2s5Z9ozgFjGrBBnu2BwfQ1Rk8XWkPil9Ee0vy6xo3nJYXDoWZiMZWMqF6fPnb1GeDUWt+G77WJ7WUX1lbSRRhJLqKykW5BzlvKlWYGNTgfKQ49dw4q9eaVetr0Opabe28B8oQXMc9s0vmIG3DaQ67G5bk7hyOOKUVSsrvv/wOgO+tvL/gk/m6p/aezyIfsfmY3/xbNmc9f73HT8O9X6KK5xmbBr9jdQzS24u5I4V3FxYzYceqHZ+8/wCA5qppXiyy1HRY9RmiuLRGCbxLbShVLttGGKAMMnqOB3xTtF0GfTL6WeW5twjptFtZW7wQ5JyXKGRxu9wB1Oc8YhTTm0bw3c2OoytfaeIjDDFa2UhmCHIwdrNuOCBkKuMZrDmqJJvs/vN+Wm20vL+tjRvL5pYb2DS7iJLy0VS5mgaREyN2CAVySPRuMgmorfW4l8PWGo6gSr3UUbeXBE8jM7LuIVFBY9zxnABPaquk6XqkPhRYZ7mGPVbkeZdTSxGVd7cEYDLnCgKOe3eq83hKa70DT7C+urG5l09l8lptP3wuoTZh42c5OCTkMOcfQ03NXstdP+CJKGzZspremvax3BvYYo5chfOby2yDhgVbBBB4IIyD1pl7dX7xpJoyW9zG0TMHLZBbjbg7hkHn8utNs9Eht9OgtnEcPlZ+XTw9pFyc8Ir8fiTWjFGsMSxoWIUYBdyx/Enk1qttTN2T0Oe8W+Lbfw3o968e+bUIbR544Y7WWdVIB2mTywdikg8sVBweeDizLrMv/CWWOlxGNY5LeSWYS28wZiNu3y5NvlnGTuGc9KpeIfCd3rEmpLZauLGDVbMWt0ptRK3yhwrIxYBc78MCGyBxtPNWb7R9XuPENlf2up2UNvaKyCCSweR2Dbd/ziZRn5ePl475rpiqXKtddfy06Evb+vIurrtk+sHTI/tMlwp2uyWcrRIdu7DShdinGOC2eR6iobLxTpGo6gtnZ3LySsXVW+zyCNmQkMokK7CwwcqDkYPHFVT4auG8WjWFurS3i37nS0tXimuMLtAmkEu2UDPG6PjtjrVLwroupeTbT6rcRrBa3NzLbWq2jRSIzSSAM7lzuG1jjCr1B5pctLlvfp+P3f13Jbd7I09D1K/nvNZttVe3lbT7pY0e1gaPchiSTlS7kkb8cHnHSnw+KtKmgml8y5hEBjEq3NlNC6h22q2x0DbSQRuxgYOTwaz7Xw1rKya39t1u2Kaup3NZ2LwyQv5SxqysZm6BQcYznnI6Vn2HhCy8K2WqXd7FBLDeWiWstto2kNEGALAERxl2Zjv5OewPAFU40mm73elkur69Cn5f1/Wp1j6tZRteq8xBsYxJcHYxEYILdcYJwM4GT09RU1ndwX9jBeWj+ZBcRrLG+CNysMg4PI4NY3hvTNStPCax6hcbNYukMlxcbQxSVhgcdDtAVfQ7a2bOKeGxgiu7j7TOkarJPsCeYwHLbRwMnnHasZxjFtJiTbt/X9f186WreIdN0SaCHUJZRNcK7QxQ28kzyBcbsKiknG4Hp0yegOIrrxVpFrb287XEs0dzCJ4za20s58sjIciNWKr/ALRwKsXOl/aPEFlqfnbfssE0Pl7c7vMMZznPGPL9Oc+1Ylv4Rv8ATbK0h0fWIYJEsI7C4knsjKJUTdtZAJF2MN79dw5HHFVFUnFcz1/4fyfl33K0saNz4u0S1vUtZLxnkdY3zDBJKiI5wjs6KVRT2ZiB154qe48Raba6oLCaWUTF1jZlt5GijdsbVeUKURjlcKzAncvqM5r+DYl03ULG2umihurKCzj3JuMSxBgCTkbsg+3SoZvA8D+LJNZWLR5hNOk8n23SVmuEZQF/dzb1KjCgjKtg5PsLUaDerdv+G/4JmnK2q1Ogj1Szl1ibS0mzewQpPJFtPyoxYKc4xyVbjOeKjtZdUa9K3cEK2/7zDL1OGwnc9V5/wqvbnV5PFl08m6LR47ZY445FjJlm3EmRCpLBdpCkNjkcDudesJJK1uxfdFe0vYrxX2bkkjO2SJxhkPoR/Xoe1Tu6xxs8jBUUZZmOAB61mTaTcG1ne2v/ACtSmUKL1oQ/ljOcKh4C+34nJpltpF8zyrrGqDUraQOBA1qse0mRmUhl5+VCq/8AAd3U1IF+3vY7m1NyA0cPJDyDbuUfxfT64rNt/EEcejW9/qgeI3bFreCG3kklZCSUHlqGYtswTgcc9MVJf6XdXejnTTcLNDNIEneYfMYP4k4+8SPlzxwc9Ryuq6TcXV1ZXWm3cVncWm9QZYPNRkcAMNoZcHhSDnjHQ5qlbqWuXZmU/iqc+GbC/XyoZ7y6WJTNazmNVM2zDbQSjEcDdgbjzW7Nq9jbSXcc9wsbWUAuJ9wI2Rndhs45HyN09KxLvwrfyeG7TSLPVoUWGYTSTXNmZGlZZhKvCyIByMHjnttq/faFLqJtHubqMSInl3flwlVuEyGKgFjtBZR1LcFh3yK923zf/ALfJb+v8i+NRg+0RRNvQTqGid1wr5/hHo2OxwfyOLVVLmwF5cKbp99uoBFvj5Wb1b+92wOn14xbrMxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArM1bxDp+iXNnFqcvkLdsypKw+VSMfePbr16Vp1z3ijwnD4pnsBeTNHb2rOzog+aTOMDPbpQB0CsHUMpDKRkEHgikSVJN3lur7G2ttOdp9D71V/s2ODSRp+nMbKNE2RmIfcH4/8A6/cHmsXV9Ou5tDsrdNMWeG3ulN3YQum27iwwIG8gEbirEMRnaQc92ldlRSbNOXXYk0y+vIbS8ufsUrxNBbxB5ZGUgHYueevtWmDkA9PrXA3Xh2ZfBF9YL4Xjkmmu5ZbS1gMBW13D5XBZlCkdPl5BPGRzW7qMGoTi01XTrCWC/wDKe2eGZ49yI/Rm2uVO1lVuCTgtjk4qnFW0/rQtwj0fV/8AAOhqtPe+Rf2tr9muJPtG/wDfRx5ji2jPzntnoPWjTrGLTNMtrG3z5VvEsa5OSQBjJPrWJqttMvi7Tr+00Ga4aAOs15EYFLKykBcs4YgE5xjHpmspvl27kwSbZt3t/FYLAZldvPnSBdoHDMcAn2qzXFy6FeS68s0ujpNcR6mtwNUkePP2fOQic7xtBwVwBwSCSeegh0u5i1AXDXm5Nxby903Q9uZSv/juPalTk5K8lb/hl/wRzjGOzH2ut211KyBZIgkbSM8oAUBXKnnPqCfpVe08V6Vfx3BtJJma3h+0FJLaSFpI/wC+nmKu9ePvLkcjnmpvEmlvrfhfU9LhlEUl5ayQLIeillIB/Wud0TV11vxrAt1CulX2l2UkElhPcRNNI0hiYsqo5PlgIMMcZ3DjiumFNSi31X9fPt5Gb7nVWOoR6gJTEkieUwU7wBklQ3r6MKt0Vk+JLKe+0tY4ITcosyPPahwv2iMH5kySBz6EgHGDwawk7K6Q4q7syfWNUGj6e15JaXFzFHzJ5GzKL3Y7mXI+mT7VfByK5jU7aX/hC57HR/Dk1s1wrxrZxfZ4/KJ/iOJNuD7EnnpVfxPp99r0VgraPK0GyQvG0dpJLFJ8oXJl3qFI3ElMt0+lYyqSim0r7f1sbKnF2V7bnX0Vw95ouoS2OjPLpLX+pW1lHG32pLea2STjdu3OHDZH3kz24bGKvazpU8/im2vrXSvtUy+UpmuoYJIIlDEkoSwlRxnqAR/snqLc2na3W3/BF7NdzqqoRaxBNqH2NYpg/mSJuIG3KBSe/wDtCom0u5Oo/aBeYj8zd5e6bpnp/rdv/juPatNlV1KuAysMEEZBFaGWhDa3kF6sjWz7xFK0T8EYZTgjn3qPVNRi0nS7i/uVdordN7CMAsR7ZIrmNB8Ow6Bf6pHpvhW1trhjM9tqKQwJE6MQyxHa3mAA8EbcfL16VzumeEdZttF1qODSrm1N5pwjMBFlbtJcA5JQW21QOTtZmLdc44J6lRpt35tNPx+ZEm0nY9Ou55La0kmhtZbt0GRBCUDv7Deyr+ZFQ6RqcWs6NaalbJJHFdwrMiSgBlDDODgkZ+hNYOiWUmkR6nfWPhuewinEezS4mgEsjjIaU4k8vJDLyXydnPOBWK2iazffDfSdKudJvbdrFoo7yzD2jvcxqhGUDl4mAYqcPj7vY4pKlF3V1utfz69NClqrneXN9bWlxaw3EmyS7lMUC7Sd7BGcjjp8qMefSmajqH9nRQv9kurrzZ44dttHvKb2A3sOyjOSewrko9IvdL0fw61hpWp3I0+/kmks5XtEnjRopkAARlhABdcKp4B/CrHimC51S10i6h8KXVzewXUVwpY2vm2ipKrOu5pcAsqn7hIPcij2UedK+l+6E3ZXXb/M7CoBeQG/ayD/AOkLEJSmDwpJAOenUGuS8U6Vc6nqmn31t4fkvLuOJRGL6G1ntrclgTuDSCRXGPvREjpw+AKm1Hw3Yp44i1c+FbfUvPjRWuI4bffbyq+RKxkZSeCOVy3ydOlKNOFleW9+3T5g3vbyN/8AtiH+0/sPlTeZ5nl7sDbnZv659Kv0UVzjCobO8g1Cziu7R/MgmXcj4IyPoea5fw9oXk3F5Bc6IkdjPGRI9/b25nnYtnDNEzCRev3gDnHLZOGaR4bhtvC1xpkukR6XcRxjdfBIgszoSUlyjbjggN8wB/WsPaSsm10Zs6cU2r9jqb66ayspLhLaa6MYz5UJQMR3xuZRx160tjdpf6fb3kIZY7iJZVDjkBhkZ9+a57SJbm58OXGttp00t7qqh/s8TIGVNu1Bl2UYx83X+I9apXmk6lqHg/SbObTruP7GUS6tA1szzKse3IDl42AYg4bHTPBAqnNq+l9gVNPRux2tUNS1eHTCBPHK+Y3k/dgHhcZ6keorNsNCmj0S0t7ea5tBFv8A3d02HXLZx/o8ioAOwGQBgDFblrE0FrHFI/mMowW+bn/vok/mTWq2uZuyZBqupQ6Ro13qdysjQ2kDTusYBYqoyQMkDPHrRLqHl6na2YtLp/tMbv56R5ii244ds8E54HfBrjPHXhy+1qbVUXQItZNzp4i0+aaSIJZS4fecOcqxymGQHJADFQAa07+1nh8dafqNp4ZnnMcDwXGoQm2UsG24BLSByFwcjH0zXTGnBxTvrr27adSXt/XkdZRXGjRZ0+Ix1O30YuJJMy399BbOI1Ee3/R5Ffzkz0IZWB5xtySaHg7TPPvrW/h0aS1lt7m78/U5WjJuozJIoiUhy+0EqcMFA2cCl7KPLzc3T+lv/XYlys7HX6RrS6tNfQmyubOaxnEEsdx5ZJJRXBBRmGCrDvn2rSrjrBtcN14mePw/cWst8TNZvey27RMywJGFcJKx5ZSemMdSOlZHhvwdc21vrENzaS6bZXNrCYhcR2cZjuI2dvM2WwCDB2EE5J28ngCm6ULOTklZLz3369Cn5HpFFcp4fWXWPC13rV5p4e61mDebXzNu6IJtjj39gRls9jIa39Hh+zaHYwfZPsXl28afZvM8zycKBs3fxY6Z74rKcOVtPdCvcuUVzmveHItd8S6XJqFhFe6fBbXKypNhk3sYtgKH733WPQgEA8HFc+fD1/8A2VpkeueHW19k0qK3WF5YW+x3C53OTI4HzAqN6bmGz3qo04yinza/8P5+XluiraXPQ6K4G88GXc8V5Pd2yahqcFhaJY3cjKzC4jB3um4/I2Qp3cE8c8Ul94Wu7n4gPqN5b6nMv2mGW1u7T7EUgjUKChaVfPQblYssZIIc92YVapQbtz/1oZqTau0d/VC11iC7vTbJFMrjzPmYDHyNtPf1NZlpc2UvxE1CO1sle4SwiW5vo7jcEIdisLp0VsMWB6kH2FdFWEo8tvQvuhsciTRrJE6ujDKspyCPrTqxRFqFjb3l9aWXmSyYaPTUmVFJzyxY5AY8k44+p5pYZ9Y1Lz7a705tKQq+y5S5SU5EjKowBkbkCv7bsZBGakDXSVJN3lur7G2ttOdp9D71Bp9/HqVqbiBXEXmOis2Pn2sV3DB6HHHtWZdC8t/Dv2KztWtrqVhbI1uNyx7uDNnnAAy3zdxjnPNbXNGxDpVtBpA1TS7UGKTTwYwp+UCNirkKwXHTtkEA4qkkWop6M0f7dibR49Rgs7y4SSYRCKGINIP3mwsQD90HknsBmtSuBvtBvI/Buk2K+HBdX1rdJMn2doCtoFuFchWdlI3ICBtHscVs6rpl5ezefZ2ssH9q2otL5WkUNAuchzhiMhWkX5STkr2GRXKrb9WW4Rte50YkQytGHUyKAWUHkA9Dj8DTqzLmwea6tktkFrHbKMXCkbgP7ij0453ZHTgnkadZmIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMaeJJkheRVkkBKITy2OuB3xmn1x3jvw/qfiC60hNJbyWhkd3uN23yfu4PHOeOMUAdjRVJYr2z0ZY45ft13HHjzJsJ5h9SBx+HH171h6pqzWGh2si6jJbpPdiG9v5wqtZgqSThwVT5gqjIIG4Hnu0ruxUYuTsjoZdQs4LWa5mu4I4ICRLK8oCxkdQxzgfjVjOelebXV5bQfD/AFaW41rarX05jkvY4B9tPUIyPHtYHr8qgkAEcV0+oa+totpqlneRXelzxPEqwlWV5usZVx6lWTGeSy9+tONl/XYt02tu7/A6KopLmCK4iglmjSabPlRs4DPjk4HfHtUenR3UWmWyahMJ7tYlE0gUKGfHJAHQZrn9Z1OwsvG2ki71a1jbEitbztCDFlDhgSN6ljgfewcYxWU5KH3kwjzN2Omkmih2+dIke9gi7mA3MegHv7U+uFvtTe912GG41J0nt9YSMaZGiYWMN8sj/KXG4EEHcFOQPr00M+qtqASaDFvuI3eSg47c+cT/AOO/gKVOaqK6/rRP9Rzg4bl6K7tp32QXEUjYLbUcE4BwTx78VI7pFG0kjKiKMszHAA9SaytR020tNH1CW3h2P9klXO4ng7mPX3JNcn4G0+K21O4srjSrTSRc6TbsLaxP7m7T5g0u4KmZBuCsNvGV+ZsjHRGnzQlK+xm3b+vT/M7+K4hn3eRLHJtOG2MDjjPb2qSoLazgsw4to9gkIZsEnJAA/kBVDxJfT2GlrJBMLVGmSOa6Khvs8ZODJg8cep4GcngGsZSUVccYuTsXr3UbLTY0k1G8t7RHbYrTyqgZvQEnk+1WK5LXtT0+L4f3jtr0N8k0bxxXUs0P71uflBQKpI9AM8U3xN4jCRWA0fVYoRcxySJcrdRJFKF2jaGaKXe2TwqjJweaxlWjBNvyNlRlKyXn+B19FcPeeJbhbHRr241VbZbiyjnks7WaBbmZ2x92OVTvXqMKVbrjccCr2s6zJZeKbaFtU2wv5SrY2s0HnsxY5LxyLuKYxyjZH93qRbqJO3nYXsZHVVCt3bPN5SXETSZK7A4JyOox7ZFUWn1X+0diwf6N5mN3kp93PXPnZ/Hb+FWRplqlwZ449kxLt5gJyCwAJ54/hH5VoZFumTzxW0DzXMqQxIMtJIwVVHqSelcT4Xlj0q91i2uvEl1e3lvNcSvpb/ZvNK7twlCJGr5IIxzt+bpXOw+J77VPDGvpd6pb39v/AGYLlJRdR3CwNnlHaKGFQQCNy5YjjkZGepYaTej0VvxIlKyZ6rd3ltYWkl1fXEVtbxDMk0zhEQepJ4FOt7mC8to7m0mjnglUPHLEwZXU9CCOCPeuZ0TXrdI9TurrxJBqWkQCNl1OV4UiR2yHjDoFUgfJ1yRuwSa52z8TGD4T6E+hanZJgQ2t3eG6RUs/3efnfy5FjOQq/OhHzdsg0lh5O6W90vLUpaq56ZUNzd21miNd3EUCySLEhlcKGdjhVGepJ4A71wsmtLHp3hPU9e1jTJYl1SUNqEV4jwFfInVSZQqKT0BwqjParfjLX9HWy0W+/wCEhsEt3voHjjeS3eK5QTIGcF1J+QZO5CNp5Jo+ry51Hu7CbSV/K/5na0VxfinxGLHVNPkg1+OK0liWRbSxurb7TdFmG0qkynzEI/uMrdcbiQAmoKtj8R0mvvFFxp0d3bRrbwyG2RJ2EhzCpePceo4B3fN16YUaEmld7379Ab3+X4nX/a7bz/J+0Rebu27N43ZxnGPXHNTVV/s20+2favJ/f79+/ceu3b/LirVc4wqG7srW/tzb39tDcwsQTHNGHUkcjg8Vy/h7U59VuLyzfXHurgxF/PsJbaaCH5uNpCblb/ZkB4BwWwTVbwy1wng1odM1p7rUrSJd9k3kEwMhOYiAoI3YK/MSR2rD2ydtNGr/AHG/spRb11VvxOxu7y10+1a4vriG1gTAaWZwirk4GSeKkilSaJJYXWSN1DK6HIYHoQe4rnrbXIrrRdQ1m6vo4dLm+S0MxWNQoXaTk92fIGT0Ax1rIfXnh8CaG+j6haRxssUFxdm4VUtyIs4LlJFQ7gB8ynrjgkGqdRRu30t+IlSbskd1UU13b2xxcXEUR2lv3jheB1PPbmsOwvdYl0S0ljlttQkffuntdk6OA3yndviBOOpC4yDwOlabWEWo20TapBul8tkYfdwGxkYDH0Hc/WtVqrmbVnZlqe4htreS4uZY4YY1LvJIwVUUckkngD3pr3dtHdRWz3ESzzKzRRFwGkC4yQOpAyM49a8++I+rMLTXNMuNXl01E0ova2sMSM9+zLIHHzIxZVCjOzBUEsxxgjV1HV9LsfiHpUd5rlmkr20kYtLh7cNCzbNu0lfMBf03YOBxxXTGg3FPvf8ABEvRf15f5nZVHDBFbRCO3iSKMEkIihQCTknA9SSa5Ea7MnxGOny6yJ43k2RafY3Fs5iAjyTcRsgmXnkMjMOmQo61/DfiC61PWLYDxBHqExnuYrzTolixaxozhHbaN6tlUHzNg7uBU+wko38rkuSTsdhYapp+qxyPpd9bXqROY5Gt5lkCOOqnaTg+1OvtPs9Us2tNTtILy2cgtDcRCRGwcjKkEHnmuO0jxTo/9p+MJ7HUre+kjkFysNlOkssiJaxAlFBOfmGPTPBql4Z17XtWh1aCDVYdQkgtoLq1nguIblWbc+6EukESchACACV3Z3dMX7CavNaWs9fP/Ip6f1/Xc9GHHSiuc03WX1fRdS1qG+aDTpEb7HIYQ3lKikNLtxljv3cHghBjrzr6PN9p0Oxn+1/bfMt43+0+X5fnZUHft/hz1x2zWEoON7iui5RXOa9JqU/iXS9M0/VJdOhuLa5lmeGGN3JQxbcF1YD757Hgnvgjnz4quLjStMm1bxAugefpUV1HMiRD7ZOc70AkVgcYQ7Vwx39auNGUopp/n5/5PYqztc9DorgbzWPEDRXl9LfPYNpthaXUlhHBGVeRwTIjsys235cYUgjJ5pL7xBrP/CwHsI9W0ywiiuYY4rK7vVie6iYKWYRtAWkJJcKUlUZUAjg5tYeUnZNf1b/MzU01c7+oY7u2lk8uK4id+flVwTwcHj2PFZ0V6B4yuLF9VDsbKOZNONvjyxvYGXzP4s8Db22571dh020t7gzwxbZTvy24/wATbm7+tc7Vty/ItUVhxasmnWd1d3k7NpMGCl1KGLnJxgAAl1yeG4P160+HxJZ6n58GhyrdXkauwjdHQfJI0bckAHDow684645pAbNMininDGCRJArFGKMDhgcEHHcHtWO2pfYfDkt1DI91dZ2KlxlS07EKsZH8I3EDA6Dnnqc/Upf+EdsdI02XVjplvLvE+pN5e5pQN2AXUoGdix5BzggD0pK5cYOWh0b6hZR2q3Ml3AsDOEWVpQFLFtoGc4zu4x68VYrza71G1sPh/o8l3q0du325CIb1IR9pX7UA7MkiZBUEtldpU88YrpNV1m5gm36deRTw6pahNNZQrqLjOAQR98FWDY9I2PSq5Ha/m0W6TSudLRWVcSXEN/BHZzPcXOxRNG/EZX++xH3DnOMDnpg4yNWszEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuM8e6prGmX2inQN8lxLJIpgVdwlGF4I9Pft6igDs6KpLfTW+jLd6pb+TMse6WKE+ZtPoD/AF6D1xzVS61m4s7G0doIZru/nEVrCsuEyVLjdJg8BVYkgH0APdpXGk2bFFcPdXurP4K1qWcMs0d3Msxt9ReN4Ixz+6kMZJI7Aqo5PSumu9WXT76KG6j220lvJL9pL9GQAlSPdctn/ZNNxsv69SnBrT1/A0qKradcy3mmW1zcW5tZZoldoC24xkjO0nuRWbqEtwvi7SUbzEtmEoUxXRAdtmSHi2YYDHB3cE9KiT5dGKKubdFctqOtX11eWwsoVisY9US2kn+0lZHZWwwEYXBXPHLDp0rVh162n1AWir85Yrnz4TyPYOW7emaUJKauv60T/UcoOO5qUVlxafe2gllivWuZfJdYo5y2zeWLKTyemQv0FZPh+4u7tbyw1PUNWi1R4NzW19BCggzxvieFQrrkj+NiPlB2mtVBuLa6EPQ6qiqljZyWglEt1Jcb2BBcn5QFAx19QT+NM1bUjptrG0UH2ieeVYYYt+wM7dMtzgcEk4PTgE8VnJpDSbdkXqK53xGLyTwfd3F5usry3RpU+w3smFI6fMAhYexGPrU+v69Joy2621vHdTTBm8ombdtXGWAiikOORkkADI55qJVFFNy2LVNyso76/gbdFc5ceK2WHTriC1hS1vbdZzc3s7QxRhsYXeI2Xdz0YrnjGe1i/wBelstdgsTb28cEgT/Srud4VdmJGyM+WVZ8DO0sCfTHNPnje3nYXs5djborLbXrZdR+xlf3nmeXnz4eucfd37vwxn2p6adcRXxuReySLvkcQMxCncAAvU8DB7d+lWTY0aK5jwzq2vXYvpNcttPhtoLidPOivWdk2tgLtMKjaBn5ic8dKxZ/G9zqvhvWV+ySWM0NkLm3ltjOPMQnGVaaGHnpgrkc9RW6oTbt2t+JDkkmz0GisO1u7nWG1DStZs/sMsaI/wDod85LRvu2nzFCMrZRgQPwJzWPYeJZtI+G+gXckVxqV7dwRRoG82RpHKFizlEkfopOQrHP5iVSk9Fvdfj/AMMUtVc7SiuWj8RXt7/wjkv2eXTze38kFzBLEyllWCZuPMRXwWRSCVUkdqseLZruGPTPJEi2zajbrNLBeGCQZlUKu3YwdCT8ykrkd+aPZSUlF9RNpK/lf+vuOhorA13xHPo+p21uttarbSrulvL65e3hTLBQocRuu/0ViueMZ5xA+p+Iv+E4lsILOwk09baOTL3rI4UuQXwIT83GNu7HA5GeCNKTV/60BtK/l+p01FUP7Om/tP7V9um8vzN/kZO3Gzbt6+vzf5zV+shhVe+tXvLN4I7ue0L8ebBt3ge25SP0+lZGma/ean9qjWztILmNN0drNduk2M4BkQxAoP8AaG4HsT1qro+u6v8A8IbHq2q2lvLthSVniuTudM/OxXywFIXJwM5xjisvaQkvJq5r7OcX5o6OztINPsobSzjEUECBI0H8IAwKmrHmuV1i21OALLHb2+FS4guWjaRgoY4KEEAZA688j60Rr8umeEtGm8iW+u7uGJVGJH3Hy9zMxRHboDyFPJHbJFOaSbeyt+IlBvbc6aisOHxMn9m29ze2ctrJNuBildYiNpxkCUoxB6g7QcEZA6VYuLaTWLeK4tb2W0VomAEbg5Jxg5VsHGD0PfrVrVXIas7M1KK43xvrupQaLrlpoduhkstOaa4u5LtoGh3K+0x7UYsw2E8lR05640biW7/4TfSkk8xLVrWYoYrwhZGwmfMh2YOP4W38ZPFbKk7J+v4K4un9eR0NVNM06LSrBbS3Z2jV3cFyCcs5Y9AO7GsoeJZv+EvOjy2ttbQ7tsct1cvFLcnZuJhQxbZQOh2yZXkkDjMemeKLy/vLTz9KS3sbyaa3hm+1b5DJGXzlNuApEbYO4npkCl7Oaj5bidrnSVW1G0kvrGS3hvbixd+PPtgnmL9N6sOenT6YrB0KVdNvPFCy3czWtndq6m8u3kESm3jdvmcsVXJJ9BnpVTTPHdxe2uovNpBimsIYrlkDToHhdmDMPOgjYkBGOApB4G7rhqlJ6x1St+OxTujq7Gxt9N0+CysoxFb28YjjQHO1QMDr1qesyHVpbttS+xWgnS0AWFhMB9ok2bio4wByo3ZPJPpzds5Z5rGCW7t/s07xq0kG8P5bEcruHBweM96zknuyVboTUVia1rd9Y6tY6bpemxXtxeRTSgzXXkpGIymckIx539gecdiSKUXiy71K0tpdC0uK4eSwiv5kurowiNJN21QQj7myjdgOOvNUqcnHm6f8P/kVZnUUVyM3jedg1zYaUsunw2tveXE8115brFLyNqBW3MACSCVHTmn3XjSaHxQ2l2ujXV1BDcR289xHDcMVZgpyu2ExlVDgktIpGG44GaVCo3ZIhSi1dM6CHTLW31K4v40c3NwFV5HlZ8KOiqCSEHfC4BPJ5q3VSO4vG1ia3ex2WSQo8d35wPmOSwZNnUYAU56Hd7VHa6dPb3pne+mmQ+Z+6YnA3Nkd+w4/wrJ36lF+iqNlfPLczWdyqi4gwWaLJRgeh/2T/snn0yOasXd0llaSXEocpGMkIuT/AJ9zwO9IB8kMUxQzRJIY23oWUHa2MZHocE8+9Pqh/aBtdFl1HUdixxxtMVhy+EAyBkfeP06549TmxXupadY2FoYFvNXvvMmaOe4ZIo/4nG/axCruCgBfTpyaaTZSi2dDRXDy3+o/8IPptxOZSXv40uZYb9o5EzdBAFYod65OCDtytdBqOvHTbi8jmtCwhtPtMBWQZuDkqYwD0IOwenzinyu39dCnTZsUVn3F/NZSQNdRL5MwCFYzudJPQD+MfQZGM4x00KkzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApCqlgxA3AYBxyKWuZ8X+LT4Um06SS38+2uGdZQpwygbcFe3c8d/agDpqz7nQtPu7L7JLCywiXzl8qV42jfOcoykFP+AkdT6mp7S/t7zTY76JitvInmBpFKYX1IPSoZNZtIdP8Ats5ljgLbY8xMzS56bEXLNnsAMn0pq99Bq99CrL4U0eXSm037PNFaPI0jxwXUsW9m+9uKsC2epB4J561Zk0Oxn0+GyuEmmhgcOnm3EjvkZ6uWLMOSCCSCCQeOKw5/Fsx8L6hqNuqwyx3MkFs1xZXGxdvQyoql0GM5JAHSujN/bpfJZSShbl4TMqEEbkUgMQenBYe/IqnzJaly51v5/wDBLNZt7oFjqGoRXtybvz4v9WY72aNV+iq4HPfjnvVuyvINQsYbyzk8y3nQSRvgjcp5B5qjd6pJF4ksNOiMapMsjS+bBLlsLlQjgbM8HIJzisppbSQo813YVvDelNqJvWtmM3nCcZmfYsgx84TO1W45IGTznOTWpWHqXiWG21C2srPdNM93HBKfs8jRpu6gyAbA2McE59q0k1OwkuPIjvrZ5skeWsyls+mM5pQ5bWj/AFsElPRyJ5olngkhcuFkUqSjlGAIxwykEH3ByKoaboFhpMzzWouZJnXYZbu7luXC5ztDSsxUZ5wMA0kM2snzPNtbYkROYwZCgZwxCgsNxAK4JOD1/CqOk6xrupR6h9o0qwtjatJDH5N88xeVccYMSALz1zn2rePNyuz09SHbZnQ1XvrG31G1a3vI98ZIbhipUg5BDAgggjIIIIpli984l/tCKOMhgI9ncbRk9T3yPwp99fW2m2jXN5J5cSkDOCxJJwAAOSSeABkmspWtqON76FO48PWF3pY0+5N5JbAkkNfz7mz2Z9+5hz0JIpJ/Dem3KW6zpcObdGjRzeTbyjEFlZt2XU4HDEjioNX1e5Tw3NqmkFY/IBdkvrOVS6jqNrFGU+5B+hrQv9Tg02JHuUuWD9Ps9rLPj6hFOPxrNqnZtpW/qxp+80s31/4JWk8N6bLb29uyXAt7eIQpAl5MsZQcBWQMA4xwdwORwamudFs7y8S5uPtDshUiP7VKIjtORmINsPPqKbNr1hC9uu+aY3EYkjFtbSTfIejHYp2g+px39DT59YtLfUUsX+0POwU4htZZFQMSBuZVKr0P3iKp8l9bb/j/AJi/eeZeoqqdTsBcfZzfWwm3bfL85d2fTGc5qBJ9TF8fPgjFoHky6jLbQBs4B6k7u3boKsiwi+H9PS+uroRzbrtWWeI3MphfIAJ8otsBIHULnr6mqcPgrQoLW4gW2uJFuYPs8jTXs8jmLsgdnLKB2AIxk4xk0aB4ttdfluIobW/geGSRMzWM8akI2M7njVQx/uZyPwqLUPF9smg6nd6eJY7ixh80pqFnNbDGfvYkVCV4PI4HrXRasny6rb/gEuxfh8OafBp89nEbwJcEGWU385nbHT98X8wAY6bvX1NV4fBuiwaMmlxw3X2WKRZIQ19OzwMowDHIX3x4HGFI6n1NT2+sx61aXaaHceVdQ4GbyylAQnkN5bbGZSM4IOD2PFVtK8RrJ4M03WdX+WW6t43ZLWB5CzsM4SNdznucDJwCe2aX73XV3utNd+g1toT3HhjTbrT7WzuDeulpKZYZP7RuBMjEMCfN37zwzDluhxTL3wnpeo2dra3jag8Vqd0WNUuVbIIYMzCQFyCAQWJI7YpzeI7d30j7JG00epXT2+5w0TRFY5HO5GG4HMeCpwRn2xTfEOsy6W2nxWzRpLdXkURae3mePYXAYb41IRyDhd5AJoTrcyV3cTta77fgS3nhvT79oftbXzrDGIxH/aE4SRR2kQPtkz33g575qa90Syv763vJxcJcW/CPBdSw5GQdrBGAdcjo2R145NNvtcstOvYbSf7U88wyEtrOWfaM4BYxqwQZ7tgcH0NUZPF1pD4pfRHtL8usaN5yWFw6FmYjGVjKhenz529Rng0oqrKzV+v/AAQdlub9FUPN1T+09nkQ/Y/Mxv8A4tmzOev97jp+Her9YjKFjotnp87TQfaJJWXbvubqWcqM5IBkZtoOBnGM4HpUH9k/2XZ3A0KBXlm6Q3V5L5K5JzgHcFHJ4UAHpxUkGv2N1DNLbi7kjhXcXFjNhx6odn7z/gOaqaV4sstR0WPUZori0Rgm8S20oVS7bRhigDDJ6jgd8Vlem7R0/wCAa/vNW7k2n+HLay8MW+ivJM8UaAPJHM8TyNnLHchBGSSevelHhnSxpkVh5dwYIHDwk3cpkiIGBsk3bl44wCBgkd6mvL5pYb2DS7iJLy0VS5mgaREyN2CAVySPRuMgmorfW4l8PWGo6gSr3UUbeXBE8jM7LuIVFBY9zxnABPan7jbbX9f0gvU7mha2yWlskETSsiDgyytI34sxJP4mpaopremvax3BvYYo5chfOby2yDhgVbBBB4IIyD1pl7dX7xpJoyW9zG0TMHLZBbjbg7hkHn8utaGdnfUr6v4T0XXZpJdUszMZYfJlUTSIsqDOA6qwD7SxKlgSpORg0+78M6de6tDqU5vRcwYEZj1C4jRRxxsVwuDgZGOe+apeLfFtv4b0e9ePfNqENo88cMdrLOqkA7TJ5YOxSQeWKg4PPBxZl1mX/hLLHS4jGsclvJLMJbeYMxG3b5cm3yzjJ3DOeldEfbWTTdtbfqJ7a/1sWP7BsTq/9pObuScNuVZL2ZolOMZERfYDjuFqh4b8KwaMnn3BkmvTJM25rqWSNA8jN8iOdqHBAO0DvWguu2T6wdMj+0yXCna7JZytEh27sNKF2KcY4LZ5HqKhsvFOkajqC2dncvJKxdVb7PII2ZCQyiQrsLDByoORg8cVP73ltra34f5EtK92RW3g7RrWS8ZI7uUXyMlylzqFxOkwICncruQTgAZxkAYFInh+PRbW5m8O2aXGoTRrEW1G/mYOoJwGkbzGwNzYGO+OKdoepX895rNtqr28rafdLGj2sDR7kMSScqXckjfjg846U+HxVpU0E0vmXMIgMYlW5spoXUO21W2OgbaSCN2MDByeDTftXo22tO/yKfmGi+HLXSPCcGgsTPAsBilY5XzS2d565GSSevGa0rO0gsLGCztE8uC3jWKNMk7VUYAyeTwKhfVrKNr1XmINjGJLg7GIjBBbrjBOBnAyenqKms7uC/sYLy0fzILiNZY3wRuVhkHB5HBrOTnK8pdRaKw2SxtpdQgvZI83EEbxxvuPyq5UsMdDnYv5VmTeD9FmtbW3NvNHFaw/Z4xBdzRExf3HKMC6+zZHX1NWNW8Q6bok0EOoSyia4V2hiht5JnkC43YVFJONwPTpk9AcRXXirSLW3t52uJZo7mETxm1tpZz5ZGQ5EasVX/aOBVRVWycb/wBX/wCD+I3tqWJtC02eO6jktV2XcSQzKrMoZEztAAPGMnpio5PDunPrB1NVuYbpmVnMF5NEkpXgF40YI5xgZYHgAdBUNz4u0S1vUtZLxnkdY3zDBJKiI5wjs6KVRT2ZiB154qe48Raba6oLCaWUTF1jZlt5GijdsbVeUKURjlcKzAncvqMtKqtr/iJJW0I7fQyniy612edXkktltYo40KBIwxb5/mIdtxODhcDjB61r1Uj1Szl1ibS0mzewQpPJFtPyoxYKc4xyVbjOeKjtZdUa9K3cEK2/7zDL1OGwnc9V5/wrOTk7c3Yfdi3GjWF1pUmmz24a0l/1ibmBbnOSwOScjrmotO8O6XpN09zp9r5MrhwzeYzZDyNI3Unq7sfxx04q3aXsV4r7NySRnbJE4wyH0I/r0Pap3dY42eRgqKMszHAA9anzDyKM2j2s1vHbgPFAlwtwYo2wrMDuAIPRdwBwMcj65dqWj2erLD9tSQmFy8bxTvEykjBG5CDgg8jOD3qW3vY7m1NyA0cPJDyDbuUfxfT64rNt/EEcejW9/qgeI3bFreCG3kklZCSUHlqGYtswTgcc9MU1foWua90Lc+EtHutNt9PaCaKztm3RQW13LCqncGHCMM4YAjP3e2KtyaPZSrZiaOSX7EwaFpJnZsjpuJOX6A/NnkA9QDWG/iqc+GbC/XyoZ7y6WJTNazmNVM2zDbQSjEcDdgbjzW7Nq9jbSXcc9wsbWUAuJ9wI2Rndhs45HyN09Kp81te5TVS1ix9mh+1faSmZtuwMTnA9B6fh149KlqqNRg+0RRNvQTqGid1wr5/hHo2OxwfyOLVQZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVRv8ARrDU7q1nv7dZ2tCzRB+VBOOcd+lXqzNW8Q6folzZxanL5C3bMqSsPlUjH3j269elAF64tobuBobmNZI26qf5+x96y9Q0S5u7S0EWoBbqxuRcW088PmAfKy4dQy7vldhnI7HtzsKwdQykMpGQQeCKRJUk3eW6vsba2052n0PvTTaeg02tjnLjwxqD+Hb3TINWh8y+mkknuJ7Pfw45CqrrjB6E549etXL/AEW71LT7eO4vo0vIiyvcQQFVZGBV1ClyVyp4O44IB56VNLrsSaZfXkNpeXP2KV4mgt4g8sjKQDsXPPX2rTByAen1p3di3KS/H/gjY40iiWONQqIoVVHYDoKydS0vUrvWbO8tdQtYIrQsViks2kZiw2tlhIvbpxx71sVWnvfIv7W1+zXEn2jf++jjzHFtGfnPbPQetZySe5MW1sY58M3P23K6kq2S3/25YBb/AD7ydzKX3crkkjABGRycYOumnwx3HnK9yWyThrqQr/3yWx+lLe38VgsBmV28+dIF2gcMxwCfarNEEoq0f60X6WHKUpbhVLTdO/s77X+98z7Tcvcfdxt3Y4689OtVh4jsVhuJpxNBDbQSXEsjpkKiMVbgEk/dJ4HSrNzq9nbP5buzSm2e6WNVOWjTG4g9P4l4J71or20Ia7/1/Vy7VHVtObUrWNYZ/IngmWeGQpvCuvquRkEEgjI68EHmn2OoR6gJTEkieUwU7wBklQ3r6MKt1Eo30Y02ndGLqelarqnh+TT5NRs0mmBSWZbJtpQ9lTzcg9OSx+lVdX8L3Gtiza+urGZ4I5EkSaw8yJixHzqjOdrgDAJLdTxWrrGqDR9Pa8ktLi5ij5k8jZlF7sdzLkfTJ9qvg5FZunCV0/1NFUnGzXn2OYm8Jztp2nWdve28P2K1S3F2LVxcjAAJSRZF2Zx0IYeuRxVvUtAnv9YhvI7m3thGUzJFbutyyqclPNWQAof7pUj2zgjcoqnCLd/mL2kiqdPhNx5++537t2PtUm3P+7uxj2xirVFUItYgm1D7GsUwfzJE3EDblApPf/aFX5GZTttFvrW41COPUolsLxpJEjS2Inhkfqwl34IByQNmeRzxXP2Hw1+xaffwpd6dBNd2Is99lpYgXggiRx5hZ3znJLc8YxzntLW8gvVka2feIpWifgjDKcEc+9R6pqMWk6XcX9yrtFbpvYRgFiPbJFbxq1I6Lrb8NiZJNO5n2+k6rDHeXMmpWcmq3KpGJxYsIERCSB5Xm7ifmbnf3Hpisc+Bbifwjp+jalfadetpsiNbPNpe+FlVCm2WJpDv4LchlwcY6c9bdzyW1pJNDay3boMiCEoHf2G9lX8yKh0jU4tZ0a01K2SSOK7hWZElADKGGcHBIz9CaI1KiTku67fL+titkYbeFLqLS9Jh0y40rT7rTbp7lfs2llLZiySIR5IlBHEmc7+oz3xU+s6LrmradZQLq2nwywTRzzSHTnZZHRw6bV88bR8uCCWz6itm5vra0uLWG4k2SXcpigXaTvYIzkcdPlRjz6UzUdQ/s6KF/sl1debPHDtto95TewG9h2UZyT2FHtKjkn1v2Qmlaz7fgY2t+G77WJ7WUX1lbSRRhJLqKykW5BzlvKlWYGNTgfKQ49dw4q9eaVetr0Opabe28B8oQXMc9s0vmIG3DaQ67G5bk7hyOOK1qgF5Ab9rIP8A6QsQlKYPCkkA56dQaj2k9F2uFkT0VQ/tiH+0/sPlTeZ5nl7sDbnZv659Kv1mMxNF0GfTL6WeW5twjptFtZW7wQ5JyXKGRxu9wB1Oc8YhTTm0bw3c2OoytfaeIjDDFa2UhmCHIwdrNuOCBkKuMZroahs7yDULOK7tH8yCZdyPgjI+h5rL2cbcq7GntJN8zMbSdL1SHwosM9zDHqtyPMuppYjKu9uCMBlzhQFHPbvVebwlNd6Bp9hfXVjcy6ey+S02n74XUJsw8bOcnBJyGHOPod++umsrKS4S2mujGM+VCUDEd8bmUcdetLY3aX+n295CGWO4iWVQ45AYZGffmm4RldPy/wCANTmtUU7PRIbfToLZxHD5Wfl08PaRcnPCK/H4k1oxRrDEsaFiFGAXcsfxJ5NOqhqWrw6YQJ45XzG8n7sA8LjPUj1FaLsZ6yZj+IfCd3rEmpLZauLGDVbMWt0ptRK3yhwrIxYBc78MCGyBxtPNWb7R9XuPENlf2up2UNvaKyCCSweR2Dbd/wA4mUZ+Xj5eO+a0tV1KHSNGu9TuVkaG0gad1jALFVGSBkgZ49aJdQ8vU7WzFpdP9pjd/PSPMUW3HDtngnPA74NbKdSyt59F21/AXT+vIyj4auG8WjWFurS3i37nS0tXimuMLtAmkEu2UDPG6PjtjrVLwroupeTbT6rcRrBa3NzLbWq2jRSIzSSAM7lzuG1jjCr1B5rrqKXtZOPKyXG7ucva+GtZWTW/tut2xTV1O5rOxeGSF/KWNWVjM3QKDjGc85HSs+w8IWXhWy1S7vYoJYby0S1lttG0hogwBYAiOMuzMd/Jz2B4ArptI1pdWmvoTZXNnNYziCWO48skkorggozDBVh3z7VpVcqtRXi9nba23T8Cn5/1/VjA8N6ZqVp4TWPULjZrF0hkuLjaGKSsMDjodoCr6HbWzZxTw2MEV3cfaZ0jVZJ9gTzGA5baOBk847VNRWUpuTb7iSsZ9zpf2jxBZan5237LBND5e3O7zDGc5zxjy/TnPtWJb+Eb/TbK0h0fWIYJEsI7C4knsjKJUTdtZAJF2MN79dw5HHFdXRTVSSVlt/w/+bKu7WOafwbEum6hY2100UN1ZQWce5NxiWIMAScjdkH26VDN4HgfxZJrKxaPMJp0nk+26Ss1wjKAv7ubepUYUEZVsHJ9h1dFUq1RO6f9f0jNQilZIyLc6vJ4sunk3RaPHbLHHHIsZMs24kyIVJYLtIUhscjgdzr0VQtdYgu702yRTK48z5mAx8jbT39TWTdy/Mim0m4NrO9tf+VqUyhRetCH8sZzhUPAX2/E5NMttIvmeVdY1QalbSBwIGtVj2kyMykMvPyoVX/gO7qa1Y5EmjWSJ1dGGVZTkEfWnUgMm/0u6u9HOmm4WaGaQJO8w+YwfxJx94kfLnjg56jldV0m4urqyutNu4rO4tN6gyweajI4AYbQy4PCkHPGOhzWmkqSbvLdX2Ntbac7T6H3qDT7+PUrU3ECuIvMdFZsfPtYruGD0OOPammylJrUwLvwrfyeG7TSLPVoUWGYTSTXNmZGlZZhKvCyIByMHjnttq/faFLqJtHubqMSInl3flwlVuEyGKgFjtBZR1LcFh3yJf7dibR49Rgs7y4SSYRCKGINIP3mwsQD90HknsBmtSq5nb5lOUrWZUubAXlwpun326gEW+PlZvVv73bA6fXjFumiRDK0YdTIoBZQeQD0OPwNOqDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACue8UeE4fFM9gLyZo7e1Z2dEHzSZxgZ7dK6GmNPEkyQvIqySAlEJ5bHXA74zQBW/s2ODSRp+nMbKNE2RmIfcH4//r9weaxdX067m0Oyt00xZ4be6U3dhC6bbuLDAgbyARuKsQxGdpBz36aimnZ3KjJxdzgbrw7Mvgi+sF8LxyTTXcstpawGAra7h8rgsyhSOny8gnjI5rd1GDUJxaarp1hLBf8AlPbPDM8e5EfozbXKnayq3BJwWxycVsy6hZwWs1zNdwRwQEiWV5QFjI6hjnA/GrGc9KpybWpbqN7+f4lbTrGLTNMtrG3z5VvEsa5OSQBjJPrWJqttMvi7Tr+00Ga4aAOs15EYFLKykBcs4YgE5xjHpmukqKS5giuIoJZo0mmz5UbOAz45OB3x7VlNc2rZMZNM5CXQryXXlml0dJriPU1uBqkjx5+z5yETneNoOCuAOCQSTz0EOl3MWoC4a83JuLeXum6HtzKV/wDHce1aMk0UO3zpEj3sEXcwG5j0A9/an0qcVBWX9aL/ACHObluUNesH1Xw7qOnQuqSXdrLArN0UshUE/nWVpEWoXuvW+oX+lT6YtnYtahLiWJzKzshJXy2YbR5fUkE56VvRXdtO+yC4ikbBbajgnAOCePfipHdIo2kkZURRlmY4AHqTW0ZuKt/XYzkrqz/rb/IdWT4ksp77S1jghNyizI89qHC/aIwfmTJIHPoSAcYPBrSiuIZ93kSxybThtjA44z29qkrOUeZWZUZcrucxqdtL/wAIXPY6P4cmtmuFeNbOL7PH5RP8RxJtwfYk89Kr+J9PvteisFbR5Wg2SF42jtJJYpPlC5Mu9QpG4kplun0rp73UbLTY0k1G8t7RHbYrTyqgZvQEnk+1WKylSjNOLZpGpKLUrd/xOHvNF1CWx0Z5dJa/1K2so42+1JbzWyScbt25w4bI+8me3DYxV7WdKnn8U219a6V9qmXylM11DBJBEoYklCWEqOM9QCP9k9R1VFU6abv53D2r/Qy20u5Oo/aBeYj8zd5e6bpnp/rdv/juPatNlV1KuAysMEEZBFLUK3ds83lJcRNJkrsDgnI6jHtkVoZXe5yeg+HYdAv9Uj03wra21wxme21FIYEidGIZYjtbzAAeCNuPl69K53TPCOs22i61HBpVzam804RmAiyt2kuAckoLbaoHJ2szFuuccE+qUyeeK2gea5lSGJBlpJGCqo9ST0rpWJnr1vb8CGk0cxollJpEep31j4bnsIpxHs0uJoBLI4yGlOJPLyQy8l8nZzzgVitoms33w30nSrnSb23axaKO8sw9o73MaoRlA5eJgGKnD4+72OK767vLawtJLq+uIra3iGZJpnCIg9STwKdb3MF5bR3NpNHPBKoeOWJgyup6EEcEe9JVpL3rdV36fMpaKxxcekXul6P4daw0rU7kaffyTSWcr2iTxo0UyAAIywgAuuFU8A/hVjxTBc6pa6RdQ+FLq5vYLqK4UsbXzbRUlVnXc0uAWVT9wkHuRXYVDc3dtZojXdxFAskixIZXChnY4VRnqSeAO9HtpOalbW/n/mJq6t5WOR8U6Vc6nqmn31t4fkvLuOJRGL6G1ntrclgTuDSCRXGPvREjpw+AKm1Hw3Yp44i1c+FbfUvPjRWuI4bffbyq+RKxkZSeCOVy3ydOlddRSVeUUkul+/UGr38/0Cioftdt5/k/aIvN3bdm8bs4zjHrjmpqwGcj4e0Lybi8gudESOxnjIke/t7czzsWzhmiZhIvX7wBzjlsnDNI8Nw23ha40yXSI9LuI4xuvgkQWZ0JKS5RtxwQG+YA/rXY1Dd2Vrf25t7+2huYWIJjmjDqSORweKw9jFJJdFY39tJt362/A53SJbm58OXGttp00t7qqh/s8TIGVNu1Bl2UYx83X+I9apXmk6lqHg/SbObTruP7GUS6tA1szzKse3IDl42AYg4bHTPBArr7u8tdPtWuL64htYEwGlmcIq5OBknipIpUmiSWF1kjdQyuhyGB6EHuKp01K6v2EqjjqkYFhoU0eiWlvbzXNoIt/wC7umw65bOP9HkVAB2AyAMAYrctYmgtY4pH8xlGC3zc/wDfRJ/Mmpaimu7e2OLi4iiO0t+8cLwOp57c1qtFYybcnc4Xx14cvtam1VF0CLWTc6eItPmmkiCWUuH3nDnKscphkByQAxUAGtO/tZ4fHWn6jaeGZ5zHA8FxqEJtlLBtuAS0gchcHIx9M11E9xDbW8lxcyxwwxqXeSRgqoo5JJPAHvTXu7aO6itnuIlnmVmiiLgNIFxkgdSBkZx610KtKyVtr9+q16iev9ehyY0WdPiMdTt9GLiSTMt/fQWziNRHt/0eRX85M9CGVgecbckmh4O0zz761v4dGktZbe5u/P1OVoybqMySKIlIcvtBKnDBQNnAr0Go4YIraIR28SRRgkhEUKASck4HqSTR7eXLy+VvkS43dzkrBtcN14mePw/cWst8TNZvey27RMywJGFcJKx5ZSemMdSOlZHhvwdc21vrENzaS6bZXNrCYhcR2cZjuI2dvM2WwCDB2EE5J28ngCu+sNU0/VY5H0u+tr1InMcjW8yyBHHVTtJwfanX2n2eqWbWmp2kF5bOQWhuIhIjYORlSCDzzT9tKKcbWvb8Nt2U9f6/rsc54fWXWPC13rV5p4e61mDebXzNu6IJtjj39gRls9jIa39Hh+zaHYwfZPsXl28afZvM8zycKBs3fxY6Z74q4OOlFZTnzN2WgktjnNe8ORa74l0uTULCK90+C2uVlSbDJvYxbAUP3vusehAIB4OK58+Hr/8AsrTI9c8Otr7JpUVusLywt9juFzucmRwPmBUb03MNnvXodFVGtKMVHov+D/n+RV9LHA3ngy7nivJ7u2TUNTgsLRLG7kZWYXEYO903H5GyFO7gnjnikvvC13c/EB9RvLfU5l+0wy2t3afYikEahQULSr56DcrFljJBDnuzCu/oq1iZp3/rp/kZqCSsjnbS5spfiJqEdrZK9wlhEtzfR3G4IQ7FYXTorYYsD1IPsK6KioY7u2lk8uK4id+flVwTwcHj2PFYSlzWL63MsRahY295fWll5ksmGj01JlRSc8sWOQGPJOOPqeaWGfWNS8+2u9ObSkKvsuUuUlORIyqMAZG5Ar+27GQRmtmipAw7oXlv4d+xWdq1tdSsLZGtxuWPdwZs84AGW+buMc55ra5o2IdKtoNIGqaXagxSaeDGFPygRsVchWC46dsggHFdLTIp4pwxgkSQKxRijA4YHBBx3B7VSbRcZOOqOEvtBvI/Buk2K+HBdX1rdJMn2doCtoFuFchWdlI3ICBtHscVs6rpl5ezefZ2ssH9q2otL5WkUNAuchzhiMhWkX5STkr2GRuvqFlHarcyXcCwM4RZWlAUsW2gZzjO7jHrxVinzu3zKdSVjMubB5rq2S2QWsdsoxcKRuA/uKPTjndkdOCeRp0UVBkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXHeO/D+p+ILrSE0lvJaGR3e43bfJ+7g8c544xXY0UAUlivbPRljjl+3XccePMmwnmH1IHH4cfXvWHqmrNYaHayLqMluk92Ib2/nCq1mCpJOHBVPmCqMggbgee/U0U1oyotJ6nm11eW0Hw/1aW41rarX05jkvY4B9tPUIyPHtYHr8qgkAEcV0+oa+totpqlneRXelzxPEqwlWV5usZVx6lWTGeSy9+vRUVTkmv69C3NPp3/EradHdRaZbJqEwnu1iUTSBQoZ8ckAdBmuf1nU7Cy8baSLvVrWNsSK1vO0IMWUOGBI3qWOB97BxjFdTRWU05bExkk9Thb7U3vddhhuNSdJ7fWEjGmRomFjDfLI/wApcbgQQdwU5A+vTQz6q2oBJoMW+4jd5KDjtz5xP/jv4CtSilTi4Kzd/wDhkv0HOalsjKvvDmn3mmXln5OwXVvJAzBjkBySe/qSawPDEz+J76W51NFd9MtP7MmGCP8ASD/x8YPp8sYBHvXaUVvGdotf1/TM3r/X9diC2s4LMOLaPYJCGbBJyQAP5AVQ8SX09hpayQTC1Rpkjmuiob7PGTgyYPHHqeBnJ4BrWorKSbW44tJ3OS17U9Pi+H947a9DfJNG8cV1LND+9bn5QUCqSPQDPFN8TeIwkVgNH1WKEXMckiXK3USRShdo2hmil3tk8KoycHmuvorKdOUotJ2/r1NY1IpptX3/AB+Rw954luFsdGvbjVVtluLKOeSztZoFuZnbH3Y5VO9eowpVuuNxwKvazrMll4ptoW1TbC/lKtjazQeezFjkvHIu4pjHKNkf3epHVUVTg73v1v8A8APaR/lMtp9V/tHYsH+jeZjd5Kfdz1z52fx2/hVkaZapcGeOPZMS7eYCcgsACeeP4R+VW6K0MrnDeF5Y9KvdYtrrxJdXt5bzXEr6W/2bzSu7cJQiRq+SCMc7fm6VzsPie+1Twxr6XeqW9/b/ANmC5SUXUdwsDZ5R2ihhUEAjcuWI45GRn1uiupV43bcddPw+REo3TOV0TXrdI9TurrxJBqWkQCNl1OV4UiR2yHjDoFUgfJ1yRuwSa52z8TGD4T6E+hanZJgQ2t3eG6RUs/3efnfy5FjOQq/OhHzdsg16ZRUqrBNtx6r8Pl5lLRWPP5NaWPTvCep69rGmSxLqkobUIrxHgK+ROqkyhUUnoDhVGe1W/GWv6Otlot9/wkNglu99A8cbyW7xXKCZAzgupPyDJ3IRtPJNdrRR7WPOpcuz/roJptW8rfn/AJnF+KfEYsdU0+SDX44rSWJZFtLG6tvtN0WYbSqTKfMQj+4yt1xuJACagq2PxHSa+8UXGnR3dtGtvDIbZEnYSHMKl49x6jgHd83XpjtaKI1YxSSj37dfkDV7/Iq/2bafbPtXk/v9+/fuPXbt/lxVqiiucZyPh7U59VuLyzfXHurgxF/PsJbaaCH5uNpCblb/AGZAeAcFsE1W8MtcJ4NaHTNae61K0iXfZN5BMDITmIgKCN2CvzEkdq7eq99aveWbwR3c9oX482DbvA9tykfp9Kw9m0k76pNG/tE29LJ2MS21yK60XUNZur6OHS5vktDMVjUKF2k5PdnyBk9AMdayH154fAmhvo+oWkcbLFBcXZuFVLciLOC5SRUO4AfMp644JBrtLO0g0+yhtLOMRQQIEjQfwgDAqaqlCTTSe9hKcU9jnrC91iXRLSWOW21CR9+6e12To4DfKd2+IE46kLjIPA6VptYRajbRNqkG6Xy2Rh93AbGRgMfQdz9avUVqtFYzbu7o84+I+rMLTXNMuNXl01E0ova2sMSM9+zLIHHzIxZVCjOzBUEsxxgjV1HV9LsfiHpUd5rlmkr20kYtLh7cNCzbNu0lfMBf03YOBxxXZUV0KtFRSttft1XoS9V/Xl/kcaNdmT4jHT5dZE8bybItPsbi2cxAR5JuI2QTLzyGRmHTIUda/hvxBdanrFsB4gj1CYz3MV5p0SxYtY0ZwjttG9WyqD5mwd3AruqqaZp0WlWC2luztGru4LkE5Zyx6Ad2NHtIctuXW1v+Dt/Xclp3OR0jxTo/9p+MJ7HUre+kjkFysNlOkssiJaxAlFBOfmGPTPBql4Z17XtWh1aCDVYdQkgtoLq1nguIblWbc+6EukESchACACV3Z3dMejVW1G0kvrGS3hvbixd+PPtgnmL9N6sOenT6Yp+1hZpR7K71tb5FvUxdN1l9X0XUtahvmg06RG+xyGEN5SopDS7cZY793B4IQY686+jzfadDsZ/tf23zLeN/tPl+X52VB37f4c9cds1LY2NvpunwWVlGIre3jEcaA52qBgdetT1lOUW3yrQlX0Oc16TUp/Eul6Zp+qS6dDcW1zLM8MMbuShi24LqwH3z2PBPfBHPnxVcXGlaZNq3iBdA8/SorqOZEiH2yc53oBIrA4wh2rhjv616HRVRqRUUmvy8/LzW/YrSxwN5rHiBory+lvnsG02wtLqSwjgjKvI4JkR2ZWbb8uMKQRk80l94g1n/AIWA9hHq2mWEUVzDHFZXd6sT3UTBSzCNoC0hJLhSkqjKgEcHPf0VarRTu4r+rf18zNRaVrmRFegeMrixfVQ7GyjmTTjb48sb2Bl8z+LPA29tue9XYdNtLe4M8MW2U78tuP8AE25u/rSQ6Za2+pXF/Gjm5uAqvI8rPhR0VQSQg74XAJ5PNW6wk07WLMOLVk06zuru8nZtJgwUupQxc5OMAAEuuTw3B+vWnw+JLPU/Pg0OVbq8jV2Ebo6D5JGjbkgA4dGHXnHXHNbNFSBiNqX2Hw5LdQyPdXWdipcZUtOxCrGR/CNxAwOg556nP1KX/hHbHSNNl1Y6Zby7xPqTeXuaUDdgF1KBnYseQc4IA9OokhimKGaJJDG29Cyg7WxjI9Dgnn3p9UnYuMkjza71G1sPh/o8l3q0du325CIb1IR9pX7UA7MkiZBUEtldpU88YrpNV1m5gm36deRTw6pahNNZQrqLjOAQR98FWDY9I2PSulop8yta3Up1E1sZVxJcQ38EdnM9xc7FE0b8Rlf77EfcOc4wOemDjI1aKKgyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkfHPie+8M3GlS2MazpPI6SwEf6wfLjB6g88fyNddUMtpbzXEM8sKPLBnynZclM9cenSgCGLUU/sqO+vY3slZAzRz4DIT2IHf261Bca0LOxjnubSYS3EvlW1qhUyzMQSBgkBTgE8nAA5IrSdFkjZJFDIwwysMgj0rLu/D8N1Yw26XV1btbTCe2mjZS8DAEYXcpBGCwwwPBPthq19So2vqYVxr+qN4R1W88u9tLiO6liV0it5JLNF/iZS4RwPYsee9dLLqcNvqEVnOJFaSB51lKjYQhG4Z7H5gcemfQ1mz+EoZdDn0uLU9QgiuZXknkV43kl3feBLo2ATzwBjtgcVau9Bjv9NgtL69up2hbJuD5aySAgqyttULgqxU4A46YPNU7Naf1oW3B/e/+AXdPvF1HTre8jjliS4jWRUmXa4BGRkdj7Vn3t9cx+KdNtENxDbyLIWIijaOchchd27epXGeFwc9a2AAqgKMAcADtWVf6G9/qlvfDVb22a2yY4oVh2DIwfvRk8j3+mKyn/d7kxtd3KOo+IpTfW0GnW9wYv7QjtprvEflZzhk5bcT2yFxnvWymoQyXHkqlyGyRlrWQL/30Vx+tZ58L2xv/ALR9svBELoXi2odREsuclvu7jk5OCSMkkAcY0E0ywjuPPjsbZJsk+YsKhs+ucZpU+a3v/wBaL8L3HPl+yZOp3OsaLoeo6lLcQT/ZbOWVEZMjcpZgTgAkbcDg/wCNSS62bzVF03Sp4vNaC53syHMckflgdRjH70Hoc1qX9nFqOm3NlcZ8q5iaJ8YztYYPX61n6f4btdN1KO+hnuXkS1+zlZGUq/ILSHAHznaMnpx0rePLy6+Zn1uXbGK9jEv2+dZiWHl7QBgbRnsP4smjUtRi0y1E0qSSsziOOKJcvK56KM4GfqQB1JAq3VTUtOj1O1EMkkkTI6yRTREB43U5DDII/AgggkEVlK9tBxtfUy9dvL7/AIRW4v7c3ek3FurSCNxC7Njs331wevBB9xVnXfENt4ftoZrxC6ykqMTwxYIGf+WsiA/hmkvtCk1DRTp1zrF+VfIlmCwCSRT/AAn93tA+gB96bc+HPtUlrLJqt+Li3ieEzp5QaVHILBvkwPujlQp96ylz2fLvp/X+f4Gy5NObzEfxPbG4sIbO2nvJL6AXESxNEp8s45/eOuevRckd+2Zp9djj15dIhtJ7i48tZXMbxARoWI3EM4YgY5Kg/nxVW58KQXWk2ulvfXQsLeFITb7YWEgXoSWjLBuOqlcdRg81Y1LQI9VuoJLu8uGggkSVLXZEUDr0bcULg+4YfrVPnvp3/D+vmL3C4dQhFx5Gy537tufssm3P+9txj3zioEi1NL4ySXCyWweRhEoG4qQNgzgcg7u/cc1OdMsDcfaDY2xm3bvM8ld2fXOM5q1Whkc74b8RX+syXS3uhXlksM8sazSPBs+VsBCFlZt3qcbeDzWVL8QrTVNA1p9Ic215p9v5ufOt7nAzjOIZJBxjoefQGugj8PJFdXzC/vDaXwfzLH92IlZwNzKQnmAnk/fxyeKzo/AtsLC4trjVtSufOsxZLJI0QMUQwQFVYwoIx1KknPOcDHUnRvdrt3+ZEk7NIv22pvrcd7ZLHqGi3cIU7pFhMgVs7ZF5kXB2sMMMjByBWXaeMIdK+Hmkaz4guBJPdQRAkvFCZpGXJ5cpGvAJ5KjjjsK1YNAkgtboDWL97252htQdYPOVV6KB5flgDLfwfxHvzVS18Gx2mg2umJrOpn7DIr2d0TCJbfC7doxGFYbSQQ6tncfbCXs9b7XX/B17FLbUbb+L4tUj0G40ny3ttSvZLaXcyuU2RSsQGRipO6MDILDGcetWPE+o3diNOW0NzAk19BHLcwxRSKqmRRsYO4ID5xuUMR1p154be+s7CObW9RF1YzmeK+VYBKWKumCPK8vG1yPuenfmm6n4Zm1WxtLafxBqcf2aRZTLGltumdWDKzZhI4IHCgA9waP3fOmrWv5/5f11Qne2nb8dSXUfEUdhrdrpUVlcXl3cRmUJDJCuxAcFsSSKWA77QxHfGRmrJ4j1BPGMmkJoN5NbLCji4jeAD5mILndKDsGOm3dkHjpUuseGBrkENvqGqXj2qKglt/Ktys5U53MTEWVj6oVx1GDzVq80X7Tq0GoW+oXdlNGgjkEAjKzoG3bX3o3Gc8rtPJ5pR9mkr269/l/X9Id9fkSeRqX9p+Z9qj+yeZnytozs2YxnH97nr079qv0UVzjMbTvEQ1aznurDTrqWGPPlsJID5xBxhR5mVPs+3HfmqukeKJ7nwzHqup6Xc267EZ3XyyjBjgsoEhIVepzg49avafoKWWqS6jNeXF7dyRiIyzpEpC5zj92i5/4FnHbGTmFdKOj6Pc29st5q1uymOKwYwgIpz8oJC/Lz/ExOB3rD94km+34/1/XU39xtpeX9f8OT3V4b6HUbaynubSWzABuY1Q/NtD7V3BgeCM5HfjnpSbxPb6V4T0zUdXl3S3cUYA3xx+Y5TceXZUHAJ5IHYckCpdL0Ce08KQ6ZLfzR3RTNxdQ7SzueWxvVhjtyOmOlLH4aWPS7SzXVL/fZMDbXIMQkiAXbt4Taw25HzKevriqfPrby/wCCJcnUmsfEVjqGmw31uJ3imLAeXC0u0qdpBMe5eo6gkHqCRUl6uoXcaSaVci3Vom4ljwd3G04Zcjv/AIVINLt5beKPUQuovGCBNdRRljn6KAPwA6VbiijgiWOFFjjUYVEGAB7CtVsZu19Dl/GXiifSNG1WPSbS7ub+1sXneaBYtlrlW2O/mMAeVJwoY4HI5Gbk+oXn/CY6dZA3MNq9tK7fuomiuWG3+LfvUrnptwc9eKbrng+112W7aa/v7WO+thbXcVrKqrOo3bckqSCN5+6Rno24cVNe+HZLvXLbUl1vULc2o2x28SwGPBxuB3RFvm2jPzfTFdMXT5UvX8v6/wCHIe39eQsHiSK78SXOj2llcTPaFRc3CyQ7ISy7l3KZPMwegIQgnvwcRaf4rt9RvoYY7C+ihuHkihu5kRY5JIy25AN27PyMQSu044NSz+G47vxDb6teX1zcG0dntrd4oNkBK7TtYRiQZ7jfg98jiqPhjw1cWMcU+q3l1LJFPPJBaSGLyrcvI/zLsUMSVb+JmxuPSlany36289/6+XqJt30/r+v6RPoFzeLf6/bX19NfpY3arC0yxqyoYI5NvyKo6scE/iaqaX8Q9J1azvp7aKU/YRG06Rz285VHYjfuildcDDEjO4AZxyM2IPByIdVW81rUr6LVo2S6inECqxKCPcDHErAhVA649QTzTRoH9i297eKNR8Q3U9slq0MrwKXjUthQMRoAN7Z7kepqn7Kzvq9PLXr95T8v6/rU1v7XjaTUUit7iX+z1G8xoD5jFd2xBnJbG3jj7w98WbO4+2WMFz5MsHnRrJ5U67XTIztYdiOhFZPh/QZdL8IxaXd3cj3TREXF1G53mRhyyseeM4B7ACtazt/sdjBbedLP5Max+bO253wMbmPcnqTWM1FNpCV9DO1jxAmk31rZJp97qF1dxySRRWipkhNu7JdlUffHU9sdSAazeL7aS1t5tMsL7U/OtUvGS2WMNFC2drN5jqOcMMDJ+U8VqTaZDPrFrqTtIJrWGWFFBG0iQoTnjOfkGOfWsgeDLeGztbfT9U1Gw8i0Wzd4Gi3TxLnaH3IcEZbBXafmPNVH2fKr7/8AD/8AAK0sJP43sYpgLezvru3WGG4mu4UQRQxS/ddi7KSOpIUFgB0qO++IOiaf4mXRJ5QbjzY4JGE8I8uR8bV8tnEjZ3LyqMBnk8Ni9J4U057S9to/NhhvLaK1ZI2GI0jBChcg9j3zT/7AaPWpL+z1a/tEnkWWe0j8poZmAC5O9GZcgAHay9M9cmrTo31Wn/Df8H8DNc1tS5Hf79YmsPsl0vlQpL9paPEL7iw2q3dhtyR2BHrUdrBqaXpe6uo5Lf8AeYQKAeW+Tt2Xj/Gq9vYaj/wll1qNxclLH7MtvBapOzq5DFjKylQEbnbwTkdT2rXrCVla3YvuipaX4nla3nTyLqMZaFjnI/vKf4l9/wA8Gpri5htIGmuZFjjXqx/l7n2qnLo0UmnT2qXN1BJcYMl3DJtmJB67scdMdMAcCmWOhJZTyu+oX94squrRXc/mJhpGfpjtu2j0UAdqkCyt+I9Olvr9PscMatIxlblYwM7m9OOcdqzINZubTS7N762ubvUL4tLFZQCMOi/e25JVRsUgEluT65FW7jRhNp6WMdxItsJld0f5i0YOfKB7KSAOc8ZH0dqmjrqcttMl5c2VxbM2ya2KbtrDDKd6sMHjtngYIqlYuPL1Ofk1/UT4Q068c3UE1xeJHLcRwwyeSDcBAjqXA5yFyu7HWt+71y2sZr2O5jmX7Hai6ZgmRInzcJzyQVxj3X1qjdeEIZ9EttKg1PULS1t5BIBG0btIwkEilmkRicMM+/fNXbnQob37E13cTzSWuN0h2AzjIOHwoGCyq2FC8r6ZBr3bfNltwaJpdSFu8bXcLQW8ijEzEYRj/C/93tzyM8ccZu1XeyilvEuZS0jRj92jH5UP94D19z+GOasVmYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVheIvFVp4ZuLEagj+RdMytKnPlkY5I7jn/8AXW7WRrfhqw8Q3Fk+pq0kdozMIgcK5OOvtx0oA0ra6gvbWO4tJUmhkG5JEOQwqI6nYrZS3kl1FHawkh55G2Rrjqdx4x79KdPYwT2DWe0xQldgWI7No9Bjt7dKydS0rUrixsPs/wBlluNOu1mjjdjFFOoVlAbCttIDZGARlR07NavUqKTepBL40tP+EeutUtGspglw9vaq9/HHHdsOgWRvlBPPr0roRcRGcQGVBOU8zytw3bc4zj0zxmuXutE1xvC+pWES6fNd6jPK7s07xRxq47fIxJHTtnrx0q9qOmalf21pcxLa2mpxq8LlZmdVjkGG2vsBJBCMAVGSuOOtU0raf1p/mW4x6d3/AMA24ZoriFZreRJYnGVdGDKw9iKoXGsJFr9ppcX2eWSZHeUG6RZIlA+U+WfmYE5GR0xV20tYbGzhtbVBHDBGscaAYCqBgD8qydUtdXm16wubG2spLe0LEma7dHbcu0/KI2HHXrz7VlN227kxSbdybUvENjp1/a2JuLeS8uJ0jFt56iQKx+9t6kCtWuX/ALB1QXxjRrP7H/aYvzMzsZZBnJQrtwMdAcnIAGB21IdBtoNQF2rfOGLY8iEcn3CBu/rmlTcmry/rRfrcc1FfCNGsXSRTSzaTc7YYXl2x/MzlWI2qCACSBkc96QeIrW4dU0tHvy1l9sVoSNoQ/cBOc5fDYwD90+la9ZHh/Q10T+0dqxj7XeyXA2MThWxgc9O/A4Ga2XLyu+5my5Y3c10JfPtWttjAKGOd2VBz0Hc4/Cp554bW3ee5lSGGNSzySMFVQO5J4AqSszXdOm1GyhFt5TS29xHcJHOSI5CpztYgHHscHBAODis5NpaDik3qQ6lr6w6A+raN9k1O3iyzsl1hSo67WVWBOe3H1q9fatp2lxo+p39rZLIcIbiZYwx9skZrN1m21rVPDM1mlpYR3VwrRupvHMaKehDeVlj042j61BrGma3qi2ZBhhVY5Fnt4tRmhUOSNrh41DOAA3ynaDnr3rKUpJPl1enT+v8AgGyjF2v59TYu9Y02waEX2o2lsZ/9SJp1TzOn3cnnqOnrS3GradZ3kVpd6hawXM2PKhlmVXkycDCk5PPHFc8dA1i30/TItPaCK9trKO2kvheOu0jr+6MbLIvf5sHk4K9avahpmpya7Hd6YY7UHy1muftbZkRSSVMBjKHqcMGVvcDg05Sv8/6/rYXJHv8A1/XzN6s5NSnN8YprFooVeQGdmO0KoBDdOhye/Y9aY2g2zaj9sLfvPM8zHkQ9c5+9s3fjnPvWpWhloYmi+MNB8QTTQ6VqtncTRM4MUdxGzlVOC4CsTt6YPuKSfxZpb6LfX+i3tnq5sky8dpdK+CegJXOM02xsNYsp9Stols0tLiSWe3u/OZpUd+QGi2bcAk87+cDjmuah8Ea5Jpepx3r27TXmnfZAk+qXN4sjg53s0q/IDk/Kq4HvnA6lCk3e9tuv3kSvZ2OyTV4NRsLibw7c2OpywsYyq3Y8sOOqs6Btpx7E+1Q6b4itbnwnaa9qTwabbz26TSGacBItwHBc4HU4zxVazstYt/t+otZacl/PHFDFZx3b+SFTdgmXys5+c/wdgPesZPCuuS+C9J0y6SzS60mSMoltqdxElyixlDmVEV4z8xPAYcAHOeEoQ1T7rr9/6alLVanUPr1jnTDbyi6i1SUxW81uyvGSI3kzuB6YQ8jPOKi1vXY9HksYF+zSXV7cxwxwTXiQMylgHdQ33yoOdo5PTvWM3h7U7bTdGfTLKzS6sL6S6ltrjVJ5UffHKh/fvGzk/vA3K+o96ta/a+ItT0yxjtbDTBOlxFcTrJqEgVDHIrhVYQEtnbjJC49DRyQ51ba/df1/n0E3ppvb8df+Aa9/relaVNBDqmp2dlLcHEKXFwsbSngYUMRnqOnqKpS+MvD8HiJtEn1azivlVf3clzGpLMcBAC2d/Q4x0I9ap61peuXl9bXWlR29ld+Ssct4uovmP5ssvkmFklUc4LbTycFM5q7d2epReJYtR06G0uIpYFt7hZ7homjUPu3JhG3HDNwdvQc0owhZX8+qB31t5Fv7fc/2n9m+wSeV5mzz8nGNm7d09fl69av0UVzjKC69o7/admq2LfZQTcYuUPk4OPm5+Xnjmq+leKdG1iwW7s9Qt9p2bkaZN0ZY4VWAJwSeAO5qDQNM1PT7h0nEVtYLHtitI7trkK2eoZ41ZRjjblhzwFxzVS0/svwhPpviKWztbCCLyYrxbglm5O1irIArfdIALc1hzzSUn2/r+v8AhjfkhdpeX9f8Mbl7evFb3H9ni3ubuBQ7QST+XgH1IViOAccc4qODWLU6Db6rfyw2ME0KSs00oVU3AYBY4HU4rM0i31U+F3upbaE6vqI82eOeQxKuQFAJCsRhQOMdc9KrS+H9VufDuk206Wy3OmOuI4b+aNZVEZTPmoqsh5J6Edu/FOUle3l/wRKMep1EFxDdW6T2ssc0Mi7kkjYMrD1BHBFVNSv7myI+zWEl2DG7nYSMEYwOh65/SqNv4agbTLeCeJbZoy7MiyC7G5m3E+ZMhY5PPbrWxa262trHBGcrGMD5VX9FAA/AVqtrszdk9DJ8UeKtO8K6NPeahdWscywPJBbT3KxNcMozsXPJPQcA9alfXox4mtdHh+zSySQPNOPtaCWADG39195g2TyOBj3rF8T+G9Z1GbWV0ltP8vV9PW0eW6Zw9uVEnRVU7g2/1XacnDdKv6haa6/ifT7qzs9Pks7RHRnlvXSRt+3cQgiYcbePm59q6Yxp8q769fLT8f6sQ9v68jTbW9KTV10p9Ts11FxlbM3CCZhjOQmc9AT06Clg1rS7nUDYW2pWc14qeYbeOdWkC5xu2g5xnvWQmkatF4ve8s/Ks7CaXzLorfvL9qwm0ZgeLbGeByjjOBndwBl+D9OvbiGzmltbK2srO9u5opIZmaWd2klQ7l2AJ94nhmzgUvZw5ea/T8f66b+gnKzsdDo+s3F9capBqNrBZyadcCJjFcGVGUxrIGyUXHD8jHGOpqa08RaJf2z3FhrFhcwJIsTSw3SOquxAVSQcAkkADvmsSy03xOtx4geSPTbF9TzJbzwXjztBIIUjXKtCoI+TdnPtg9azbXw//YlprF94rvoLGyu7KK2d5dWmuvLZWfD+bOBgkuMKAMEcZJqnThZ3300WuvUp+X9f1+h3DXtqjzI9zCrW6CSZTIAY1OcM3oODyfQ0+GaK4gSa3kSWKRQySIwZWU8ggjqK57w7a6jP4TlutTt4Bq2pxmaaKdD5YYptRGXrgKFBHrurb02GW30u1huI7eKWOFFeO1UrErAAEID0X09qxnFRbV9hJ3sM1DWNM0iMPquo2lihBYNczrGCAQCfmI7so/EetNvtc0nTIYJdS1SytI7g4he4uEjEvf5STz+FVr7R2vPFOmamRC0Vlb3EeHGWDyeXgrx6KwJyOvuawrPw1rekafZx2Uem3k39lRadcC5ndFi2bvmTEbbwd5yp252rzVRjBxV3r/w/+S+8qyte5011relWN5DaXup2dvczsEihmuER5GPQKpOSTkcD1p02saZb6pFptxqNpFfTDdFavOqyyDnlUJyeh6Dsa5tvBc0Wn6lbW0sLyT6da2UE8mQ/7kNyxA4GSCMZptz4QuZPFlxevAl5ZXV3DdMW1i6tzEyBAP3CAxyYMasCSvoematQpN2v/Wn9fIzUm1qjrVu7drx7RbiI3MaCR4Q43qpJAYr1AJB59jVW11C5nvTDLYSQxjzP3pJIO1sDt3HP+NUraW4l8cXoj06FbSOzjSS+a3aOV5dxIjDkYkQKc/LkAkjOTW5WEly29C+6Ira5hu4RLbuHTJHTBBHUEHkH2NS1kPY6jFDdXlm1qdUnACrJuEC4I4O3ljj+I8/QcU2G11m98+31xrEWsiuFNk0iyA+Y2zOeCPL259W3cYqQNS3uobqMyW7h0DFdwHBI64Pf6is+28QWbaIurX89vYWUjHypp5wqum7CNk4A3DBA9xUd/aahLoP9nIEZpmFu80J8vZCeGfHG1tuQAueSD06JqumXn2vTLrR4rWRrHegguZGjQKy43AhW+YYxjHIJ5FUki4pPRlZvF8B0Kxv4RatJf3Aiggkvkj81fM2FkZsBsD5sDk9B1reN3bq8yGeINAoeVS4zGpzgt6Dg8n0rlbzQdcHhKz0m1XT7idLlZ55ZJ3hXKXAlAVQjnnGOTx/tVf1TRLrVHilZLaFrqAWupIJCwaLO4hTtG7+NRkLxIT2wasrfNluMbXNpLy3knWFJVLsgkQdnX1B6H8PUetTVQu7Br24hWQrHawkOoj4ct7H+ED25PsOt+szEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqt1qdnZXVtb3dwkMt0SIQ5wHIxxn15HHerVcr408JzeK5tNiSdbeCB3aaTGWwQuAo9eKAOqoqktlLZ6Mtnp07eZFHsjluCZGP1Pr7849D0rD1Tz7fQ7VYbfUIYDdhdS8gSPcFCpyytH87ZfZ8yc7c4xjhpXdioxuzZutd02z0y81C5udlrZMyXEnlsdhU4PAGT17ZrQByAR0NefTQPZ+CNQEdvrsE7Xs0lksRuXnJIyhcoSxB/2yR0B54roNRvbpRaavpcd7MkkT25tWhkT5m5jdo2UMuGXaWIGA5J4GRTjpp/Whbprp3f4HQ1Wn1G1tr+1sp5dtxd7/JTaTv2jLcgYGB60adavZaZbW008lzJFEqPNK25pGA5Yn1JrE1W7W08XadIi6qww63AhhuZINpU7chQUzu79R3rKb5fvJjHmbN65u4LQRG4fYJZFiTgnLN0HFTVxF1FdXWux/abfVJbuHVVYFfNFtHbg/KwGRG3BGTywOc4A46OGDVV1APNPm33E7fOQ8duPJB/8e/E0qcnNX/rZfiOcFEni1iwmL7LhQI42kcupUKqsVJJIwMEH8qr2fijQdRWc6brVhffZ4zLKtrcpMyKO5CknFXjFb2kbzpbqpRCT5UWWI+8QABk5POB1NYPhq/t9Wkuprm1vlvbtd0y3mmTwLHECQkIaRArYDHIBOSzEcHjeMbxbtsZuyN61vre9Dm1k3iMgN8pGCQD39iKnpkcMUO7yo0TccttUDJxj+QArM8Sfav7LX7L9oEfnILn7ID53k5+bZt+bP8Au/NjOOcVlJ2VxxV3YtalqlrpFr9pvjKsOcF44Hk2+52A4HueKuda5XWZbdPAt1DYQ6rMLhHjiSW3uppixz1DguB7txUXie6ur+KwWwj1CGGWOR/OS3uwwcbQqMkTxsuck7nIUY981lKrypvfb+v8jZU726bnX0Vw95NqLWOjXNyupT3gsozJYRJdQh5TjJaWL5VbPG2QEe6gk1e1lrhPFNtJEL66H7pBaxi6hjj+Ykv5ifum4PKOO33h0NOpZ287C9mdVVSPVLSW7+ypLmbcybdjdVALc4x3H51WaDVf7R3rP/o3mZ2+cn3c9MeTn8N341eNpb7iwhRXO471XDZPBORzk4HPtWhkPininDGGVJArFGKMDhhwQfcelR3t7b6dYy3d5J5cEK7nfaTgfQc1yPhzT4NDvtWgig1qW+jknkjSee7kgmQkMu13JiLnIGc7s5965yzTXJvD+uRuNTnin00OqyWd4GScHlEW5kkZyAf4VCt6HBx1KhFvR6afiRJtJnqV3dR2VpJczLKyRjLCGF5XP0RAWP4A03T7+21TTre/sZPMtrmMSROVK7lIyDggEfiK53RLlLGPU71P7ak0vEZjW9gupZzLyJCkbqZdvKcBdvDEADNYMU2pSfC/RbWwj1Kya3MVvqG7TroTRqIznaiGOVhu2ZMZ9eoBFJUb3Xml9/6lKzVz0SS4hhkiSaWON5m2RKzAGRsE4A7nAJwOwNQajqlnpMUMmoTeUk88dvGdpbdI7BVXgHqSBnpXHbriy0vwxd3Umo6lFa6jK8kq6ZdCVEMM6LuiffNgFlG5sk5BzzVzxTqcT2ukX9nHrol+1RSKtraXg/dCVfN82JF/u5wJBk84FHsffS1abt/X9aCbsr+V/wAzsKZ58RuDAJU84KHMe4bgpOM464yDzXHeKbiV9U0+6tF1W6/dK0enwx31urlmGGaWIbFOOqSjHqUBJLtR0q0tvH8eoXa60VuoUWNrSe8eNZVk6OsRKomCDhgE+970o0k0r31v07A3vbyOn/tS0+3fZPN/f79mzY3Xbu64x05q3Uf2aDzvN8mPzN27fsGc4xnPrjj6VJXOMKZDNFcQpNbyJLE4yrowZWHqCOtcp4eiluLi8tbk6lcRyREvfSveWxJLfdEchAQ9fmjOOOi8CovD+mPF4TksLNtTtdUt41DfaJLhYxIhJAQv8pQkYOzgg1gqr0dtLX+42dNK6v2OsvbyKwtHubgSmNPveVC8rf8AfKAk/lTra4ivLWK5t23wzIHRsEZUjIODXPadqZvPD95rswu2hvx/o9ukbylIwNq4RAT8xyxIHQjPSs6eW/m8E6NFZC+tEi8uG9xZXHmoFjx9xCkpG/byh/MZqnUtf5f1+QKlfQ7eqt5qdpp5Au5fLyjOPkY8DGeg9xWRYW2rf2JaLb38s7DfukmRrZyN3ygrKkj8DjLHJxk5zmtiO1EttGNQjjmlCFWLgPnPUZ2jg4HYVqtVczas7C319b6bp099eyeXbW8bSyvtJ2qBknA5PHpTJdVs4NTtdPlm23V2jyQR7Sd6pjcc4wMbh19a4f4gQXd8msWclrrVyr6ZjTYtOMyxPIQ/meYYyFJGE+WQ4I4UEkg699epZeOtPZU1pg0DRXAit7uW2BO3y+FUxA/eyw5Hc10xopxT6u/5af18iHov68jrKK40G5T4jEr/AGjexySYwRe28NoojwfW3nBP+6QT1Y4xT8Kzz32p2txFc6zPOlxdLetdeeLbyQ8gRU3ARsQQmCmWwDk1Psfd5r9L/wBf5/cJys7HYaZrNlq5uRZNNutZfJmSa3khZGwGxh1BIwwORwc1eritM1d/t3iuWz0zU5ZpW+0Wsc1hcWwn2W8abQ7oACWUjrnuBWb4ZtNduIdWt/tmoeU1tBNaTXEV5b7bhWcsv+kyvIV4QMMhSO3JJp0Uk29LJb+e/wBxT0/r+u56PRXMaLfSa34dv9df7ekWoRE28ETHzI4lUgFF6B2O5ge+Vz0rb0f/AJAdj/x9/wDHvH/x+/6/7o/1n+36++aylBxun0FcuUVzmvafc6n4l0u38/UYdP8As1y1wbO4khDODFsDOhBB+8RggnBHTIPPmXUJdK0w+I11/LaVEYhpy3Cyfa+fM83ycEHHl48zCfeqo0uaKd/61/yKtpc9Dorgbyx1+WK8vLyfUzf2VhaSQRWs0iQvcYJl+RMCTJABU5GO3NJfRa1L8QHM2pX1nEtzCbRItOu5oXhwu5S8cohGW8wEyoWXOc424tUU3bm/rT/P8zNTTVzv6qQapaXN0beCXdKN2V2MMbTtbqPWs+K5hXx3c2vm6iZ30+OXy2ObVVEjDKjtISefUBfStZLaCOTfHDGr8/MqAHk5P5nmsGrF+RLRWHFPNpdndXiWl09imDDZRx75jzglVyNo77TnHt0p8Or3Gqefb2dhfWEyq5Sa9ttsZ2yMnByeTt3Dj7pU4OcVIGzUNrdw3sbSWz70WRoydpHzKSrDnryCM9Kx57ptO8OstpFJBfzyeREs43lp243E/wAYH3iR/Cp6YwKmrWn9mWmkaeq6idKjDRznT/NMzMF+Tc0XzgEhiSCOcZODzSVy4xvobM2vabBpiahLc7bWSVYVk8tjly+wDGM/e4/+tWhXn1ws+neCNIQW+tQX0V2rrFbpcSMqC5BkEvlbg37sn75OecZrc1V795vN0tr7y9WtRAn7t1+ySZ4l2sMx/KzE7scooxk81yaad2W6atc6Wisq4tphfwDTxIk0aKJbiQkoyD+Fv7569CCOuRnB1azMQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKznu5n1qO03fZowN4LAFrj2XsAO/8XsByQDRorGKjUvFIcjMGkoccAgzuv5gqh/8in0rC0/VbvWPEOgX1xcWaRXdvPNb2aRETQrtH32Lnd6HCrg8VSjdXLULnbUVymjLfWmn+IjZxWcmppeu5ZI5EjuJPKjOSrOxXIwvBxxnFaVnqsurPdvaypBYx28ZjuNuWEjLvbOeNoUp+JPTFDXYJRszZoqnpd5Le2Ylli2nOA6/clH95QecH3/DI5q5UkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV76yh1Gze2ufN8p/vCKZ4yfbcpBx7Z5qxRSaT0Y02ndDYoo4IUihRY40UKiKMBQOgAp1FFMQUUUUAFFFFABUFlZW+n2ot7OPy4lZmC7ieWYseT7kmp6KACq2oafBqljJaXZmEMmN3kTvCx9tyEMPz5qzRTTad0AyGGK2t44LeNYoo1CJGgwqqBgADsKfRRSDYKKKKACiiigCCGytba5nuLe2himuSGnlSMK0pAwCxHLYHHNT0UUXuAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFU9XmkttEvp4W2yRW8jo2OhCkg0AXKa8aSbfMRX2tuXcM4PqPeuX8C+KbzxNprPfWLxPFwblRiOU+3fPrjI+nSt6PUVnunS3XfBED5txuwikfwj+8fXsPrxQBLaWUFjG6WyFRJI0r5YsWZjkkk89T+AwBwKig0fTLWaSa2060hllcvI8cCqzserEgck5OTWFaeJrnUvFOnRW1pd2+nXFlcTo06xgXW1otjqNxdRhjwwX7wyPSbT9elg0bVNS1Rbtltrtw8MkUSvbRjbkHY5VlUHcWznGeM8VfLLr/AFrY1cJr5mnp+gaPpMzS6VpNjZSOu1ntrZIyw9CVA4qzHYWkNs1tDawxwMxZoljAUknJOOmSefrTINQjuNRubSJHJtlQvJgbCWBO0HOcgAE8dGFJqWoxaZaiaVJJWZxHHFEuXlc9FGcDP1IA6kgVEpPdke9JluisDXby+/4RW4v7c3ek3FurSCNxC7Njs331wevBB9xVnXfENt4ftoZrxC6ykqMTwxYIGf8AlrIgP4ZqJVIxV5bDVNuyXX9DWorFfxPbG4sIbO2nvJL6AXESxNEp8s45/eOuevRckd+2Zp9djj15dIhtJ7i48tZXMbxARoWI3EM4YgY5Kg/nxT5le3yDkkalFVTqEIuPI2XO/dtz9lk25/3tuMe+cVFFBqa6hvmuo2tvMkPlhRnaQuwdOx3d+461RBforD0vxMusJeSWGmXcsNqzosoltyJnU4KKBLlW9nCY74rntK8T6vJYaprl/b6hGkc0tvbWVy1qlsXE/lIoaPdKGyAGLErkttBGK2VGTv8A1v0D/hjvaKxPtup6Np0lxr89vfyO6RwQabZNEzOxwE+eVgckjklQOScDkV5PGcEMKCXStSW8a7Fn9h2RtKJDGZF5DlMFR94MQM8kYOJ9nJ/DqB0dFcpqPjK4j0mwvdL0W8uTcXwtJoiYQ0DCXy3Q5lA3ZBAIJXjJOKk13x3p3hyC0OqwSQXV0hkFpLc20UiKOCSzyqh5IGFYn8jilRm7Jen3CvZ2/rsdPRXNXnjjT7ViYbS9vIEs47+W4gRPLht33YkYsyn+EnaAW9AcHDn8SagvjB9Jj0G8mtVgjkFzG8AHzMQX+aUHYMdNu7IPHSl7GYXVrnR0Vxlt4q1KXxe9jJJbi0W+a18ttOmj+UJkEXJfymbOPkAz+Wa1NOubq38U61a3moTXNrDBBcxiZIx5O8y7lBRVJUBB97J96JUnFXfa4X1sb9FYFr4vtJm3Xlle6dbvbPdQXF2iBJolALOArFlwCDtcK2D04IFbVPEt3/wiOqalDp95pX2e382C4vBDhx13BQ7EYHJDhTz064PZTvZg2krnUUVkQanLrdjM+jLJDHuX7PeyqvlXC55aPkkrgHDFQDkFSQc1ZV760sWedftkqyMSIyAfL3HGBgZIGOO/rWbTTsxl6iora5hu4FmtpBJG3Qj+R9D7VDd3628iwQp591IMpCpxx/eY/wAK+/5ZPFIC3RWZrF3cI1nZ2MgjuruZRuwDsjUhpGwf9kbR7sKyfEHiaeCRLfSra6Pl6ha21xehY/KjLyoGT5m3ElWxlVIBbqCDioxcmki4wctjqaKxLS/upvGN7aSm4igitY2jgkii2OS7AyK6sW5xjawGMZ71NaeILa8Wx8qGcSXjyJ5ZC7oDHkPvwcDDDbxnkj60uVicWv68rmrRVS2vxLcPbXCeRcrk+WTnev8AeU9x+o71bpEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAR/aIf+esf/AH0KPtEP/PWP/voVh0V0+xXc5vbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KZM9tPC8MzxvHIpV1LDBBGCKxqKPYruHtn2NmJrWCFIoGhjjQbVRCAFHoBUJgszeNcLKqNIuyVVcbZR23D1Hr17dKzKjNxCtwtu0sYmdS6xlhuZR1IHXAyPzo9gmHt2h2m+G7HTbq3uE1W7ne1t3trYTTIRDE235QAozjYOWyx7k8VNpejQ6absTazc6hHeMWljuvI2liACfkjU8gYx09qri4ha5a3WWMzKodogw3BT0JHXHB59qrprGmSTTwx6jaPLbqWmRZ1LRAdSwzwB3zV+xcrlPFS6m3pVnZ6TZ/Z4bkyktueWZ1LucADJAHQADp0Ap2pW1pqdqIZLkxMjrJFNE6h43U5DDOR+BBBBIIrkNP8AFdnqFzdNHdacLK23bpvtwMmFONxTGAhPRt3PHrVzTPEOl6vYG7s72BkSMSSr5qloQRn58E7eh6+hpzwkvtJ/1sQsTroa99pK6hop065127KvkSzDyBJIp/hP7vaB9AD70250SC6ktZZNauxcW8TwmdGhDSo5BYN8mB90cqFPvVKLVNPns/tcN9bSW27b5yTKUz0xuzjNSWl5bX9uJ7G4huYSSBJC4dTj3HFYvCLW9y1ipdCS58N2N1pNrpb6pOLC3hSE2/7lhIF6ElkLBuOqlcdRg81Y1LSLXVbqCS71GRoIJElS1xCUDr0bcULg+4YfrUNFDw0XuP6zM0jZ6Ubj7QbezM27d5mxN2fXPXNWvtEP/PWP/voVh1nTawF1JLK3tZrht+yR0KhY+MnqQTgEdB3654qvYruT7ZvoadhoVrZ69JrFxqk1/evCYFknEClIy27bmONCwyBjcWxzjGTmVNE0oaHc6TJKZbW5lmlfdKAwaSRpDhlwRhm4I5GBznmsg6xCLxYPJmMbS+SLj5Qhk5+XruPTqBj3rQq3FvqL2z7C/wBhiXTpLW+8R6heMXSSGeRoEkt3Q5VlKRqDzjIYMD0IwSClt4dsIZIJ59SuLu6ivPtrXM8ke6V/KaIBgqhQoVsAKF6Z6k5KKfK+4vbNdB8mgae2ky2Md9LDvvGvUnSRPMilMplyuVK4DHgEHjg5pLnRVuGtp4/EN/bXsERha7iaDdMhIOHRozH1GQQgI5x1OW0UlFrqN1m3dofe6Bp2oLqQub2UtqdiljOwkQHYu/5hxgMfMb26cVNd6ZDcapb39vq09lLEgjkEBiKzoGyFfejcZzyu08nmq1FHI+4e2b6f1/SETw7Zrqj3UmrXUsDXX2sWLvEIVl4wwIQOcEZwWIz2pbfQY4NeutTl1+9uftSCOW1l+z+UUG7avyxhsLvbHzZPcmiinyu1r+WyF7XW9iOz8L6dBlbzU7rUoFtmtIYLyVCkMLYDKNqqWyFUbnLNgdeTmRdBibSLvTL3Xr29triMRKJ2h3QqP7rLGCe3L7jx9clFDUnuw9rpaxe0+xtNMnuWtbthBcP5gtS6+XCxyWKcZG4nJGSM8gDJzYu1t7yAwyXG1GPzhJANw/uk9cH2rJoqHSu7tj9s10LF/pVtezQvHqt3ZJCiosNnciNCFkV+QB/sbf8AdZh3p8WnWkenRWsl9NO8LM0d1NOGmUkk53fjjHTHBzVSil7Fdw9s+xfjt4hrUuoS3iSEwrDDHwBEMksc9yxxn/dWs278M6feXzTvql3HE93Fem1jnQRGZCpDfd3c7Blc7e+A2CH0U1Ts7plLESWxKmkIniJtX/t27ZnURm3PkeVsBJC/6vdgFic7s+9WLbT7G11S4v458yT9EZ12x5xu28ZG4gE5J5FUqKPZeYPESe5qWsVpaGRlmV5ZW3SSyOCz+nPoOwHAqx9oh/56x/8AfQrDopexXcn2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KPtEP8Az1j/AO+hWHRR7Fdw9s+xufaIf+esf/fQo+0Q/wDPWP8A76FYdFHsV3D2z7G59oh/56x/99Cj7RD/AM9Y/wDvoVh0UexXcPbPsbn2iH/nrH/30KKw6KPYruHtn2Citz7PD/zyj/75FH2eH/nlH/3yKPbLsHsX3MOitz7PD/zyj/75FH2eH/nlH/3yKPbLsHsX3MOitz7PD/zyj/75FH2eH/nlH/3yKPbLsHsX3MOitz7PD/zyj/75FH2eH/nlH/3yKPbLsHsX3MOitz7PD/zyj/75FH2eH/nlH/3yKPbLsHsX3MOqclvM2tQXCxWhhSF0aRlPnKxIwFPTacHPuBXTSpbQwvLKkaIilmYqMADqarzXWn2+kPqcwVLSOA3Du0JBVAu4nbjPTtjNNV7bIPq8noYMdvMutTXDRWghaBEWVVPnFgTkMem3kYHqTWNpuh6pDrkN7fzLIIml3P8AbJZPND5xiNgEjxxwufrxz20t5psN5Z2svlrNehjbr5RO/aNx5xgceuKt/Z4f+eUf/fIrRYpxT03JeHb1ucrpVlJY288czKTJczSjaezuWH44NZQ0XUZPDDaPKLeMQCMW8sdxJmUI2RvwqlMgAfKTjJ9Oe/8As8P/ADyj/wC+RR9nh/55R/8AfIpLFWd7dvwH7B9zgE8PzSaaYZLeKGVr2GeQPfS3QdUZTy0ig5wuMYx05roEhjiZ2jjVDI25yqgbjgDJ9TgAfhW/9nh/55R/98ij7PD/AM8o/wDvkUpYpy3/AK/qwlh7df6/pnJaposOrGP7RIQI84HkxSDn/rojY/DFV7rwzaXXkh3wsMYjVfs1uwAH+9GcfQYHtXa/Z4f+eUf/AHyKPs8P/PKP/vkVn7Vdi/ZPuYSII0VFACqMAAYwKwRp95d+JDePbw2ggITzo5m3Sr1II2gMCMDkkDBxmu7+zw/88o/++RR9nh/55R/98ij2y7B7F9zh7LQ5orqM3PlMkMjSLKHLPJkkgEFQEAznAJyQK3K3Ps8P/PKP/vkUfZ4f+eUf/fIp+2XYPYvuYdFbn2eH/nlH/wB8ij7PD/zyj/75FHtl2F7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FH2eH/nlH/wB8ij2y7B7F9zDorc+zw/8APKP/AL5FFHtl2D2L7klFFFcx0hRRRQAUUUUAFFFFABVLVI7uW1As2OM/vERtruvorfwn/OR1q7RQBgaosN7a2Gh20ZiivAGmiaPBW2TBdSD03ZVP+BH0rD8c291e/wBqWb2+rTpJphXT4rAyrE8xDh/MMZAP8HEhwRwoJJB7uirUrO5rTqODTXT+v68jlL+7Wx8TaQ4TVyREUuRBBdSQBSh25VQY87u/Ud+KnNvqI1ptNEt0bVrsXwuNz/LFjJh3/wDXQfdz9xsYwK6Sijm1uTzWSRmQQzDWZpLRGgts/vhIOJX9UXt7t0PoetadFFQQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSOxWNmVS5AyFXGT7c8UtFAGbp9808NxdXcyRqmd0GMfZwOTuJ5zjn06Y9Tn2o1CPQL3VrC1Mup6g32hIZcZVcBUXBZRwgB27ly2eRnNbN5p1pf288F3AskdwnlyjpvX+6SOSOTx7n1p13ZWuoWj2t/bQ3Vu+N0M0YdGwcjKng8gGmmWmkzl7rxPqMGi24tRHeapPe/YyBZGARPsLkGKWZdx2jjEgByCMjg2f7Y102emWs9tbafqd9NJGXukDIoQFsiNJDlmUcL5nHJycYOx/Yek/2V/Zn9l2X2DOfsn2dPKznP3MY689OtIdC0htLGmNpdkbBTkWht08oHOc7MY689OtXzR7f1/XQvnh2/r+uhi64dfi1bQY7bVrKEzStHJmykKySCKRiSomGVwOFySCM5PSpvEEMx1Tw89z9lnjS9UEGJ1ZZfLf51IkwBjI2sG69a1ptG0y401NOuNNtJbKPAS2eBWjXHTCkYGKivPDmiaiYjqGj6fdGFBHH59qj7FH8IyOB7UKSuhc609GtjJ1TxBqNvPqk1obNLXSZI0lgmjZpbksiv8jBgEzv2jKtkg0g1zV/7Wd2+xDTk1JbDyhE5mfcB8+/dhcFhxtOQDyM8bkujaXPfQ3s2m2kl3bqFhneBTJGB0CtjIAyenrU/2O1Oc20PMgmP7scv/e/3uBz1pXSt/Xb/AIInKNrJFSO7mTWZLTP2qMjeSoANvns3Yg9v4vYjmtGmpGke7y0VNzFm2jGSepPvTqgzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOO8e+J77wxLpU1gqyLK7rLC44kHy4GeoPP8A+uujstUFxo0eoXsEmnhk3PHc4BT6/wCc+1TzWVtcXMFxPAkktuSYmYZKE4yR6HjrU5AYEEZB4IPegDMn1pbXTnvLi1nCNIsdvEozLOWICgKcbSSe5GBycc4wP+Eh1WXRPE9w1ve201ncNFBGI7d5bRfs8b7iPMCPgsWxuJOcew3rrQbe509rNZ7iBBKs0LRON1uykEbMgjGR0II5IxjiqY8IxJpeoWUeq6ip1KUy3VwWjeRyY1Rh8yEAEKOABjouBgC48tnf+tv+D+hvTcFuaEepLFJp1tOJXe8iJW4KqqllUEgjPDEZIAyPlPNTabqEWqafFe2yuIZgWjLgfMueGGD0I5HsRVN/D6zaLFp1zqF5MYmDR3R8tZVx2BVAo+XK/dzgnnPNakUSQQpFCoSONQqqBwAOAKUra2MdEjPvNZFvqIsbaxur+4EYlkW32ARISQCxdlHJBwASeDxUFxNdweMLGJbyU2t1bzM1syJtVk2YIO3d/EerEVPeaN9o1EX1rf3VhOYxFI1v5ZEqgkqGDow4JbBGD8xqO70J7vWoNS/ta+he3BWOGNYdgBxuHMZbnaO/0xWD5vx/r+u5ouX8P6/rsQy+LLCHxKuiTArcO4RW8+E5JXcPkEnmDjuUA/MVY0zXY9VvbmG1tZ/KtpXhe4LxFN6nBXaHLg/VRx+FVx4Wt11H7V9tvPLF2bxbbcnliU9W+7uPfgsRzxjAxPBoMceuf2rcXlxdXCo0cXmpEPKUnO0FEViPZifXrzSj7TTm/r+nf8L2HL2dtBNJ8QRaxby3NvaXC2seds5MbiTBwQFR2YH2ZQfbPFWWu2vbWePTzNDceWfLea3eMBscH5l55+tVbPw7Db3897d3M2oTzReSz3McIymc7T5aLuH+9nHbGTm/bWFnZszWlpBAWGGMUYXP5VpC/L725E+Xm90zr7VH8OaLeajrkwmiiddmwomA21QCWKqPmPViAM8kUs3iEW2l291c6bex3N1L5UFhmJ5pX5IAKuU+6pbJfAA5IrQvraW7s3ht72exkbGJ7dYy689g6svPTkGseHwfZ2+iw2Ftc3EEsFwbqK8iWJJElOdzBQnljIZgRswQTxk5rojycvvb3/D+vmQTXXiJrSGyEuj6iby9LiKyTymkBUZIZvM8scc5L47ZyQKjm8UiOOLyNH1O4uDALie1RI1ktkJIy+91GcqwwpYnacZHNXYtIAlsZrq9ubuey37ZpRGGk3jB3BFUdOmAKg1Xw8upXn2qDUr7TpXh8iZrQx/vo8khW3o2MbmwVwRuPNCcL2/zt/nb8RLbUqXeoTSa54dvNO1KZtP1JmRrfy08uRPIkkV8lN4PC/xYx2qW4nvbfx5YQLfzNZ3dncO1oyR7EaNogGUhd+fnbOWI9qS+8KLc3OnSWmr3+nRaaALa3tVgMaYUpn54mY/KxHXH481JeeHJLvxFb6uNb1GB7dSkdvGsHlBW2l1+aIthti5+bI7EVacLrXSz6etum+wo3+0XU1vSpNVk0uLUrOTUYxl7NbhDMoxnlM5HBH51j6L4qvL641P+09Fu7C2sZnU3MjQlY1VFbDBZWYtyT8oxjHeumrIXw9EuoXswvLo2t/uNxYHy/JdigQtnZvBIUcBse1ZxcLO66fiN9PX8Cp/wmVvFFdSX2mahYiCykvoxOsebmFPvFArnBGV4fafmHHXFmw8S2949yLq0utNW3hFz5l8ERXhOf3gIY7R8pyG2sOMgVmaj4RkGgaqsV7e6rfSaZNZ2Yu3jHlKy/cUqq9SEyz5PyjnrWtomiNpm6e6v7vULuSJIzLdGMFEXJCKI1VQMknOMnuTgY0kqXK2v1/r1v8g1sr/1t/wbEsPiHRrjS5dSt9XsJbCEkSXSXKNEh44Lg4HUd+9Q3HibTk0y3vbCUaol3L5Nqtg6Sm4fnKq24LxtYkkgDacniteqGraTHq0EStPNazwSiaC5t9vmQvgjI3BlOVLAggjBNZLkvqMqXHiKS3S1QaJqMt9cI8gsIzB5kaKQCzMZBGBll4Dknd04OKtx41tI4YJLTTtRvvOtTdlYIkBjjBwxbeygEHjb1PYHBxZufDklylq41zUob62R4/t0YgEkiMQSrKYzHjKryEBG3rycyQ+GbG3jEcBmVBZGyA35+QnJYkgktnuav92lrv8APz/Dbz3Ev6/r7zPuvFV7H4ptdPs9Du72zuLRrhZ4WgG/mPDLvlU7QHIIIznGMjNS6n4103SfEttot6Nk1y0apJ9ptxy52qPLMnmnJ4yEI/AEi1ceHEkksJbTULyxnsYTbpLB5ZLxnblWDow5KKcgA8cEZqrdeDbW61Se7OoX8cdxdw3ktrG8YjaaIptbJQv/AMs1BXdt68Z5q4ujdc23z7/5fiJc2t/L+vvJrS/u5vGt7aSm5htobSNo4JIotkhLsDKrq5fnGNrBcYz3qPTvGFrqFwqmxvbS3kSRorq5RFjl8s4cABi3HPJUAgEgmp08PSJ4kbWP7a1Biy+WbUrB5WwEkL/qt+ASTndn3p0Xhuyihs4i0rx2iyqqsw+cSZDBsD37YqG4W+RX2vIy9I+Iuia19u+xlm+yWzXXyzwSmWNepAjkYqenDhDz04ONG31a61m1uUsrG906Xylktri7jQJKGzhhgtjpyrAMMjiktPDbW2m3Gnz6zqV5aTQG3SK5MRMKYx8riMMxxxlyx9cmtiGJYLeOFCSsahQT1wBiio6V3yIS5uv9bf8ABKqfb7a2neYLdyeaWjRCFPl54HTGQM9evrU9rdw3kPm277hnawIwVI6gjqCPQ0tzB9pgaIySRhupjbaSPTPbPTjms7UfD8d9HDHDf3+nRxRPEqWM/lAhipyeOo28Htub1rAZcvb9LTaiqZriT/VQIfmf39gO5PAqrrd3cw2EVvZusV/eyLBCQQdhPLuMgg7VDNyMHAHepI9GiWxe2muLm5zM8ySzS7pImZiw2t2C5wB2AxzThp7nWEvprjzFit/KijKY2sTl3J7kgKOgxg+vDVilZamR4i8SS2cF1BpVvczz2zxJPcxiPy7csVOG3sCSVbPyq2MjpVoX903jYWTG4htVs3dY3iiMc7Bk+dXDlxt3bdpUA5z2pt/4Utb+8uZmvL2GO7ZHnt4XVUkdMBXJ27s4VRjO0gDINTS6C8niFNW/ti/Ro1KLbqsPlBCVJXmPdglQc7s+hFWuXT+v6/y8y/ctZdh8Ov204tQsNwJLm5kthEyDdGybtxbnhfk698rjrVm3vxJcta3CeRcrkhCciRf7ynuPXuO9Rw6NbwazNqStIZZRjyyRsQkKGZeM5YImef4eMZOZ7ayitWkkUs8srZklc5ZvQfQdgOKjQiVuhYooopEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEU9zDbmMTPtMjhEXGSxPYAf5FV7zUDbX1jaRw+dLdyMCN2PLRVJZz7D5R9WFJNYuupLfWzKZCBHIkpJBTP8J6qfYcHv6iKytbh9bvb+8j8vAFvarvz+6HJbA6FmJ/BVpoehOmsaZLqb6bHqNo98gy9qs6mVRjPKZyOCO3eltdW02+u57Wy1C1uLi3JE0MMyu8RzjDKDkc8c1kWelarB4gmljEVlpskkskscd68/ns3Rtjxjyjn5jsfGc8HORn+H/CN1py+RfRr+6tXtor2PVrmViGwMiCQbI8gAnDHBGBxVcsbfI15IWev9f12N5/E2hpDdyf2xYFbL/j5xdJ+5OcANz8pzxzjnio7LxXo2o6G2q2mo2jW8cavKWuUHkkjIWQ5IU9uTSaHZ6la6Sumaha2MEMECwRSWczHeAMZ8soAnrgM3pnvUekwa3p3huOyktNPlubSKOGAreOEmCgAsx8rKHAzgBvTPeiSWqXyFaP49yzZ65A3hu21fVpLXTopYlkkL3aPFGW6DzR8rDJGCOtSy67pMFhHez6pZR2kq7o7h7hBG4yBkMTgjJH51z+m6Drll4d0SCS30x7zRmURoblzHOoiMZbf5eY2+Yn7rdMd8izp/hq4ivbC7vBaGSK5ubqVIwSsby9AhI5xk5Y4JyTgZxVSjG7G4wXX+tf+B9/kb3261P2fE6MtyMwupysnGeG6cjketWKw7PRLmLw9aaTO8IjQETMo3HG7ICZHH17Y49RtIgjjVF3EKMDcxY/iTyazMmOooopCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCQASeAOtVNTju5bJlsHCSdxnDMO4Vuin3wfw6jK1MpLo9rpFij2zaifJ2OpDxxDmUnnIO3I3Z+8ynJzRuUldm1aXUN9ZxXVqxeGZQ6MVK7gehweamrite0/Up/FKxWcup29gkNpGq2cjxxgGSVZPu8ZCbQT2BU8EKRgahP4lPh/TgkWqR6hbaRFKjiK8ka4nwdyP5ciorDaM+aGLbsYPQ6xpqWzNo0eZ2v2/H+tT0qXU7SDVLbTpZdt1dI8kMe0ncqY3HOMDG4dfWrVctfXotfHFi6pq7K8Lx3IjgupLcMdnl8AGMH72SOnc1DFZajHq39oGbU3kOrtEImlk8pbYg/8s/u7cnO4gkcYOMCp5dv662M+Vct/I6+isy0hmGrTSWyNBZknzEkH+skzyyD+Eep6H07nTqDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuFm1fxDF8Trqx0uA3liViM0chwkWUHzBv4T7d/SgDuqKpahfm0EUcSb5522RbztQH/ab+nU9hXPeL5taN5o2n2ccLQXlzsldNQltXlZYpHKZRCyLlAchiTjaRgk1UY8zsXCHM7f1oddRXNXuv3Oj21z9n09Z7PSIk+2yzXrGRRsDHZlWMpCnOWZcmpLrxLdQXEssemo+m29yltLObnbLuYqNyx7SCoLjOWU8NgHjJytvQOSVrnQ0Vzmk6lr1x4l1O2u7Wy+xW86qGW7YvGpjDDC+UN2c5OWGMkDOOY9I8Xy6tqRjTSrhLNkdobkxTgEL0LFolQA9trt2ocWlf5j9nI6eisPQda1LW7W2u5NLjtbO8tVuIJhciQqSAQrptXGc5GC3AOdpwKv6fftdNLBOgW4gO2Qx/MhPs3/sp5H6kcWnZkOLi7Mu0VXvr1LC0aeVWZV7KP5noB7nAFVrrUZdO0Oa+vER5UQssUHO4k4RAT1JJAzxkntUgld2NGiuQ11ddsPD+m2UBjuZLieKK7uGvpIHZ2fLBCqMVUnIyCCo4FXDqV/p4XTNP06O5uLS0S4uRcajIQisWACyMjNIco/3gvQcjNVy6XL9m2ro6OiuXufGEgsZtSsNPWbTrSFJ7qWW48uRUZBIdiBWDEIQcFl54z3pY9V19/Hd1YR21k+nx2sEoDXbKyq0kgLgCI5YhfuFsDaOeTh8kg9nLl5v66f5nT0VzNn4vlvfERsYdJuDZ+e8AuxDPwyZBY5iEYXcpGRIT046gW9K1rUdUmWQaUkdg0ksXn/ag0isjsuSm0DadvUMTyOO9Jxa3FKnKO5t0VRsr55bmazuVUXEGCzRZKMD0P8Asn/ZPPpkc1eqSAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkCqpJAALHJIHWlooAjngiuYHhuEWSNxhlYcGopdOtp5LOSaMu9k/mQMXbKtsKZ68/KzDnPX1qWe4itYHmuHWONBlmbtVO61m2sbOG4vEuY/ObbHEls8spOCfuIGboM9OO+Kav0GrvRDLzw9pt/ffa7qGRpDt3qs8iJLtOV3orBXx/tA0kvhvSptT+3yW7mYyLMyieQRPIuNrtEG2MwwMMQT8o9BS3fiDT7GK2e4a433S74YI7SWSZhgEkxKpcAZGcgYJAOCabf+JdL0yQR3ksyyeUJiiWssjLGc/OwVSVUYOScY4zjIqlzrYte06XJ20ezbVxqYE6XOAG8u5kRHwCBujDBGOD1IJ6egqOz8P6fp9zJNZrcR+ZuzCLuUwjccnERbYvPoBUMmsOfFVnp1u8fkyW8ksnmQS7nxt2mOTHlkcncM55FOXxPpL6p/Z6XEjXAlMLYt5DGsgBOxpNuxWwMgE5ORjqKLSt/Wwe/b+ti9Z2NvYabDYWiGK2giWGNAxO1QMAZJz075zUVxo1hc6fHYzW4NtHIkqxhiuGRw6nIOT8wB9++aoaN4qtdZ1C6tIrW+iaCYxq0tlOisAqtksyAKfm+6TnjPeti4nS1t3mkEjKgyRHG0jH6KoJP4Cplday9SZRkpWe5Q0rw5pWiO76ZaCAyRJC3zs2UVnZRyT3kc56nPPapX0i2ZbVF3xw203nJEjfKW5wCD2BOQBgAgelUNK8WWWo6LHqM0VxaIwTeJbaUKpdtowxQBhk9RwO+KuXev6ZYtOLq52GB0jkxGxwzjKrwOSfQc8j1FR7SNua4+SSdrFu5tILxYxcJvEUiypyRhlOQeKp6l4f07V5lmvYpTIqGMmG4kh3oTna+xhvX2bI5PqaQeIdONgLwSTFDKYRGLaTzS46r5W3fnAJxt6DPTmpU1vTXtY7g3sMUcuQvnN5bZBwwKtggg8EEZB61Slrow9+OpDc+G9Ku7pZ5rdgwCqUjneOOQL90PGrBXx23A1NdaNZ3moQ30onS4hACvDcyRbgDkBgjAOM9myOT6mmXt1fvGkmjJb3MbRMwctkFuNuDuGQefy61QvvF9rp/iaLRp7S/d3gaVpYbC4lUEFAANkZBHz8sDhcYPJrSKnJ2juS5NK7Zdg8P6fa6m9/bLcQyySNI8cd3KsLOw+ZjEG2EnqTt689eauWlnBY2/kWqeXHvZ9u4nlmLE8+5JqnceItNtdUFhNLKJi6xsy28jRRu2NqvKFKIxyuFZgTuX1GSLxFpk0whinZpvtLWpiEL71kUbiCuMgbcHceCCpzgjKcZtXaY5Sb3ZetraG0hEVugRMk9ckk9SSeSfc1LWBoXi6112/u7SG0v4Xt5mjVprGeNWAVTks8YVT833Sc8Z71bj1SR9U1FfLzZWESh3jjZ5HlILMoC5JwuzgAklsduSVOcXaSIvc1KKwNI8RNfLq91MHNpaTBYY0sLlLgJ5asQ8ToGZsk42AgjHfNWrbxJpl1CkqSzIHuRa7Z7aWJ0lIyFZXUFMgjBYAHIx1GW6c10C5q0VnTa7YwQ3UmbiYWkwgmW2tJZmVyobAVFJPDDJAIHfoail8TaZFp9ve77mSO5YrGkNlNLKSM7gYlQuuCCDkDB4ODSUJPZDNaisu/8AEWnaatt9qa4Ml0peKCG0lmmZQBljEilwBkAkgYJAPJFR6j4q0jSp2hvriVJEiWaRUtpX8qNs4d9qnYvynLNgDHOKFTm9kxXRsUViy61J/wAJla6RE0axNayzSiS3mDOQU2mOTb5bAbjuGcjK+9LB4s0a51MWEFzI85meDItpfL81N26PzNu3f8rHbnJHIGCDR7OVr28xmzRWBoXi6112/u7SG0v4Xt5mjVprGeNGAVTks8aqp+b7pOeM96v2E2qMGOo20aARKwERGWfJyOW9Av59aUoSg7SVgWpoUVBaXkV7D5kBPB2srDDI3dWHY1M7rGjO7BVUZLE4AHrUvTcBaKyLHWWbwy2s6mggiKPcKgUhlh5KZBP3iuCRxycYo/tltN8P2t5r6rFeTKoNtApZmlYZ8pFySzdR+BPA6AGvRWTquqz2VzosccSqNQvPIlWUZZF8mR+MHGcoB3HX61Fd3+pHxhZ6ZZy2sVqbV7m482BpHcB1XapDqF+91Ib6U7a2/ruD0V/63sbdFYdvrWpahq00WmaZbvp1tcG3mu7i8Mbsy/f8uNY23AdPmZckHtyaWm+LNQuZrSW/0iC30++uZLWC4hvTK6urMB5iGNQobYeQzYJA75CWtvMNjqaKw7LX59QvNRtYLKNZIFLWbSTkLcgMyEkhDsw6kcBuCp74qHRfEGp3iahPrOnWNha2DyRvJBfvOSyfe4MKALjPOc+1K/8AmH/DHRUVzTeJ7pvBesao1lHaahpsMzPau5kVHWPzEBICkgqyEjjqRnjNbWl/bTpsLanPBPcsu5nt4GiQ55GFLsRx/tH8KqzDpf8ArQt0VVn1Kztbpbe5uEikeMyLv4BUMqk56dXUYznmsfWPEywLYDS5oy1xqK2jyT2s7xACXy5F3opCvnIUsQpNLdrz/wCGDpf+u50VFY2p+LNG0jUDZX91IlwsayuqW8knlxkkB3KqQq5ByzYA7kVT8R+MLfSGFrZ7p777TbQuFtZZIohJKikPIo2I21sgMwPKnByMi1dgOlorIbxTpK6p/Z5uJPO8zyfMFtKYfM/55+dt8vf227s54xmp4dd024htZYLtJFu9nk7cktvUsuR1GVBPOOlG6uBoUUUUAFFVNTmvoLFpNLtre5nU58u5uGhUjv8AMqOc+2Kx9J8UyTeFbbXNds47GO7WN7eGzklvJHDqCo2rErFueihuhOaAOjorDvvGWh6Zb202pXUtmt0jPGLi1ljYKrBWZlK5QAsMlgMA56c1R/4WL4fS+EdxqNrZ272xmimvZvsxkYSPG0eyQKQVKc9/ak3YOlzqqK5WLxbJex+F5LZIrb+2lSaVJoZpF2NEz7ElVdm/I6MRlQeOlS+I/GFvpDi0s98999ptoXUWsskUQklRSHkUbUba2QGYHlTg5Gas7287AdLRXOan4utrbV7PTbHfPPJfJbTsLWVoo8gkr5oGwOOPlLZ56Veg8SaZc6k1jFLN5q7gHa2lWKQr94JKV2ORg5CsTwfQ4lO6v/XcNnY1aK5+28aaPqNncz6VM9yYbV7pA0EkSzIo5KOygMAcAlc4J5qDw14wGu6Xc38p0t44I1kKaRftqEi5BJV0WJSG44ADE8+nL7+QHT0Vg6P4hEvhGHV9XmhJcsGNpbzAMd5VVWNl8wtwBtxnOcCotZ8QzP4M1DWfDk0SS2UUkrJf2coP7tSxRoy0boTxyexBwQRQNe80l1OjorLvvEFlpVtbPftKZblcxw21tJPI+ACxEcas20ZGTjAyMnkUeGNUm1vwrpmp3Kok13bJM6xghQWXJwCSR+NO2/kJaq5qUVlX/ijw/pd79j1PXNNs7rAPkXF3HG+D0+UkHmtWkAUVymjeK7/W/GN7p1vY2cdhYbkuGe6b7Sj7iqkxBMKG2MQC3KlWz/DV+28Y6Ld6smnW89w88nmGN/sUwhcR/fIlKeWQDwSGxkgdSKOiDq12NyisaDxXpV1HcNbteP5EfmlfsE4aVM43RApmVenKbhyPUVX8PeMLPXvDY1Y291ZolstxMs9rKioCpJ2u6KJAMHlc9vUUbK4LXY6Gisqzu9VufDr3j20UV9LE8tvbHnZkZjRznlum7BAzkDpmiXWo9K0Wzudf/cXMyojwQRtKzTFclERNzNjB4GeAT0GaNtw32NWiub1fxrZ6S2k7rPUZU1KXYNun3G6NdjtkoIyd2VxsOGwScYBqbU9Wvob3RJrJ4RYX9wsMsNxaSLN8yMwIJZdhG3BVkJ+lH+dg/wArm9RXKa743XRbq5b7LDJY2MqQ3cz3BSTeyhysUYQ+YVQh2yygDPocOk8XzL4uGjpYwMvmrGQblhclCAfOWHy8NECcF9+OCPvfLQtQeiuzqaKRywRtgBbHAJwCfrXM6Z4j1m4vdVj1LRrOCHSztma0v3uJHbylkARDCmchgOoOexpX3HZs6eiuVs/Ft5deF7jW1s9MngCr9lFnqZm81i23Y7eUAhBIBxuwc+lXtM8RjVdZms7e22wraxzx3DPy5bkrtx/Dlec9SRgY5b0dhdLm5RWTaT67J4VhnurW2i1ryA8lsT+68zqUyCcA9M5OM55xig+JdNj8MJr9zK1vYNEsjM8ZLJuIGCoBOQTgj1oA1qKpaxqI0rR7i9Cea8a/uogcGWQnCIM92YgD61W1S/vdO0OIqIZdUnMcEaqh8tpmwCdu7O0csRnO1TzQBrUVia1f6lp+raR9nltTZXdyLaeJ7djJkq7blcOAPujgqfrS3d9qVr4u0+0821fT72OX935DCVGRQc+ZvwQc9Ng+tK4G1RVG21a2uNUuNOIeG7gG7ypVwZE/56J2ZcnGR0PBwavUwCiq9texXckgtwzpGcebj5GPcA98d+361Rg1oC31C+vdsVhBOYoGRGZ5AuFY4GSSX3KABk4HXNMdmzWorObXrBNL/tCZriGAvsVZrSWORmzgKsbKHJPYAc9qZL4i06Czt7mdriJblmSGN7OVZXYAkgRld+cKTjHI6Ucr7D5ZdjUorA1DxIn2XTJdKkQi9ukj33FrOUCbwrqSq/u5OcAPjng9DVnUfE2k6TdPb31y6SxxrLIqQSSeXGSQHYqpCr8pyxwB3Ip8rHyS7GtRWE/iu1j8TPo7W16WWNGEyWU7qSzEYyEwF4Hz529fQ1qrexG9a1cNHKBlQ4x5g9VPfHfuPypWaJcWtyxRRRSEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVlp4j04+IJtFkm8q9jClUfgSAgH5T3PPTrQBdu7OG9h8ucHKncjqcMjdmU9jWZrOiXOraZBbNNYvLE+/wA66s2kIOCA6bJEMbjP3lOR2xWyzBFLMQqgZJJ6UI6yIrowZWGVYHII9aabWqKjJxd0YTaBfwfYZtN1VVvLW3NtJLewNcLMhIOSN6tuyvB3HgnOeovxaaya2+pSTBne1S3ZFTAyrM27qeu7p+tX6KfMwcm1YxL/AEnVbnxFaajbajZwwWqsiwSWTOzB9u7LiUDPy8fLx71R0zSNRn1C8a8nSKwTU3uI7f7KyySEEFT5hbBXPPCjp161vrfbtXksPstyPLhWX7QY/wBy2SRtDd2GMkehFWqOZr+vMblK1v6/rUyrPS7uy1q8uIryFrK8l857d7c+Yr7FXiQPjb8oOCpPJ5rVqG0vIL638+1fzI97JuwRyrFSOfcEVJLKkMLyynaiKWY4zgDk1LemondvUwE05tG8N3NjqMrX2niIwwxWtlIZghyMHazbjggZCrjGaoHSdWh8L6YshDatJfQ3FzK0RlVXzyWCkZCgAdR0611sE8dzbxzwtujlQOjYxkEZBp9Z+zS09Pwdy/aM5q+8I/2hZKLqe1uLz7Ubp2uLISwOxXZgxFum3GPmzkZyea0rPRIbfToLZxHD5Wfl08PaRcnPCK/H4k1p0U4wjF3RLqSas2NijWGJY0LEKMAu5Y/iTyaytT0m8uNYtNS0u9gtbiCKSBxcWxmR43ZGOAHQhsoMHJHJ4NWLvWILO8FtJFMzkIcoBj532Dv61Ot9bvqUlgsmbmKJZnj2nhGLBTnp1RvyrWLknzIhrSzOcm8DwP4sk1lYtHmE06TyfbdJWa4RlAX93NvUqMKCMq2Dk+wtxeGZYvER1wXsZ1CRzHM/2c7Xtc/LCF3cEYB3knktxghR0FFX7abSV9lb5CcUzHtdKv8AT9Wv7i1vLZ7O7kM/2aS3YSCUoq/60PgL8oONhPJ5qXTrf+w9BH2wmWZFaa6e3iZzJIcs5VACxyScAAnGBVyyvbfULfz7OTzI97x7tpHzIxVhz6FSKZb6hFdX93awhibQqsr8bd7Ddt65yAVJyP4h+Cbk9H0/QNDmhp0vinTdfVVnsLe/uozA13bMplREjDb4W2tsYqylTtLLnsQal0jwRFpej6lZrJaI19Otyos7IW8NvIqoFKRhj0ZFbk5z3rf0+/8A7Qimf7JdWvlTvDtuY9hfacb19VPUHuKt1bqziuRaL/K3+Q+pzGq+DzqWh2lj9ptmeG5N1Ot3aefb3TsG3b4t4yNz7gN3BVeuKrJ4GktfDFrpFlcacPs9xNOks+nMfKMjsw8ny5YzEV3kBlOfTFdhRSVeolZPS9xWMCXQNRhexuNK1dUu7a0+ySy39ubkXC8HcwDod+RnO7HzHIPBF620pofEF3qjzh2ubWC3MYTAUxtId2cnr5nTtjqc1o0VLqSasxmBfaLq9z4rtNVt9Usore1jeJbd7B3dkcoXy4mAz+7GDt4zyDWd4d0XVHuJZNQuUhsYdWu7mG0+yMkrEyybWaQuQUIbcMIufl5IznpY7/frE1h9kul8qFJftLR4hfcWG1W7sNuSOwI9at1XtZxjy/5f1+oN3Vv62f8AmZNjpV5Ya1ezxXsDWF5KZ3t2tj5qyFVXiTfjb8ucbM89a1WDFCEIDY4JGQD9KqJqlrNpcmoW7NLbxhySqkE7CQwAOO6kUlrqtvdRTSfNCkLKrNNhRkqCO/8AtCs5NvR9BK266j7KwS03OzGa4k5lnf7z/wCAHYDgVBrunzarphsImjWG4dUui5PMOfnUY7sPl7Y3E9sVo0E4GTwKkZmarpsuotY26+UtjHOstyjZy4TlFA6Y3hSfZcd6XVtEh1QxTpI1rf2+fs17EBviz1HoyHAyh4OB3AItXF9bWumy38syC1iiMrShgV2AZzn6VJBKZ7eOUxvEZEDeXJjcuR0OCRmiw+hUvLG6upNOdLuOI2s4lmH2cN5w2MpVdxJTls5BJwMdzWXeTG1+IVjJJb3TRTWEkCyxWskiK5kQgMyqQnAPLECujooWjv8A1tYl6q39aO5g2mh6jpmqzvpWpW0em3Nybma0uLNpHDscvskEihQTz8ytgk9sAUbTwjqUMMdvc6zBJa2s0txZxxWRRllcuVaRjI28LvJAUJkgZrokvt+rTWP2W5Xyoll+0NHiJ9xI2q3dhjJHbIq1Q1pYp6M5nSPBFroN5p1xpl3dhrWJoJhc3U06yxsvIVXkKxneqt8o7YxzxLdeFRd6LqOmSXjLDqN4Z5iiFT5bMpeMENkZUFdw6Zzitm3v7a6svtcMym3+bMjfKBtJBznpgg1YBBAIOQehFHW/9b3Ftocdq3hX+zPDviY6TLeXC3+lyR/ZZpprqRpQjgMru7Mcghdv+yMV0mkXcd9pNvNEk8alAu24t5IHBHByjgMOncc1dop3B9P67f5GLrvh0a3eWkr3AijhSWOZPL3GVH2nAbI24ZEboc4xWbdeFNWfQdP06y1mzja2uBdTzT6e0hmlEvm5AEy7QWzkc8HqK6yilsD13Oc1DwtLqcesfaL9Fl1XTI7B2SAhY2XzcuAWPB837ueMdTmoL3wfd3V3ciHV1gsLq8gvpYPsoaQyxmPjzC2Ah8peNuc/xY4rqqKd3e427/18jmR4VuvtoibU4jpC35v1tfspE3mFzLgy78bPMJbGzOMDNM0zwYdP1GwunvxKLR5HMYg2h/lKRAfMcbEZh3ySTxXU0UloJ66mYv2rS31K91K+lvLRnV7e3hsyz26BQCoEYLSZOT0zzjtVQeMtMYMRa618oyc6Fejvjj9zz1reooAy9P1y01lpYLWLUImVMk3em3FsMdODKign2BzVF/DEg8F2GgxS2E5tIYojJqFiZ438tQN3liRcHIBB3cV0VFAXZyEngaaeztIrnWJZpbe1lgaWVGkLmSaOXOXcthfL2gMzHBGWOOb2i+Ff7Iv7q5+2ed9oSVdvlbdu+eWbrk5x5uPwz3xXQ0UPXf8Aq9/82O+lv60ORl8JavHp/h6z03WbKGPREjKm4055TLIsTR7jiZcKVc/L1yOvapL7wheXd5deXrCw2N3eQX0sAtNzmWMx8By3CHyl425B/ixxXVUU7u9xPU5ZfCN2uoIV1dV06LUW1GO1FqN5kZizK0hbldzMRhVI4ySBUWh+A4ND1aS5hj0d48ymOYaQqXi7yfvXAf5sZI+4CR1Ock9dRU2Vrf12/QHq7/1/WpzEHg7ybHTrf7du+w6PLpe7ycb94jHmY3cY8v7vPXrxW3HaXFrosdnZTxLcQwLFHNLEXTIGMlAwJHHTcPrVyiqbvfz/AOD/AJsd7/1/XY43/hB7u58KHRdW1HT7zy7kXNux0z93u3s5WSN5GEiksRgFSB3zzViTwldL4KutB06bRtNa8EiTSWekGKEo6lTtiE3D4x8xY9OldVRS7+Ylpa3Q5uTw9rEklhdrrNrFf20ElrLNHYHZJE5U/KhkO1xsXDFmHXKnoNTQdKGh+H7HS1mM4s4EhErLtL7RjOO1aFFO7FaxlX/h2y1G9+1XE+pJJgDbb6pcwJx/sRyBf05rVoopDOOj8Kajd+Pn13Vrm0KWpVbNrey8uUoA/wAhkMjHb+8O4YG4qp4Awec8J6Xef2xHbT2M7JcR3MV2lzY3cRsEfJby5pJDAxZtoIhRQ2dw4XFeqUUrLZjv1OX8J+DU8MyORFop/dCJZrLSFtJ3A7yOrkPnAJwqjPOO1SWPhi7t/Ct54eu7+3nsXtWtLXy7Vo5IoypX52MjBzgjkBeh4546Sim7sS913RR0a5ubrSYWv7Zra6QeXNGw43rwSp7qcZB7gjoeKg1vSbjUWs7nT7uO0vrKUyQySwmaM7lKsrIGUkEMejAgge4OrRQ9RJWVjF1PR7/UdPsCb+2j1OxnFwlx9kYwl9rIcxeZnBV2438HBz2qvrWi65qZ0xrfV9Pt3spFncyaa8gllCsuQBOu1fmPy8n/AGq6Kij/AIcf/DHJaj4H+3atfXSXcEUWqRCO/U2peRl2qrCJy+Ig4RAw2tnaOeBh0vg2VtZNwL63FidQXUWj+xZuRKqgACbfgLgAY2E7crnmuroo21QPXR/10MSDxbp1xcxwR22sB5HCKZNEvEUEnHLNEAB7kgCp7bSZbK71m6trlPO1GVZo/MiLLCwhSMZAYFhlM9V64961KKB3OUXwddXF7d32p39mby6EKSPY2Bt1kWORXBkBkcu2F2glhgE8GtuPSY4NaW+gMcUYt3iMKR4yzPvLZB9c545JzmtCijsL+v6+4r3901lYTXEVvLdSIvyQwjLSN0Cj0ye54HU4ArAurLXNN8ApYaKd+tNEEWeIJ5cUrHLSESH7gYnOATjoDXT0UDMu8064vtR00ztC1pakzyrzukmAwnHTaMs3XOQtOl0+a58RwXlx5RtbSE/Z0BJbzWyGY8YGF4GCfvt04zpUUEnO+JJjJrWg2kVvdSSLfrO7x2sjRogjkBLSBdi8kcEg80ahMZ/HWjwxW9032aOd5ZfssgiUMgA/e7dhPsDmuiopW0t53/L/ACG9Xcy00RJNaOp6jKbyaNj9kRlxHajGCVX++RnLnnBIGASK03RZI2SRQyMMMrDII9KWin0sBmS2F5babdW+k3KKzJtthOCRAx4znqVHUL7YzjoXGjofDv8AZNmlqI1iWJVvLfz4ioxncm5d2R79eea06KdylJp3Rzkfhe5TS4IzqQa9tbv7XbzNE7RRNtKbBG0hbZtZht38Z4wMAX/7Mu7iXTJ9Qu4ZLiyleR2gtzGkm5GQAKXYrgMO5zjtnjUopuTe43OT3MfxBpWo6tHbx2F/a2iRTJM3n2jTFmRgy4xImBkc9c+1Y9zo+rX/AIr1KMXMVvaXOmW0FzMbNm875pt4ibfhCA3ffjcv49hRQpNKw1UklZf1rcybjSbpdahv9Nu4IAIVt5457dpd6K2RtIddp5bk7uo44q21gJr4XF0/nCMgwxEYWM/3sd29+3bHObdFK7IuFFFFIQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXMXHgexv/F02uak3n/c8q3xhVKqBlvXkdOn1rp6KAKGq2Ut3EhiIkEbbmtpDhJvYnr9Oo9Qe2D4w0mbVXspoNHe/niRtkVxBbT2yFsf61JHVsjHBjOR7jg9bTJp4reIy3EiRRr1d2Cgduppxlyu6LhNwd0czqGlNJ4mS71PQBrURhiW3ZTE62TgneQsrLjOVO5csduD0GZ08M2t34i1K+1WwjlJniks5mOWj2omShByh3LzjGcDORXRUVXO+gc7t+By9nbTWvjy8u4PDs1vb3UKxSXiG3VZHVmPmMBJvIIIGSufasjwlosN2LW5OheQuydLu8uPLf7cjEqI+GZmTgcOAAFAA9O/pkMMVvEsVvGkUa/dRFCgfgKOd2sV7R6+dvwOa8IaJDob3Vuvh+KwlEsuL6FIQs8ZkZkUFTv4UjhlAGMCt3VNPh1XS7iyuYYpklQjbMgZc9jg+hwada6lY3008VleW9xJbttmSKVXMTejAHg8Hr6VPLLHBC8s7rHHGpZ3c4CgdSSegrOdqi97qS6jc+fqcaunQ6Z4KaYaKmj3Wlql1uKwgSyRr8zZjY53DcuTg4bpUWpWOy00Rr3TZL2a/wBRe5urRCm5y0Mh2HeyqQoCrgnBC/hXZXFnaX6xG6t4bkRuJYjIgfYw6Mueh9xTL+awtIVvNTkt4Yrdtyz3DKqxkjbncehOSPxxWbprW/8AX9afcWqvX1/I42/8MXsum6bC9jNJZRvO7WFt9mcwb33RjbODGdq5Xg8Z+XIzXQR6LcHT7KOG7nhEMCoVuXcycf3jFIqk9uAfrWzFLHPCk0EiyRSKGR0bKsD0II6in1Uaag20TKq5Jf1uMiQxwojNuKqATzz+ZJ/MmuSvfDNlD4/XWD4Xg1EXMUS/aY4LfdazJIxMzF2Vs4ZeV3N8n0rq57qC18v7TPHD5jiNPMcLvc9FGepPpUtbwqSg7oz6WOB0zwxeQ+PJNS1C11Jp/tUrrfRCx8l4iG2IzbRc4CkLt5AIHYcT6N4buLfVw9/pSvpNwJlttOcxuulhs7sjOGEg6hd2zO0fKSa7eitHiJP7rf1/X4N3Hrc4zwxpEHhO31Ly/CotpoTPILyzghP2uMyM6RqEPmEhSo2soAxgdq3dO0WL/hH/ALFrEEV410WlvI5kEiO7ncwIPBAJwPZR6VrVBe2Fpqdm9pqVrBd20mN8M8YkRsHIyp4PIqJVXN3YkrbHEy6Utx4KvtN0DTYZrP8AtWRHtbaC3OIll+fy0m/dbgR/FwOe+Kfonh/UtJ0G1nSwk+2afeSyWtqWgV2t5Bgxnywsa9QxC4G5Bgnqe1trWCytY7azgjt4IlCxxRIFVAOgAHAFS1brys4ra/z7Ba7v/XX/ADOA8ReE7ufTNJ0tdPGoWqCWW6khhtZJBcuQd+LkMoQlpCSoLfdxxmotQ8P6pPo/h83Oitqmr2dhHE/2yK1uLSOXC7i+91kByPvxfXDYC16DDPFcR+ZbypKmSu5GDDIOCMj0II/Cn044mcUtFpr+f+YWTRyepaT5ni8XupeHf7chZIhaTZhcWLKTvOyVl25O1tyZY4wfurmWz8K21x4h1XUdXsI5Jf7QSewuGbLxqsMQyhBygLowI43AcgiunoqPbSS07W/L/ILHI6fa3Fp8QtSu4PDNxaWl7BHFJeIbZVkkRpSZGCybyCGUAld3qBisXwBocN3pul3TeH/ssLaYYbu6uTE/9ohwmBhWYsgCn/WY2jCgYJx6RVaJrKxNvYQm3tyUIgtkKp8q9dq+g46dKr275Wrb2XXpfz8ym76nO+C9Bg0AXNqnhyLTpVkkzfxRwKtyhkZkAKNv4UjhlGO1dNdZ+yyBYBcEqR5RIAfPY54xUtMimjniWWCRZI25V0YEH8RWVSbnLmluSklsY0h1fRtNjTT9P/taQrITELlYliwhKIpbJILALknjOeAMU+WLUdVtJBdWgtDDOQtu8weO6QAYLFRkAnIx7cgjitmio6jMfUo5dRk0+wNvLFBIwnuePlVYyCIyw4yW2jHdQ3asrxdpM99qVrc2ej/2lcwxlYTdQ28tqhLA5YO6yKePvR+2Q2AK62iqjJxaaLjNxehy9/pZfxWbzUdA/tmJliFrNmJxZEE7jtlZdvOG3JknGD90ZfZ+GLefXtVv9WsUeU6gk9jOW+dFWKIZUg5UFlYEcbscgg10tFNTa2H7SVrfI5PT7W4tPHupXcPh2e1tLyCOJ7pTbhZJEeUmRgsm4hgygHG71AxWN4C0WK70nSbhtC+zQNpflXc9wY2/tAOE2gqrMWUBT9/GBgAYJx3keo2M1/JYRXlu93Eu6S3WVTIg45K5yByPzqWCCG1t44LaJIYY1CpHGoVVA6AAcAU1U0fy/C5TrNp/L8DmvCujRaFb3VvH4cS0mjMn+lQpAou13sVAKtu6EcOABW3pVlLZwOJWCh23LbocpCP7qk8/09AKvUVDk27szlJyd2FFFV73ULPTbf7RqN3BaQ5C+ZPIEXJ6DJ4qW0tySxRSKyuoZCGVhkEHIIpaYBRUU11b28kSTzxxPM+yJXcAyNjOFz1OATgelS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBna7NqMGlu+kRCSb+I43Mi92RDgOw7KSPx6HL1Z7F/ALsuou1qVQm7uNzsT5gzuAGQc8YwMHjAxgdLRStuS1cqX8moxqn9l2trckk7xcXLQ7R7bY3z+lJdy6kk8IsbS1miP+taa6aNk5/hAjbd+JFXKKB2CvPJLmzt9aiku/7Mm1w6v5TxX8Ae5ETSgRmAlgVUIQwIBGc9816HRSt7yfYU480bHJ2et6fJ431qKzv7Se6NpCscKTqWd084soAOSRxkdqyJtanvdFvY49Z/tQTaRcS3sPlxgWUmwYX5VDJyWG1yW+X2Neh0UnFtb/1qJRaad+pxFv4gkttI1O6g1htXtYLJH8+3EIW3mJIKKwUqABtJ37yoGTnPL9B8Rs+k6w2taraTQWxUR3v2qN42Dr0EgjjVvmBHC9cjJxXaUUpRcr6ijFxad9jD8GXlteeDdKNncw3AitIo5DE4bY4RcqcdCPSofF+pS6bb2rx6tBp0ZdjJuuIYZZQB0jMyshPsdvb5h36KirneY4xcYKNzjPEWr2cNn4fu7vVFtt9xbyG3v1gDOpIzIwZcqyg9UIAyaNZaKLxnp+oTeI5NPs7iykEMoe3EZO6IhFZ0Odw+bqTxwQK7Oii2t/O/4WJcG7q/Rfg7nFXeuaqfGr2S6lYWMcVxFHHaXN2sbXEZCksEMJZySWAKyAZABHBz2p5HXHvRRSirKzLSabdzjPDzrput61Bd67cT3KXUkv2CTyN8y+Wh8wKqBj6cEDjp1rN0fxbqcsOoyLfRXqjS3vIczpP5Lrj5H8uGMA/MMrliMDkd/RaralYQ6pplxY3W7ybiMxvsOCAfQ1LTS32VvwJ5HfR9b/jc5vwVqlzqtxeyy6w19BGsapDJNaSOjHO5j9nGAD0GTng8Vs+JppLfwzfSRStCfLwZVODGpIBYH2BJ/Cl07RRY30l7PfXV/dSRiLzrkRgqgJO0CNFHUk5xn3rRlijnheKZFeORSrowyGB4INVvCwqXw7nL+KtRPhzT9MgsZjYWZkMTtA0EbIgQ7QrT4jHOODyRnFZV4bmXQPDmp6l4lkRVuQ1xeQtbGJCUkAbf5ZXgkJ/d57nBrp5vDqPb2SQahe28tjuEFwjI7hWGCp3qwIxgZIzx165u6XpsOlWK2tuzuNzO8khBaR2YszHAAySSeAB6ACps5SevVCtd28jkfFfiKewis4dL1ja7WbXCXMlxCi3fQKF/cv5jnrtQL19xVbWfE+oNqcNvHqy6WZre2kiPm2saZc5kL+fl2AHTyweevNehViaj4Yh1G6upDf3kEV6ipd28Jj2TqBjBLIWXI4+Vl/Pmk00993/n/XyComk3f+tDQfU7SHVINMknP2yaJpY0Kn5lXAJyBgdRWVNayweMrCaS8kuVmSfbHNDDiEYU4RggcD6sc9631UKoVRgAYA9KzodHCav/AGhc311dyKrLCk3lhIAxBIUIqk9AMsSePrVPWSRcttTG0LWZLjxPdWVxqwv3/essdnNBLBCgcABgqiVHA4wxZevOeBo6SPI8QazbQn/Rw8UwUdEkdSXA9M4VvqxPetqq1jYRafFIsRZ2lkMssjnLSOepJ+gA9gAB0ppWsmHK/wASWdplt3NqiSTBTsSRyisewLAEge+DUdk95JbhtRgggmycpBOZVx2+Yop/SrFFUUcz4tNt9s05dXkhj0phL5puhm383aPL80EgFfvEAkAkDvisay1tE0uwik1ey0DTytz5d1YQRRQzMkxVQnmb0AK5bAyT1BwDXf0VHLqTKN3c4O48RX/2ONtS1b+xrn+z0nt4fJQG8mO7K7ZFJPIT5Eww39emI9Z8RaoNeWwOqDSZGjtii+daxoCxzLvE2XY44UoCM8HkGvQKw9Q8LQahdXbvfXkUF8FF3axmPy5wBjBJQsMgAHaw/PmlJNNa7v8Az/r9DOaajv8A1/X9Mp3OsaZH8R7O2k1K0WdbGWExtOoYSNJEVXGc7iOQOpqlpGuare+LWguNSsIlW4ljfTXu1EwRd20rF5IfJAVs+YVIJIHIx2oGBgdKKpJ6a7X/ADuW4ttu/wDVrFXU7+PTNLub6YZS3iaQgfxYHT8elcLFqGo6BpmphrKbTLy4tBeIbgxOJLgECZgEdsg7kPOD1r0Sihq7/r+v+GKlFvZnHXmr32jWutW93qM1y1sLcxXbiKJozKdvzHyyioCM7ipwCeuKq2/iEz+BdebWtStnERltobk3CFZt0IZQHCRq2SxAwoz79T3dFTKDkmr7qwJNNNPY5aXxBFZaHpmsW17Hc6XGnlXXkFZBkqArZHOQ4C4H97npVHW4L2D/AIR291rXprApM32mYCBI4HaKQ9XQgdQgzwRjuc11Go6THqktv9pnm+zwuJGtl2iOZgQVL8buCAcAgHvmr9U7yu/MhR05ey/r+vU5DxBqunWOreHpLrXbXb5oJS5a3wyGN8TgldykkAblIHOMc1Zl1bd4rktb3XhpcaNF9ktQYl+2hhknMiktlsrhMEY9SK6aii2vzv8A1/XyK5X3OUGsyJ46NlNqwnSSTZDZWc0D+WBHk+dGV81ecnKsR0yFHXq6KKcVZWY0mmynay6m80wvbS0hjX/UtDdNIX/3gY129uhNQia6fS7ptfjt9PjVDmS1vXfauOW3lEKke1aVFFtB9TK8Pz6hPYsdQVjGGxbzTJ5c0ydmkjxhT09M91TpWrRRTBKysFFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z"
    }
   },
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "![ss_1.JPG](attachment:ss_1.JPG)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Exploring the HTML-Extracting data for all drugs starting with alphabet \"A\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<div class=\"tableList\" id=\"A\">\n",
       "<table>\n",
       "<thead>\n",
       "<tr>\n",
       "<th width=\"23.19%\">Active Ingredient(s)</th>\n",
       "<th width=\"15.51%\">Dosage Form</th>\n",
       "<th width=\"19.92%\">Strength(s)</th>\n",
       "<th width=\"10.67%\">Subsidy Class</th>\n",
       "<th>Clinical Indication (where applicable)</th>\n",
       "</tr>\n",
       "</thead>\n",
       "<tbody>\n",
       "<tr><td>Abacavir &amp; Lamivudine</td><td>Tablet</td><td>Abacavir 600 mg + Lamivudine 300 mg</td><td>SDL</td><td></td></tr><tr><td>Abacavir, Dolutegravir &amp; Lamivudine</td><td>Tablet</td><td>Abacavir 600 mg + Dolutegravir 50 mg + Lamivudine 300 mg</td><td>SDL</td><td></td></tr><tr><td>Abiraterone Acetate (Abiranat)</td><td>Tablet</td><td>250 mg</td><td>SDL</td><td><br/></td></tr><tr>\n",
       "<td>Absolute Alcohol </td>\n",
       "<td>Injection</td>\n",
       "<td>100%</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Acetazolamide</td>\n",
       "<td>Tablet</td>\n",
       "<td>250 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Acetic acid</td>\n",
       "<td>Ear drops</td>\n",
       "<td>2%, 3%, 4%, 5%</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Acetylcysteine</td>\n",
       "<td>Injection</td><td>5 g/25 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aciclovir</td>\n",
       "<td>Concentrate for infusion</td>\n",
       "<td>250 mg/10 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aciclovir</td>\n",
       "<td>Infusion</td>\n",
       "<td>250 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aciclovir</td>\n",
       "<td>Eye ointment</td>\n",
       "<td>3%</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Acitretin</td>\n",
       "<td>Capsule</td>\n",
       "<td>10 mg, 25 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr><td>Adalimumab Biosimilar (Amgevita)</td><td>Prefilled autoinjector</td><td>40 mg/0.8 mL</td><td>SDL</td><td></td></tr><tr><td>Adalimumab Biosimilar (Amgevita)</td><td>Prefilled syringe</td><td>20 mg/0.4 mL, 40 mg/0.8 mL</td><td>SDL</td><td></td></tr><tr>\n",
       "<td>Adefovir Dipivoxil </td>\n",
       "<td>Tablet</td>\n",
       "<td>10 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Adrenaline</td>\n",
       "<td>Injection</td>\n",
       "<td>1:1,000 (1 mg/mL), 1:10,000 (1 mg/10 mL)</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Albendazole</td>\n",
       "<td>Oral suspension</td>\n",
       "<td>400 mg/10 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Albendazole</td>\n",
       "<td>Tablet</td>\n",
       "<td>400 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Alendronic Acid</td>\n",
       "<td>Tablet</td>\n",
       "<td>10 mg, 70 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Alendronic Acid &amp; Colecalciferol </td>\n",
       "<td>Tablet</td>\n",
       "<td>Alendronic Acid 70 mg + Colecalciferol 2,800 international units, Alendronic Acid 70 mg + Colecalciferol 5,600 international units</td>\n",
       "<td>MAF</td>\n",
       "<td>1) For patients with osteoporosis (T-score  -2.5)\n",
       "          <br/> 2) For patients with osteopenia (T-score  -1.5) and a history of non-trauma induced fracture</td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Alfacalcidol</td>\n",
       "<td>Capsule</td>\n",
       "<td>0.25 mcg, 1 mcg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Alfacalcidol</td>\n",
       "<td>Oral drops</td>\n",
       "<td>2 mcg/mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Alfacalcidol</td>\n",
       "<td>Tablet</td>\n",
       "<td>0.25 mcg, 1 mcg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Alfuzosin Hydrochloride</td>\n",
       "<td>Tablet</td>\n",
       "<td>10 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Allopurinol</td>\n",
       "<td>Tablet</td>\n",
       "<td>100 mg, 300 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Alteplase</td>\n",
       "<td>Infusion</td>\n",
       "<td>50 mg/50 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aluminium Hydroxide</td>\n",
       "<td>Tablet</td>\n",
       "<td>600 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aluminium Hydroxide, Magnesium Trisilicate &amp; Simeticone</td>\n",
       "<td>Chewable tablet</td>\n",
       "<td>Aluminium Hydroxide 250 mg + Magnesium Trisilicate 250 mg + Simeticone 30 mg </td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aluminium Hydroxide, Magnesium Trisilicate &amp; Simeticone</td>\n",
       "<td>Oral suspension</td>\n",
       "<td>Aluminium Hydroxide 400 mg/5 mL + Magnesium Trisilicate 400 mg/5 mL + Simeticone 30 mg/5 mL </td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aluminium Oxide </td>\n",
       "<td>Oral suspension</td>\n",
       "<td>4%</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr><td>Ambrisentan</td><td>Tablet</td><td>5 mg, 10 mg</td><td>MAF</td><td>Treatment of adults with a confirmed diagnosis of WHO Functional Class II or III pulmonary arterial hypertension (PAH) who have one of the following PAH aetiologies:<br/> Idiopathic PAH<br/> Heritable or familial PAH<br/> PAH associated with connective tissue disease<br/> Anorexigen-induced PAH<br/> PAH associated with HIV infection<br/></td></tr><tr>\n",
       "<td>Amikacin </td>\n",
       "<td>Injection</td>\n",
       "<td>500 mg/2 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amiloride &amp; Hydrochlorothiazide</td>\n",
       "<td>Tablet</td>\n",
       "<td>Amiloride Hydrochloride 5 mg + Hydrochlorothiazide 50 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amino Acids</td>\n",
       "<td>Infusion</td>\n",
       "<td>5%, 10%</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aminophylline</td>\n",
       "<td>Injection</td>\n",
       "<td>250 mg/10 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amiodarone Hydrochloride</td>\n",
       "<td>Injection</td>\n",
       "<td>50 mg/mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amiodarone Hydrochloride</td>\n",
       "<td>Tablet</td>\n",
       "<td>200 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amitriptyline</td>\n",
       "<td>Tablet</td>\n",
       "<td>10 mg, 25 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amlodipine </td>\n",
       "<td>Tablet</td>\n",
       "<td>5 mg, 10 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amoxicillin</td>\n",
       "<td>Capsule</td>\n",
       "<td>250 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amoxicillin</td>\n",
       "<td>Oral suspension</td>\n",
       "<td>125 mg/5 mL, 250 mg/5 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amoxicillin &amp; Clavulanic Acid </td>\n",
       "<td>Injection</td>\n",
       "<td>Amoxicillin 500 mg + Clavulanic Acid 100 mg, Amoxicillin 1 g + Clavulanic Acid 200 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amoxicillin &amp; Clavulanic Acid </td>\n",
       "<td>Oral suspension</td>\n",
       "<td>Amoxicillin 200 mg/5 mL + Clavulanic Acid 28.5 mg/5 mL, Amoxicillin 600 mg/5 mL + Clavulanic Acid 42.9 mg/5 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amoxicillin &amp; Clavulanic Acid </td>\n",
       "<td>Tablet</td>\n",
       "<td>Amoxicillin 500 mg + Clavulanic Acid 125 mg, Amoxicillin 875 mg + Clavulanic Acid 125 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amphotericin B</td>\n",
       "<td>Injection</td>\n",
       "<td>50 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Amphotericin B</td>\n",
       "<td>Eye drops</td>\n",
       "<td>1 mg/mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Ampicillin</td>\n",
       "<td>Injection</td>\n",
       "<td>0.5 g</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Anastrozole</td>\n",
       "<td>Tablet</td>\n",
       "<td>1 mg</td>\n",
       "<td>MAF</td>\n",
       "<td>Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer</td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Antazoline Hydrochloride &amp; Tetryzoline Hydrochloride</td>\n",
       "<td>Eye drops</td>\n",
       "<td>Antazoline Hydrochloride 0.5 mg/mL + Tetryzoline Hydrochloride 0.4 mg/mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Anti-Rabies Immunoglubulin</td>\n",
       "<td>Injection</td>\n",
       "<td>300 units/2 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr><td>Apixaban</td><td>Tablet</td><td>2.5 mg, 5 mg</td><td>MAF</td><td>1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)* and CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1 or more for men, and 2 or more for women<br/>*This excludes patients with rheumatic mitral stenosis or prosthetic heart valves<br/>2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults. MAF assistance does not apply to patients with isolated distal DVT</td></tr><tr>\n",
       "<td>Aprepitant</td>\n",
       "<td>Capsule</td>\n",
       "<td>80 mg</td>\n",
       "<td>MAF</td>\n",
       "<td>Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy</td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aprepitant</td>\n",
       "<td>Capsule</td>\n",
       "<td>80 mg &amp; 125 mg (Tripack)</td>\n",
       "<td>MAF</td>\n",
       "<td>Prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy</td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aqueous Cream</td>\n",
       "<td>Cream</td>\n",
       "<td>Emulsifying Ointment 30% with either Chlorocresol 0.1% or Phenoxyethanol 0.1%</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Ascorbic Acid</td>\n",
       "<td>Tablet</td>\n",
       "<td>100 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Ascorbic Acid </td>\n",
       "<td>Injection</td>\n",
       "<td>1 g/20 mL, 500 mg/5 mL </td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Aspirin</td>\n",
       "<td>Tablet</td>\n",
       "<td>100 mg, 300 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr><td>Atazanavir</td><td>Capsule</td><td>200 mg, 300 mg</td><td>SDL</td><td></td></tr><tr>\n",
       "<td>Atenolol</td>\n",
       "<td>Tablet</td>\n",
       "<td>50 mg, 100 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Atorvastatin</td>\n",
       "<td>Tablet</td>\n",
       "<td>10 mg, 20 mg, 40 mg, 80 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Atracurium</td>\n",
       "<td>Injection</td>\n",
       "<td>25 mg/2.5 mL, 50 mg/5 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Atropine Sulfate</td>\n",
       "<td>Eye drops</td>\n",
       "<td>0.5%, 1%</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Atropine Sulfate </td>\n",
       "<td>Injection</td>\n",
       "<td>0.6 mg/mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Azathioprine</td>\n",
       "<td>Tablet</td>\n",
       "<td>25 mg, 50 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Azithromycin </td>\n",
       "<td>Extended-release oral suspension</td>\n",
       "<td>2 g</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Azithromycin </td>\n",
       "<td>Injection</td>\n",
       "<td>500 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Azithromycin </td>\n",
       "<td>Oral suspension</td>\n",
       "<td>200 mg/5 mL</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "<tr>\n",
       "<td>Azithromycin </td>\n",
       "<td>Tablet</td>\n",
       "<td>250 mg</td>\n",
       "<td>SDL</td>\n",
       "<td></td>\n",
       "</tr>\n",
       "</tbody>\n",
       "</table>\n",
       "</div>"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "soup.find(\"div\",{\"id\":{\"A\"}})"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Exploring the HTML-Extracting data for all drugs starting with alphabet \"A\" into a list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are 67 drugs inList of Drugs* (as of 1 April 2021)starting with alphabet letter \"A\"\n"
     ]
    }
   ],
   "source": [
    "list_a=soup.find(\"div\",{\"id\":{\"A\"}}).table.tbody.find_all(\"tr\")\n",
    "print('There are '+ str(len(list_a))+' drugs in' +title + 'starting with alphabet letter \"A\"')\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Exploring the HTML-Extracting data for the first drug starting with alphabet \"A\" (i.e. target first row)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[<td>Abacavir &amp; Lamivudine</td>,\n",
       " <td>Tablet</td>,\n",
       " <td>Abacavir 600 mg + Lamivudine 300 mg</td>,\n",
       " <td>SDL</td>,\n",
       " <td></td>]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "first_row=list_a[0].find_all(\"td\")\n",
    "first_row"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Exploring the HTML-Extracting the required information for the for the  target first row"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The Active ingredient(s) for the first row is Abacavir & Lamivudine\n",
      "The Dosage Form for the first row is Tablet\n",
      "The Stength(s) for the first row is Abacavir 600 mg + Lamivudine 300 mg\n",
      "The Subsidy Class for the first row is SDL\n",
      "The Clinical Indication for the first row is \n"
     ]
    }
   ],
   "source": [
    "print('The Active ingredient(s) for the first row is '+ first_row[0].text)\n",
    "print('The Dosage Form for the first row is '+ first_row[1].text)\n",
    "print('The Stength(s) for the first row is '+ first_row[2].text)\n",
    "print('The Subsidy Class for the first row is '+ first_row[3].text)\n",
    "print('The Clinical Indication for the first row is '+ first_row[4].text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Note: As per above code, most of the \"Clinical Indication\" information is left blank so we will need to use a Try-Except block in our code to catch for any potential error"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "####  Exploring the HTML-Creating a list of alphabet letters"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- As mentioned before,there are some alphabet letters not inside the div id(s) (i.e. \"J\" and \"X\")\n",
    "- Since this list of drug may be updated to include these alphabets, there is a need to dynamically create a list of alphabets that are inside (variable named as alphabet)\n",
    "- The tag div id= \"A\"  has an attribute \"id\" whose value is \"A\". You can access the tag's attributes by treating the tag like a dictionary. Please see BeautifulSoup documentation [here](https://beautiful-soup-4.readthedocs.io/en/latest/#attributes)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The first alphabet is A\n",
      "The second alphabet is B\n",
      "The third alphabet is C\n"
     ]
    }
   ],
   "source": [
    "print(\"The first alphabet is \"+ soup.find_all(\"div\",class_='tableList')[0][\"id\"])\n",
    "print(\"The second alphabet is \"+ soup.find_all(\"div\",class_='tableList')[1][\"id\"])\n",
    "print(\"The third alphabet is \"+ soup.find_all(\"div\",class_='tableList')[2][\"id\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are 24 alphabets in the List of Drugs now\n"
     ]
    }
   ],
   "source": [
    "print(\"There are \"+ str(len(soup.find_all(\"div\",class_='tableList')))+ \" alphabets in the List of Drugs now\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number 1 in the alphabet list is A\n",
      "Number 2 in the alphabet list is B\n",
      "Number 3 in the alphabet list is C\n",
      "Number 4 in the alphabet list is D\n",
      "Number 5 in the alphabet list is E\n",
      "Number 6 in the alphabet list is F\n",
      "Number 7 in the alphabet list is G\n",
      "Number 8 in the alphabet list is H\n",
      "Number 9 in the alphabet list is I\n",
      "Number 10 in the alphabet list is K\n",
      "Number 11 in the alphabet list is L\n",
      "Number 12 in the alphabet list is M\n",
      "Number 13 in the alphabet list is N\n",
      "Number 14 in the alphabet list is O\n",
      "Number 15 in the alphabet list is P\n",
      "Number 16 in the alphabet list is Q\n",
      "Number 17 in the alphabet list is R\n",
      "Number 18 in the alphabet list is S\n",
      "Number 19 in the alphabet list is T\n",
      "Number 20 in the alphabet list is U\n",
      "Number 21 in the alphabet list is V\n",
      "Number 22 in the alphabet list is W\n",
      "Number 23 in the alphabet list is Y\n",
      "Number 24 in the alphabet list is Z\n"
     ]
    }
   ],
   "source": [
    "divs=soup.find_all(\"div\",class_='tableList')\n",
    "alphabet=[]\n",
    "\n",
    "for i in range(0,len(divs)):\n",
    "    print(f'Number {i+1} in the alphabet list is {divs[i][\"id\"]}')\n",
    "    alphabet.append(divs[i]['id'])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 5- Setting up Script<a id='Script'></a>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### (i) Scraping the data and creating pandas dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Active Ingredient(s)</th>\n",
       "      <th>Dosage Form</th>\n",
       "      <th>Strength(s)</th>\n",
       "      <th>Subsidy Class</th>\n",
       "      <th>Clinical Indication</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Abacavir &amp; Lamivudine</td>\n",
       "      <td>Tablet</td>\n",
       "      <td>Abacavir 600 mg + Lamivudine 300 mg</td>\n",
       "      <td>SDL</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Abacavir, Dolutegravir &amp; Lamivudine</td>\n",
       "      <td>Tablet</td>\n",
       "      <td>Abacavir 600 mg + Dolutegravir 50 mg + Lamivud...</td>\n",
       "      <td>SDL</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Abiraterone Acetate (Abiranat)</td>\n",
       "      <td>Tablet</td>\n",
       "      <td>250 mg</td>\n",
       "      <td>SDL</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Absolute Alcohol</td>\n",
       "      <td>Injection</td>\n",
       "      <td>100%</td>\n",
       "      <td>SDL</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Acetazolamide</td>\n",
       "      <td>Tablet</td>\n",
       "      <td>250 mg</td>\n",
       "      <td>SDL</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                  Active Ingredient(s) Dosage Form  \\\n",
       "0                Abacavir & Lamivudine      Tablet   \n",
       "1  Abacavir, Dolutegravir & Lamivudine      Tablet   \n",
       "2       Abiraterone Acetate (Abiranat)      Tablet   \n",
       "3                    Absolute Alcohol    Injection   \n",
       "4                        Acetazolamide      Tablet   \n",
       "\n",
       "                                         Strength(s) Subsidy Class  \\\n",
       "0                Abacavir 600 mg + Lamivudine 300 mg           SDL   \n",
       "1  Abacavir 600 mg + Dolutegravir 50 mg + Lamivud...           SDL   \n",
       "2                                             250 mg           SDL   \n",
       "3                                               100%           SDL   \n",
       "4                                             250 mg           SDL   \n",
       "\n",
       "  Clinical Indication  \n",
       "0                     \n",
       "1                     \n",
       "2                      \n",
       "3                      \n",
       "4                      "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df=pd.DataFrame(columns=column_headers)\n",
    "\n",
    "for i in alphabet:\n",
    "    \n",
    "    for article in soup.find(f\"div\",{\"id\":{i}}).table.tbody.find_all('tr'):\n",
    "\n",
    "        active_ingredient=article.find_all('td')[0].text\n",
    "\n",
    "        dosage_form=article.find_all('td')[1].text\n",
    "\n",
    "        strength=article.find_all('td')[2].text\n",
    "        subsidy_class=article.find_all('td')[3].text\n",
    "        try:\n",
    "            clinical_indication=article.find_all('td')[4].text\n",
    "        except Exception:\n",
    "            clinical_indication=None\n",
    "   \n",
    "        append_series = pd.Series([active_ingredient,dosage_form,strength,subsidy_class,clinical_indication], index = df.columns)\n",
    "        df=df.append(append_series,ignore_index=True)\n",
    "\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### (ii) Scraping the data and saving to csv file"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Data has been scrapped and saved in your local directory as mohlist.csv\n"
     ]
    }
   ],
   "source": [
    "file_name=\"mohlist.csv\"\n",
    "\n",
    "csv_file=open(file_name,'w',newline='', encoding=\"utf-8\")\n",
    "csv_writer=csv.writer(csv_file)\n",
    "title=soup.find('div',{\"id\":{\"ContentPlaceHolder_contentPlaceholder_TB03B381D008_Col00\"}}).h2.text\n",
    "csv_writer.writerow([title])\n",
    "csv_writer.writerow(column_headers)\n",
    "\n",
    "\n",
    "for i in alphabet:\n",
    "    \n",
    "    for article in soup.find(f\"div\",{\"id\":{i}}).table.tbody.find_all('tr'):\n",
    "\n",
    "        active_ingredient=article.find_all('td')[0].text\n",
    "\n",
    "        dosage_form=article.find_all('td')[1].text\n",
    "\n",
    "        strength=article.find_all('td')[2].text\n",
    "        subsidy_class=article.find_all('td')[3].text\n",
    "        try:\n",
    "            clinical_indication=article.find_all('td')[4].text\n",
    "        except Exception:\n",
    "            clinical_indication=None\n",
    "        \n",
    "\n",
    "        csv_writer.writerow([active_ingredient,dosage_form,strength,subsidy_class,clinical_indication])\n",
    "\n",
    "print(\"Data has been scrapped and saved in your local directory as \" + file_name)\n",
    "csv_file.close()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Section 6: References<a id='References'></a>"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- MOH's Website (https://www.moh.gov.sg/cost-financing/healthcare-schemes-subsidies/drug-subsidies-schemes)\n",
    "- How to reference a IPython notebook cell in markdown?(https://stackoverflow.com/questions/28080066/how-to-reference-a-ipython-notebook-cell-in-markdown)"
   ]
  }
 ],
 "metadata": {
  "authors": [
   {
    "name": "Chong Junn Teo"
   }
  ],
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
